(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of ‘‘large accelerated filer,’’ ‘‘accelerated filer,’’ ‘‘smaller reporting company,’’ and ‘‘emerging growth company’’ in Rule 12b–2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Number of registrant’s ordinary shares, nominal value $0.0001, outstanding as of ~~August 1, 2019: 186,447,820.~~

	As of			As of			As of			As of
	June 30,			December 31,			June 30,			December 31,
	2019			2018			2020			2019
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	865,997		$	958,712		$	718,062		$	1,076,287
Restricted cash		3,739			3,405			3,625			3,752
Accounts receivable, net		395,018			464,730			543,755			408,685
Inventories, net		51,019			50,751			66,099			53,802
Prepaid expenses and other current assets		85,728			68,218			157,548			143,577
Total current assets		1,401,501			1,545,816			1,489,089			1,686,103
Property and equipment, net		24,808			20,101			138,801			30,159
Developed technology, net		1,813,950			1,945,639
Other intangible assets, net		4,229			4,630
Developed technology and other intangible assets, net								1,891,100			1,702,628
Goodwill		413,669			413,669			413,669			413,669
Deferred tax assets, net		6,080			3,148			564,643			555,165
Other assets		43,767			8,959			40,889			48,310
Total assets	$	3,708,004		$	3,941,962		$	4,538,191		$	4,436,034
LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES:
Long-term debt—current portion	$	—		$	—
Exchangeable Senior Notes—current							$	174,504		$	—
Accounts payable		42,672			30,284			106,015			21,514
Accrued expenses		188,192			215,739			415,545			235,234
Accrued trade discounts and rebates		398,657			457,763			288,592			466,421
Deferred revenues—current portion		7,311			4,901
Total current liabilities		636,832			708,687			984,656			723,169
LONG-TERM LIABILITIES:
Exchangeable notes, net		341,682			332,199
Long-term debt, net of current		1,025,096			1,564,485
Exchangeable Senior Notes, net								—			351,533
Long-term debt, net								1,002,318			1,001,308
Deferred tax liabilities, net		109,443			107,768			99,164			94,247
Other long-term liabilities		74,078			38,717			90,201			80,328
Total long-term liabilities		1,550,299			2,043,169			1,191,683			1,527,416
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ EQUITY:
Ordinary shares, $0.0001 nominal value; 600,000,000 and 300,000,000 shares authorized at June 30, 2019 and December 31, 2018, respectively; 186,470,230 and 169,244,520 shares issued at June 30, 2019 and December 31, 2018, respectively, and 186,085,864 and 168,860,154 shares outstanding at June 30, 2019 and December 31, 2018, respectively		19			17
Treasury stock, 384,366 ordinary shares at June 30, 2019 and December 31, 2018		(4,585	)		(4,585	)
Ordinary shares, $0.0001 nominal value; 600,000,000 shares authorized at June 30, 2020 and December 31, 2019; 199,991,807 and 188,402,040 shares issued at June 30, 2020 and December 31, 2019, respectively, and 199,607,441 and 188,017,674 shares outstanding at June 30, 2020 and December 31, 2019, respectively								20			19
Treasury stock, 384,366 ordinary shares at June 30, 2020 and December 31, 2019								(4,585	)		(4,585	)
Additional paid-in capital		2,743,793			2,374,966			3,067,586			2,797,602
Accumulated other comprehensive loss		(1,666	)		(1,523	)		(1,886	)		(1,905	)
Accumulated deficit		(1,216,688	)		(1,178,769	)		(699,283	)		(605,682	)
Total shareholders’ equity		1,520,873			1,190,106			2,361,852			2,185,449
Total liabilities and shareholders' equity	$	3,708,004		$	3,941,962		$	4,538,191		$	4,436,034

The accompanying notes are an integral part of these condensed consolidated financial statements.

	For the Three Months Ended June 30,						For the Six Months Ended June 30,						For the Three Months Ended June 30,						For the Six Months Ended June 30,
	2019			2018			2019			2018			2020			2019			2020			2019
Net sales	$	320,647		$	302,835		$	601,018		$	526,716		$	462,779		$	320,647		$	818,688		$	601,018
Cost of goods sold		89,163			91,337			177,305			201,625			121,515			89,163			218,931			177,305
Gross profit		231,484			211,498			423,713			325,091			341,264			231,484			599,757			423,713
OPERATING EXPENSES:
Research and development		28,314			24,265			50,039			41,910			81,068			28,314			108,277			50,039
Selling, general and administrative		167,095			176,674			339,394			356,273			222,332			167,095			470,107			339,394
Loss on sale of assets		10,963			—			10,963			—			—			10,963			—			10,963
Impairment of long-lived assets		—			—			—			33,647
Total operating expenses		206,372			200,939			400,396			431,830			303,400			206,372			578,384			400,396
Operating income (loss)		25,112			10,559			23,317			(106,739	)
Operating income														37,864			25,112			21,373			23,317
OTHER EXPENSE, NET:
Interest expense, net		(22,033	)		(31,030	)		(49,563	)		(61,484	)		(18,571	)		(22,033	)		(35,915	)		(49,563	)
Loss on debt extinguishment		(11,878	)		—			(17,464	)		—			(17,254	)		(11,878	)		(17,254	)		(17,464	)
Foreign exchange gain (loss)		76			(5	)		15			(115	)
Other (expense) income, net		(1,272	)		346			(1,083	)		497
Foreign exchange gain														283			76			1,059			15
Other income (expense), net														632			(1,272	)		1,074			(1,083	)
Total other expense, net		(35,107	)		(30,689	)		(68,095	)		(61,102	)		(34,910	)		(35,107	)		(51,036	)		(68,095	)
Loss before (benefit) expense for income taxes		(9,995	)		(20,130	)		(44,778	)		(167,841	)
(Benefit) expense for income taxes		(4,875	)		4,621			(6,795	)		5,566
Income (loss) before expense (benefit) for income taxes														2,954			(9,995	)		(29,663	)		(44,778	)
Expense (benefit) for income taxes														82,964			(4,875	)		63,938			(6,795	)
Net loss	$	(5,120	)	$	(24,751	)	$	(37,983	)	$	(173,407	)	$	(80,010	)	$	(5,120	)	$	(93,601	)	$	(37,983	)
Net loss per ordinary share—basic and diluted	$	(0.03	)	$	(0.15	)	$	(0.21	)	$	(1.05	)	$	(0.42	)	$	(0.03	)	$	(0.49	)	$	(0.21	)
Weighted average ordinary shares outstanding—basic and diluted		185,327,383			165,536,826			178,866,391			164,921,722			192,705,535			185,327,383			191,426,864			178,866,391
OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX
Foreign currency translation adjustments	$	344		$	(897	)	$	(143	)	$	(434	)	$	344		$	344		$	19		$	(143	)
Pension remeasurements		—			289			—			289
Other comprehensive income (loss)		344			(608	)		(143	)		(145	)		344			344			19			(143	)
Comprehensive loss	$	(4,776	)	$	(25,359	)	$	(38,126	)	$	(173,552	)	$	(79,666	)	$	(4,776	)	$	(93,582	)	$	(38,126	)

The accompanying notes are an integral part of these condensed consolidated financial statements.

										Additional			Accumulated Other						Total												Additional			Accumulated Other						Total
	Ordinary Shares				Treasury Stock					Paid-in			Comprehensive			Accumulated			Shareholders’			Ordinary Shares				Treasury Stock					Paid-in			Comprehensive			Accumulated			Shareholders’
	Shares		Amount		Shares		Amount			Capital			Loss			Deficit			Equity			Shares		Amount		Shares		Amount			Capital			Loss			Deficit			Equity
Balances at December 31, 2018		169,244,520	$	17		384,366	$	(4,585	)	$	2,374,966		$	(1,523	)	$	(1,178,769	)	$	1,190,106
Cumulative effect adjustments from adoption of ASU 2016-02		—		—		—		—			—			—			64			64
Issuance of ordinary shares - public offering		14,081,632		1		—		—			326,848			—			—			326,849
Issuance of ordinary shares in conjunction with vesting of restricted stock units and stock option exercises		1,804,196		—		—		—			10,042			—			—			10,042
Balances at December 31, 2019																							188,402,040	$	19		384,366	$	(4,585	)	$	2,797,602		$	(1,905	)	$	(605,682	)	$	2,185,449
Issuance of ordinary shares in conjunction with the exercise of stock options and the vesting of restricted stock and performance stock units																							2,560,573		—		—		—			7,049			—			—			7,049
Ordinary shares withheld for payment of employees’ withholding tax liability		—		—		—		—			(17,171	)		—			—			(17,171	)		—		—		—		—			(46,664	)		—			—			(46,664	)
Share-based compensation		—		—		—		—			27,548			—			—			27,548			—		—		—		—			56,421			—			—			56,421
Currency translation adjustment		—		—		—		—			—			(487	)		—			(487	)		—		—		—		—			—			(325	)		—			(325	)
Net loss		—		—		—		—			—			—			(32,863	)		(32,863	)		—		—		—		—			—			—			(13,591	)		(13,591	)
Balances at March 31, 2019		185,130,348	$	18		384,366	$	(4,585	)	$	2,722,233		$	(2,010	)	$	(1,211,568	)	$	1,504,088
Issuance of ordinary shares - public offering		—		—		—		—			(55	)		—			—			(55	)
Issuance of ordinary shares in conjunction with vesting of restricted stock units and stock option exercises		781,026		1		—		—			1,986			—			—			1,987
Balances at March 31, 2020																							190,962,613	$	19		384,366	$	(4,585	)	$	2,814,408		$	(2,230	)	$	(619,273	)	$	2,188,339
Issuance of ordinary shares in conjunction with the exercise of stock options and the vesting of restricted stock and performance stock units																							1,427,108		—		—		—			18,838			—			—			18,838
Issuance of ordinary shares in conjunction with ESPP program																							376,718		—		—		—			7,979			—			—			7,979
Issuance of ordinary shares in conjunction with Exchangeable Senior Notes																							7,225,368		1		—		—			205,649			—			—			205,650
Ordinary shares withheld for payment of employees’ withholding tax liability		—		—		—		—			(7,203	)		—			—			(7,203	)		—		—		—		—			(6,345	)		—			—			(6,345	)
Issuance of ordinary shares in conjunction with ESPP program		558,856		—		—		—			5,465			—			—			5,465
Share-based compensation		—		—		—		—			21,367			—			—			21,367			—		—		—		—			27,057			—			—			27,057
Currency translation adjustment		—		—		—		—			—			344			—			344			—		—		—		—			—			344			—			344
Net loss		—		—		—		—			—			—			(5,120	)		(5,120	)		—		—		—		—			—			—			(80,010	)		(80,010	)
Balances at June 30, 2019		186,470,230	$	19		384,366	$	(4,585	)	$	2,743,793		$	(1,666	)	$	(1,216,688	)	$	1,520,873
										Additional			Accumulated Other						Total
	Ordinary Shares				Treasury Stock					Paid-in			Comprehensive			Accumulated			Shareholders’
	Shares		Amount		Shares		Amount			Capital			Loss			Deficit			Equity
Balances at December 31, 2017		164,785,083	$	16		384,366	$	(4,585	)	$	2,248,979		$	(983	)	$	(1,141,975	)	$	1,101,452
Cumulative effect adjustments from adoption of ASUs 2014-09 and 2016-16		—		—		—		—			—			—			1,586			1,586
Issuance of ordinary shares in conjunction with vesting of restricted stock units and stock option exercises		574,810		1		—		—			945			—			—			946
Ordinary shares withheld for payment of employees’ withholding tax liability		—		—		—		—			(3,517	)		—			—			(3,517	)
Issuance of ordinary shares in conjunction with ESPP program		—		—		—		—			14			—			—			14
Share-based compensation		—		—		—		—			27,833			—			—			27,833
Currency translation adjustment		—		—		—		—			—			463			—			463
Net loss		—		—		—		—			—			—			(148,656	)		(148,656	)
Balances at March 31, 2018		165,359,893	$	17		384,366	$	(4,585	)	$	2,274,254		$	(520	)	$	(1,289,045	)	$	980,121
Issuance of ordinary shares in conjunction with vesting of restricted stock units and stock option exercises		1,103,716		—		—		—			2,727			—			—			2,727
Ordinary shares withheld for payment of employees’ withholding tax liability		—		—		—		—			(5,668	)		—			—			(5,668	)
Issuance of ordinary shares in conjunction with ESPP program		511,261		—		—		—			4,720			—			—			4,720
Share-based compensation		—		—		—		—			30,721			—			—			30,721
Currency translation adjustment		—		—		—		—			—			(897	)		—			(897	)
Pension remeasurement		—		—		—		—			—			289			—			289
Net loss		—		—		—		—			—			—			(24,751	)		(24,751	)
Balances at June 30, 2018		166,974,870	$	17		384,366	$	(4,585	)	$	2,306,754		$	(1,128	)	$	(1,313,796	)	$	987,262
Balances at June 30, 2020																							199,991,807	$	20		384,366	$	(4,585	)	$	3,067,586		$	(1,886	)	$	(699,283	)	$	2,361,852

										Additional			Accumulated Other						Total
	Ordinary Shares				Treasury Stock					Paid-in			Comprehensive			Accumulated			Shareholders’
	Shares		Amount		Shares		Amount			Capital			Loss			Deficit			Equity
Balances at December 31, 2018		169,244,520	$	17		384,366	$	(4,585	)	$	2,374,966		$	(1,523	)	$	(1,178,769	)	$	1,190,106
Cumulative effect adjustments from adoption of ASU 2016-02		—		—		—		—			—			—			64			64
Issuance of ordinary shares - public offering		14,081,632		1		—		—			326,848			—			—			326,849
Issuance of ordinary shares in conjunction with vesting of restricted stock units and stock option exercises		1,804,196		—		—		—			10,042			—			—			10,042
Ordinary shares withheld for payment of employees’ withholding tax liability		—		—		—		—			(17,171	)		—			—			(17,171	)
Share-based compensation		—		—		—		—			27,548			—			—			27,548
Currency translation adjustment		—		—		—		—			—			(487	)		—			(487	)
Net loss		—		—		—		—			—			—			(32,863	)		(32,863	)
Balances at March 31, 2019		185,130,348	$	18		384,366	$	(4,585	)	$	2,722,233		$	(2,010	)	$	(1,211,568	)	$	1,504,088
Issuance of ordinary shares - public offering		—		—		—		—			(55	)		—			—			(55	)
Issuance of ordinary shares in conjunction with vesting of restricted stock units and stock option exercises		781,026		1		—		—			1,986			—			—			1,987
Ordinary shares withheld for payment of employees’ withholding tax liability		—		—		—		—			(7,203	)		—			—			(7,203	)
Issuance of ordinary shares in conjunction with ESPP program		558,856		—		—		—			5,465			—			—			5,465
Share-based compensation		—		—		—		—			21,367			—			—			21,367
Currency translation adjustment		—		—		—		—			—			344			—			344
Net loss		—		—		—		—			—			—			(5,120	)		(5,120	)
Balances at June 30, 2019		186,470,230	$	19		384,366	$	(4,585	)	$	2,743,793		$	(1,666	)	$	(1,216,688	)	$	1,520,873

The accompanying notes are an integral part of these condensed consolidated financial statements.

	For the Six Months Ended June 30,						For the Six Months Ended June 30,
	2019			2018			2020			2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(37,983	)	$	(173,407	)	$	(93,601	)	$	(37,983	)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization expense		118,017			124,467			139,396			118,017
Equity-settled share-based compensation		48,915			58,554			83,478			48,915
Impairment of long-lived assets		—			33,647
Acquired in-process research and development expense								47,517			—
Loss on debt extinguishment		17,464			—			17,254			17,464
Amortization of debt discount and deferred financing costs		11,622			11,185			10,817			11,622
Loss on sale of assets		10,963			—			—			10,963
Deferred income taxes		(1,257	)		(1,753	)		(4,561	)		(1,257	)
Foreign exchange and other adjustments		493			459			661			493
Changes in operating assets and liabilities:
Accounts receivable		69,787			1,742			(135,125	)		69,787
Inventories		(504	)		11,549			(12,343	)		(504	)
Prepaid expenses and other current assets		(17,696	)		(21,738	)		(20,410	)		(17,696	)
Accounts payable		11,554			(3,592	)		83,555			11,554
Accrued trade discounts and rebates		(59,151	)		(52,138	)		(177,721	)		(59,151	)
Accrued expenses		(28,071	)		13,654			81,505			(28,071	)
Deferred revenues		2,410			333			—			2,410
Other non-current assets and liabilities		873			(1,988	)		16,586			873
Net cash provided by operating activities		147,436			974			37,008			147,436
CASH FLOWS FROM INVESTING ACTIVITIES:
Payment related to license agreement		—			(12,000	)
Payments for acquisitions								(262,305	)		—
Purchases of property and equipment								(119,970	)		(6,858	)
Change in escrow deposit for property purchase								6,000			—
Proceeds from sale of assets		6,000			—			—			6,000
Purchases of property and equipment		(6,858	)		(762	)
Net cash used in investing activities		(858	)		(12,762	)		(376,275	)		(858	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from the issuance of ordinary shares		326,793			—			—			326,793
Repayment of term loans		(818,026	)		(27,722	)		—			(818,026	)
Repayment of senior notes		(258,282	)		—			—			(258,282	)
Net proceeds from term loans		517,378			—			—			517,378
Proceeds from the issuance of ordinary shares in conjunction with ESPP program		5,465			4,734			7,979			5,465
Proceeds from the issuance of ordinary shares in connection with stock option exercises		12,029			3,672			25,887			12,029
Payment of employee withholding taxes relating to share-based awards		(24,374	)		(9,185	)		(53,009	)		(24,374	)
Net cash used in financing activities		(239,017	)		(28,501	)		(19,143	)		(239,017	)
Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash		58			(1,003	)		58			58
Net decrease in cash, cash equivalents and restricted cash		(92,381	)		(41,292	)		(358,352	)		(92,381	)
Cash, cash equivalents and restricted cash, beginning of the period		962,117			757,897			1,080,039			962,117
Cash, cash equivalents and restricted cash, end of the period	$	869,736		$	716,605		$	721,687		$	869,736

SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	$	49,516	$	55,516	$	30,068	$	49,516
Net cash paid for income taxes		7,644		27,322
Cash paid for amounts included in the measurement of lease liabilities		2,906		—		3,797		2,906
Cash paid for income taxes, net of refunds received						597		7,644
SUPPLEMENTAL NON-CASH FLOW INFORMATION:
Principal amount of Exchangeable Senior Notes exchanged for ordinary shares					$	207,044	$	—
Milestone payments for TEPEZZA intangible asset included in accrued expenses						98,606		—
Purchases of property and equipment included in accounts payable and accrued expenses		1,941		107		2,912		1,941

The accompanying notes are an integral part of these condensed consolidated financial statements.

The unaudited condensed consolidated financial statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments, including normal recurring adjustments, considered necessary for a fair statement of the financial statements have been included. Operating results for the three and six months ended June 30, ~~2019~~2020 are not necessarily indicative of the results that may be expected for the year ending December 31, ~~2019.~~2020. The December 31, ~~2018~~2019 condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP.

Unless otherwise indicated or the context otherwise requires, references to “Horizon”, the “Company”, “we”, “us” and “our” refer to Horizon Therapeutics plc ~~(formerly known as Horizon Pharma plc)~~ and its consolidated subsidiaries.

During the six months ended June 30, 2020, the Company recorded out of period adjustments that decreased income tax benefit by $3.2 million and increased share-based compensation expense by $1.9 million to correct for expenses that should have been recorded in the year ended December 31, 2019. The ~~unaudited condensed consolidated~~Company evaluated the materiality of the adjustments to prior-period financial statements ~~presented herein include~~and the ~~accounts~~current period, and concluded the effect of the ~~Company~~adjustments were immaterial to both the current and ~~its wholly owned subsidiaries. All intra-company transactions and balances have been eliminated.~~

On May 2, 2019, the shareholders of the Company approved changing the name of the Company from “Horizon Pharma Public Limited Company” to “Horizon Therapeutics Public Limited Company” to better reflect the Company’s long-term strategy to develop and commercialize innovative new medicines to address rare diseases with very few effective options.prior-period financial statements.

Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. The Company’s pipeline is purposeful: it applies scientific expertise and courage to bring clinically meaningful therapies to patients. Horizon believes science and compassion must work together to transform lives. The Company has ~~two~~2 reportable segments, the orphan segment and the inflammation segment, and its portfolio is currently composed of eleven medicines in the areas of rare diseases, gout, ophthalmology and inflammation.

Effective in the first quarter of 2020, the Company (i) reorganized its commercial operations and moved responsibility for and reporting of RAYOS® to the inflammation segment and (ii) renamed the orphan and rheumatology segment ~~and~~ the ~~inflammation segment (previously named~~orphan segment. Net sales generated by TEPEZZA®, which was approved on January 21, 2020, are reported as part of the ~~primary care segment), and currently markets ten medicines in~~renamed orphan segment.

As of June 30, 2020, the ~~areas~~Company’s medicine portfolio consisted of ~~orphan diseases, rheumatology and inflammation.~~

When accounting for business combinations under ASC Topic 805, Business Combinations, the Company previously separately identified and recorded at fair value intangible assets acquired and their related third-party contingent royalties at the date of acquisition. Third-party contingent royalties are royalties payable to parties other than sellers of the businesses. Effective January 1, 2019, the Company retrospectively changed its accounting for business combinations and now records acquired intangible assets and their related third-party contingent royalties on a net basis (“New Method”). The Company changed its accounting principle on the basis that the use of the New Method is preferable primarily due to improved comparability with the Company’s peers. The Company has adjusted the accompanying condensed consolidated balance sheet as at December 31, 2018, condensed consolidated statement of comprehensive loss for the three and six months ended June 30, 2018 and the condensed consolidated statements of cash flows for the six months ended June 30, 2018 to reflect this change in accounting. Total shareholders’ equity at December 31, 2018 was adjusted by $135.9 million to reflect the cumulative impact of the change to the earliest year presented. The impact on the condensed consolidated statement of cash flows consisted of adjustments to reconcile net loss to net cash provided by operating activities and changes in operating assets and liabilities for all periods presented. There was no impact on total operating, investing or financing cash flows for any prior period. ~~The following are selected line items from the Company’s condensed consolidated financial statements illustrating the effect of the change in accounting method (in thousands, except per share data):~~

From time to time, the Company adopts new accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”) or other standard-setting bodies.

~~Effective~~In June 2016, the FASB issued Accounting Standards Update No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which modifies the measurement of expected credit losses on certain financial instruments and became effective for the Company as of January 1, ~~2019, the Company adopted Accounting Standards Updated (“ASU”) No. 2016-02,~~ ~~Leases (Topic 842)~~ (“ASU No. 2016-02”). Under ASU No. 2016-02, an entity is required to recognize right-of-use lease assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements. The Company adopted this standard on January 1, 2019, using a modified retrospective approach at the adoption date through a cumulative-effect adjustment to retained earnings. The Company elected the package of transition provisions available for expired or existing contracts, which allowed the Company to carry forward its historical assessments of (i) whether contracts are or contain leases, (ii) lease classification and (iii) initial direct costs. In addition, the Company elected the hindsight practical expedient to determine the lease term for existing leases. The Company applied the new guidance to all operating leases within the scope of the standard that were in effect on January 1, 2019, or entered into after, the adoption date. Comparative information for prior periods has not been restated and continues to be reported under the accounting standards in effect for those periods.2020. The adoption of ASU 2016-13 did not have a material impact on the Company’s condensed consolidated statement of comprehensive loss. However, the new standard established $37.1 million of liabilities and corresponding right-of-use assets of $34.9 million on the Company’s condensed consolidated balance sheet for leases, primarily related to ~~operating leases on rented office properties, that existed as of the January 1, 2019, adoption date.~~

~~Effective January 1, 2019, the Company adopted ASU No. 2018-07,~~ ~~Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting~~ (“ASU No. 2018-07”). ASU No. 2018-07 largely aligns the accounting for share-based payment awards issued to employees and non-employees. The Company adopted ASU No. 2018-07 in the first quarter of 2019, and the adoption of ASU No. 2018-07 did not have a material impact on the Company’s condensed consolidated financial statements and related disclosures.

~~Effective~~In December 2019, the FASB issued Accounting Standards Update No. 2019-12, Income Taxes (Topic 740): Simplification and reduce the cost of accounting for income taxes (“ASU 2019-12”), which is effective for the Company as of January 1, ~~2019, the Company adopted ASU No. 2018-08,~~ ~~Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made~~ ~~(“ASU No. 2018-08”). The new guidance applies to all entities that receive or make contributions, including business entities.~~2021. The Company ~~adopted~~is currently evaluating the ~~standard in the first quarter of 2019, using prospective application to any new agreements entered into after the effective date. The adoption~~impact of ASU ~~No. 2018-08 did not have a material impact on the Company’s condensed consolidated financial statements and related disclosures.~~

Other recent authoritative guidance issued by the FASB (including technical corrections to the Accounting Standards Codification (“ASC”)), the American Institute of Certified Public Accountants and the Securities and Exchange Commission (“SEC”) did not, or are not expected to, have a material impact on the Company’s condensed consolidated financial statements and related disclosures.

AsThe Company's significant accounting policies have not changed from those previously described in ~~Note 1, effective January 1,~~the Company's Annual Report on Form 10-K for the year ended December 31, 2019, with the ~~Company modified its~~exception of the change to the accounting policy related to ~~intangible~~property and equipment due to the purchase of land and buildings as described below.

Land is stated at cost. Property and equipment, other than land, are stated at cost less accumulated depreciation. Depreciation is recognized using the straight-line method over the estimated useful lives of the related assets for financial reporting purposes and ~~contingent royalty liabilities acquired through business combinations following a change in accounting principle,~~an accelerated method for income tax reporting purposes. Upon retirement or sale of an asset, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the ~~Company’s updated policy~~resulting gain or loss is reflected in ~~respect~~operations. Repair and maintenance costs are charged to expenses as incurred and improvements are capitalized.

Leasehold improvements are amortized on a straight-line basis over the term of ~~all royalties~~the applicable lease, or the useful life of the assets, whichever is ~~described below.~~shorter.

In addition, as described above, the Company adopted ASU No. 2016-02 effective January 1, 2019. The Company modified its accounting policy related to leases following the adoption of ASU No. 2016-02,Depreciation and amortization periods for the Company’s ~~updated policy is described below.~~property and equipment are as follows:

The Company ~~records royalty expense based on each periods’ net sales as part of cost of goods sold.~~

The Company’s leases primarily relate to operating leases of rented office properties. For contracts entered into on or after January 1, 2019, at the inception of a contract the Company assesses whether the contract is, or contains, a lease.~~The Company’s assessment is based on: (1) whether the contract involves the~~capitalizes software development costs associated with internal use of a distinct identified asset, (2) whether the Company obtains the right to substantially all the economic benefit from the use of the asset throughout the period, and (3) whether the Company has the right to direct the use of the asset. At inception of a lease, the Company allocates the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments.

For leases with terms greater than 12 months, the Company records the related asset and obligation at the present value of lease payments over the term. The right-of-use lease asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease.

~~The right-of-use lease asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial~~software, including external direct costs ~~incurred. All right-of-use lease assets~~of materials and services and payroll costs for employees devoting time to a software project. Costs incurred during the preliminary project stage, as well as costs for maintenance and training, are reviewed for impairment. The lease liability is initially measured at the present value of the lease payments, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined,expensed as incurred.

Software includes internal-use software acquired and modified to meet the Company’s ~~secured incremental borrowing rate~~internal requirements. Amortization commences when the software is ready for ~~the same term as the underlying lease.~~its intended use.

~~The Company identified and assessed the following significant assumptions in recognizing the right-of-use lease assets and corresponding liabilities.~~

~~Expected lease term~~ – The expected lease term includes both contractual lease periods and, when applicable, cancelable option periods. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option.

~~Incremental borrowing rate~~ – As the Company’s leases do not provide an implicit rate, the Company obtained the incremental borrowing rate (“IBR”) based on the remaining term of each lease. The IBR is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.

~~The Company has elected not to recognize right-of-use lease assets and lease liabilities for short-term leases that have a term of 12 months or less.~~

The Company reports right-of-use lease assets within non-current “Other assets” in its condensed consolidated balance sheet. The Company reports the current portion of lease liabilities within “Accrued expenses” and long-term lease liabilities within “Other long-term liabilities” in its condensed consolidated balance sheet.

The following table presents basic and diluted net loss per share for the three and six months ended June 30, ~~2019~~2020 and ~~2018~~2019 (in thousands, except share and per share data):

	For the Three Months Ended June 30,						For the Six Months Ended June 30,						For the Three Months Ended June 30,						For the Six Months Ended June 30,
	2019			2018			2019			2018			2020			2019			2020			2019
Basic and diluted net loss per share calculation:
Net loss	$	(5,120	)	$	(24,751	)	$	(37,983	)	$	(173,407	)
Weighted average ordinary shares outstanding		185,327,383			165,536,826			178,866,391			164,921,722
Numerator - net loss													$	(80,010	)	$	(5,120	)	$	(93,601	)	$	(37,983	)
Denominator - weighted average ordinary shares outstanding														192,705,535			185,327,383			191,426,864			178,866,391
Basic and diluted net loss per share	$	(0.03	)	$	(0.15	)	$	(0.21	)	$	(1.05	)	$	(0.42	)	$	(0.03	)	$	(0.49	)	$	(0.21	)

Basic net loss per share is computed by dividing net loss by the weighted-average number of ordinary shares outstanding during the period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue ordinary shares were exercised, converted into ordinary shares or resulted in the issuance of ordinary shares that would have shared in the Company’s earnings.

The computation of diluted net loss per share excluded 9.7 million and 12.0 million shares subject to equity awards for the three and six months ended June 30, 2020, respectively, and 12.4 million and 13.1 million shares (based on the if-converted method) related to the Company’s 2.5% Exchangeable Senior Notes due 2022 (the “Exchangeable Senior Notes”) for the three and six months ended June 30, 2020, respectively, because their inclusion would have had an anti-dilutive effect on diluted net loss per share.

The computation of diluted net loss per share excluded 8.8 million shares subject to equity awards for each of the three and six months ended June 30, 2019, ~~and 11.0 million and 11.6 million shares subject to equity awards for the three and six months ended June 30, 2018, respectively,~~ because their inclusion would have had an anti-dilutive effect on diluted net loss per share.

~~The~~ During the three and six months ended June 30, 2019, the potentially dilutive impact of the ~~March 2015 private placement of $400.0 million aggregate principal amount of 2.50%~~ Exchangeable Senior Notes ~~due 2022 (the “Exchangeable Senior Notes”) by Horizon Pharma Investment Limited (“Horizon Investment”), a wholly owned subsidiary of the Company, is~~was determined using a method similar to the treasury stock method. Under this method, no numerator or denominator adjustments ~~arise~~arose from the principal and interest components of the Exchangeable Senior Notes because the Company ~~has~~had the intent, at that time, and ability to settle the Exchangeable Senior Notes’ principal and interest in cash. Instead, the Company iswas required to increase the diluted net ~~income (loss)~~loss per share denominator by the variable number of shares that would be issued upon conversion if it settled the conversion spread obligation with shares. For diluted net ~~income (loss)~~loss per share purposes, the conversion spread obligation iswas calculated based on whether the average market price of the Company’s ordinary shares over the reporting period iswas in excess of the exchange price of the Exchangeable Senior Notes. There was no calculated spread added to the denominator for the three and six months ended June 30, 2019. Beginning in the fourth quarter of 2019, with the ordinary share price significantly above the $28.66 exchange price, the Company decided that it no longer had the intent to settle the notes for cash and, ~~2018.~~

as a result, began to prospectively apply the if-converted method to the Exchangeable Senior Notes when determining the diluted net loss per share. By August 3, 2020, the Exchangeable Senior Notes were fully extinguished through exchanges for ordinary shares or cash redemption. Refer to Note 13 for further detail.

On April 1, 2020, the Company acquired Curzion Pharmaceuticals, Inc. (“Curzion”), a privately held development-stage biopharma company, and its development-stage oral selective lysophosphatidic acid 1 receptor (LPAR1) antagonist, CZN001 (renamed HZN-825).

Under terms of the agreement, the Company acquired Curzion for a $45.0 million upfront cash payment with additional payments contingent on the achievement of development and regulatory milestones. Pursuant to ASC 805 (as amended by ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business (“ASU No. 2017-01”)), the Company accounted for the Curzion acquisition as the purchase of an in-process research and development asset and, pursuant to ASC Topic 730, Research and Development (“ASC 730”), recorded the purchase price as research and development expense during the three and six months ended June 30, 2020. HZN-825 was originally discovered and developed by Sanofi-Aventis U.S. LLC (“Sanofi-Aventis U.S.”), which is eligible to receive contingent payments upon the achievement of development and commercialization milestones and royalties based on revenue thresholds. A member of the Company’s board of directors was also a member of the board of directors of, and held a beneficial interest in, Curzion. This related party transaction was conducted in the normal course of business on an arm’s length basis.

On June 28, 2019, the Company sold its rights to MIGERGOT to Cosette Pharmaceuticals, Inc., for $6.0 million and total potential contingent consideration payments of $4.0 million (the “MIGERGOT transaction”).

Pursuant to ~~ASC 805 (as amended by~~ ASU No. 2017-01, ~~Business~~ ~~Combinations~~ ~~(Topic 805): Clarifying the Definition of a Business~~ ~~(“ASU No. 2017-01”)~~), the Company accounted for the MIGERGOT transaction as a sale of assets, specifically a sale of intellectual property rights, and a sale of inventory.

The loss on sale of assets recorded to the ~~condensed~~ consolidated statement of comprehensive ~~loss~~income (loss) during the ~~three and six months~~year ended ~~June 30,~~December 31, 2019, was determined as follows (in thousands):

Acquisition of ~~RAVICTI and AMMONAPS Rights outside of North America and Japan~~River Vision

On ~~December 28, 2018,~~May 8, 2017, the Company ~~sold its rights to RAVICTI and AMMONAPS (known as BUPHENYL in the United States) outside of North America and Japan to Medical Need Europe AB, part~~acquired 100% of the ~~Immedica Group,~~equity interests in River Vision Development Corp. (“River Vision”) for ~~$35.0~~upfront cash payments totaling approximately $150.3 million, ~~(the “Immedica transaction”). The Company previously distributed RAVICTI~~including cash acquired of $6.3 million, with additional potential future milestone and ~~AMMONAPS through a commercial partner in Europe~~royalty payments contingent on the satisfaction of certain regulatory milestones and ~~other non-U.S. markets. The Company has retained the rights to RAVICTI and BUPHENYL in North America and Japan.~~

sales thresholds. Pursuant to ~~ASC 805 (as amended by~~ ASU No. ~~2017-01),~~2017-01, the Company accounted for the ~~Immedica transaction~~River Vision acquisition as ~~a sale~~the purchase of ~~assets, specifically a sale of intellectual property rights.~~

~~The gain on sale of assets~~ an in-process research and development asset (teprotumumab, now known as TEPEZZA) and, pursuant to ASC 730recorded to the ~~consolidated statement of comprehensive loss~~purchase price as research and development expense during the year ended December 31, ~~2018, was determined as follows (in thousands):~~

~~On June 30, 2017,~~2017. Further, the Company ~~completed its acquisition~~recognized approximately $32.4 million of ~~certain rights to interferon gamma-1b from Boehringer Ingelheim International GmbH (“Boehringer Ingelheim International”) in all territories outside~~federal net operating losses, $2.2 million of state net operating losses and $9.5 million of federal tax credits. The acquired tax attributes were set up as deferred tax assets which were further netted within the net deferred tax liabilities of the ~~United States, Canada~~U.S. group, offset by a deferred credit recorded in long-term liabilities.

Under the acquisition agreement for River Vision, the Company agreed to pay up to $325.0 million upon the attainment of various milestones, composed of $100.0 million related to U.S. Food and ~~Japan~~Drug Administration (“FDA”) approval and ~~in connection therewith, paid Boehringer Ingelheim International €19.5~~$225.0 million related to net sales thresholds for TEPEZZA. The agreement also includes a royalty payment of 3 percent of the portion of annual worldwide net sales exceeding $300.0 million (if any). The Company made the milestone payment of $100.0 million related to FDA approval during the first quarter of 2020 which is now capitalized as a finite-lived intangible asset representing the developed technology for TEPEZZA.

Additionally, under the Company’s license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (together referred to as “Roche”), the Company made a milestone payment of CHF5.0 million ($~~22.3~~5.2 million when converted using a ~~Euro-to-Dollar~~CHF-to-Dollar exchange rate at the date of payment of ~~1.1406). Boehringer Ingelheim International commercialized interferon gamma-1b as IMUKIN in an estimated thirty countries, primarily in Europe and the Middle East. Upon closing,~~1.0382), during the ~~year ended December 31, 2017,~~first quarter of 2020 which the Company ~~accounted~~also capitalized as a finite-lived intangible asset representing the developed technology for TEPEZZA.

In April 2020, a subsidiary of the Company entered into an agreement with S.R. One, Limited (“S.R. One”) and an agreement with Lundbeckfond Invest A/S (“Lundbeckfond”) pursuant to which the Company acquired all of S.R. One’s and Lundbeckfond’s beneficial rights to proceeds from certain contingent future TEPEZZA milestone and royalty payments in exchange for a one-time payment of $55.0 million to each of the respective parties. The total payments of $110.0 million were capitalized as a finite-lived intangible asset representing the developed technology for TEPEZZA during the second quarter of 2020.

During the second quarter of 2020, the Company recorded an additional $98.7 million as a finite-lived intangible asset representing the developed technology for TEPEZZA, composed of $67.0 million in relation to the expected future attainment of various net sales milestones payable under the acquisition ~~of an asset which was immediately impaired as projections~~agreement for ~~future net sales of IMUKIN in these territories did not exceed the related costs,~~River Vision and ~~included the payment in the “impairment of long-lived assets” line item in its condensed consolidated statement of comprehensive loss.~~

On July 24, 2018, the Company sold its rights to interferon gamma-1b in all territories outside the United States, Canada and Japan to Clinigen Group plc (“Clinigen”) for an upfront payment of €7.5CHF30.0 million ($~~8.8~~31.7 million when converted using a ~~Euro-to-Dollar~~CHF-to-Dollar exchange rate ~~at date~~as of ~~payment~~June 30, 2020 of 1.1683) and a potential additional contingent consideration payment of €3.0 million ($3.5 million when converted using a Euro-to-Dollar exchange rate of 1.1673) (the “IMUKIN sale”). The Company continues to market interferon gamma-1b as ACTIMMUNE1.0556) in ~~the United States.~~

~~Pursuant to ASC 805 (as amended by ASU No. 2017-01), the Company accounted for the IMUKIN sale as a sale of assets, specifically a sale of intellectual property rights, and a sale of inventory.~~

~~The gain on sale of assets recorded~~relation to the expected future attainment of various net sales milestones payable to Roche. The liabilities relating to these net sales milestones have been recorded in accrued expenses on the condensed consolidated ~~statement~~balance sheet as of ~~comprehensive loss during~~June 30, 2020 and the ~~year ended December 31, 2018, was determined as follows (in thousands):~~timing of the payments is dependent on when the applicable milestone thresholds are attained.

On January 3, 2019, the Company entered into a collaboration agreement with HemoShear Therapeutics, LLC (“HemoShear”), a biotechnology company, to discover novel therapeutic targets for gout. The collaboration provides the Company with an opportunity to address unmet treatment needs for people with gout by evaluating new targets for the control of serum uric acid ~~levels as well as new targets to address the inflammation associated with acute flares of gout.~~levels. Under the terms of the agreement, the Company paid HemoShear an upfront cash payment of $2.0 million with additional potential future milestone payments upon commencement of new stages of development, contingent on the Company’s approval at each stage. In June 2019, ~~the Company incurred~~ a $4.0 million progress payment became due, which ~~was~~the Company subsequently paid in July 2019. In June 2020, a $3.0 million progress payment became due, which the Company subsequently paid in July 2020.

Inventories are stated at the lower of cost or net realizable value. Inventories consist of raw materials, work-in-process and finished goods. The Company has entered into manufacturing and supply agreements for the manufacture of drug substance and finished goods inventories, and the purchase of raw materials and production supplies. The Company’s inventories include the direct purchase cost of materials and supplies and manufacturing overhead costs.

The components of inventories as of June 30, ~~2019~~2020 and December 31, ~~2018~~2019 consisted of the following (in thousands):

	June 30, 2019		December 31, 2018		June 30, 2020		December 31, 2019
Raw materials	$	6,340	$	5,092	$	14,422	$	6,750
Work-in-process		28,224		27,068		22,969		22,465
Finished goods		16,455		18,591		28,708		24,587
Inventories, net	$	51,019	$	50,751	$	66,099	$	53,802

Prepaid expenses and other current assets as of June 30, ~~2019~~2020 and December 31, ~~2018~~2019 consisted of the following (in thousands):

	June 30, 2019		December 31, 2018		June 30, 2020		December 31, 2019
Deferred charge for taxes on intra-company profit	$	21,178	$	21,734	$	53,673	$	46,388
Prepaid income taxes		15,690		5,899
Advance payments for inventory						48,514		31,203
Rabbi trust assets		11,582		8,203		15,142		12,704
Advance payments for inventory		9,432		1,449
Medicine samples inventory		3,122		4,539
Prepaid income taxes and income tax receivable						7,832		12,583
Other prepaid expenses and other current assets		24,724		26,394		32,387		40,699
Prepaid expenses and other current assets	$	85,728	$	68,218	$	157,548	$	143,577

Advance payments for inventory as of June 30, 2020 and December 31, 2019, ~~includes $9.0 million related to~~primarily represented payments made to the manufacturer of ~~teprotumumab~~TEPEZZA drug substance.

Property and equipment as of June 30, ~~2019~~2020 and December 31, ~~2018~~2019 consisted of the following (in thousands):

	June 30, 2019			December 31, 2018			June 30, 2020			December 31, 2019
Buildings							$	80,341		$	—
Land								38,076			—
Leasehold improvements								26,472			25,985
Software	$	14,843		$	14,843			15,106			14,890
Leasehold improvements		10,560			9,982
Machinery and equipment		4,800			4,800			4,171			5,217
Construction in process								3,750			265
Computer equipment		2,561			2,485			3,513			3,316
Other		2,736			2,501			6,262			6,334
		35,500			34,611			177,691			56,007
Less accumulated depreciation		(22,069	)		(19,197	)		(38,890	)		(25,848	)
Construction in process		11,377			4,687
Property and equipment, net	$	24,808		$	20,101		$	138,801		$	30,159

Depreciation expense was ~~$1.4~~$6.9 million and ~~$1.6~~$1.4 million for the three months ended June 30, ~~2019~~2020 and ~~2018,~~2019, respectively, and was ~~$2.9~~$14.1 million and ~~$3.1~~$2.9 million for the six months ended June 30, 2020 and 2019, respectively. The increase in depreciation expense in both periods primarily relates to the reduction in the useful lives of leasehold improvements relating to the Company’s Lake Forest office.

In February 2020, the Company purchased a 3-building campus in Deerfield, Illinois for total consideration and ~~2018, respectively.~~ directly attributable transaction costs of $118.5 million. The Deerfield campus totals 70 acres and consists of approximately 650,000 square feet of office space.

Effective January 1, 2019, the Company retrospectively changed its accounting for business combinations, which impacted the carrying amounts of its goodwill and intangible assets. Refer to Note 1 for further detail.

The gross carrying amount of goodwill as of June 30, ~~2019~~2020 and December 31, ~~2018~~2019 was $413.7 million.

Effective in the first quarter of 2020, the Company (i) reorganized its commercial operations and moved responsibility for and reporting of RAYOS to the inflammation segment and (ii) renamed the orphan and rheumatology segment the orphan segment. This resulted in a $3.2 million increase in the Company’s allocation of goodwill to its inflammation segment and a corresponding decrease in the goodwill allocated to the orphan segment in the first quarter of 2020. The Company allocated goodwill to its new reporting units using a relative fair value approach. In addition, the Company completed an assessment of any potential goodwill impairment for all reporting units immediately prior to the allocation and determined that no impairment existed.

The table below presents goodwill for the Company’s reportable segments as of June 30, ~~2019~~2020 (in thousands):

As of June 30, ~~2019,~~2020, there were no0 accumulated goodwill impairment losses.

As of June 30, ~~2019,~~2020, the Company’s finite-lived intangible assets consisted of developed technology related to ACTIMMUNE, BUPHENYL, KRYSTEXXA, PENNSAID 2%, PROCYSBI, RAVICTI, RAYOS and ~~RAYOS,~~TEPEZZA as well as customer relationships for ACTIMMUNE. The intangible asset related to VIMOVO developed technology was fully amortized as of December 31, 2019.

~~During~~In connection with the ~~three and~~acquisition of River Vision, the Company capitalized payments of $313.9 million related to TEPEZZA developed technology during the six months ended June 30, 2020. See Note 4 for further details on the River Vision acquisition.

During the year ended December 31, 2019, in connection with the MIGERGOT transaction, the Company ~~recorded a write~~wrote off of the remaining net book value of developed technology related to MIGERGOT of $17.0 million. See Note 4 for further details.

During the year ended December 31, 2018, in connection with the Immedica transaction, the Company recorded a reduction in the net book value of developed technology related to RAVICTI and AMMONAPS of $4.1 million. See Note 4 for further details.

The Company tests its intangible assets for impairment when events or circumstances may indicate that the carrying value of these assets exceeds their fair value. During the six months ended June 30, 2018, the Company recorded an impairment of $33.6 million to fully write off the book value of developed technology related to PROCYSBI in Canada and Latin America due primarily to lower anticipated future net sales based on a Patented Medicine Prices Review Board review. The fair value of developed technology was determined using an income approach.

The Company also recorded an impairment of $10.6 million during the three months ended December 31, 2018 to fully write off the book value of developed technology related to LODOTRA as result of amendments to its license and supply agreements with Jagotec AG (“Jagotec”) and Skyepharma AG, which are affiliates of Vectura Group plc (“Vectura”). Under these amendments, effective January 1, 2019, the Company agreed to transfer all economic benefits of LODOTRA in Europe to Vectura during an initial transition period, with full rights transferring to Vectura when certain transfer activities have been completed. The Company no longer recorded LODOTRA revenue from January 1, 2019. The fair value of developed technology was determined using an income approach.

Intangible assets as of June 30, ~~2019~~2020 and December 31, ~~2018~~2019 consisted of the following (in thousands):

	June 30, 2019							December 31, 2018										June 30, 2020							December 31, 2019
	Cost Basis		Accumulated Amortization			Net Book Value		Cost Basis		Impairment			Accumulated Amortization			Net Book Value		Cost Basis		Accumulated Amortization			Net Book Value		Cost Basis		Accumulated Amortization			Net Book Value
Developed technology	$	2,758,403	$	(944,453	)	$	1,813,950	$	2,828,648	$	(44,245	)	$	(838,764	)	$	1,945,639	$	3,072,199	$	(1,184,517	)	$	1,887,682	$	2,758,403	$	(1,059,595	)	$	1,698,808
Customer relationships		8,100		(3,871	)		4,229		8,100		—			(3,470	)		4,630		8,100		(4,682	)		3,418		8,100		(4,280	)		3,820
Total intangible assets	$	2,766,503	$	(948,324	)	$	1,818,179	$	2,836,748	$	(44,245	)	$	(842,234	)	$	1,950,269	$	3,080,299	$	(1,189,199	)	$	1,891,100	$	2,766,503	$	(1,063,875	)	$	1,702,628

Amortization expense for the three months ended June 30, 2020 and 2019 ~~and 2018~~ was ~~$57.7~~$66.7 million and ~~$60.5~~$57.7 million, respectively, and was ~~$115.1~~$125.3 million and ~~$121.4~~$115.1 million for the six months ended June 30, ~~2019~~2020 and ~~2018,~~2019, respectively. As of June 30, ~~2019,~~2020, estimated future amortization expense was as follows (in thousands):

2019 (July to December)	$	115,319
2020		228,766
2020 (July to December)			$	127,901
2021		221,262		247,400
2022		220,090		246,227
2023		219,470		245,610
2024				244,178
Thereafter		813,272		779,784
Total	$	1,818,179	$	1,891,100

Accrued expenses as of June 30, ~~2019~~2020 and December 31, ~~2018~~2019 consisted of the following (in thousands):

	June 30, 2019		December 31, 2018		June 30, 2020		December 31, 2019
Accrued milestone payments					$	98,606	$	—
Payroll-related expenses	$	56,461	$	78,555		85,982		84,516
Income taxes payable						66,418		2,541
Consulting and professional services						39,513		32,423
Allowances for returns		36,248		39,041		39,155		45,082
Consulting and professional services		32,348		35,799
Accrued royalties		16,930		15,746		32,634		19,985
Accrued interest		12,148		13,196		15,821		18,709
Pricing review liability		10,108		9,091		13,375		9,831
Accrued other		23,949		24,311		24,041		22,147
Accrued expenses	$	188,192	$	215,739	$	415,545	$	235,234

As of June 30, 2020, accrued milestone payments represented the expected future attainment of various TEPEZZA net sales milestones payable under the acquisition agreement for River Vision and license agreement with Roche. Refer to Note 4 for further detail.

Income taxes payable as of June 30, 2020, includes an expense for income taxes recognized during the six months ended June 30, 2020. This expense primarily arises due to the mix of pre-tax income and losses incurred in various tax jurisdictions.

Accrued trade discounts and rebates as of June 30, ~~2019~~2020 and December 31, ~~2018~~2019 consisted of the following (in thousands):

	June 30, 2019		December 31, 2018		June 30, 2020		December 31, 2019
Accrued government rebates and chargebacks					$	159,483	$	164,508
Accrued commercial rebates and wholesaler fees	$	124,354	$	153,083		76,811		138,272
Accrued co-pay and other patient assistance		142,242		179,463		52,298		163,641
Accrued government rebates and chargebacks		132,061		125,217
Accrued trade discounts and rebates	$	398,657	$	457,763	$	288,592	$	466,421
Invoiced commercial rebates and wholesaler fees, co-pay and other patient assistance costs, and government rebates and chargebacks in accounts payable		14,939		3,666		64,373		489
Total customer-related accruals and allowances	$	413,596	$	461,429	$	352,965	$	466,910

The following table summarizes changes in the Company’s customer-related accruals and allowances from December 31, ~~2018~~2019 to June 30, ~~2019~~2020 (in thousands):

The Company has ~~two~~2 reportable segments, the orphan ~~and rheumatology~~ segment and the inflammation segment, and the Company reports net sales and segment operating income for each segment.

~~The~~Effective in the first quarter of 2020, the Company (i) reorganized its commercial operations and moved responsibility for and reporting of RAYOS to the inflammation segment and (ii) renamed the orphan and rheumatology segment the orphan segment. Net sales generated by TEPEZZA, which was approved in the first quarter of 2020, are reported as part of the renamed orphan segment.

The orphan segment includes the ~~marketed~~ medicines TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL ~~KRYSTEXXA, PROCYSBI, QUINSAIR, RAVICTI~~ and ~~RAYOS.~~QUINSAIR. The inflammation segment includes the ~~marketed~~ medicines ~~DUEXIS,~~ PENNSAID 2%, DUEXIS, RAYOS and VIMOVO and previously included MIGERGOT prior to the MIGERGOT transaction.

The Company’s chief operating decision maker (“CODM”) evaluates the financial performance of the Company’s segments based upon segment operating income. Segment operating income is defined as income (loss) before expense (benefit) ~~expense~~ for income taxes adjusted for the items set forth in the reconciliation below. Items below income from operations are not reported by segment, since they are excluded from the measure of segment profitability reviewed by the Company’s CODM. Additionally, certain expenses are not allocated to a segment. The Company does not report balance sheet information by segment as no balance sheet by segment is reviewed by the Company’s CODM.

The following table reflects net sales by medicine for the Company’s reportable segments for the three and six months ended June 30, ~~2019~~2020 and ~~2018~~2019 (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,				Three Months Ended June 30				Six Months Ended June 30
	2019		2018		2019		2018		2020		2019		2020		2019
TEPEZZA									$	165,936	$	—	$	189,387	$	—
KRYSTEXXA	$	79,801	$	58,608	$	132,058	$	105,326		75,201		79,801		168,450		132,058
RAVICTI		50,441		56,958		100,344		106,051		65,550		50,441		126,738		100,344
PROCYSBI		41,174		38,433		80,745		73,367		41,357		41,174		79,700		80,745
ACTIMMUNE		29,276		27,382		51,022		52,240		28,299		29,276		54,840		51,022
RAYOS		20,284		13,452		39,708		24,142
BUPHENYL		2,368		5,244		5,138		10,986		2,846		2,368		5,160		5,138
QUINSAIR		170		97		338		218		59		170		336		338
LODOTRA		—		1,535		—		1,650
Orphan and Rheumatology segment net sales	$	223,514	$	201,709	$	409,353	$	373,980
Orphan segment net sales									$	379,248	$	203,230	$	624,611	$	369,645

PENNSAID 2%		51,472		47,610		101,661		74,413		35,048		51,472		76,611		101,661
DUEXIS		30,066		30,728		59,523		46,405		27,798		30,066		59,145		59,523
RAYOS										14,459		20,284		32,668		39,708
VIMOVO		14,616		21,856		28,659		30,235		6,226		14,616		25,653		28,659
MIGERGOT		979		932		1,822		1,683		—		979		—		1,822
Inflammation segment net sales	$	97,133	$	101,126	$	191,665	$	152,736	$	83,531	$	117,417	$	194,077	$	231,373

Total net sales	$	320,647	$	302,835	$	601,018	$	526,716	$	462,779	$	320,647	$	818,688	$	601,018

The table below provides reconciliations of the Company’s segment operating income to the Company’s total ~~loss~~income (loss) before expense (benefit) ~~expense~~ for income taxes for the three and six months ended June 30, ~~2019~~2020 and ~~2018~~2019 (in thousands):

	For the Three Months Ended June 30,						For the Six Months Ended June 30,						For the Three Months Ended June 30,						For the Six Months Ended June 30,
	2019			2018			2019			2018			2020			2019			2020			2019
Segment operating income:
Orphan and Rheumatology	$	74,502		$	70,609		$	121,180		$	113,713
Orphan													$	151,541		$	63,696		$	205,897		$	100,400
Inflammation		49,694			45,883			91,139			36,311			38,096			60,500			90,038			111,919
Reconciling items:
Amortization and step-up:
Intangible amortization expense		(57,683	)		(60,480	)		(115,100	)		(121,364	)		(66,749	)		(57,683	)		(125,324	)		(115,100	)
Inventory step-up expense		25			(53	)		(90	)		(17,129	)		—			25			—			(90	)
Interest expense, net		(22,033	)		(31,030	)		(49,563	)		(61,484	)
Acquisition/divestiture-related costs														(46,988	)		(73	)		(47,272	)		(1,275	)
Share-based compensation		(21,367	)		(30,721	)		(48,915	)		(58,554	)		(27,057	)		(21,367	)		(83,478	)		(48,915	)
Loss on debt extinguishment		(11,878	)		—			(17,464	)		—			(17,254	)		(11,878	)		(17,254	)		(17,464	)
Interest expense, net														(18,571	)		(22,033	)		(35,915	)		(49,563	)
Depreciation														(6,907	)		(1,443	)		(14,072	)		(2,916	)
Upfront, progress and milestone payments related to license and collaboration agreements														(3,000	)		(4,000	)		(3,000	)		(6,000	)
Impairment of long-lived asset														(1,072	)		—			(1,072	)		—
Loss on sale of assets		(10,963	)		—			(10,963	)		—			—			(10,963	)		—			(10,963	)
Upfront, progress and milestone payments related to license and collaboration agreements		(4,000	)		—			(6,000	)		(90	)
Depreciation		(1,443	)		(1,551	)		(2,916	)		(3,104	)
Charges relating to discontinuation of Friedreich's ataxia program		(1,300	)		(272	)		(1,221	)		(1,222	)		—			(1,300	)		—			(1,221	)
Fees related to refinancing activities		(1,033	)		(15	)		(1,175	)		(42	)		—			(1,033	)		(54	)		(1,175	)
Litigation settlements		(1,000	)		(4,250	)		(1,000	)		(4,250	)		—			(1,000	)		—			(1,000	)
Drug substance harmonization costs		(234	)		(475	)		(314	)		(1,279	)		—			(234	)		(290	)		(314	)
Acquisition/divestiture-related costs		(73	)		(1,077	)		(1,275	)		(5,775	)
Restructuring and realignment costs		(13	)		(7,039	)		(33	)		(10,307	)		—			(13	)		—			(33	)
Impairment of long-lived assets		—			—			—			(33,647	)
Foreign exchange gain (loss)		76			(5	)		15			(115	)
Other (expense) income, net		(1,272	)		346			(1,083	)		497
Loss before (benefit) expense for income taxes	$	(9,995	)	$	(20,130	)	$	(44,778	)	$	(167,841	)
Foreign exchange gain														283			76			1,059			15
Other income (expense), net														632			(1,272	)		1,074			(1,083	)
Income (loss) before expense (benefit) for income taxes													$	2,954		$	(9,995	)	$	(29,663	)	$	(44,778	)

The following table presents the amount and percentage of gross sales to customers that represented more than 10% of the Company’s gross sales included in its two reportable segments and all other customers as a group for the three and six months ended June 30, ~~2019~~2020 and ~~2018~~2019 (in thousands, except percentages):

	For the Three Months Ended June 30,										For the Three Months Ended June 30,
	2019					2018					2020					2019
	Amount		% of Gross			Amount		% of Gross			Amount		% of Gross			Amount		% of Gross
			Sales					Sales					Sales					Sales
Customer A	$	366,676		37	%	$	292,914		26	%	$	314,288		35	%	$	366,676		37	%
Customer B		152,057		15	%		277,705		25	%		194,576		22	%		189,220		19	%
Customer C		189,220		19	%		126,881		11	%		160,814		18	%		152,057		15	%
Customer D		110,434		11	%		104,101		9	%		112,676		13	%		86,591		9	%
Other Customers		172,938		18	%		326,195		29	%		115,639		12	%		196,781		20	%
Gross Sales	$	991,325		100	%	$	1,127,796		100	%	$	897,993		100	%	$	991,325		100	%

	For the Six Months Ended June 30,										For the Six Months Ended June 30,
	2019					2018					2020					2019
	Amount		% of Gross			Amount		% of Gross			Amount		% of Gross			Amount		% of Gross
			Sales					Sales					Sales					Sales
Customer A	$	711,923		37	%	$	569,725		27	%	$	561,063		33	%	$	711,923		37	%
Customer B		336,926		17	%		495,562		24	%		401,853		24	%		311,277		16	%
Customer C		311,277		16	%		239,047		12	%		294,689		17	%		336,926		17	%
Customer D		226,186		12	%		159,520		7	%		197,464		12	%		161,578		8	%
Other Customers		350,179		18	%		618,381		30	%		246,447		14	%		414,787		22	%
Gross Sales	$	1,936,491		100	%	$	2,082,235		100	%	$	1,701,516		100	%	$	1,936,491		100	%

Geographic revenues are determined based on the country in which the Company’s customers are located. The following table presents a summary of net sales attributed to geographic sources for the three and six months ended June 30, ~~2019~~2020 and ~~2018~~2019 (in thousands, except percentages):

	Three Months Ended June 30, 2019			Three Months Ended June 30, 2018			Three Months Ended June 30, 2020			Three Months Ended June 30, 2019
	Amount		% of Total Net Sales	Amount		% of Total Net Sales	Amount		% of Total Net Sales	Amount		% of Total Net Sales
United States	$	319,404	100%	$	295,939	98%	$	460,827	100%	$	319,404	100%
Rest of world		1,243	*		6,896	2%		1,952	*		1,243	*
Net sales	$	320,647		$	302,835		$	462,779		$	320,647

	Six Months Ended June 30, 2019			Six Months Ended June 30, 2018
	Amount		% of Total Net Sales	Amount		% of Total Net Sales
United States	$	598,612	100%	$	515,310	98%
Rest of world		2,406	*		11,406	2%
Net sales	$	601,018		$	526,716
* Less than 1%
*Less than 1%

The following tables and paragraphs set forth the Company’s financial instruments that are measured at fair value on a recurring basis within the fair value hierarchy. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. The following describes three levels of inputs that may be used to measure fair value:

Level 1—Observable inputs such as quoted prices in active markets for identical assets or liabilities;

Level 2—Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The Company utilizes the market approach to measure fair value for its money market funds. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities.

Other current assets and other long-term liabilities recorded at fair value on a recurring basis are composed of investments held in a rabbi trust and the related deferred liability for deferred compensation arrangements. Quoted prices for this investment, primarily in mutual funds, are available in active markets. Thus, the Company’s investments related to deferred compensation arrangements and the related long-term liability are classified as Level 1 measurements in the fair value hierarchy.

The following tables set forth the Company’s financial assets and liabilities at fair value on a recurring basis as of June 30, ~~2019~~2020 and December 31, ~~2018~~2019 (in thousands):

	June 30, 2019										June 30, 2020
	Level 1			Level 2		Level 3		Total			Level 1			Level 2		Level 3		Total
Assets:
Money market funds	$	825,925		$	—	$	—	$	825,925		$	640,125		$	—	$	—	$	640,125
Other current assets		11,582			—		—		11,582			15,203			—		—		15,203
Total assets at fair value	$	837,507		$	—	$	—	$	837,507		$	655,328		$	—	$	—	$	655,328
Liabilities:
Other long-term liabilities		(11,582	)		—		—		(11,582	)		(15,203	)		—		—		(15,203	)
Total liabilities at fair value	$	(11,582	)	$	—	$	—	$	(11,582	)	$	(15,203	)	$	—	$	—	$	(15,203	)

	December 31, 2018										December 31, 2019
	Level 1			Level 2		Level 3		Total			Level 1			Level 2		Level 3		Total
Assets:
Bank time deposits	$	—		$	6,500	$	—	$	6,500
Money market funds		915,800			—		—		915,800		$	1,029,725			—		—	$	1,029,725
Other current assets		8,203			—		—		8,203			12,704			—		—		12,704
Total assets at fair value	$	924,003		$	6,500	$	—	$	930,503		$	1,042,429		$	—	$	—	$	1,042,429
Liabilities:
Other long-term liabilities		(8,203	)		—		—		(8,203	)		(12,704	)		—		—		(12,704	)
Total liabilities at fair value	$	(8,203	)	$	—	$	—	$	(8,203	)	$	(12,704	)	$	—	$	—	$	(12,704	)

The Company’s outstanding debt balances as of June 30, ~~2019~~2020 and December 31, ~~2018~~2019 consisted of the following (in thousands):

On ~~May 22,~~December 18, 2019, Horizon Therapeutics USA, Inc. (formerly known as Horizon Pharma USA, Inc.) (the “Borrower”), a wholly owned subsidiary of the Company, borrowed approximately ~~$518.0~~$418.0 million aggregate principal amount of loans (the ~~“May~~“December 2019 Refinancing Loans”) pursuant to an amendment (the ~~“May~~“December 2019 Refinancing Amendment”) to the credit agreement, dated as of May 7, 2015, by and among the Borrower, the Company and certain of its subsidiaries as guarantors, the lenders party thereto from time to time and Citibank, N.A., as administrative agent and collateral agent, as amended by Amendment No. 1, dated as of October 25, 2016, Amendment No. 2, dated March 29, 2017, Amendment No. 3, dated October 23, 2017, Amendment No. 4, dated October 19, 2018, ~~and~~ Amendment No. 5, dated March 11, 2019 and Amendment No. 6, dated May 22, 2019 (the “Term Loan Facility”). Pursuant to Amendment No. 5, the Borrower received $200.0 million aggregate principal amount of revolving commitments (the ~~“New Incremental~~“Incremental Revolving Commitments”). The ~~New~~ Incremental Revolving Commitments were established pursuant to an incremental facility (the “Revolving Credit Facility”) and provide the Borrower with $200.0 million of additional borrowing capacity, which includes a $50.0 million letter of credit sub-facility. The ~~New~~ Incremental Revolving Commitments will terminate in March 2024. Borrowings under the Revolving Credit Facility are available for general corporate purposes. As of June 30, ~~2019,~~2020, the Revolving Credit Facility was undrawn. As used herein, all references to the “Credit Agreement” are references to the original credit agreement, dated as of May 7, 2015, as amended through the ~~May~~December 2019 Refinancing Amendment.

The ~~May~~December 2019 Refinancing Loans were incurred as a separate new class of term loans under the Credit Agreement with substantially the same terms as the previously outstanding senior secured term loans incurred on ~~October 19, 2018~~May 22, 2019 (the “Refinanced Loans”) to effectuate a repricing of the Refinanced ~~Loans, including lowering the interest rate by 0.25% and extending the final maturity date to May 22, 2026.~~Loans. The Borrower used the proceeds of the ~~May~~December 2019 Refinancing Loans to repay the Refinanced Loans, which totaled approximately ~~$518.0~~$418.0 million. The ~~May~~December 2019 Refinancing Loans bear interest at a rate, at the Borrower’s option, ~~at a rate~~ equal to ~~either~~ the London Inter-Bank Offered Rate (“LIBOR”), plus ~~an applicable margin of 2.50%~~2.25% per ~~year~~annum (subject to a 0.00% LIBOR ~~floor of 0.00%),~~floor) or the ~~alternate~~adjusted base rate ~~(the “Base Rate”)~~ plus ~~1.50%~~1.25% per ~~year.~~annum, with a step-down to LIBOR plus 2.00% per annum or the adjusted base rate plus 1.00% per annum at the time the Company’s leverage ratio is less than or equal to 2.00 to 1.00. The ~~Base Rate~~adjusted base rate is defined as the greatest of (a) LIBOR (using one-month interest period) plus 1.00%, (b) the prime rate, (c) the federal funds rate plus 0.50%, and (d) ~~2.00%~~1.00%.

The loans under the Revolving Credit Facility bear interest, at the Borrower’s option, at a rate equal to either LIBOR plus an applicable margin of ~~3.00%~~2.25% per ~~year~~annum (subject to a LIBOR floor of 0.00%), or the ~~Base Rate~~adjusted base rate plus 1.25% per annum, with a step-down to LIBOR plus 2.00% per ~~year. The applicable margins for loans under~~annum or the ~~Revolving Credit Facility will be reduced by 0.25% if~~adjusted base rate plus 1.00% per annum at the time the Company’s ~~ratio of consolidated total indebtedness to consolidated EBITDA, or total~~ leverage ratio is less than or equal to ~~3.50~~2.00 to 1.00. The Credit Agreement provides for (i) the ~~May~~December 2019 Refinancing Loans, (ii) the Revolving Credit Facility, (iii) one or more uncommitted additional incremental loan facilities subject to the satisfaction of certain financial and other conditions, and (iv) one or more uncommitted refinancing loan facilities with respect to loans thereunder. The Credit Agreement allows for the Company and certain of its subsidiaries to become additional borrowers under incremental or refinancing facilities.

The obligations under the Credit Agreement (including obligations in respect of the ~~May~~December 2019 Refinancing Loans and the Revolving Credit Facility) and any swap obligations and cash management obligations owing to a lender (or an affiliate of a lender) are guaranteed by the Company and each of the Company’s existing and subsequently acquired or formed direct and indirect subsidiaries (other than certain immaterial subsidiaries, subsidiaries whose guarantee would result in material adverse tax consequences and subsidiaries whose guarantee is prohibited by applicable law). The obligations under the Credit Agreement (including obligations in respect of the ~~May~~December 2019 Refinancing Loans and the Revolving Credit Facility) and any related swap and cash management obligations are secured, subject to customary permitted liens and other agreed upon exceptions, by a perfected security interest in (i) all tangible and intangible assets of the Borrower and the guarantors, except for certain customary excluded assets, and (ii) all of the capital stock owned by the Borrower and guarantors thereunder (limited, in the case of the stock of certain non-U.S. subsidiaries of the Borrower, to 65% of the capital stock of such subsidiaries). The Borrower and the guarantors under the Credit Agreement are individually and collectively referred to herein as a “Loan Party” and the “Loan Parties,” as applicable.

The Company elected to exercise its reinvestment rights under the mandatory prepayment provisions of the Credit Agreement with respect to the net proceeds from the Company’s sale of its rights to PROCYSBI and QUINSAIR in the Europe, Middle East and Africa regions to Chiesi Farmaceutici S.p.A. To the extent the Company had not applied such net proceeds to permitted acquisitions (including the acquisition of rights to products and products lines) and/or the acquisition of capital assets within 365 days of the receipt thereof (or committed to so apply and then applied within 180 days after the end of such 365-day period), the Company was required to make a mandatory prepayment under the Credit Agreement in an amount equal to the unapplied net proceeds. In June 2018, the Company repaid $23.5 million under the mandatory prepayment provisions of the Credit Agreement.

On March 18, 2019, the ~~Borrower~~Company completed the repayment of $300.0 million of the outstanding principal amount of term loans under the Credit Agreement following the closing of its underwritten public equity offering on March 11, 2019. In July 2019, the Company repaid an additional $100.0 million of term loans under the Credit Agreement following the private placement of the Company’s 5.5% Senior Notes due 2027 (the “2027 Senior Notes”).Following ~~this repayment,~~these repayments, the outstanding principal balance of term loans under the Credit Agreement was ~~$518.0 million and the Company’s total aggregate outstanding principal amount of indebtedness was $1,693.0~~$418.0 million.

Additionally, the Company elected to exercise its reinvestment rights under the mandatory prepayment provisions of the Credit Agreement with respect to the net proceeds from the Company’s sale of its rights to RAVICTI and AMMONAPS (known as BUPHENYL in the United States) outside of North America and Japan to Medical Need Europe AB, part of the Immedica ~~transaction.~~Group (the “Immedica transaction”). To the extent the Company had not applied such net proceeds to permitted acquisitions (including the acquisition of rights to products and products lines) and/or the acquisition of capital assets within 365 days of the receipt of proceeds from the Immedica transaction (or commit to so apply and then apply within 180 days after the end of such 365-day period), the Company was required to make a mandatory prepayment under the Credit Agreement in an amount equal to the unapplied net proceeds. In March 2019, the Company repaid $35.0 million under the mandatory prepayment provisions of the Credit ~~Agreement.~~Agreement which was included in the $300.0 million repayment referred to above.

The Borrower is permitted to make voluntary prepayments of the loans under the Credit Agreement at any time without payment of a premium, except that with respect to the May 2019 Refinancing Loans, a 1% premium will apply to a repayment of the May 2019 Refinancing Loans in connection with a repricing of, or any amendment to the Credit Agreement in a repricing of, such loans effected on or prior to the date that is six months following May 22, 2019. The Borrower is required to make mandatory prepayments of loans under the Credit Agreement (without payment of a premium) with (a) net cash proceeds from certain non-ordinary course asset sales (subject to reinvestment rights and other exceptions), (b) casualty proceeds and condemnation awards (subject to reinvestment rights and other exceptions), (c) net cash proceeds from issuances of debt (other than certain permitted debt), and (d) 50% of the Company’s excess cash flow (subject to decrease to 25% or 0% if the Company’s first lien leverage ratio is less than 2.25:1 or 1.75:1, respectively). The ~~May 2019 Refinancing Loans will amortize in equal quarterly installments beginning on March 31, 2025, in an aggregate annual amount equal to 1.00% of the original~~ principal amount of the loans under the Credit Agreement (i.e. $850.0 million), as the same may be reduced from time to time pursuant to the Credit Agreement (including by prepayments made prior to or after the date of the MayDecember 2019 Refinancing ~~Amendment), with any remaining balance~~ Loans are due and payable on May 22, 2026, the final maturity date of the ~~May~~December 2019 Refinancing Loans.

The Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, prepayment of other indebtedness and dividends and other distributions. The Credit Agreement also contains a springing financial maintenance covenant, which requires that the Company maintain a specified leverage ratio at the end of each fiscal quarter. The covenant is tested if both the outstanding loans and letters of credit under the Revolving Credit Facility, subject to certain exceptions, exceed 25% of the total commitments under the Revolving Credit Facility as of the last day of any fiscal quarter. If the Company fails to meet this covenant, the commitments under the Revolving Credit Facility could be terminated and any outstanding borrowings, together with accrued interest, under the Revolving Credit Facility could be declared immediately due and payable.

Other events of default under the Credit Agreement include: (i) the failure by the Borrower to timely make payments due under the Credit Agreement; (ii) material misrepresentations or misstatements in any representation or warranty by any Loan Party when made; (iii) failure by any Loan Party to comply with the covenants under the Credit Agreement and other related agreements; (iv) certain defaults under a specified amount of other indebtedness of the Company or its subsidiaries; (v) insolvency or bankruptcy-related events with respect to the Company or any of its material subsidiaries; (vi) certain undischarged judgments against the Company or any of its restricted subsidiaries; (vii) certain ERISA-related events reasonably expected to have a material adverse effect on the Company and its restricted subsidiaries taken as a whole; (viii) certain security interests or liens under the loan documents ceasing to be, or being asserted by the Company or its restricted subsidiaries not to be, in full force and effect; (ix) any loan document or material provision thereof ceasing to be, or any challenge or assertion by any Loan Party that such loan document or material provision is not, in full force and effect; and (x) the occurrence of a change of control. If one or more events of default occurs and continues beyond any applicable cure period, the administrative agent may, with the consent of the lenders holding a majority of the loans and commitments under the facilities, or will, at the request of such lenders, terminate the commitments of the lenders to make further loans and declare all of the obligations of the Loan Parties under the Credit Agreement to be immediately due and payable.

The interest on the ~~Company’s~~ Term Loan Facility is variable and as of June 30, ~~2019,~~2020 the interest rate on the Term Loan Facility was ~~4.94%~~2.56% and the effective interest rate was ~~5.26%~~2.86%.

As of June 30, ~~2019,~~2020, the fair value of the amounts outstanding under the Term Loan Facility was approximately ~~$518.0~~$404.4 million, categorized as a Level 2 instrument, as defined in Note 12.

~~In July 2019, the Company redeemed $100.0 million of senior secured term loans under the Credit Agreement. See Note 20 for further details.~~

On ~~April 29, 2015,~~July 16, 2019, Horizon Therapeutics USA, Inc. (formerly known as Horizon Pharma ~~Financing~~USA, Inc. ~~(“Horizon Financing”~~), athe Company’s wholly owned subsidiary ~~of the Company,~~(“HTUSA”), completed a private placement of ~~$475.0~~$600.0 million aggregate principal amount of ~~6.625%~~2027 Senior Notes ~~due 2023 (the “2023 Senior Notes”)~~ to ~~certain~~several investment banks acting as initial purchasers, who subsequently resold the ~~2023~~2027 Senior Notes to persons reasonably believed to be qualified institutional ~~buyers as defined in Rule 144A under~~buyers.

The Company used the ~~Securities Actof 1933, as amended (the “Securities Act”), and in offshore transactions to non-U.S. persons in reliance on Regulation S under the Securities Act.~~ ~~The~~ net proceeds from the offering of the ~~2023~~2027 Senior Notes, ~~were~~together with approximately ~~$462.3~~$65.0 million ~~after deducting~~in cash on hand, to redeem or prepay $625.0 million of its outstanding debt, consisting of (i) the ~~initial purchasers’ discount~~ outstanding $225.0 million principal amount of its 6.625% Senior Notes due 2023, (ii) the outstanding $300.0 million principal amount of its 8.750% Senior Notes due 2024 and ~~offering expenses payable by Horizon Financing.~~

~~In connection with the closing~~(iii) $100.0 million of the ~~acquisition~~outstanding principal amount of ~~Hyperion Therapeutics, Inc. (“Hyperion”) on May 7, 2015, Horizon Financing merged~~senior secured term loans under the Credit Agreement, as well as to pay the related premiums and fees and expenses, excluding accrued interest, associated with such redemption and ~~into Horizon Pharma, Inc. (“HPI”) and on October 31, 2018, HPI merged with and into Horizon Pharma USA, Inc. (“HPUSA”). As a result, the 2023~~prepayment.

The 2027 Senior Notes ~~became the~~are HTUSA’s general unsecured senior obligations, rank equally in right of ~~HPUSA, which was previously a guarantor under the 2023 Senior Notes.~~payment with all existing and future senior debt of HTUSA and rank senior in right of payment to any existing and future subordinated debt of HTUSA. The ~~obligations under the 2023~~2027 Senior Notes are ~~fully~~effectively subordinate to all of the existing and future secured debt of HTUSA to the extent of the value of the collateral securing such debt.

The 2027 Senior Notes are unconditionally guaranteed on a senior ~~unsecured~~ basis by the Company and all of the Company’s ~~direct~~restricted subsidiaries, other than HTUSA and ~~indirect~~certain immaterial subsidiaries, that guarantee the Credit Agreement. The guarantees are ~~guarantors from time~~each guarantor’s senior unsecured obligations and rank equally in right of payment with such guarantor’s existing and future senior debt and senior in right of payment to ~~time~~any existing and future subordinated debt of such guarantor. The guarantees are effectively subordinated to all of the existing and future secured debt of each guarantor, including such guarantor’s guarantee under the Credit ~~Agreement.~~Agreement, to the extent of the value of the collateral securing such debt. The guarantees of a guarantor may be released under certain circumstances. The 2027 Senior Notes are structurally subordinated to all of the liabilities of the Company’s subsidiaries that do not guarantee the 2027 Senior Notes.

The ~~2023~~2027 Senior Notes accrue interest at an annual rate of ~~6.625%~~5.5% payable semiannually in arrears on ~~May~~February 1 and ~~November~~August 1 of each year, beginning on ~~November~~February 1, ~~2015.~~2020. The ~~2023~~2027 Senior Notes will mature on ~~May~~August 1, ~~2023,~~2027, unless earlier exchanged, repurchased or redeemed.

~~Some~~Except as described below, the 2027 Senior Notes may not be redeemed before August 1, 2022. Thereafter, some or all of the ~~2023~~2027 Senior Notes may be redeemed at any time at specified redemption prices, plus accrued and unpaid interest to the redemption date. At any time prior to August 1, 2022, some or all of the 2027 Senior Notes may be redeemed at a price equal to 100% of the aggregate principal amount thereof, plus a make-whole premium and accrued and unpaid interest to the redemption date. Also prior to August 1, 2022, up to 40% of the aggregate principal amount of the 2027 Senior Notes may be redeemed at a redemption price of 105.5% of the aggregate principal amount thereof, plus accrued and unpaid interest, with the net proceeds of certain equity offerings. In addition, the ~~2023~~2027 Senior Notes may be redeemed in whole but not in part at a redemption price equal to 100% of the principal amount plus accrued and unpaid interest and additional amounts, if any, to, but excluding, the redemption date, if on the next date on which any amount would be payable in respect of the ~~2023~~2027 Senior Notes, ~~HPUSA~~HTUSA or any guarantor is or would be required to pay additional amounts as a result of certain ~~tax-related~~tax related events.

If the Company undergoes a change of control, ~~HPUSA~~HTUSA will be required to make an offer to purchase all of the ~~2023~~2027 Senior Notes at a price in cash equal to 101% of the aggregate principal amount thereof plus accrued and unpaid interest to, but not including, the repurchase ~~date.~~date, subject to certain exceptions. If the Company or certain of its subsidiaries engages in certain asset sales, ~~HPUSA~~HTUSA will be required under certain circumstances to make an offer to purchase the ~~2023~~2027 Senior Notes at 100% of the principal amount thereof, plus accrued and unpaid interest to the repurchase date.

The indenture governing the ~~2023~~2027 Senior Notes contains covenants that limit the ability of the Company and its restricted subsidiaries to, among other things, pay dividends or distributions, repurchase equity, prepay junior debt and make certain investments, incur additional debt and issue certain preferred stock, incur liens on assets, engage in certain asset sales, merge, consolidate with or merge or sell all or substantially all of their assets, enter into transactions with affiliates, designate subsidiaries as unrestricted subsidiaries, and allow to exist certain restrictions on the ability of restricted subsidiaries to pay dividends or make other payments to the Company. Certain of the covenants will be suspended during any period in which the ~~notes~~2027 Senior Notes receive investment grade ratings. The indenture governing the ~~2023~~2027 Senior Notes also includes customary events of default.

As of June 30, ~~2019,~~2020, the interest rate on the ~~2023~~2027 Senior Notes was ~~6.625%~~5.5% and the effective interest rate was ~~6.96%~~5.76%.

As of June 30, ~~2019,~~2020, the fair value of the ~~2023~~2027 Senior Notes was approximately ~~$232.0~~$621.0 million, categorized as a Level 2 instrument, as defined in Note 12.

The Company redeemed $250.0 million of 2023 Senior Notes on May 1, 2019. In connection with this early redemption, the Company paid a premium of $8.3 million on May 1, 2019. Following this redemption, $225.0 million of the 2023 Senior Notes remained outstanding.

~~On July 10, 2019, the Company delivered notice to redeem the remaining $225.0 million of 2023 Senior Notes on August 9, 2019. See Note 20 for further details.~~

~~On October 25, 2016, HPI and HPUSA~~ ~~(together, in such capacity, the “2024 Issuers”)~~, completed a private placement of $300.0 million aggregate principal amount of 8.750% Senior Notes due 2024 (the “2024 Senior Notes”) to certain investment banks acting as initial purchasers who subsequently resold the 2024 Senior Notes to qualified institutional buyers as defined in Rule 144A under the Securities Act. The net proceeds from the offering of the 2024 Senior Notes were approximately $291.9 million, after deducting the initial purchasers’ discount and offering expenses payable by the 2024 Issuers. On October 31, 2018, HPI merged with and into HPUSA, and as a result, HPI’s obligations as co-issuer under the 2024 Senior Notes became HPUSA’s general unsecured senior obligations.

The obligations under the 2024 Senior Notes are HPUSA’s general unsecured senior obligations and are fully and unconditionally guaranteed on a senior unsecured basis by the Company and all of the Company’s direct and indirect subsidiaries that are guarantors from time to time under the Credit Agreement.

~~The Company used the net proceeds from the offering of the 2024 Senior Notes as well as $375.0 million principal amount of~~ ~~senior secured term loans~~ ~~under the~~ ~~Company’s term loan facility~~ to fund a portion of the acquisition of Raptor Pharmaceutical Corp. (“Raptor”), repay Raptor’s outstanding debt, and pay any prepayment premiums, fees and expenses in connection with the foregoing.

The 2024 Senior Notes accrue interest at an annual rate of 8.750% payable semiannually in arrears on May 1 and November 1 of each year, beginning on May 1, 2017. The 2024 Senior Notes will mature on November 1, 2024, unless earlier repurchased or redeemed.

Except as described below, the 2024 Senior Notes may not be redeemed before November 1, 2019. Thereafter, some or all of the 2024 Senior Notes may be redeemed at any time at specified redemption prices, plus accrued and unpaid interest to the redemption date. At any time prior to November 1, 2019, some or all of the 2024 Senior Notes may be redeemed at a price equal to 100% of the aggregate principal amount thereof, plus a make-whole premium and accrued and unpaid interest to the redemption date. Also prior to November 1, 2019, up to 35% of the aggregate principal amount of the 2024 Senior Notes may be redeemed at a redemption price of 108.75% of the aggregate principal amount thereof, plus accrued and unpaid interest, with the net proceeds of certain equity offerings. In addition, the 2024 Senior Notes may be redeemed in whole but not in part at a redemption price equal to 100% of the principal amount plus accrued and unpaid interest and additional amounts, if any, to, but excluding, the redemption date, if on the next date on which any amount would be payable in respect of the 2024 Senior Notes, HPUSA or any guarantor is or would be required to pay additional amounts as a result of certain tax-related events.

If the Company undergoes a change of control, HPUSA will be required to make an offer to purchase all of the 2024 Senior Notes at a price in cash equal to 101% of the aggregate principal amount thereof plus accrued and unpaid interest to, but not including, the repurchase date. If the Company or certain of its subsidiaries engages in certain asset sales, HPUSA will be required under certain circumstances to make an offer to purchase the 2024 Senior Notes at 100% of the principal amount thereof, plus accrued and unpaid interest to the repurchase date.

The indenture governing the 2024 Senior Notes contains covenants that limit the ability of the Company and its restricted subsidiaries to, among other things, pay dividends or distributions, repurchase equity, prepay junior debt and make certain investments, incur additional debt and issue certain preferred stock, incur liens on assets, engage in certain asset sales, merge, consolidate with or merge or sell all or substantially all of their assets, enter into transactions with affiliates, designate subsidiaries as unrestricted subsidiaries, and allow to exist certain restrictions on the ability of restricted subsidiaries to pay dividends or make other payments to the Company. Certain of the covenants will be suspended during any period in which the notes receive investment grade ratings. The indenture also includes customary events of default.

~~As of June 30, 2019, the interest rate on the 2024 Senior Notes was 8.75% and the effective interest rate was 9.20%.~~

~~As of June 30, 2019, the fair value of the 2024 Senior Notes was approximately $323.3 million, categorized as a Level 2 instrument, as defined in Note 12.~~

~~On July 10, 2019, the Company delivered notice to redeem all $300.0 million of 2024 Senior Notes on August 9, 2019. See Note 20 for further details.~~

On March 13, 2015, Horizon TherapeuticsInvestmentLimited (formerly known as Horizon Pharma Investment Limited) (“Horizon Investment”), a wholly owned subsidiary of the Company, completed a private placement of $400.0 million aggregate principal amount of Exchangeable Senior Notes to certain investment banks acting as initial purchasers who subsequently resold the Exchangeable Senior Notes to qualified institutional buyers as defined in Rule 144A under the Securities ~~Act.~~Act of 1933, as amended. The net proceeds from the offering of the Exchangeable Senior Notes were approximately $387.2 million, after deducting the initial purchasers’ discount and offering expenses payable by Horizon Investment.

The Exchangeable Senior Notes are fully and unconditionally guaranteed, on a senior unsecured basis, by the Company (the “Guarantee”). The Exchangeable Senior Notes and the Guarantee are Horizon Investment’s and the Company’s senior unsecured obligations. The Exchangeable Senior Notes accrue interest at an annual rate of ~~2.50%~~2.5% payable semiannually in arrears on March 15 and September 15 of each year, beginning on September 15, 2015. The Exchangeable Senior Notes ~~will~~were scheduled to mature on March 15, ~~2022, unless earlier exchanged, repurchased or redeemed.~~2022. The ~~initial~~ exchange rate is 34.8979 ordinary shares of the Company per $1,000 principal amount of the Exchangeable Senior Notes (equivalent to an initial exchange price of approximately $28.66 per ordinary share). The exchange rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date or upon a tax redemption, Horizon Investment will increase the exchange rate for a holder who elects to exchange its Exchangeable Senior Notes in connection with such a corporate event or a tax redemption in certain circumstances.

~~Other than as described below, the Exchangeable Senior Notes may not be redeemed by the Company.~~

~~Optional Redemption for Changes in the Tax Laws of a Relevant Taxing Jurisdiction~~: ~~Horizon Investment may redeem the Exchangeable Senior Notes at its option, prior to March 15, 2022, in whole but not in part, in connection with certain tax-related events.~~

~~Provisional Redemption on or After March 20, 2019~~: On or after March 20, 2019, Horizon Investment may redeem for cash all or a portion of the Exchangeable Senior Notes if the last reported sale price of ordinary shares of the Company has been at least 130% of the exchange price then in effect for at least twenty trading days whether or not consecutive) during any thirty consecutive trading day period ending on, and including, the trading day immediately preceding the date on which Horizon Investment provide written notice of redemption. The redemption price will be equal to 100% of the principal amount of the Exchangeable Senior Notes to be redeemed, plus accrued and unpaid interest to, but not including, the redemption date; provided that if the redemption date occurs after a regular record date and on or prior to the corresponding interest payment date, Horizon Investment will pay the full amount of accrued and unpaid interest due on such interest payment date to the record holder of the Exchangeable Senior Notes on the regular record date corresponding to such interest payment date, and the redemption price payable to the holder who presents an Exchangeable Senior Note for redemption will be equal to 100% of the principal amount of such Exchangeable Senior Note.

Holders may exchange all or any portion of their Exchangeable Senior Notes at their option at any time prior to the close of business on the business day immediately preceding December 15, 2021 only upon satisfaction of one or more of the following conditions:

~~As of June 30, 2019, none of the above conditions had been satisfied and no exchange of Exchangeable Senior Notes had been triggered.~~

On or after December 15, 2021, a holder may exchange all or any portion of its Exchangeable Senior Notes at any time prior to the close of business on the second scheduled trading day immediately preceding the maturity date regardless of the foregoing conditions.

Upon exchange, Horizon Investment will settle exchanges of the Exchangeable Senior Notes by paying or causing to be delivered, as the case may be, cash, ordinary shares or a combination of cash and ordinary shares, at its election.

The Company recorded the Exchangeable Senior Notes under the guidance in ASC Topic 470-20, Debt with Conversion and Other Options, and separated them into a liability component and equity component. The initial carrying amount of the liability component of $268.9 million was determined by measuring the fair value of a similar liability that does not have an associated equity component. The initial carrying amount of the equity component of $119.1 million represented by the embedded conversion option was determined by deducting the fair value of the liability component of $268.9 million from the initial proceeds of $387.2 million ascribed to the convertible debt instrument as a whole. The initial debt discount of $131.1 million is being charged to interest expense over the life of the Exchangeable Senior Notes using the effective interest rate method.

On June 3, 2020, Horizon Investment issued a notice of redemption (the “Redemption Notice”) for all of the outstanding Exchangeable Senior Notes. During the three months ended June 30, 2020, the Company issued an aggregate of 7,225,368 of its ordinary shares to noteholders as a result of exchanges of $207.0 million in aggregate principal amount of Exchangeable Senior Notes following the issuance of the Redemption Notice. As of June 30, 2020, an aggregate principal amount of $193.0 million of Exchangeable Senior Notes were outstanding. Pursuant to the Redemption Notice, on August 3, 2020, Horizon Investment was required to redeem any Exchangeable Senior Notes that had not been exchanged prior to such date at a redemption price in cash equal to 100% of the principal amount of such Exchangeable Senior Notes to be redeemed, plus accrued and unpaid interest, if any.

From July 1, 2020 through July 30, 2020, a total of $191.2 million in aggregate principal amount of Exchangeable Senior Notes were exchanged for an aggregate of 6,673,046 of the Company’s ordinary shares. On August 3, 2020, the Company redeemed the remaining $1.7 million in aggregate principal amount of Exchangeable Senior Notes and made aggregate cash payments to the holders of such Exchangeable Senior Notes of $1.8 million. As of the date of this Quarterly Report on Form 10-Q, there are 0 Exchangeable Senior Notes outstanding. The Company expects to record a loss on debt extinguishment of approximately $15.0 million in the third quarter of 2020 relating to the Exchangeable Senior Notes outstanding as of June 30, 2020.

As of June 30, ~~2019,~~2020, the interest rate on the Exchangeable Senior Notes was ~~2.50% and the effective interest rate was 8.88%~~2.5%.

As of June 30, ~~2019,~~2020, the fair value of the Exchangeable Senior Notes was approximately ~~$450.0~~$373.7 million, categorized as a Level 2 instrument, as defined in Note 12.

During the three months ended June 30, 2019, the Company recorded a loss on debt extinguishment of $11.9 million in the condensed consolidated statement of comprehensive loss, which reflected the write-off of the deferred financing fees and debt discount fees related to the prepayment of $225.0 million of the 2023 Senior Notes and term loan refinancing in May 2019.

During the six months ended June 30, 2019, the Company recorded a loss on debt extinguishment of $17.5 million in the condensed consolidated statement of comprehensive loss, which reflected the write-off of the deferred financing fees and debt discount fees related to the prepayment of $225.0 million of the 2023 Senior Notes and term loan refinancing in May 2019 and the $300.0 million term loan repayment in March 2019. 20

~~As discussed in Note 2, the Company elected the Topic 842 transition provision that allows entities to continue to apply the legacy guidance in Topic 840,~~ ~~Leases~~, including its disclosure requirements, in the comparative periods presented in the year of adoption. Accordingly, the Topic 842 disclosures below are presented as of and for the three and six-month period ended June 30, 2019 only.

The Company has the following office space lease agreements in place for real properties:

The above table does not include details of an agreement for lease entered into on October 14, 2019, relating to approximately 63,000 square feet of office space under construction in Dublin, Ireland. Lease commencement will begin when construction of the offices is completed by the lessor and the Company has access to begin the construction of leasehold improvements. The Company expects to incur leasehold improvement costs during 2020 and 2021 in order to prepare the building for occupancy.

In February 2020, the Company purchased a 3-building campus in Deerfield, Illinois. The Company expects to move its Lake Forest office employees to the Deerfield campus in the fourth quarter of 2020 and market its Lake Forest office for sub-lease. As of June 30, 2020, the right-of-use lease asset relating to the Lake Forest lease was $17.4 million. If the expected rent payments received from sub-leasing the Lake Forest office are lower than the rent payments that the Company will continue to pay on its lease, the Company will record an impairment charge relating to the right-of-use lease asset upon vacating the Lake Forest office. Refer to Note 7 for further detail on the purchase of the Deerfield campus.

As of June 30, 2020 and December 31, 2019, the Company had right-of-use lease assets included in other assets of $37.1 million and $39.8 million, respectively; current lease liabilities included in accrued expenses of $4.7 million and $4.4 million, respectively; and non-current lease liabilities included in other long-term liabilities of $44.2 million and $46.5 million, respectively, in its condensed consolidated balance sheets. During the three months ended June 30, 2020, the Company recorded an impairment charge of $1.1 million related to the Novato, Californiaoffice lease, which was obtained through an acquisition. This charge was reported within selling, general and administrative expenses in the condensed consolidated statement of comprehensive loss.

The Company recognizes rent expense on a monthly basis over the lease term based on a straight-line method. Rent expense was ~~$1.4~~$1.8 million and ~~$1.5~~$1.4 million for the three months ended June 30, 2020 and 2019, respectively, and ~~2018, respectively,~~$3.4 million and $3.0 million for ~~each of~~ the six months ended June 30, 2020 and 2019, ~~and 2018.~~respectively.

The table below reconciles the undiscounted cash flows for each of the first five years and total of the remaining years to the operating lease liabilities recorded on the Company’s condensed consolidated balance sheet as of June 30, ~~2019~~2020 (in thousands):

2019 (July to December)	$	(1,691	)
2020		6,670
2020 (July to December)				$	4,004
2021		5,778			7,118
2022		4,555			5,942
2023		4,433			5,869
2024					6,487
Thereafter		36,350			39,618
Total lease payments ~~(1)~~		56,095			69,038
Imputed interest		(19,669	)		(20,176	)
Total operating lease liabilities	$	36,426		$	48,862

The Company has certain leases that provide for lease incentives payable to the Company for construction of leasehold improvements. The cash inflows for these incentives are expected to be received in 2019 and are in excess of the Company’s expected lease payments resulting in a net cash inflow, as shown in the above table.

The weighted-average discount rate and remaining lease term for operating leases as of June 30, ~~2019~~2020 was ~~7.54%~~7.10% and ~~10.57~~10.13 years, respectively.

~~The following table, which was included in the Company’s 2018 Annual Report on Form 10-K, depicts the minimum future cash payments due under lease obligations at December 31, 2018 (in thousands):~~

Under the Company’s supply agreement with AGC Biologics A/S (formerly known as CMC Biologics A/S) (“AGC Biologics”), the Company has agreed to purchase certain minimum annual order quantities of ~~teprotumumab~~TEPEZZA drug substance. In addition, the Company must provide AGC Biologics with rolling forecasts of ~~teprotumumab~~TEPEZZA drug substance requirements, with a portion of the forecast being a firm and binding order. Under the Company’s supply agreement with Catalent Indiana, LLC (“Catalent”), the Company must provide Catalent with rolling forecasts of ~~teprotumumab~~TEPEZZA drug product requirements, with a portion of the forecast being a firm and binding order. At June 30, ~~2019,~~2020, the Company had total purchase commitments, including the minimum annual order quantities and binding firm orders, with AGC Biologics for TEPEZZA drug substance of €100.9 million ($113.4 million converted at an exchange rate as of June 30, 2020 of 1.1236), to be delivered through June 2022. In addition, the Company had binding purchase commitments with ~~AGC Biologics for teprotumumab drug substance of €35.4 million ($40.2 million converted at an exchange rate of 1.1372 as of June 30, 2019), to be delivered through September 2020, and with~~ Catalent for ~~teprotumumab~~TEPEZZA drug product of ~~$2.3~~$17.7 million, to be delivered through ~~December 2019.~~

Patheon Pharmaceuticals Inc. (“Patheon”) is obligated to manufacture PROCYSBI for the Company through December 31, 2021. The Company must provide Patheon with rolling, non-binding forecasts of PROCYSBI, with a portion of the forecast being a firm written order. Cambrex Profarmaco Milano (“Cambrex”) is obligated to manufacture PROCYSBI active pharmaceutical ingredient (“API”) for the Company through November 2, 2020. The Company must provide Cambrex with rolling, non-binding forecasts, with a portion of the forecast being the minimum floor of the firm order that must be placed. At June 30, ~~2019,~~2020, the Company had a binding purchase commitment with Patheon for PROCYSBI of ~~$1.2~~$1.4 million, to be delivered through December ~~2019,~~2020 and with Cambrex for PROCYSBI API of ~~$0.8~~$1.2 million, to be delivered through ~~December~~October 2020.

Under an agreement with Boehringer Ingelheim Biopharmaceuticals GmbH (“Boehringer Ingelheim Biopharmaceuticals”), Boehringer Ingelheim Biopharmaceuticals is required to manufacture and supply ACTIMMUNE and IMUKIN to the Company. Following the Company’s sale of the rights to IMUKIN ~~sale,~~in all territories outside of the United States, Canada and Japan to Clinigen Group plc (“Clinigen”), purchases ~~by the Company~~ of IMUKIN inventory are ~~expected to be sold~~being resold to Clinigen. The Company is required to purchase minimum quantities of finished medicine during the term of the agreement, which term extends to at least June 30, 2024. As of June 30, ~~2019,~~2020, the minimum ~~binding~~ purchase commitment to Boehringer Ingelheim Biopharmaceuticals was ~~$20.1~~$15.1 million (converted using a Dollar-to-Euro exchange rate of ~~1.1372)~~1.1236 as of June 30, 2020) through ~~July~~June 2024. As of June 30, ~~2019,~~2020, the Company also committed to incur an additional ~~$0.8~~$0.4 million for the harmonization of the drug substance manufacturing process with Boehringer Ingelheim Biopharmaceuticals.

Under the Company’s agreement with Bio-Technology General (Israel) Ltd (“BTG Israel”), the Company has agreed to purchase certain minimum annual order quantities and is obligated to purchase at least ~~eighty~~80 percent of its annual world-wide bulk product requirements for KRYSTEXXA from BTG Israel. The term of the agreement runs until December 31, 2030, and will automatically renew for successive three-year periods unless earlier terminated by either party upon three years’ prior written notice. The agreement may be terminated earlier by either party in the event of a force majeure, liquidation, dissolution, bankruptcy or insolvency of the other party, uncured material breach by the other party or after January 1, 2024, upon three years’ prior written notice. Under the agreement, if the manufacture of the bulk product is moved out of Israel, the Company may be required to obtain the approval of the Israel Innovation Authority (formerly known as Israeli Office of the Chief Scientist) (“IIA”) because certain KRYSTEXXA intellectual property was initially developed with a grant funded by the IIA. The Company issues eighteen-month forecasts of the volume of KRYSTEXXA that the Company expects to order. The first ~~six~~nine months of the forecast are considered binding firm orders. At June 30, ~~2019,~~2020, the Company had a ~~binding~~total purchase commitment, including the minimum annual order quantities and binding firm orders with BTG Israel, for KRYSTEXXA of ~~$48.7~~$38.0 million, to be delivered through December ~~31,~~ 2026. Additionally, there were other purchase orders relating to the manufacture of KRYSTEXXA of ~~$0.9~~$0.8 million ~~were~~ outstanding at June 30, ~~2019.~~

Jagotec or its affiliates are required to manufacture and supply RAYOS exclusively to the Company in bulk. The earliest the agreement can expire is December 31, 2023, and the minimum purchase commitment is in force until December 2023. At June 30, 2019, the minimum purchase commitment based on tablet pricing in effect under the agreement was $4.3 million through December 2023. Additionally, purchase orders relating to the manufacture of RAYOS of $0.6 million were outstanding at June 30, 2019. Effective January 1, 2019, the Company amended its license and supply agreements with Jagotec AG and Skyepharma AG, which are affiliates of Vectura. Under these amendments, from the earlier of the completion of certain transfer activities related to the transfer of the Company’s rights to LODOTRA in Europe, or January 1, 2020, the Company will no longer be subject to a minimum purchase commitment in respect of the supply agreement with Jagotec AG.

Nuvo Pharmaceuticals Inc. (formerly known as Nuvo Research Inc.) (“Nuvo”) is obligated to manufacture and supply PENNSAID 2% to the Company. The term of the supply agreement is through December 31, 2029, but the agreement may be terminated earlier by either party for any uncured material breach by the other party of its obligations under the supply agreement or upon the bankruptcy or similar proceeding of the other party. At least ninety days prior to the first day of each calendar month during the term of the supply agreement, the Company submits a binding written purchase order to Nuvo for PENNSAID 2% in minimum batch quantities. At June 30, ~~2019,~~2020, the Company had a binding purchase commitment with Nuvo for PENNSAID 2% of ~~$5.0~~$4.1 million, to be delivered through ~~December 2019.~~November 2020.

Sanofi-Aventis U.S. ~~LLC (“Sanofi-Aventis U.S.”)~~ is obligated to manufacture and supply DUEXIS to the Company in final, packaged form and the Company is obligated to purchase DUEXIS exclusively from Sanofi-Aventis U.S. for the commercial requirements of DUEXIS in North America, South America and certain countries and territories in ~~Europe, including the European Union (“EU”) member states and Scandinavia.~~Europe. The agreement term extends until May ~~2021 and automatically renews for successive two-year terms unless terminated by either party upon two years’ prior written notice.~~2023. At June 30, ~~2019,~~2020, the Company had a binding purchase commitment to Sanofi-Aventis U.S. for DUEXIS of ~~$7.2~~$5.8 million, to be delivered through December ~~2019.~~2020.

Excluding the above, additional purchase orders and other commitments relating to the manufacture of RAVICTI, BUPHENYL, RAYOS and QUINSAIR ~~and VIMOVO~~ of ~~$8.2~~$8.4 million were outstanding at June 30, ~~2019.~~2020.

The Company is subject to claims and assessments from time to time in the ordinary course of business. The Company’s management does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company’s business, financial condition, results of operations or cash flows. In addition, the Company from time to time has billing disputes with vendors in which amounts invoiced are not in accordance with the terms of their contracts.

In November 2015, the Company received a subpoena from the U.S. Attorney’s Office for the Southern District of New York requesting documents and information related to its patient ~~access~~assistance programs and other aspects of its marketing and commercialization activities. The Company is unable to predict how long this investigation will continue or its outcome, but it anticipates that it may continue to incur significant costs in connection with the investigation, regardless of the outcome. The Company may also become subject to similar investigations by other governmental agencies. The investigation by the U.S. Attorney’s Office and any additional investigations of the Company’s patient ~~access~~assistance programs and sales and marketing activities may result in damages, fines, penalties or other administrative sanctions against the Company.

On March 5, 2019, the Company received a civil investigative demand (“CID”) from the United States Department of Justice (“DOJ”) pursuant to the Federal False Claims Act regarding assertions that certain of the Company’s payments to pharmacy benefit managers (“PBMs”) were potentially in violation of the Anti-Kickback Statute. The CID requests certain documents and information related to the Company’s payments to PBMs, pricing and the Company’s patient assistance program regarding DUEXIS, VIMOVO and PENNSAID 2%. The Company is cooperating with the investigation. While the Company believes that its payments and programs are compliant with the Anti-Kickback Statute, no assurance can be given as to the timing or outcome of the DOJ’s investigation, or that it will not result in a material adverse effect on the Company’s business.

On April 1, 2020, the Company acquired Curzion for an upfront cash payment of $45.0 million with additional payments of up to $15.0 million contingent on the achievement of certain development and regulatory milestones. Under ~~the agreement for the acquisition of River Vision Development Corp.,~~separate agreements, the Company is also required to make contingent payments upon the achievement of certain development and regulatory milestones and certain net sales thresholds. These separate agreements also include mid to high-single-digit royalty payments based on the portion of annual worldwide net sales.

Under the acquisition agreement for River Vision, the Company agreed to pay up to $325.0 million upon the attainment of various milestones, composed of $100.0 million related to ~~U.S. Food and Drug Administration (“FDA”)~~FDA approval and $225.0 million related to net sales thresholds for ~~teprotumumab.~~ TEPEZZA. The Company made the $100.0 million milestone payment related to FDA approval during the first quarter of 2020.

The aggregate potential milestone payments of $225.0 million are payable based on certain TEPEZZA worldwide net sales thresholds being achieved as noted in the following table:

The agreement also includes a royalty payment of ~~three~~3 percent of the portion of annual worldwide net sales exceeding $300.0 million (if any).

S.R. One and Lundbeckfond, as two of the former River Vision stockholders, both held rights to receive approximately 35.66% of any future TEPEZZA payments. As a result of the Company’s agreements with S.R. One and Lundbeckfond in April 2020, the Company’s remaining net obligations to make TEPEZZA payments to the former stockholders of River Vision was reduced by approximately 70.25%, after including payments to a third party.

Under ~~a separate~~the Company’s license agreement with ~~F. Hoffmann-La~~ Roche, ~~Ltd and Hoffmann-La Roche Inc. (together referred to as “Roche”),~~ the Company is required to pay Roche up to CHF103.0 million ~~($105.5~~($108.7 million when converted using a CHF-to-Dollar exchange rate at June 30, ~~2019~~2020 of ~~1.0243)~~ 1.0556) upon the attainment of various development, regulatory and sales milestones ~~related to filing, approval~~for TEPEZZA. During the years ended December 31, 2019 and ~~net sales thresholds for teprotumumab. In connection with submission of the~~2017, ~~teprotumumab biologics license application (“BLA”), the Company incurred a milestone of~~ CHF3.0 million ($~~3.1~~3.0 million when converted using a CHF-to-Dollar exchange rate at ~~June 30, 2019~~the date of ~~1.0243) payable to Roche which will be recorded~~payment of 1.0023) and ~~paid during the third quarter of 2019.~~ ~~During the year ended December 31, 2017,~~ CHF2.0 million ($2.0 million when converted using a CHF-to-Dollar exchange rate at the date of payment of 1.0169), respectively, was paid in relation to these milestones. The Company made a milestone payment of CHF5.0 million ($5.2 million when converted using a CHF-to-Dollar exchange rate at the date of payment of 1.0382) during the first quarter of 2020. The agreement with Roche also includes ~~a royalty payment of between nine percent and twelve percent of~~tiered royalties on annual worldwide net ~~sales.~~ sales between 9 and 12 percent.

As of June 30, 2020, the Company recorded a liability of $98.7 million in accrued expenses representing net sales milestones for TEPEZZA, composed of $67.0 million in relation to the expected future attainment of various net sales milestones payable under the acquisition agreement for River Vision and CHF30.0 million ($31.7 million when converted using a CHF-to-Dollar exchange rate as of June 30, 2020 of 1.0556) in relation to the expected future attainment of various net sales milestones payable to Roche. The timing of the payments is dependent on when the applicable milestone thresholds are attained. In addition, the Company recorded a corresponding amount of $98.7 million as a finite lived intangible asset representing the developed technology for TEPEZZA on the condensed consolidated balance sheet as of June 30, 2020.

Under ~~a separate~~the Company’s license agreement with Lundquist Institute (formerly known as Los Angeles Biomedical Research Institute at Harbor-UCLA Medical ~~Center~~Center) (“~~LA BioMed”~~Lundquist”), the Company is required to pay ~~LA BioMed~~Lundquist a royalty payment of less than ~~one~~1 percent of TEPEZZA net sales.

Under the Company’s license agreement with Boehringer Ingelheim Biopharmaceuticals, the Company is required to pay Boehringer Ingelheim Biopharmaceuticals milestone payments totaling low-single-digit million Euros upon the achievement of certain TEPEZZA sales milestones.

In July 2020, the Company invested as a strategic limited partner in two venture capital funds: Forbion Growth Opportunities Fund I C.V. (the “Forbion Fund”) and Aisling Capital V, LP (the “Aisling Fund”). The Company is committed to investing an aggregate $34.6 million in the two funds, comprising of a $20.0 million commitment to the Aisling Fund and a €13.0 million ($14.6 million when converted using a EUR-to-Dollar exchange rate at June 30, 2020 of 1.1236) commitment to the Forbion Fund, over each fund’s respective investment periods.

In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. The Company may record charges in the future as a result of these indemnification obligations.

In accordance with its memorandum and articles of association, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Company’s request in such capacity. Additionally, the Company has entered into, and intends to continue to enter into, separate indemnification agreements with its directors and executive officers. These agreements, among other things, require the Company to indemnify its directors and executive officers for certain expenses, including attorneys’ fees, judgments, fines and settlement amounts incurred by a director or executive officer in any action or proceeding arising out of their services as one of the Company’s directors or executive officers, or any of the Company’s subsidiaries or any other company or enterprise to which the person provides services at the Company’s request. The Company also has a director and officer insurance policy that enables it to recover a portion of any amounts paid for current and future potential claims. All of the Company’s officers and directors have also entered into separate indemnification agreements with ~~HPUSA.~~HTUSA.

~~On March 17, 2014, Hyperion received notice from Par Pharmaceutical, Inc. (“Par Pharmaceutical”) that it had filed an Abbreviated New Drug Application (an “ANDA”) with the~~ ~~FDA~~ seeking approval for a generic version of the Company’s medicine RAVICTI. On September 4, 2015 and November 6, 2015, the Company received notices from Lupin Limited of Lupin Limited’s Paragraph IV Patent Certification against the Company’s patents covering RAVICTI, advising that Lupin Limited had filed an ANDA with the FDA for a generic version of RAVICTI. The Company subsequently filed suits against Par Pharmaceutical and Lupin Limited, and engaged in ANDA litigation with both in multiple venues. All litigation with Par Pharmaceutical and Lupin Limited, relating to RAVICTI, is now settled.

The Company is still pursuing an appeal before the Federal Circuit Court of Appeals over U.S. Patent No. 9,095,559 against the United States Patent Office, seeking to overturn the Patent Trial and Appeal Board’s invalidity finding in an inter partes review (“IPR”) initiated by Lupin Limited.

On November 13, 2014, the Company received a Paragraph IV Patent Certification from Watson Laboratories, Inc., now known as Actavis Laboratories UT, Inc. (“Actavis UT”), advising that Actavis UT had filed an ~~ANDA~~Abbreviated New Drug Application (“ANDA”) with the FDA for a generic version of PENNSAID 2%. On December 23, 2014, June 30, 2015, August 11, 2015 and September 17, 2015, the Company filed four separate suits against Actavis UT and Actavis plc (collectively “Actavis”), in the United States District Court for the District of New Jersey, with each of the suits seeking an injunction to prevent approval of the ANDA. The lawsuits alleged that Actavis has infringed nine of the Company’s patents covering PENNSAID 2% by filing an ANDA seeking approval from the FDA to market a generic version of PENNSAID 2% prior to the expiration of certain of the Company’s patents listed in the FDA’s Orange Book (the “Orange Book”). These ~~four~~4 suits were consolidated into a single suit. On October 27, 2015 and on February 5, 2016, the Company filed ~~two~~2 additional suits against Actavis, in the United States District Court for the District of New Jersey, for patent infringement of ~~three~~3 additional Company patents covering PENNSAID 2%.

On August 17, 2016, the District Court issued a Markman opinion holding certain of the asserted claims of seven of the Company’s patents covering PENNSAID 2% invalid as indefinite. On March 16, 2017, the Court granted Actavis’ motion for summary judgment of non-infringement of the asserted claims of three of the Company’s patents covering PENNSAID 2%. In view of the Markman and summary judgment decisions, a bench trial was held from March 21, 2017 through March 30, 2017, regarding a claim of one of the Company’s patents covering PENNSAID 2%. On May 14, 2017, the Court issued its opinion upholding the validity of the claim of the patent, which Actavis had previously admitted its proposed generic diclofenac sodium topical solution product would infringe. Actavis filed its Notice of Appeal on June 16, 2017. The Company also filed its Notice of Appeal of the District Court’s rulings on certain claims of ~~eleven of~~ the Company’s patents covering PENNSAID 2%. ~~The parties are awaiting the decision of~~On October 10, 2019, the Federal Circuit Court of ~~Appeals.~~Appeals affirmed the District Court’s judgment of validity of U.S Patent No. 9,066,913 (the “‘913 patent”), and its finding that the Actavis generic product would infringe the ‘913 patent. The Federal Circuit also affirmed the District Court’s summary judgment finding that certain patents are invalid for indefiniteness and would not be infringed.

On August 18, 2016, the Company filed suit in the United States District Court for the District of New Jersey against Actavis for patent infringement of four of the Company’s newly issued patents covering PENNSAID 2%. All four of such patents are listed in the Orange Book. This litigation is currently stayed by agreement of the parties. The Company received from Actavis a Paragraph IV Patent Certification notice, dated September 27, 2016, against an additional newly issued patent covering PENNSAID 2%, advising that Actavis had filed an ANDA with the FDA for a generic version of PENNSAID 2%. The subject patent is listed in the Orange Book.

On March 29, 2019, the Company received notice from Aurolife Pharma, Inc. (“Aurolife”) that it had filed an ANDA with the FDA seeking approval for a generic version of PENNSAID 2%. The ANDA contained a Paragraph IV Patent Certification alleging that the patents covering PENNSAID 2% are invalid and/or will not be infringed by Aurolife’s manufacture, use or sale of its generic version of PENNSAID 2%.

On May 29, 2018, the Company received notice from Alkem Laboratories, Inc. (“Alkem”) that it had filed an ANDA with the FDA seeking approval ~~for~~of a generic version of DUEXIS. The ANDA contained a Paragraph IV Patent Certification alleging that the patents covering DUEXIS are invalid and/or will not be infringed by Alkem’s manufacture, use or sale of the medicine for which the ANDA was submitted. The Company filed suit in the United States District Court of Delaware against Alkem on July 9, 2018, seeking an injunction to prevent the approval of Alkem’s ANDA and/or to prevent Alkem from selling a generic version of DUEXIS. The litigation is scheduled for a bench trial beginning on September 14, 2020.

On September ~~27,~~26, 2018, the Company received notice from Teva Pharmaceuticals USA, Inc. (“~~Teva”~~Teva USA”) that it had filed an ANDA with the FDA seeking approval ~~for~~of a generic version of DUEXIS. The ANDA contained a Paragraph IV Patent Certification alleging that the patents covering DUEXIS are invalid and/or will not be infringed by ~~Teva’s~~Teva USA’s manufacture, use or sale of ~~its~~the medicine for which the ANDA was submitted. The Company filed suit in the United States District Court of New Jersey against Teva USA on July 2, 2020, seeking an injunction to prevent the approval of Teva USA’s ANDA and/or to prevent Teva USA from selling a generic version of DUEXIS.

~~Currently, patent litigation is pending in~~On February 18, 2020, the ~~United States District Court~~FDA granted final approval for ~~the District of New Jersey and the Court of Appeals for the Federal Circuit against~~ Dr. Reddy’s Laboratories Inc. and Dr. Reddy’s Laboratories Ltd. (collectively, “Dr. Reddy’s”) ~~which seeks to market~~ generic version of VIMOVO. On February 27, 2020, Dr. Reddy’s launched its generic version of VIMOVO ~~prior to the expiration of certain of the Company’s patents listed~~ in the ~~Orange Book.~~United States, and the Company now faces generic competition with respect to VIMOVO. The Company continues to assert claims of infringement against Dr. Reddy’s based on U.S. Patent No. 8,858,996 and U.S. Patent No. 9,161,920 in the District Court for the District of New Jersey. Settlements ~~have been~~were reached with ~~three~~four other generic companies: (i) Teva Pharmaceuticals Industries Limited (formerly known as Actavis Laboratories FL, Inc., which itself was formerly known as Watson Laboratories, Inc. – Florida) and Actavis Pharma, Inc. (collectively, “Actavis Pharma”), (ii) ~~Lupin;~~Lupin Limited (“Lupin”) and Lupin Pharmaceuticals, Inc., (iii) Mylan Pharmaceuticals Inc., Mylan Laboratories Limited, and Mylan Inc. (collectively, “Mylan”), and (iv) Ajanta Pharma Ltd. and Ajanta Pharma USA Inc. (collectively, “Ajanta”). Under the ~~Settlement Agreements,~~settlement agreements, the license entry date ~~is now~~was August 1, 2024; however, the entry date under all ~~three may be able to enter~~four licenses was accelerated and the ~~market earlier in certain circumstances.~~

~~The Company understands that~~licenses became effective upon Dr. Reddy’s ~~has entered into a settlement with AstraZeneca with respect to patent rights directed to Nexium~~^® (esomeprazole) for the commercialization of VIMOVO. The settlement agreement, however, has no effect on the Nuvo VIMOVO patents, which are still the subject of patent litigations. As part of the Company’s acquisition of the U.S. rights to VIMOVO, the Company has taken over and is responsible for the patent litigation that includes the Nuvo patents licensed to the Company under the amended and restated collaboration and license agreement for the United States with Nuvo.

The VIMOVO cases were filed on April 21, 2011, July 25, 2011, October 28, 2011, January 4, 2013, May 10, 2013, June 28, 2013, October 23, 2013, May 13, 2015 and November 24, 2015 and collectively include allegations of infringement of certain of the Company’s patents covering VIMOVO.

The District Court consolidated all of the cases pending against the generic companies into two separate cases for purposes of discovery. The District Court entered final judgment for one of the consolidated cases on July 21, 2017, upholding the validity of the ‘907 and ‘285 patents, and finding the generic products would infringe one or both of the two patents. Both sides appealed the District Court’s judgment to the Court of Appeals for the Federal Circuit. On May 15, 2019, the Federal Circuit reversed the District Court’s judgment in favor of the Company, and entered judgment that the ‘285 and ‘907 patents are invalid for lack of a sufficient written description. On July 30, 2019, the Federal Circuit Court of Appeals denied the Company’s request for a rehearing of the Court’s invalidity ruling against the ‘285 and ‘907 patents for VIMOVO coordinated-release tablets. As a result, the District Court will enter judgment invalidating the ‘285 and ‘907 patents, which could subsequently result in Dr. Reddy’s initiating an at-risk launch of aits generic version of ~~VIMOVO.~~

On November 19, 2018, the District Court granted Dr. Reddy’s and Mylan’s summary judgment ruling that U.S Patent Numbers 9,220,698 and 9,393,208 are invalid, and on January 21, 2019, it entered final judgment against the ‘698 and ‘208 patents and U.S. Patent Number 8,945,621. On February 21, 2019, the Company appealed the adverse judgments on the ‘208 and ‘698 patents to the Federal Circuit Court of Appeals. This appeal remains pending before the Federal Circuit.

On December 4, 2017, Mylan filed a Petition for ~~IPR~~inter partes review (“IPR”) against the ‘208 patent. The ~~PTAB~~Patent Trial and Appeals Board (“PTAB”) instituted an IPR proceeding on Mylan’s Petition on June 14, 2018. On July 2, 2018, Dr. Reddy’s filed a motion seeking to join Mylan’s ‘208 IPR. On April 1, 2019, the PTAB granted Dr. Reddy’s request to join the Mylan ‘208 IPR. ~~The parties are awaiting~~On September 6, 2019, the PTAB issued a Final Written Decision invalidating the ‘208 patent on the basis of obviousness. On November 18, 2019, the Company filed an appeal with the Federal Circuit Court of Appeals to review the PTAB’s ruling invalidating the ‘208 patent. On April 17, 2020, the Federal Circuit vacated the PTAB’s decision and remanded the case to the PTAB for proceedings consistent with the Federal Circuit’s decision in Arthrex, Inc. v. Smith & Nephew, Inc.

On July 22, 2020, the Company received notice from Anchen Pharmaceuticals, Inc. (“Anchen”) that it had filed an ANDA with the FDA seeking approval of a generic version of VIMOVO. The ANDA previously contained a Paragraph III Patent Certification, and the notice advised that Anchen has now made a Paragraph IV Patent Certification alleging that the patents covering VIMOVO are invalid and/or will not be infringed by Anchen’s manufacture, use or sale of the medicine for which ~~is expected by September 8, 2019.~~the ANDA was submitted.

On ~~February 28, 2019,~~June 27, 2020, the Company ~~entered into~~received notice from Lupin that it had filed an ANDA with the FDA seeking approval of a ~~Rights Agreement (the “Rights Agreement”), with Computershare Trust Company, N.A., as rights agent.~~generic version of PROCYSBI. The ~~Board of Directors~~ANDA contained a Paragraph IV Patent Certification alleging that the patents covering PROCYSBI are invalid and/or will not be infringed by Lupin’s manufacture, use or sale of the medicine for which the ANDA was submitted. The Company ~~(the “Board”) has authorized~~anticipates future litigation against Lupin over the ~~issuance of one ordinary share purchase right (a “Right”) for each outstanding ordinary share~~validity and infringement of the Company. Each Right represents the right to purchase one-fifth of an ordinary share of the Company, upon the terms and subject to the conditions of the Rights Agreement. The Rights were issued to the shareholders of record on March 11, 2019 and will expire on February 28, 2020.patents covering PROCYSBI.

The Board has adopted the Rights Agreement to enable all shareholders of the Company to realize the long-term value of their investment in the Company and to guard against attempts to acquire control of the Company at an inadequate price. In general terms, the Rights Agreement works by causing significant dilution to any person or group that acquires 10% (or 15% in the case of an existing “13G Investor” as defined in the Rights Agreement) or more of the outstanding ordinary shares of the Company without the prior approval of the Board. The Rights Agreement is not intended to prevent an acquisition of the Company on terms that the Board considers favorable to, and in the best interests of, all shareholders. Rather, the Rights Agreement aims to provide the Board with adequate time to fully assess any takeover proposal and therefore comply with its fiduciary duties and to encourage anyone seeking to acquire the Company to negotiate with the Board prior to attempting a takeover. The Rights Agreement was adopted in response to the takeover environment in general, particularly in light of the Company’s evolution into a biopharma company focused on rare diseases and rheumatology, the Phase 3 clinical trial results of its rare disease drug candidate teprotumumab announced on February 28, 2019 and the market opportunity for KRYSTEXXA and teprotumumab and was not in response to any specific approach to the Company or perceived imminent takeover proposal for the Company. The issuance of Rights is not taxable to the Company or to shareholders and does not affect reported earnings per share.

During the six months ended June 30, 2019, the Company issued an aggregate of 14.1 million of ordinary shares in connection with the closing of its underwritten public equity offering on March 11, 2019. The Company received a total of approximately $326.8 million after deducting underwriting discounts and other estimated offering expenses payable by the Company in connection with such offering.

During the six months ended June 30, 2019, the Company issued an aggregate of 3.1 million of ordinary shares in connection with stock option exercises, the vesting of restricted stock units and employee share purchase plan purchases. The Company received a total of $17.5 million in net proceeds in connection with such issuances.

~~During the six months ended June 30, 2019, the Company made payments of $24.4 million for employee withholding taxes relating to share-based awards.~~

~~On May 2, 2019, the shareholders of the Company approved an increase in the Company’s authorized share capital of an additional 300,000,000 ordinary shares of nominal value $0.0001 per share.~~

On May 2, 2019, the shareholders of the Company approved the renewal of the Board’s existing authority to allot and issue ordinary shares for cash and non-cash considerations under Irish law for a five-year period to expire on May 2, 2024. Additionally, on May 2, 2019, the shareholders of the Company approved the renewal of the Board’s existing authority to allot and issue ordinary shares for cash without first offering those ordinary shares to existing shareholders pursuant to the statutory pre-emption right that would otherwise apply under Irish law for a five-year period to expire on May 2, 2024.

The Company’s equity incentive plans at June 30, ~~2019, include~~2020 included its ~~2005 Stock Plan,~~ 2011 Equity Incentive Plan, as amended, 2014 Employee Share Purchase Plan, as amended (“2014 ESPP”), Amended and Restated 2014 Equity Incentive Plan (“2014 EIP”) ~~and~~, 2014 Non-Employee Equity Plan, as amended (“2014 Non-Employee Plan”), 2020 Employee Share Purchase Plan (“2020 ESPP”) and 2020 Equity Incentive Plan (“2020 EIP”).

On February 19, 2020, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) adopted, subject to shareholder approval, the 2020 EIP, as successor to and continuation of the 2014 EIP, including increasing the number of ordinary shares available for the grant of equity awards to the Company’s employees by an additional 6,900,000 shares. On April 30, 2020, the shareholders of the Company approved the 2020 EIP.

On February 19, 2020, the Compensation Committee adopted, subject to shareholder approval, the 2020 ESPP, as successor to and continuation of the 2014 ESPP, including increasing the number of ordinary shares available for issuance to the Company’s employees pursuant to the exercise of purchase rights by an additional 2,500,000 shares. On April 30, 2020, the shareholders of the Company approved the 2020 ESPP.

As of June 30, ~~2019,~~2020, an aggregate of ~~1,525,809~~3,360,057 ordinary shares were authorized and available for future issuance under the ~~2014~~2020 ESPP, an aggregate of ~~9,249,654~~12,440,055 ordinary shares were authorized and available for future grants under the ~~2014~~2020 EIP (of which 364,368 shares are to be used exclusively for grants of awards to individuals who were not previously employees or non-employee directors of the Company (or following a bona fide period of non-employment with the Company)) and an aggregate of ~~715,341~~574,193 ordinary shares were authorized and available for future grants under the 2014 Non-Employee Plan.

On February 20, 2019, the Compensation Committee of the Board (the “Compensation Committee”) approved, subject to shareholder approval, an amendment to the 2014 EIP, increasing the number of ordinary shares that may be issued under the 2014 EIP by 9,000,000 ordinary shares, subject to adjustment for certain changes in our capitalization. On May 2, 2019, the shareholders of the Company approved such amendment to the 2014 EIP.

On February 20, 2019, the Compensation Committee approved, subject to shareholder approval, an amendment to the 2014 Non-Employee Plan, increasing the number of ordinary shares that may be issued under the 2014 Non-Employee Equity Plan by 750,000 ordinary shares, subject to adjustment for certain changes in our capitalization. On May 2, 2019, the shareholders of the Company approved such amendment to the 2014 Non-Employee Plan.

The following table summarizes stock option activity during the six months ended June 30, ~~2019:~~2020:

	Options			Weighted Average Exercise Price		Weighted Average Contractual Term Remaining (in years)		Aggregate Intrinsic Value (in thousands)		Options			Weighted Average Exercise Price		Weighted Average Contractual Term Remaining (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding as of December 31, 2018		11,827,765		$	19.06		6.24	$	37,257
Outstanding as of December 31, 2019											9,564,202		$	19.85		5.43	$	156,270
Exercised		(776,977	)		15.49						(1,601,809	)		16.19		—		—
Forfeited		(97,159	)		23.41						(54,747	)		15.98		—		—
Expired		(326,019	)		29.76						(25,257	)		23.08		—		—
Outstanding as of June 30, 2019		10,627,610			18.95		5.83		64,048
Exercisable as of June 30, 2019		9,806,055		$	19.16		5.68	$	57,822
Outstanding as of June 30, 2020											7,882,389			20.62		5.06		275,601
Exercisable as of June 30, 2020											7,593,802		$	20.66		4.97	$	265,146

The following table summarizes restricted stock unit activity for the six months ended June 30, ~~2019:~~2020:

	Number of Units			Weighted Average Grant-Date Fair Value Per Unit		Number of Units			Weighted Average Grant-Date Fair Value Per Unit
Outstanding as of December 31, 2018		6,772,818		$	15.56
Outstanding as of December 31, 2019							6,541,224		$	18.77
Granted		3,113,029			20.93		2,494,655			35.47
Vested		(2,367,613	)		15.61		(2,432,224	)		17.93
Forfeited		(343,037	)		17.32		(300,535	)		24.02
Outstanding as of June 30, 2019		7,175,197		$	17.79
Outstanding as of June 30, 2020							6,303,120		$	25.23

The grant-date fair value of restricted stock units is the closing price of the Company’s ordinary shares on the date of grant.

The following table summarizes performance stock unit awards (“PSUs”) activity for the six months ended June 30, ~~2019:~~2020:

	Number of Units			Weighted Average Grant-Date Fair Value Per Unit		Average Illiquidity Discount			Recorded Weighted Average Fair Value Per Unit		Number of Units			Weighted Average Grant-Date Fair Value Per Unit		Average Illiquidity Discount			Recorded Weighted Average Fair Value Per Unit
Outstanding as of December 31, 2018		1,393,943
Outstanding as of December 31, 2019												3,558,900
Granted		2,290,632		$	25.31		0.8	%	$	25.12		587,802		$	42.38		8.1	%	$	38.94
Forfeited		(82,568	)		23.44		0.5	%		23.33		(211,065	)		25.58		4.2	%		24.51
Vested		(515,629	)		13.87		0.0	%		13.87		(1,393,960	)		20.82		0.0	%		20.82
Performance Based Adjustment (1)		560,746			13.87		0.0	%		13.87		89,941			20.24		0.0	%		20.24
Outstanding as of June 30, 2019		3,647,124
Outstanding as of June 30, 2020												2,631,618

On January 5, 2018, the Company awarded PSUs to key executive participants (“2018 PSUs”). Vesting of the 2018 PSUs was contingent upon receiving shareholder approval of amendments to the 2014 EIP, which were approved on May 3, 2018. The 2018 PSUs utilize two performance metrics, a short-term component tied to business performance and a long-term component tied to total compounded annual shareholder rate of return (“TSR”), as follows:

On January 4, 2019, the Company awarded PSUs to key executive participants (“2019 PSUs”). The 2019 PSUs utilize two performance metrics, a short-term component tied to business performance and a long-term component tied to relative compounded annual ~~TSR,~~shareholder rate of return (“TSR”), as follows:

On January 3, 2020, the Company awarded PSUs to key executive participants (“2020 PSUs”). The 2020 PSUs utilize two performance metrics, a short-term component tied to business performance and a long-term component tied to relative compounded annual TSR, as follows:

All PSUs outstanding at June 30, ~~2019,~~2020 may vest in a range of between 0% and 200%, based on the performance metrics described above. The Company accounts for the ~~2018~~2019 PSUs and ~~2019~~2020 PSUs as equity-settled awards in accordance with ASC 718. Because the value of the ~~2018~~2019 Relative TSR PSUs and ~~2019~~2020 Relative TSR PSUs are dependent upon the attainment of a level of TSR, it requires the impact of the market condition to be considered when estimating the fair value of the ~~2018~~2019 Relative TSR PSUs and ~~2019~~2020 Relative TSR PSUs. As a result, the Monte Carlo model is applied and the most significant valuation assumptions used related to the ~~2019~~2020 PSUs during the six months ended June 30, ~~2019,~~2020, include:

Valuation date stock price	$	20.39		$	36.10
Expected volatility		38.9	%		47.3	%
Risk free rate		2.6	%		1.5	%

The value of the ~~2018 Net Sales PSUs and 2019~~2020 Net Sales PSUs is calculated at the end of each quarter based on the expected payout percentage based on estimated ~~full period~~full-period performance against targets, and the Company adjusts the expense quarterly.

On January 4, 2019, the Company awarded a company-wide grant of PSUs (the ~~“Teprotumumab~~“TEPEZZA PSUs”). Vesting of the ~~Teprotumumab~~TEPEZZA PSUs was contingent upon receiving shareholder approval of amendments to the 2014 EIP, which approval was received on May 2, 2019. The ~~Teprotumumab~~TEPEZZA PSUs ~~are~~were generally eligible to vest contingent upon receiving approval of the ~~teprotumumab BLA~~TEPEZZA biologics license application from the FDA no later than September 30, 2020 and the employee’s continued service with the Company. AtIn January 2020, the Company received TEPEZZA approval from the FDA and the Company started recognizing the expense related to the TEPEZZA PSUs on that date. As of June 30, ~~2019,~~2020, there were ~~1,540,096 Teprotumumab~~717,618 TEPEZZA PSUs outstanding.

For members of the executive committee, one-third of the TEPEZZA PSUs vested on the FDA approval date and one-third will vest on each of the first two anniversaries of the FDA approval date, subject to the employee’s continued service through the applicable vesting dates. For all other participants, one-half of the TEPEZZA PSUs vested on the FDA approval date and one-half will vest on the one-year anniversary of the FDA approval date, subject to the employee’s continued service through the vesting date.

The following table summarizes share-based compensation expense included in the Company’s condensed consolidated statements of operations for the six months ended June 30, ~~2019~~2020 and ~~2018~~2019 (in thousands):

	For the Six Months Ended June 30,				For the Six Months Ended June 30,
	2019		2018		2020		2019
Share-based compensation expense
Cost of goods sold	$	1,990	$	1,893	$	3,977	$	1,990
Research and development		4,979		4,649		8,928		4,979
Selling, general and administrative		41,946		52,012		70,573		41,946
Total share-based compensation expense	$	48,915	$	58,554	$	83,478	$	48,915

During the six months ended June 30, ~~2019~~2020 and ~~2018,~~2019, the Company recognized $19.3 million and $4.2 million of tax benefit, ~~and $0.8 million of tax detriment,~~ respectively, related to share-based compensation resulting primarily from the ~~current share prices in effect~~fair value of equity awards at the time of the exercise of stock options and vesting of restricted stock ~~units.~~units and PSUs. As of June 30, ~~2019,~~2020, the Company estimates that pre-tax unrecognized compensation expense of ~~$133.4~~$166.5 million for all unvested share-based awards, including stock options, restricted stock units and PSUs, will be recognized through the ~~first~~second quarter of ~~2022.~~2023. The Company expects to satisfy the exercise of stock options and future distribution of shares for restricted stock units and PSUs by issuing new ordinary shares which have been reserved under the ~~2014~~2020 EIP.

The above table does not include expense related to the Teprotumumab PSUs as the recognition of expense related to these awards is not expected to commence until the Company receives approval of the teprotumumab BLA from the FDA.

On January 5, 2018, the Compensation Committee approved a performance cash incentive program for the Company’s executive leadership team, including its executive officers (the “Cash Incentive Program”). Participants receiving awards under the Cash Incentive Program are eligible to earn a cash bonus based upon the achievement of specified Company goals, which both performance criteria were met on or before December 31, 2018. The Company determined that the cash bonus award under the Cash Incentive Program is to be paid out at the maximum 150% target level of $14.1 million. The first ~~installment was~~and second installments were paid in January 2019 and January 2020, respectively, and the remaining ~~installments~~installment will vest and become payable in January ~~2020 and~~ 2021, subject to the participant’s continued services with the Company through ~~the applicable~~such vesting ~~dates,~~date, the date of any earlier change in control, or a termination due to death or disability.

The Company accounted for the Cash Incentive Program as a deferred compensation plan under ASC 710 and is recognizing the payout expense using straight-line recognition through the end of the 36-month vesting period. During the three and six months ended June 30, ~~2019,~~2020, the Company recorded an expense of ~~$1.2~~$0.9 million and ~~$2.3~~$1.9 million, respectively, to the condensed consolidated statement of comprehensive loss related to the Cash Incentive Program.

The Company accounts for income taxes based upon an asset and liability approach. Deferred tax assets and liabilities represent the future tax consequences of the differences between the financial statement carrying amounts of assets and liabilities versus the tax basis of assets and liabilities. Under this method, deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carryforwards. Deferred tax liabilities are recognized for taxable temporary differences. Deferred tax assets are reduced by valuation allowances when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are recorded at the currently enacted rates which will be in effect at the time when the temporary differences are expected to reverse in the country where the underlying assets and liabilities are located. The impact of tax rate changes on deferred tax assets and liabilities is recognized in the period in which the change is enacted.

The following table presents the expense (benefit) ~~expense~~ for income taxes for the three and six months ended June 30, ~~2019~~2020 and ~~2018~~2019 (in thousands):

During the three and six months ended June 30, 2020, the Company recorded an expense for income taxes of $83.0 million and $63.9 million, respectively. During the three and six months ended June 30, 2019, the Company recorded a benefit for income taxes of $4.9 million and $6.8 million, respectively. ~~During the three and six months ended June 30, 2018, the Company recorded an~~The increase in expense ~~for income taxes of $4.6 million and $5.6 million, respectively. The benefit~~ for income taxes recorded during the three and six months ended June 30, 2020 compared to the three and six months ended June 30, 2019 resulted primarily from ~~the net excess tax benefits recognized on share-based compensation, the release of a reserve related to an uncertain tax position and~~ the mix of pre-tax income and losses incurred in various tax ~~jurisdictions.~~jurisdictions and a $15.2 million provision recorded following the publication, on April 8, 2020, by the U.S. Department of the Treasury, of Final Regulations for Section 267A (commonly referred to as the “Anti-Hybrid Rules”). The Final Regulations for Section 267A permanently disallow for U.S. tax purposes certain interest expense accrued to a foreign related party during the year ended December 31, 2019. As a result, the Company recorded a write off of a deferred tax asset related to this interest expense during the three months ended June 30, 2020 and recognized a corresponding tax provision of $15.2 million. These increases in expense are partially offset by an increase in the tax benefits recognized on share-based compensation.

On July 16, 2019, HPUSA completed a private placement of $600.0 million aggregate principal amount of 5.5% Senior Notes due 2027 (the “2027 Senior Notes”) to several investment banks acting as initial purchasers, who subsequently resold the 2027 Senior Notes to persons reasonably believed to be qualified institutional buyers.

The Company used the net proceeds from the offering of the 2027 Senior Notes, together with approximately $65.0 million in cash on hand, to redeem or prepay $625.0 million of its outstanding debt, consisting of (i) the outstanding $225.0 million principal amount of its 2023 Senior Notes, (ii) the outstanding $300.0 million principal amount of its 2024 Senior Notes and (iii) $100.0 million of the outstanding principal amount of senior secured term loans under the Credit Agreement, as well as to pay the related premiums and fees and expenses, excluding accrued interest, associated with such redemption and prepayment. On July 10, 2019, the Company delivered notice to redeem the 2023 Senior Notes and 2024 Senior Notes with a redemption date of August 9, 2019. On July 16, 2019, the Company irrevocably deposited sufficient funds with the trustee to redeem the 2023 Senior Notes and 2024 Senior Notes on August 9, 2019.

The 2027 Senior Notes are HPUSA’s general unsecured senior obligations, rank equally in right of payment with all existing and future senior debt of HPUSA and rank senior in right of payment to any existing and future subordinated debt of HPUSA. The 2027 Senior Notes are effectively subordinate to all of the existing and future secured debt of HPUSA to the extent of the value of the collateral securing such debt.

The 2027 Senior Notes are unconditionally guaranteed on a senior basis by the Company and all of the Company’s restricted subsidiaries, other than HPUSA and certain immaterial subsidiaries, that guarantee the Credit Agreement. The guarantees are each guarantor’s senior unsecured obligations and rank equally in right of payment with such guarantor’s existing and future senior debt and senior in right of payment to any existing and future subordinated debt of such guarantor. The guarantees are effectively subordinated to all of the existing and future secured debt of each guarantor, including such guarantor’s guarantee under the Credit Agreement, to the extent of the value of the collateral securing such debt. The guarantees of a guarantor may be released under certain circumstances. The 2027 Senior Notes are structurally subordinated to all of the liabilities of the Company’s subsidiaries that do not guarantee the 2027 Senior Notes.

The 2027 Senior Notes accrue interest at an annual rate of 5.5% payable semiannually in arrears on February 1 and August 1 of each year, beginning on February 1, 2020. The 2027 Senior Notes will mature on August 1, 2027, unless earlier exchanged, repurchased or redeemed.

Except as described below, the 2027 Senior Notes may not be redeemed before August 1, 2022. Thereafter, some or all of the 2027 Senior Notes may be redeemed at any time at specified redemption prices, plus accrued and unpaid interest to the redemption date. At any time prior to August 1, 2022, some or all of the 2027 Senior Notes may be redeemed at a price equal to 100% of the aggregate principal amount thereof, plus a make-whole premium and accrued and unpaid interest to the redemption date. Also prior to August 1, 2022, up to 40% of the aggregate principal amount of the 2027 Senior Notes may be redeemed at a redemption price of 105.5% of the aggregate principal amount thereof, plus accrued and unpaid interest, with the net proceeds of certain equity offerings. In addition, the 2027 Senior Notes may be redeemed in whole but not in part at a redemption price equal to 100% of the principal amount plus accrued and unpaid interest and additional amounts, if any, to, but excluding, the redemption date, if on the next date on which any amount would be payable in respect of the 2027 Senior Notes, HPUSA or any guarantor is or would be required to pay additional amounts as a result of certain tax related events.

If the Company undergoes a change of control, HPUSA will be required to make an offer to purchase all of the 2027 Senior Notes at a price in cash equal to 101% of the aggregate principal amount thereof plus accrued and unpaid interest to, but not including, the repurchase date, subject to certain exceptions. If the Company or certain of its subsidiaries engages in certain asset sales, HPUSA will be required under certain circumstances to make an offer to purchase the 2027 Senior Notes at 100% of the principal amount thereof, plus accrued and unpaid interest to the repurchase date.

~~The indenture governing the~~ ~~2027 Senior Notes~~ contains covenants that limit the ability of the Company and its restricted subsidiaries to, among other things, pay dividends or distributions, repurchase equity, prepay junior debt and make certain investments, incur additional debt and issue certain preferred stock, incur liens on assets, engage in certain asset sales, merge, consolidate with or merge or sell all or substantially all of their assets, enter into transactions with affiliates, designate subsidiaries as unrestricted subsidiaries, and allow to exist certain restrictions on the ability of restricted subsidiaries to pay dividends or make other payments to the Company. Certain of the covenants will be suspended during any period in which the ~~2027 Senior Notes~~ ~~receive investment grade ratings. The indenture~~ ~~governing the 2027 Senior Notes~~ ~~also includes customary events of default.~~

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis should be read in conjunction with our condensed consolidated financial statements and the related notes that appear elsewhere in this report. This discussion contains forward-looking statements reflecting our current expectations that involve risks and uncertainties which are subject to safe harbors under the Securities Act of 1933, as amended, or the Securities Act, and the Securities Exchange Act of 1934, as amended, or the Exchange Act. These forward-looking statements include, but are not limited to, statements concerning our strategy and other aspects of our future operations, future financial position, future revenues, projected costs, expectations regarding demand and acceptance for our medicines, growth opportunities and trends in the market in which we operate, prospects and plans and objectives of management. The words “anticipates”, “believes”, “estimates”, “expects”, “intends”, “may”, “plans”, “projects”, “will”, “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, the risks set forth in Part II, Item 1A, “Risk Factors” in this report and in our other filings with the Securities and Exchange Commission, or SEC. We do not assume any obligation to update any forward-looking statements.

Unless otherwise indicated or the context otherwise requires, references to “Horizon”, “we”, “us” and “our” refer to Horizon Therapeutics plc ~~(formerly known as Horizon Pharma plc)~~ and its consolidated subsidiaries.

When accounting for business combinations under ASC Topic 805, Business Combinations, we previously separately identified and recorded at fair value intangible assets acquired and their related third-party contingent royalties at the date of acquisition. Third-party contingent royalties are royalties payable to parties other than sellers of the businesses. Effective January 1, 2019, we retrospectively changed our accounting for business combinations and we now record acquired intangible assets and their related third-party contingent royalties on a net basis, or the New Method. We changed our accounting principle on the basis that the use of the New Method is preferable primarily due to improved comparability with our peers. We adjusted the accompanying condensed consolidated balance sheet as at December 31, 2018, the condensed consolidated statement of comprehensive loss for the three and six months ended June 30, 2018 and the condensed consolidated statement of cash flows for the six months ended June 30, 2018, and the adjusted amounts are presented herein. There was no impact on total operating, investing or financing cash flows for any period. In addition, there was no impact from the change in accounting principle on our previously reported adjusted EBITDA, non-GAAP net income and non-GAAP diluted earnings per share for any prior period.

~~Horizon is~~We are focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives.

On January 21, 2020, the U.S. Food and Drug Administration, or FDA, approved TEPEZZA® (teprotumumab-trbw), for the treatment of thyroid eye disease, or TED, a serious, progressive and vision-threatening rare autoimmune condition.

We have two reportable segments, (i) the orphan segment (previously the orphan and rheumatology ~~segment,~~segment), our strategic growth business, and (ii) the inflammation segment, ~~(previously the primary care segment),~~ and we report net sales and segment operating income for each segment. Effective in the first quarter of 2020, we (i) reorganized our commercial operations and moved responsibility for and reporting of RAYOS^® to the inflammation segment and (ii) renamed the orphan and rheumatology segment the orphan segment. Net sales generated by TEPEZZA, which was approved in the first quarter of 2020, are reported as part of the renamed orphan segment.

~~Our marketed medicines are:~~As of June 30, 2020, our medicine portfolio consisted of the following:

Since January 1, ~~2018,~~2019, we completed the following acquisitions and divestitures:

~~We aspire to be~~Horizon today is a leading ~~rare disease~~ biopharma company ~~that delivers~~focused on rare diseases, delivering innovative therapies to patients and ~~generates high returns~~generating value for our shareholders. Our strategy is to ~~build a robust and differentiated pipeline and to~~ maximize the ~~growth~~benefit and value of our ~~marketed~~key growth drivers TEPEZZA and KRYSTEXXA, both rare disease medicines, ~~in particular, KRYSTEXXA,~~and expand our ~~medicine~~pipeline for ~~uncontrolled gout.~~sustainable growth. We ~~are executing on~~believe our strategy ~~by accelerating~~allows more patients to benefit from our on-market medicines and the ~~growth~~medicines we develop as part of our ~~rare disease medicine portfolio through differentiated commercial strategies, business development efforts,~~pipeline. Our vision is to build healthier communities, urgently and ~~the expansion~~responsibly, which in turn, we believe, generates value for our many stakeholders, including our shareholders.

As of June 30, 2020, our orphan segment consisted of our ~~pipeline with post-marketing and development-stage programs. We are strongly committed to helping ensure patients have access to~~ medicines ~~and support services and to investing in the further development of medicines for patients with rare or underserved diseases.~~

On May 2, 2019, our shareholders approved changing our name from “Horizon Pharma Public Limited Company” to “Horizon Therapeutics Public Limited Company”. We believe that the name “Horizon Therapeutics Public Limited Company” better reflects our long-term strategy to develop and commercialize innovative new medicines to address rare diseases with very few effective treatment options.

TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL and ~~QUINSAIR~~QUINSAIR.

TEPEZZA is the first and only FDA-approved medicine for the treatment of TED, a serious, progressive and vision-threatening rare autoimmune condition. TEPEZZA was launched commercially shortly after receiving FDA approval for the treatment of TED on January 21, 2020. The FDA approval was obtained well in advance of the TEPEZZA Prescription User Fee Act (PDUFA) action date of March 8, 2020, after an accelerated review of the medicine and its statistically significant Phase 3 data. We believe TEPEZZA represents a significant driver of potential future growth for Horizon.

Our commercialization strategy for TEPEZZA has four components: (i) driving uptake by continuing to define the role of TEPEZZA in the treatment of TED and promoting the medicine to treating physicians and TED patients; (ii) continuing to develop the TED market by driving awareness of the disease severity and benefits of treatment, educating the appropriate treating physicians on the urgency to diagnose and treat TED and continuing to drive patients’ awareness of TED; (iii) supporting TEPEZZA with our comprehensive approach that includes a high-touch, patient-centric model; and (iv) facilitating patient and physician access to TEPEZZA. Our launch followed significant market preparation investment in TEPEZZA in 2019 to drive awareness about TED in the medical and patient community and establish a potential pathway for treatment. Our pre-launch market preparation initiatives have proved effective in driving the highly successful launch of TEPEZZA, which has significantly exceeded expectations.

Our clinical strategy for TEPEZZA is to maximize the potential of the medicine for patients. In July 2020, we announced new topline results from our OPTIC-X open-label clinical trial, an extension trial of OPTIC, the TEPEZZA Phase 3 pivotal confirmatory clinical trial, as well as data from the OPTIC 48-week off-treatment follow-up period. OPTIC-X results demonstrated that 89 percent of patients who received placebo during OPTIC and then entered OPTIC-X and received TEPEZZA achieved the primary endpoint of 2 mm or more reduction in proptosis at Week 24. These patients had TED diagnoses for an average of one year compared with an average of six months in OPTIC. The results of the OPTIC 48-week off-treatment follow-up period demonstrated the majority of TEPEZZA patients who were proptosis responders at Week 24 of OPTIC maintained their proptosis response at Week 72 without receiving additional TED treatment. Of the small number of TEPEZZA patients who relapsed during the OPTIC follow-up period, the majority experienced improvements in proptosis with an additional course of TEPEZZA in OPTIC-X.Additionally, in 2020, we announced plans to initiate three new TEPEZZA development programs: the evaluation of TEPEZZA in chronic (inactive) TED to support the broad indication received upon approval; the assessment of a subcutaneous route of administration; and an exploratory trial for TEPEZZA in the treatment of diffuse cutaneous systemic sclerosis (dcSSc) as part of our evaluation of additional indications for TEPEZZA. dcSSC is a rare, autoimmune rheumatic fibrotic disease, and scientific literature suggests that the mechanism of action of TEPEZZA could have an impact on fibrotic processes such as those that are relevant to dcSSC. The three TEPEZZA trials are expected to initiate in the second half of 2020.

Our other growth driver, KRYSTEXXA, is the only approved biologic indicated for the treatment of uncontrolled gout, or gout that is refractory (unresponsive) to conventional therapies. We are focused on optimizing and maximizing the benefit the medicine offers for patients as well as to maximize its peak sales potential which we are doing through: (i) our ~~marketed orphan medicines – all~~patient-centric commercialization efforts; (ii) the clinical evaluation of the use of immunomodulation with KRYSTEXXA; and (iii) investing in education, patient and physician outreach that demonstrates the benefits KRYSTEXXA offers in treating uncontrolled gout.

Three areas are driving growth for ~~rare diseases.~~ KRYSTEXXA: (i) an increase in new and existing accounts; (ii) accelerating uptake by nephrologists; and (iii) growth in the adoption of the use of KRYSTEXXA with immunomodulators such as methotrexate to improve the KRYSTEXXA response rate in patients with uncontrolled gout.

Our clinical strategy for KRYSTEXXA is primarily focused on evaluating the use of immunomodulation to improve the response rate of the medicine and increase the number of patients who can benefit from KRYSTEXXA. The body of evidence supporting the immunomodulation approach is growing. Results of several trials and case series using KRYSTEXXA with methotrexate, the immunomodulation agent most used by rheumatologists, demonstrated response rates ranging between 70 and 100 percent, significantly higher than the 42 percent response rate achieved in the KRYSTEXXA Phase 3 clinical program, which evaluated the use of KRYSTEXXA alone. We are currently evaluating the efficacy and safety of the concomitant use of KRYSTEXXA with methotrexate in our MIRROR placebo-controlled randomized controlled trial, or RCT. Initiated in June 2019, MIRROR RCT reached its target enrollment of 135 patients in July 2020. The registrational trial is designed to enable the potential submission of results to the FDA to update the prescribing information. The MIRROR RCT follows our MIRROR open-label trial, completed in 2019, which demonstrated a 79 percent complete response rate for patients using KRYSTEXXA with methotrexate. While our immunomodulation clinical program focuses on methotrexate, additional trials and case series have shown improved response rates through the use of other immunomodulation agents with KRYSTEXXA. Our immunomodulation strategy for KRYSTEXXA enables flexibility in the choice of immunomodulation agents physicians can use with their patients.

In addition to our immunomodulation program, we are investing to expand the use of KRYSTEXXA among nephrologists by providing additional data about the effectiveness of KRYSTEXXA in treating uncontrolled gout with its kidney-friendly mechanism of action. In October 2019, we initiated our PROTECT open-label trial to evaluate the use of KRYSTEXXA in adult uncontrolled gout patients who have undergone a kidney transplant, a population that was not originally studied in the KRYSTEXXA pivotal trials. We have achieved more than 50 percent enrollment in our PROTECT open-label clinical trial, and we expect to complete enrollment by the end of 2020. We have also announced plans to initiate an open-label trial to evaluate the impact of administering KRYSTEXXA over a shorter infusion duration, which could improve the experience and convenience for patients. We currently expect to initiate the KRYSTEXXA shorter-infusion duration trial in 2020.

Our strategy for RAVICTI, our medicine for the treatment of urea cycle disorders, is to drive growth through increased awareness and diagnosis of urea cycle disorders; to drive conversion to RAVICTI from older-generation nitrogen scavengers, such as generic forms of sodium phenylbutyrate based on the medicine’s differentiated benefits; to position RAVICTI as the first line of therapy; and to increase ~~awareness of label expansion of RAVICTI to position the medicine as first line of therapy. With respect to~~compliance rates.

Our strategy for PROCYSBI, our ~~strategy~~medicine for the treatment of nephropathic cystinosis, is to drive conversion of patients ~~to PROCYSBI~~ from older-generation immediate-release capsules of cysteamine bitartrate; to increase the ~~uptake~~use of the medicine by diagnosed but untreated patients; to identify previously undiagnosed patients who are suitable for treatment; ~~and increase awareness of the expanded label~~ to position PROCYSBI as a first line of ~~therapy.~~ therapy; and to increase compliance rates.

In February 2020, the FDA approved PROCYSBI Delayed-Release Oral Granules in Packets for adults and children one year of age and older living with nephropathic cystinosis. The PROCYSBI Delayed-Release Oral Granules in Packets product is the same as the currently available PROCYSBI capsules product except in respect of the packaging format. This dosage form, which became commercially available in April 2020, provides another administration option for patients in addition to the PROCYSBI capsules.

Our strategy ~~with respect to~~for ACTIMMUNE, our medicine for the treatment of chronic granulomatous disease, includes increasing awareness and diagnosis of chronic granulomatous disease and increasing ~~the persistence~~compliance rates.

As of June 30, 2020, our inflammation segment consisted of our medicines PENNSAID 2%, DUEXIS, RAYOS and ~~adherence to treatment.~~

With our May 2017 acquisition of River Vision Development Corp., or River Vision, we added the late-stage rare disease biologic medicine candidate teprotumumab to our pipeline. Teprotumumab targets the treatment of active thyroid eye disease, or TED, a debilitating autoimmune condition for which there is no approved treatment.VIMOVO. Our strategy for ~~teprotumumab is to support its continued clinical development and pursue regulatory approval.~~

On February 28, 2019, we reported statistically significant topline results from our Phase 3 confirmatory trial evaluating teprotumumab for the treatment of active TED. The study met its primary endpoint of the percentage of study participants with a 2 mm or more reduction in proptosis, or bulging of the eye, which is the main cause of morbidity in TED, at 24 weeks of treatment. The percent of patients treated with teprotumumab who had a meaningful improvement in proptosis was 82.9 percent compared to 9.5 percent of placebo patients. In addition, all secondary endpoints were met. The primary endpoint data was presented on April 26, 2019, at the Annual Scientific and Clinical Congress of the American Association of Clinical Endocrinologists (AACE). The safety profile of teprotumumab in the Phase 3 study was consistent with the Phase 2 study, which also met its primary endpoint and secondary endpoints, with the results published in The New England Journal of Medicine.

In July 2019, we submitted a biologics license application, or BLA, to the U.S. Food and Drug Administration, or FDA, seeking approval for teprotumumab for the treatment of active TED, with the potential for approval in 2020. In connection with submission of the BLA, we incurred a milestone of CHF3.0 million ($3.1 million when converted using a CHF-to-Dollar exchange rate at June 30, 2019 of 1.0243) payable to F. Hoffmann-La Roche Ltd, or Roche, which will be recorded and paid during the third quarter of 2019. Furthermore, we are currently investing in initiatives to prepare for the potential U.S. commercial launch of teprotumumab. Should we obtain FDA approval, we anticipate incurring significant additional costs related to the launch of the medicine and will also incur additional milestone payments, including $100.0 million payable to River Vision and CHF5.0 million ($5.1 million when converted using a CHF-to-Dollar exchange rate at June 30, 2019 of 1.0243) payable to Roche. If we do not obtain FDA approval, we expect to incur additional expense, including the write-off of advance payments for inventory of $9.0 million, inventory on hand of $3.6 million and other non-current assets of $4.3 million as of June 30, 2019, and payments related to purchase commitments of approximately $42.5 million. For further detail regarding purchase commitments, see Note 15, ~~Commitments and Contingencies,~~ ~~of the Notes to Condensed Consolidated Financial Statements, included in Item 1 of this Quarterly Report on Form 10-Q.~~

The rare disease medicine KRYSTEXXA is our primary marketed rheumatology medicine, the only approved medicine indicated for the treatment of uncontrolled gout, or gout that is refractory (unresponsive) to conventional therapies. We are focused on optimizing and maximizing the peak sales potential of KRYSTEXXA by expanding our commercialization efforts as well as investing in education, patient and physician outreach that demonstrates the benefits KRYSTEXXA offers in treating uncontrolled gout. In addition, we are investing in clinical development programs to increase the number of patients who can benefit from KRYSTEXXA by evaluating ways to improve its response rate. For example, our MIRROR clinical trial is evaluating the administration of KRYSTEXXA with methotrexate, the most commonly used immunomodulator by rheumatologists. We believe that KRYSTEXXA represents a significant opportunity as a growth driver within our orphan and rheumatology segment.

~~Our strategy with respect to~~ our inflammation segment medicines ~~which consist of PENNSAID 2%, DUEXIS and VIMOVO,~~ is to educate physicians about these clinically differentiated medicines and the benefits they offer. Patients are able to fill prescriptions for these medicines through pharmacies participating in our HorizonCares patient ~~access~~assistance program, as well as other pharmacies. We offer discount-card and other programs to patients under which the patient receives a discount on his or her prescription. In certain circumstances when a patient’s prescription is rejected by a managed care vendor, we will pay for the full cost of the prescription. In addition, we have entered into business arrangements with pharmacy benefit managers, or PBMs, and other payers to secure formulary status and reimbursement of our inflammation segment medicines. The business arrangements with the PBMs generally require us to pay administrative fees and rebates to the PBMs and other payers for qualifying prescriptions. Effective in the first quarter of 2020, we reorganized our commercial operations and moved responsibility for and reporting of RAYOS to the inflammation segment.

On February 18, 2020, the FDA granted final approval for Dr. Reddy’s Laboratories Inc. and Dr. Reddy’s Laboratories Ltd., or collectively Dr. Reddy’s, generic version of VIMOVO. On February 27, 2020, Dr. Reddy’s launched its generic version of VIMOVO in the United States, and we now face generic competition with respect to VIMOVO, which has negatively impacted net sales of VIMOVO in 2020. Patent litigation against Dr. Reddy’s for infringement continues with respect to certain patents in the New Jersey District Court. We have repositioned our promotional efforts previously directed to VIMOVO to our other inflammation segment medicines and expect that our VIMOVO net sales will continue to decrease in future periods.

We market all of our medicines in the United States through our field sales ~~force,~~forces, which numbered approximately ~~435~~450 representatives as of June 30, ~~2019.~~2020.

The table below should be referenced in connection with a review of the following discussion of our results of operations for the three months ended June 30, ~~2019,~~2020, compared to the three months ended June 30, ~~2018.~~2019.

	For the Three Months Ended June 30,									For the Three Months Ended June 30,
	2019			2018			Change			2020			2019			Change
	(in thousands)									(in thousands)
Net sales	$	320,647		$	302,835		$	17,812		$	462,779		$	320,647		$	142,132
Cost of goods sold		89,163			91,337			(2,174	)		121,515			89,163			32,352
Gross profit		231,484			211,498			19,986			341,264			231,484			109,780
Operating expenses:
Research and development		28,314			24,265			4,049			81,068			28,314			52,754
Selling, general and administrative		167,095			176,674			(9,579	)		222,332			167,095			55,237
Loss on sale of assets		10,963			—			10,963			—			10,963			(10,963	)
Total operating expenses		206,372			200,939			5,433			303,400			206,372			97,028
Operating income		25,112			10,559			14,553			37,864			25,112			12,752
Other expense, net:
Interest expense, net		(22,033	)		(31,030	)		8,997			(18,571	)		(22,033	)		3,462
Loss on debt extinguishment		(11,878	)		—			(11,878	)		(17,254	)		(11,878	)		(5,376	)
Foreign exchange gain (loss)		76			(5	)		81
Other (expense) income, net		(1,272	)		346			(1,618	)
Foreign exchange gain											283			76			207
Other income (expense), net											632			(1,272	)		1,904
Total other expense, net		(35,107	)		(30,689	)		(4,418	)		(34,910	)		(35,107	)		197
Loss before (benefit) expense for income taxes		(9,995	)		(20,130	)		10,135
(Benefit) expense for income taxes		(4,875	)		4,621			(9,496	)
Income (loss) before expense (benefit) for income taxes											2,954			(9,995	)		12,949
Expense (benefit) for income taxes											82,964			(4,875	)		87,839
Net loss	$	(5,120	)	$	(24,751	)	$	19,631		$	(80,010	)	$	(5,120	)	$	(74,890	)

Net sales. Net sales increased ~~$17.8~~$142.1 million, or ~~5.9%~~44.3%, to $462.7 million during the three months ended June 30, 2020, from $320.6 million during the three months ended June 30, ~~2019, from $302.8 million during the three months ended June 30, 2018.~~2019. The increase in net sales during the three months ended June 30, ~~2019~~2020 was primarily due to an increase in net sales in our orphan ~~and rheumatology~~ segment of ~~$21.8~~$176.0 million, primarily due to post-launch sales of TEPEZZA of $165.9 million, partially offset by a decrease in net sales in our inflammation segment of ~~$4.0~~$33.9 million.

The following table reflects net sales by medicine for the three months ended June 30, ~~2019~~2020 and ~~2018~~2019 (in thousands, except percentages):

	Three Months Ended June 30,				Change			Change			Three Months Ended June 30,				Change			Change
	2019		2018		$			%			2020		2019		$			%
TEPEZZA											$	165,936	$	—	$	165,936			100	%
KRYSTEXXA	$	79,801	$	58,608	$	21,193			36	%		75,201		79,801		(4,600	)		(6	)%
RAVICTI		50,441		56,958		(6,517	)		(11	)%		65,550		50,441		15,109			30	%
PROCYSBI		41,174		38,433		2,741			7	%		41,357		41,174		183		*
ACTIMMUNE		29,276		27,382		1,894			7	%		28,299		29,276		(977	)		(3	)%
RAYOS		20,284		13,452		6,832			51	%
BUPHENYL		2,368		5,244		(2,876	)		(55	)%		2,846		2,368		478			20	%
QUINSAIR		170		97		73			75	%		59		170		(111	)		(65	)%
LODOTRA		—		1,535		(1,535	)		(100	)%
Orphan and Rheumatology net sales	$	223,514	$	201,709	$	21,805			11	%
Orphan segment net sales											$	379,248	$	203,230	$	176,018			87	%

PENNSAID 2%		51,472		47,610		3,862			8	%		35,048		51,472		(16,424	)		(32	)%
DUEXIS		30,066		30,728		(662	)		(2	)%		27,798		30,066		(2,268	)		(8	)%
RAYOS												14,459		20,284		(5,825	)		(29	)%
VIMOVO		14,616		21,856		(7,240	)		(33	)%		6,226		14,616		(8,390	)		(57	)%
MIGERGOT		979		932		47			5	%		—		979		(979	)		(100	)%
Inflammation net sales	$	97,133	$	101,126	$	(3,993	)		(4	)%
Inflammation segment net sales											$	83,531	$	117,417	$	(33,886	)		(29	)%

Total net sales	$	320,647	$	302,835	$	17,812			6	%	$	462,779	$	320,647	$	142,132			44	%
* Less than 1%

TEPEZZA~~Orphan and Rheumatology~~. On January 21, 2020, the FDA approved TEPEZZA for the treatment of TED. Net sales generated for TEPEZZA during the three months ended June 30, 2020 were $165.9 million.

KRYSTEXXA. Net sales ~~increased $21.2~~decreased $4.6 million, or ~~36%~~6%, to $75.2 million during the three months ended June 30, 2020 from $79.8 million during the three months ended June 30, ~~2019, from $58.6~~2019. Net sales decreased by approximately $3.0 million due to lower net pricing and $1.6 million due to lower volume. As a result of the COVID-19 pandemic, KRYSTEXXA net sales were negatively impacted during the three months ended June 30, 2020, due to reduced willingness of patients to visit physician offices and infusion centers.

RAVICTI. Net sales increased $15.1 million, or 30%, to $65.5 million during the three months ended June 30, ~~2018. Net sales increased by approximately $14.9 million resulting~~2020, from ~~volume growth and by approximately $6.3 million due to higher net pricing.~~

~~RAVICTI. Net sales decreased $6.5 million, or 11%, to~~ $50.4 million during the three months ended June 30, ~~2019,~~2019. Net sales in the United States increased by approximately $14.9 million, which was composed of an increase of approximately $9.9 million resulting from ~~$56.9~~higher net pricing and an increase of approximately $5.0 million due to higher sales volume. Net sales outside the United States increased by approximately $0.2 million due to higher sales volume.

ACTIMMUNE. Net sales decreased $1.0 million, or 3%, to $28.3 million during the three months ended June 30, 2018. Net sales in the United States decreased by approximately $5.4 million, which was composed of a decrease of approximately $10.1 million due to lower net pricing, partially offset by an increase of approximately $4.7 million resulting2020, from ~~volume growth. Net sales outside the United States decreased by approximately $1.1 million primarily as a result of the Immedica transaction in December 2018.~~

~~PROCYSBI~~. Net sales increased $2.7 million, or 7%, to $41.1 million during the three months ended June 30, 2019, from $38.4 million during the three months ended June 30, 2018. Net sales increased by approximately $3.1 million resulting from volume growth, partially offset by a decrease of approximately $0.4 million due to lower net pricing.

~~ACTIMMUNE. Net sales increased $1.9 million, or 7%, to~~ $29.3 million during the three months ended June 30, ~~2019,~~2019. Net sales decreased by approximately $2.7 million due to lower sales volume, partially offset by an increase of approximately $1.7 million resulting from ~~$27.4~~higher net pricing.

BUPHENYL. Net sales increased $0.5 million, or 20%, to $2.8 million during the three months ended June 30, ~~2018. Net sales increased by approximately $1.2 million resulting~~2020, from ~~higher net pricing and by approximately $0.7 million due to volume growth.~~

~~RAYOS. Net sales increased $6.8 million, or 51%, to $20.3~~$2.3 million during the three months ended June 30, ~~2019,~~2019. Net sales increased by approximately $3.3 million due to higher sales volume, partially offset by a decrease of approximately $2.8 million resulting from ~~$13.5~~lower net pricing.

As a result of the COVID-19 pandemic, sales volumes for our inflammation medicines have been negatively impacted due to reduced demand given the absence of in-person engagement by our sales representatives with health care providers and reduced levels of non-essential patient visits to physicians.

PENNSAID 2%. Net sales decreased $16.4 million, or 32%, to $35.1 million during the three months ended June 30, ~~2018.~~2020, from $51.5 million during the three months ended June 30, 2019. Net sales ~~increased~~decreased by approximately ~~$10.5~~$20.6 million due to lower sales volume, partially offset by an increase of approximately $4.2 million resulting from higher net pricing primarily due to lower utilization of our patient assistance ~~programs, partially offset by a decrease of approximately $3.7 million due to lower sales volume.~~programs.

DUEXIS. Net sales decreased ~~$2.9~~$2.3 million, or ~~55%~~8%, to ~~$2.3~~$27.8 million during the three months ended June 30, ~~2019,~~2020, from ~~$5.2~~$30.1 million during the three months ended June 30, ~~2018.~~2019. Net sales decreased by approximately ~~$2.5~~$9.1 million resulting from lower sales volume, ~~and~~partially offset by an increase of approximately ~~$0.4 million due to lower net pricing.~~

~~LODOTRA~~. Effective January 1, 2019, we amended our license and supply agreements with Jagotec AG and Skyepharma AG, which are affiliates of Vectura. Under these amendments, we agreed to transfer all economic benefits of LODOTRA in Europe to Vectura during an initial transition period, with full rights transferring to Vectura when certain transfer activities have been completed. ~~Effective January 1, 2019, we no longer record LODOTRA revenue.~~

~~PENNSAID 2%~~. Net sales increased $3.9 million, or 8%, to $51.5 million during the three months ended June 30, 2019, from $47.6 million during the three months ended June 30, 2018. Net sales increased by approximately $13.0$6.8 million resulting from higher net pricing primarily due to lower utilization of our patient assistance ~~programs, partially offset by a decrease of approximately $9.1 million due to lower sales volume.~~ programs.

~~DUEXIS~~RAYOS. Net sales decreased ~~$0.7~~$5.8 million, or 2%29%, to ~~$30.0~~$14.5 million during the three months ended June 30, ~~2019,~~2020, from ~~$30.7~~$20.3 million during the three months ended June 30, ~~2018.~~2019. Net sales decreased by approximately ~~$5.6~~$7.9 million due to lower sales volume, partially offset by an increase of ~~approximately $4.9~~$2.1 million ~~due to~~resulting from higher net pricing primarily due to lower utilization of our patient assistance programs.

VIMOVO. Net sales decreased ~~$7.2~~$8.4 million, or ~~33%~~57%, to $6.2 million during the three months ended June 30, 2020, from $14.6 million during the three months ended June 30, ~~2019, from $21.8 million during the three months ended June 30, 2018.~~2019. Net sales decreased by approximately ~~$6.0~~$13.8 million due to lower sales volume, ~~and~~partially offset by ~~approximately $1.2~~an increase of $4.5 million resulting from higher net pricing primarily due to lower ~~net pricing.~~utilization of our patient assistance programs and an increase of $0.9 million related to authorized generic VIMOVO sales in the second quarter of 2020.

MIGERGOT. ~~Net sales increased $0.1 million, or 5%, to $1.0 million during the three months ended June 30, 2019, from $0.9 million during the three months ended June 30, 2018.~~ On June 28, 2019, we sold our rights to MIGERGOT.

The table below reconciles our gross to net sales for the three months ended June 30, ~~2019~~2020 and ~~2018~~2019 (in millions, except percentages):

	Three Months Ended June 30, 2019						Three Months Ended June 30, 2018						Three Months Ended June 30, 2020						Three Months Ended June 30, 2019
	Amount			% of Gross Sales			Amount			% of Gross Sales			Amount			% of Gross Sales			Amount			% of Gross Sales
Gross sales	$	991.3			100.0	%	$	1,127.8			100.0	%	$	898.0			100.0	%	$	991.3			100.0	%
Adjustments to gross sales:
Prompt pay discounts		(17.8	)		(1.8	)%		(20.1	)		(1.8	)%		(12.5	)		(1.4	)%		(17.8	)		(1.8	)%
Medicine returns		(5.7	)		(0.6	)%		(8.8	)		(0.8	)%		3.9			0.4	%		(5.7	)		(0.6	)%
Co-pay and other patient assistance costs		(407.3	)		(41.1	)%		(540.0	)		(47.9	)%
Co-pay and other patient assistance														(210.3	)		(23.4	)%		(407.3	)		(41.1	)%
Commercial rebates and wholesaler fees		(119.5	)		(12.1	)%		(164.2	)		(14.5	)%		(78.3	)		(8.7	)%		(119.5	)		(12.1	)%
Government rebates and chargebacks		(120.4	)		(12.1	)%		(91.9	)		(8.1	)%		(138.0	)		(15.4	)%		(120.4	)		(12.1	)%
Total adjustments		(670.7	)		(67.7	)%		(825.0	)		(73.1	)%		(435.2	)		(48.5	)%		(670.7	)		(67.7	)%
Net sales	$	320.6			32.3	%	$	302.8			26.9	%	$	462.8			51.5	%	$	320.6			32.3	%

During the three months ended June 30, ~~2019,~~2020, co-pay and other patient assistance costs, as a percentage of gross sales, decreased to ~~41.1%~~23.4% from ~~47.9%~~41.1% during the three months ended June 30, ~~2018,~~2019, primarily due to lower utilization of our patient assistance ~~programs.~~programs and the impact of generic competition on VIMOVO sales.

During the three months ended June 30, 2020, commercial rebates and wholesaler fees, as a percentage of gross sales, decreased to 8.7% from 12.1% during the three months ended June 30, 2019, primarily as a result of an increased proportion of orphan segment medicines sold and the impact of generic competition on VIMOVO sales.

During the three months ended June 30, 2020, government rebates and chargebacks, as a percentage of gross sales, increased to ~~12.1%~~15.4% from ~~8.1%~~12.1% during the three months ended June 30, ~~2018,~~2019, primarily as a result of an increased proportion of orphan ~~and rheumatology~~segment medicines sold.

~~Additionally, on January 1, 2019,~~ Government rebates and chargebacks as a percentage of gross sales are typically higher for medicines in the ~~340B ceiling price rule became effective. With respect~~orphan segment compared to ~~KRYSTEXXA,~~medicines in the “additional rebate” scheme of the 340B pricing program has resulted in a 340B ceiling price of one penny. A material portion of KRYSTEXXA infusions (approximately twenty to twenty-five percent) are performed at institutions that are eligible for 340B drug pricing and therefore the reduction in 340B pricing to a penny has negatively impacted our net sales of KRYSTEXXA.inflammation segment.

Cost of Goods Sold. Cost of goods sold ~~decreased $2.2~~increased $32.3 million to ~~$89.1~~$121.5 million during the three months ended June 30, ~~2019,~~2020, from ~~$91.3~~$89.2 million during the three months ended June 30, ~~2018. As a percentage of net sales, cost of goods sold was 27.8% during the three months ended June 30, 2019, compared to 30.2% during the three months ended June 30, 2018.~~2019. The ~~decrease~~increase in cost of goods sold during the three months ended June 30, ~~2019~~2020 compared to three months ended June 30, ~~2018,~~2019, was primarily ~~attributable~~due to ~~lower gross sales.~~a $15.0 million increase in royalty expense and a $9.1 million increase in amortization expense. These increases are mainly related to royalties payable on net sales of TEPEZZA, which was launched in the first quarter of 2020, and the amortization of the TEPEZZA developed technology intangible asset, which commenced in the first quarter of 2020. As a percentage of net sales, cost of goods sold was 26.3% during the three months ended June 30, 2020, compared to 27.8% during the three months ended June 30, 2019. The decrease in cost of goods sold as a percentage of net sales was primarily due to change in the mix of medicines sold.

Research and Development Expenses. Research and development expenses increased ~~$4.0~~$52.8 million to $81.1 million during the three months ended June 30, 2020, from $28.3 million during the three months ended June 30, ~~2019, from $24.3~~2019. The increase was primarily attributable to the $45.0 million acquisition of Curzion during the three months ended June 30, 2020. Pursuant to ASC 805 (as amended by ASU No. 2017-01), we accounted for the Curzion acquisition as the purchase of an in-process research and development, or IPR&D, asset and, pursuant to ASC 730, recorded the purchase price as a research and development expense during the three months ended June 30, 2020.

Selling, General and Administrative Expenses. Selling, general and administrative expenses increased $55.2 million to $222.3 million during the three months ended June 30, ~~2018. The increase was primarily attributable to a progress payment of $4.0 million incurred under our collaboration agreement with HemoShear Therapeutics, LLC, or HemoShear.~~

~~Selling, General and Administrative Expenses. Selling, general and administrative expenses decreased $9.6 million to~~2020, from $167.1 million during the three months ended June 30, ~~2019, from $176.7~~2019. The increase was primarily attributable to an increase of $30.9 million ~~during~~in employee costs and an increase of $8.5 million related to marketing program costs. These increases are mainly due to the launch of TEPEZZA. In addition, charitable contribution costs increased by $7.1 million in the three months ended June 30, ~~2018. The decrease was primarily attributable~~2020 compared to ~~decreases in share-based compensation of $9.4 million and legal fees and litigation settlements of $5.8 million, partially offset by an increase of $2.4 million related to marketing program costs.~~the three months ended June 30, 2019.

Loss on Sale of Assets. During the three months ended June 30, 2019, we sold our rights to MIGERGOT for cash proceeds of $6.0 million, and we recorded a loss of $11.0 million on the sale.

Interest Expense, Net. Interest expense, net, decreased ~~$9.0~~$3.5 million to $18.5 million during the three months ended June 30, 2020, from $22.0 million during the three months ended June 30, ~~2019, from $31.0 million during the three months ended June 30, 2018.~~2019. The decrease was primarily due to a decrease in ~~debt~~ interest expense of ~~$6.7~~$7.7 million, primarily related to the decrease in the principal amount ~~and interest rate~~ of our term loans in March 2019 and ~~an increase~~July 2019, redemption of our 6.625% Senior Notes due 2023, or the 2023 Senior Notes, in May 2019 and in August 2019, redemption of our 8.750% Senior Notes due 2024, or the 2024 Senior Notes, in August 2019, partially offset by a decrease in interest income of ~~$2.3~~$4.7 million.

Loss on Debt Extinguishment. During the three months ended June 30, 2020, we recorded a loss on debt extinguishment of $17.3 million in the condensed consolidated statements of comprehensive loss, which reflects the partial exchange of our 2.5% Exchangeable Senior Notes due 2022, or the Exchangeable Senior Notes. As of June 30, 2020, $207.0 million in aggregate principal amount of Exchangeable Senior Notes had been exchanged for ordinary shares. During July and August 2020, the remaining $193.0 million of aggregate principal amount of Exchangeable Senior Notes were fully extinguished. See Note 13, Debt Agreements, of the Notes to Condensed Consolidated Financial Statements, included in Item 1 of this Quarterly Report on Form 10-Q for further detail.

During the three months ended June 30, 2019, we recorded a loss on debt extinguishment of $11.9 million in the condensed consolidated statements of comprehensive loss, which reflected the write-off of the deferred financing fees and debt discount fees related to the ~~prepayment~~redemption of ~~$225.0~~$250.0 million of ~~6.625% Senior Notes due 2023, or~~ the 2023 Senior Notes and term loan refinancing in May 2019.

~~(Benefit)~~ Expense (benefit) for Income ~~Taxes~~Taxes. . During the three months ended June 30, ~~2019,~~2020, we recorded an expense for income taxes of $83.0 million compared to a benefit for income taxes of $4.9 million ~~compared to an expense for income taxes of $4.6 million~~ during the three months ended June 30, ~~2018.~~2019. The ~~benefit~~expense for income taxes recorded during the three months ended June 30, ~~2019,~~2020 resulted primarily from ~~the net excess tax benefits recognized on share-based compensation, the release of a reserve related to an uncertain tax position and~~ the mix of pre-tax income and losses incurred in various tax ~~jurisdictions.~~jurisdictions and a $15.2 million provision recorded following the publication, on April 8, 2020, by the U.S. Treasury of Final Regulations for Section 267A, or commonly referred to as the Anti-Hybrid Rules. The Final Regulations for Section 267A permanently disallow for U.S. tax purposes certain interest expense accrued to a foreign related party during the year ended December 31, 2019. As a result, during the three months ended June 30, 2020 we recorded a write off of a deferred tax asset related to this interest expense and recognized a corresponding tax provision of $15.2 million.

See Note 11, Segment and Other Information, of the Notes to Condensed Consolidated Financial Statements, included in Item 1 of this Quarterly Report on Form 10-Q for a reconciliation of our segment operating income to our total ~~loss~~income (loss) before expense (benefit) ~~expense~~ for income taxes for the three months ended June 30, ~~2019~~2020 and ~~2018.~~2019.

The following table reflects our orphan ~~and rheumatology~~segment net sales and segment operating income for the three months ended June 30, ~~2019~~2020 and ~~2018~~2019 (in thousands, except percentages).

	For the Three Months Ended June 30,									For the Three Months Ended June 30,
	2019		2018		Change		% Change			2020		2019		Change		% Change
Net sales	$	223,514	$	201,709	$	21,805		11	%	$	379,248	$	203,230	$	176,018		87	%
Segment operating income		74,502		70,609		3,893		6	%		151,541		63,696		87,845		138	%

The increase in orphan ~~and rheumatology~~segment net sales during the three months ended June 30, ~~2019~~2020 is described in the Consolidated Results section above.

Segment operating income. Orphan ~~and rheumatology~~ segment operating income increased ~~$3.9~~$87.8 million to ~~$74.5~~$151.5 million during the three months ended June 30, ~~2019,~~2020, from ~~$70.6~~$63.7 million during the three months ended June 30, ~~2018.~~2019. The increase was primarily attributable to an increase in net sales of ~~$21.8~~$176.0 million, primarily due to post-launch sales of TEPEZZA as described above, partially offset by an increase in selling, general and administrative expenses of ~~$16.7~~$52.7 million primarily due to increased costs relating to the launch of TEPEZZA and an increase of $17.5 million in ~~sales and marketing costs~~royalty expense, primarily related to ~~KRYSTEXXA and costs to prepare for the potential U.S. launch~~royalties payable on net sales of ~~teprotumumab.~~TEPEZZA.

The following table reflects our inflammation segment net sales and segment operating income for the three months ended June 30, ~~2019~~2020 and ~~2018~~2019 (in thousands, except percentages).

	For the Three Months Ended June 30,										For the Three Months Ended June 30,
	2019		2018		Change			% Change			2020		2019		Change			% Change
Net sales	$	97,133	$	101,126	$	(3,993	)		(4	%)	$	83,531	$	117,417	$	(33,886	)		(29	%)
Segment operating income		49,694		45,883		3,811			8	%		38,096		60,500		(22,404	)		(37	%)

The ~~increase~~decrease in inflammation segment net sales during the three months ended June 30, ~~2019~~2020 is described in the Consolidated Results section above.

Segment operating income. Inflammation segment operating income ~~increased $3.8~~decreased $22.4 million to ~~$49.7~~$38.1 million during the three months ended June 30, ~~2019,~~2020, from ~~$45.9~~$60.5 million during the three months ended June 30, ~~2018.~~2019. The ~~increase~~decrease was primarily attributable to a decrease in net sales of $33.9 million as described above, partially offset by a decrease in sales and marketing costs of ~~$6.5 million mainly related to lower sample and patient assistant program administration expenses, partially offset by a decrease in net sales of $4.0 million as described above.~~$9.7 million.

The table below should be referenced in connection with a review of the following discussion of our results of operations for the six months ended June 30, ~~2019,~~2020, compared to the six months ended June 30, ~~2018.~~2019.

	For the Six Months Ended June 30,									For the Six Months Ended June 30,
	2019			2018			Change			2020			2019			Change
	(in thousands)									(in thousands)
Net sales	$	601,018		$	526,716		$	74,302		$	818,688		$	601,018		$	217,670
Cost of goods sold		177,305			201,625			(24,320	)		218,931			177,305			41,626
Gross profit		423,713			325,091			98,622			599,757			423,713			176,044
Operating expenses:
Research and development		50,039			41,910			8,129			108,277			50,039			58,238
Selling, general and administrative		339,394			356,273			(16,879	)		470,107			339,394			130,713
Loss on sale of assets		10,963			—			10,963			—			10,963			(10,963	)
Impairment of long-lived assets		—			33,647			(33,647	)
Total operating expenses		400,396			431,830			(31,434	)		578,384			400,396			177,988
Operating income (loss)		23,317			(106,739	)		130,056
Operating income											21,373			23,317			(1,944	)
Other expense, net:
Interest expense, net		(49,563	)		(61,484	)		11,921			(35,915	)		(49,563	)		13,648
Loss on debt extinguishment		(17,464	)		—			(17,464	)		(17,254	)		(17,464	)		210
Foreign exchange gain (loss)		15			(115	)		130
Other (expense) income, net		(1,083	)		497			(1,580	)
Foreign exchange gain											1,059			15			1,044
Other income (expense), net											1,074			(1,083	)		2,157
Total other expense, net		(68,095	)		(61,102	)		(6,993	)		(51,036	)		(68,095	)		17,059
Loss before (benefit) expense for income taxes		(44,778	)		(167,841	)		123,063
(Benefit) expense for income taxes		(6,795	)		5,566			(12,361	)
Loss before expense (benefit) for income taxes											(29,663	)		(44,778	)		15,115
Expense (benefit) for income taxes											63,938			(6,795	)		70,733
Net loss	$	(37,983	)	$	(173,407	)	$	135,424		$	(93,601	)	$	(37,983	)	$	(55,618	)

Net sales. Net sales increased ~~$74.3~~$217.7 million, or ~~14.1%~~36.2%, to $818.7 million during the six months ended June 30, 2020, from $601.0 million during the six months ended June 30, ~~2019, from $526.7 million during the six months ended June 30, 2018.~~2019. The increase in net sales during the six months ended June 30, ~~2019~~2020 was primarily due to an increase in net sales in our ~~inflammation~~orphan segment of ~~$38.9~~$255.0 million primarily due to post-launch sales of TEPEZZA of $189.4 million and ~~an increase~~higher net sales of KRYSTEXXA and RAVICTI when compared to the six months ended June 30, 2019, partially offset by a decrease in net sales in our ~~orphan and rheumatology~~inflammation segment of ~~$35.4~~$37.3 million.

The following table reflects net sales by medicine for the six months ended June 30, ~~2019~~2020 and ~~2018~~2019 (in thousands, except percentages):

	Six Months Ended June 30,				Change			Change			Six Months Ended June 30,				Change			Change
	2019		2018		$			%			2020		2019		$			%
TEPEZZA											$	189,387	$	—	$	189,387			100	%
KRYSTEXXA	$	132,058	$	105,326	$	26,732			25	%		168,450		132,058		36,392			28	%
RAVICTI		100,344		106,051		(5,707	)		(5	%)		126,738		100,344		26,394			26	%
PROCYSBI		80,745		73,367		7,378			10	%		79,700		80,745		(1,045	)		(1	)%
ACTIMMUNE		51,022		52,240		(1,218	)		(2	%)		54,840		51,022		3,818			7	%
RAYOS		39,708		24,142		15,566			64	%
BUPHENYL		5,138		10,986		(5,848	)		(53	%)		5,160		5,138		22		*
QUINSAIR		338		218		120			55	%		336		338		(2	)	*
LODOTRA		—		1,650		(1,650	)		(100	%)
Orphan and Rheumatology segment net sales	$	409,353	$	373,980	$	35,373			9	%
Orphan segment net sales											$	624,611	$	369,645	$	254,966			69	%

PENNSAID 2%		101,661		74,413		27,248			37	%		76,611		101,661		(25,050	)		(25	)%
DUEXIS		59,523		46,405		13,118			28	%		59,145		59,523		(378	)	*
RAYOS												32,668		39,708		(7,040	)		(18	)%
VIMOVO		28,659		30,235		(1,576	)		(5	%)		25,653		28,659		(3,006	)		(10	)%
MIGERGOT		1,822		1,683		139			8	%		—		1,822		(1,822	)		(100	)%
Inflammation segment net sales	$	191,665	$	152,736	$	38,929			25	%	$	194,077	$	231,373	$	(37,296	)		(16	)%

Total net sales	$	601,018	$	526,716	$	74,302			14	%	$	818,688	$	601,018	$	217,670			36	%
*Less than 1%

TEPEZZA. On January 21, 2020, the FDA approved TEPEZZA for the treatment of TED. Net sales generated for TEPEZZA during the six months ended June 30, 2020 were $189.4 million.

KRYSTEXXA. Net sales increased ~~$26.7~~$36.4 million, or ~~25%~~28%, to $168.4 million during the six months ended June 30, 2020 from $132.0 million during the six months ended June 30, ~~2019, from $105.3~~2019. Net sales increased by approximately $25.5 million due to volume growth and $10.9 million due to higher net pricing. As a result of the COVID-19 pandemic, KRYSTEXXA net sales were negatively impacted during the six months ended June 30, 2020, due to reduced willingness of patients to visit physician offices and infusion centers.

RAVICTI. Net sales increased $26.4 million, or 26%, to $126.7 million during the six months ended June 30, ~~2018. Net sales increased by approximately $30.8 million resulting~~2020, from ~~volume growth, partially offset by a decrease of approximately $4.1 million due to lower net pricing.~~

~~RAVICTI. Net sales decreased $5.7 million, or 5%, to~~ $100.3 million during the six months ended June 30, ~~2019, from $106.0 million during the six months ended June 30, 2018.~~2019. Net sales in the United States ~~decreased~~increased by approximately ~~$3.5~~$25.8 million, which was composed of ~~a decrease of approximately $16.0 million due to lower net pricing, partially offset by~~ an increase of approximately ~~$12.5~~$17.3 million resulting from higher net pricing and an increase of approximately $8.5 million due to higher sales volume. Net sales outside the United States ~~decreased~~increased by approximately ~~$2.3~~$0.6 million ~~primarily as a result of the Immedica transaction in December 2018.~~due to higher sales volume.

PROCYSBI. Net sales ~~increased $7.4~~decreased $1.1 million, or ~~10%~~1%, to $79.7 million during the six months ended June 30, 2020, from $80.8 million during the six months ended June 30, ~~2019, from $73.4~~2019. Net sales decreased by approximately $0.6 million due to lower sales volume and by approximately $0.5 million due to lower net pricing.

ACTIMMUNE. Net sales increased $3.8 million, or 7%, to $54.8 million during the six months ended June 30, ~~2018. Net sales in the United States increased by approximately $7.7 million, which was composed of an increase of approximately $6.9 million resulting~~2020, from volume growth and approximately $0.8 million due to higher net pricing. Net sales outside the United States decreased by approximately $0.3 million primarily due to a decrease of $1.5 million due to lower net pricing, partially offset by an increase of $1.2 million due to volume growth.

~~ACTIMMUNE. Net sales decreased $1.2 million, or 2%, to~~ $51.0 million during the six months ended June 30, ~~2019,~~2019. Net sales increased by approximately $4.2 million due to higher net pricing, partially offset by a decrease of approximately $0.4 million resulting from ~~$52.2~~lower sales volume.

PENNSAID 2%. Net sales decreased $25.1 million, or 25%, to $76.6 million during the six months ended June 30, ~~2018.~~2020, from $101.7 million during the six months ended June 30, 2019. Net sales decreased by approximately ~~$1.2~~$35.8 million due to lower sales volume, partially offset by an increase of approximately $10.7 million resulting from higher net pricing primarily due to lower utilization of our patient assistance programs.

DUEXIS. Net sales decreased $0.4 million, or 1%, to $59.1 million during the six months ended June 30, 2020, from $59.5 million during the six months ended June 30, 2019. Net sales decreased by approximately $18.4 million resulting from lower sales ~~volume.~~ volume, partially offset by an increase of $18.0 million resulting from higher net pricing primarily due to lower utilization of our patient assistance programs.

RAYOS. Net sales ~~increased $15.6~~decreased $7.0 million, or ~~64%~~18%, to $32.7 million during the six months ended June 30, 2020, from $39.7 million during the six months ended June 30, ~~2019,~~2019. Net sales decreased by approximately $15.4 million due to lower sales volume, partially offset by an increase of $8.4 million resulting from ~~$24.1~~higher net pricing primarily due to lower utilization of our patient assistance programs.

VIMOVO. Net sales decreased $3.0 million, or 10%, to $25.6 million during the six months ended June 30, ~~2018.~~2020, from $28.6 million during the six months ended June 30, 2019. Net sales ~~increased~~decreased by approximately ~~$20.7~~$21.9 million due to lower sales volume, partially offset by an increase of $16.4 million resulting from higher net pricing primarily due to lower utilization of our patient assistance programs ~~partially offset by a decrease of approximately $5.1 million due to lower sales volume.~~

~~BUPHENYL~~. Net sales decreased $5.9 million, or 53%, to $5.1 million during the six months ended June 30, 2019, from $11.0 million during the six months ended June 30, 2018. Net sales decreased by approximately $6.6 million resulting from lower sales volume, partially offset byand an increase of ~~$0.7~~$2.5 million ~~due~~related to ~~higher net pricing.~~

~~LODOTRA~~. ~~Effective January 1, 2019, we amended our license and supply agreements with Jagotec AG and Skyepharma AG, which are affiliates~~authorized generic VIMOVO sales in the first half of Vectura. Under these amendments, we agreed to transfer all economic benefits of LODOTRA in Europe to Vectura during an initial transition period, with full rights transferring to Vectura when certain transfer activities have been completed. ~~Effective January 1, 2019, we no longer record LODOTRA revenue.~~

~~PENNSAID 2%~~. Net sales increased $27.3 million, or 37%, to $101.7 million during the six months ended June 30, 2019, from $74.4 million during the six months ended June 30, 2018. Net sales increased by approximately $40.3 million resulting from higher net pricing primarily due to lower utilization of our patient assistance programs, partially offset by a decrease of approximately $13.0 million resulting from lower sales volume.

~~DUEXIS~~. Net sales increased $13.1 million, or 28%, to $59.5 million during the six months ended June 30, 2019, from $46.4 million during the six months ended June 30, 2018. Net sales increased by approximately $18.3 million resulting from higher net pricing primarily due to lower utilization of our patient assistance programs, partially offset by a decrease of approximately $5.2 million resulting from lower sales volume.

~~VIMOVO~~. Net sales decreased $1.6 million, or 0.5%, to $28.6 million during the six months ended June 30, 2019, from $30.2 million during the six months ended June 30, 2018. Net sales decreased by approximately $6.7 million due to lower sales volume, partially offset by an increase of approximately $5.1 million resulting from higher net pricing.2020.

MIGERGOT. ~~Net sales increased $0.1 million, or 8%, to $1.8 million during the six months ended June 30, 2019, from $1.7 million during the six months ended June 30, 2018.~~ On June 28, 2019, we sold our rights to MIGERGOT.

The table below reconciles our gross to net sales for the six months ended June 30, ~~2019~~2020 and ~~2018~~2019 (in millions, except percentages):

	Six Months Ended June 30, 2019						Six Months Ended June 30, 2018						Six Months Ended June 30, 2020						Six Months Ended June 30, 2019
	Amount			% of Gross Sales			Amount			% of Gross Sales			Amount			% of Gross Sales			Amount			% of Gross Sales
Gross sales	$	1,936.5			100.0	%	$	2,082.2			100.0	%	$	1,701.5			100.0	%	$	1,936.5			100.0	%
Adjustments to gross sales:
Prompt pay discounts		(35.6	)		(1.8	)%		(37.8	)		(1.8	)%		(25.6	)		(1.5	)%		(35.6	)		(1.8	)%
Medicine returns		(10.8	)		(0.6	)%		(15.3	)		(0.8	)%		(4.9	)		(0.3	)%		(10.8	)		(0.6	)%
Co-pay and other patient assistance costs		(825.1	)		(42.6	)%		(1,026.9	)		(49.3	)%
Co-pay and other patient assistance														(440.4	)		(25.9	)%		(825.1	)		(42.6	)%
Commercial rebates and wholesaler fees		(229.9	)		(11.9	)%		(300.6	)		(14.4	)%		(137.6	)		(8.1	)%		(229.9	)		(11.9	)%
Government rebates and chargebacks		(234.1	)		(12.1	)%		(174.9	)		(8.4	)%		(274.2	)		(16.1	)%		(234.1	)		(12.1	)%
Total adjustments		(1,335.5	)		(69.0	)%		(1,555.5	)		(74.7	)%		(882.7	)		(51.9	)%		(1,335.5	)		(69.0	)%
Net sales	$	601.0			31.0	%	$	526.7			25.3	%	$	818.8			48.1	%	$	601.0			31.0	%

During the six months ended June 30, ~~2019,~~2020, co-pay and other patient assistance costs, as a percentage of gross sales, decreased to ~~42.6%~~25.9% from ~~49.3%~~42.6% during the six months ended June 30, ~~2018,~~2019, primarily due to lower utilization of our patient assistance ~~programs.~~programs and the impact of generic competition on VIMOVO sales.

During the six months ended June 30, 2020, commercial rebates and wholesaler fees, as a percentage of gross sales, decreased to 8.1% from 11.9% during the six months ended June 30, 2019, primarily as a result of an increased proportion of orphan segment medicines sold and the impact of generic competition on VIMOVO sales.

During the six months ended June 30, 2020, government rebates and chargebacks, as a percentage of gross sales, increased to ~~12.1%~~16.1% from ~~8.4%~~12.1% during the six months ended June 30, ~~2018,~~2019, primarily as a result of an increased proportion of orphan ~~and rheumatology~~segment medicines sold.

Cost of Goods Sold. Cost of goods sold ~~decreased $24.3~~increased $41.6 million to $218.9 million during the six months ended June 30, 2020, from $177.3 million during the six months ended June 30, ~~2019, from $201.6 million~~2019. The increase in cost of goods sold during the six months ended June 30, ~~2018.~~2020 compared to the six months ended June 30, 2019, was primarily due to a $19.5 million increase in royalty expense, a $10.2 million increase in amortization expense and a $3.0 million increase in employee-related costs. These increases are mainly related to royalties payable on net sales of TEPEZZA, which was launched in the first quarter of 2020, and the amortization of the TEPEZZA developed technology intangible asset, which commenced in the first quarter of 2020. As a percentage of net sales, cost of goods sold was 26.7% during the six months ended June 30, 2020, compared to 29.5% during the six months ended June 30, ~~2019, compared to 38.3% during the six months ended June 30, 2018.~~2019. The decrease in cost of goods sold as a percentage of net sales was primarily ~~attributable to a $17.0 million decrease in inventory step-up expense.~~

Because inventory step-up expense is acquisition-related, will not continue indefinitely and has a significant effect on our gross profit, gross margin percentage and net income (loss) for all affected periods, we disclose balance sheet and income statement amounts related to inventory step-up within the notes to the condensed consolidated financial statements. The decrease in inventory step-up expense of $17.0 million recorded to cost of goods sold during the six months ended June 30, 2019, compared to the prior year period was due to ~~KRYSTEXXA inventory step-up being fully expensed by March 31, 2018, resulting~~change in ~~no material inventory step-up expense being recorded during~~ the ~~six months ended June 30, 2019, compared to KRYSTEXXA inventory step-up expense~~mix of ~~$17.0 million recorded during the six months ended June 30, 2018.~~ medicines sold.

Research and Development Expenses. Research and development expenses increased ~~$8.1~~$58.2 million to $108.2 million during the six months ended June 30, 2020, from $50.0 million during the six months ended June 30, ~~2019, from $41.9~~2019. The increase was primarily attributable to the $45.0 million acquisition of Curzion during the six months ended June 30, ~~2018. The increase was primarily attributable~~2020. Pursuant to ~~total upfront~~ASC 805 (as amended by ASU No. 2017-01), we accounted for the Curzion acquisition as the purchase of an IPR&D asset and, ~~progress payments of $6.0 million incurred under our collaboration agreement with HemoShear.~~pursuant to ASC 730, recorded the purchase price as a research and development expense during the six months ended June 30, 2020.

Selling, General and Administrative Expenses. Selling, general and administrative expenses ~~decreased $16.9~~increased $130.7 million to $470.1 million during the six months ended June 30, 2020, from $339.4 million during the six months ended June 30, ~~2019, from $356.3 million during the six months ended June 30, 2018.~~2019. The ~~decrease~~increase was primarily attributable to ~~decreases in share-based compensation of $10.4 million and legal fees and litigation settlements of $10.0 million, partially offset by~~ an increase of ~~$3.3~~$78.8 million in employee costs and an increase of $23.1 million related to marketing program costs. These increases are mainly due to the launch of TEPEZZA.

Loss on Sale of Assets. During the six months ended June 30, 2019, we sold our rights to MIGERGOT for cash proceeds of $6.0 million, and we recorded a loss of $11.0 million on the sale.

~~During~~Interest Expense, Net. Interest expense, net, decreased $13.7 million to $35.9 million during the six months ended June 30, 2018, we recorded an impairment of $33.6 million to fully write off the book value of developed technology related to PROCYSBI in Canada and Latin America due primarily to lower anticipated future net sales based on a Patented Medicine Prices Review Board review.

~~Interest Expense, Net. Interest expense, net, decreased $11.9 million to~~2020, from $49.6 million during the six months ended June 30, ~~2019, from $61.5 million during the six months ended June 30, 2018.~~2019. The decrease was primarily due to a decrease in ~~debt~~ interest expense of ~~$6.0~~$20.3 million,, primarily related to the decrease in the principal amount ~~and interest rate~~ of our term loans in March 2019 and ~~an increase~~July 2019, redemption of our 2023 Senior Notes in May 2019 and in August 2019, redemption of our 2024 Senior Notes in August 2019, partially offset by a decrease in interest income of ~~$5.9~~$7.5 million.

Loss on Debt ~~Extinguishment.~~Extinguishment. During the six months ended June 30, 2020, we recorded a loss on debt extinguishment of $17.3 million in the condensed consolidated statements of comprehensive loss, which reflects the partial exchange of our Exchangeable Senior Notes. As of June 30, 2020, $207.0 million in aggregate principal amount of Exchangeable Senior Notes had been exchanged for ordinary shares. During July and August 2020, the remaining $193.0 million of aggregate principal amount of Exchangeable Senior Notes were fully extinguished. See Note 13, Debt Agreements, of the Notes to Condensed Consolidated Financial Statements, included in Item 1 of this Quarterly Report on Form 10-Q for further detail.

During the six months ended June 30, 2019, we recorded a loss on debt extinguishment of $17.5 million in the condensed consolidated statements of comprehensive loss, which reflected the write-off of the deferred financing fees and debt discount fees related to the ~~prepayment~~redemption of ~~$225.0~~$250.0 million of 2023 Senior Notes and term loan refinancing in May 2019 and ~~the~~ $300.0 million term loan repayment in March 2019.

~~(Benefit)~~ Expense (benefit) for Income ~~Taxes~~Taxes.. During the six months ended June 30, ~~2019,~~2020, we recorded an expense for income taxes of $63.9 million compared to a benefit for income taxes of $6.8 million ~~compared to an expense for income taxes of $5.6 million~~ during the six months ended June 30, ~~2018.~~2019. The ~~benefit~~expense for income taxes recorded during the six months ended June 30, ~~2019,~~2020 resulted primarily from ~~the net excess tax benefits recognized on share-based compensation, the release of a reserve related to an uncertain tax position and~~ the mix of pre-tax income and losses incurred in various tax ~~jurisdictions.~~jurisdictions and a $15.2 million provision recorded following the publication, on April 8, 2020, of the Anti-Hybrid Rules. The Final Regulations for Section 267A permanently disallow for U.S. tax purposes certain interest expense accrued to a foreign related party during the year ended December 31, 2019. As a result, during the three months ended June 30, 2020 we recorded a write off of a deferred tax asset related to this interest expense and recognized a corresponding tax provision of $15.2 million. These expenses were partially offset by the tax benefits recognized on share-based compensation.

See Note 11, Segment and Other Information, of the Notes to Condensed Consolidated Financial Statements, included in Item 1 of this Quarterly Report on Form 10-Q for a reconciliation of our segment operating income to our total ~~loss~~income (loss) before expense (benefit) ~~expense~~ for income taxes for the six months ended June 30, ~~2019~~2020 and ~~2018.~~2019.

The following table reflects our orphan ~~and rheumatology~~segment net sales and segment operating income for the six months ended June 30, ~~2019~~2020 and ~~2018~~2019 (in thousands, except percentages).

	For the Six Months Ended June 30,									For the Six Months Ended June 30,
	2019		2018		Change		% Change			2020		2019		Change		% Change
Net sales	$	409,353	$	373,980	$	35,373		9	%	$	624,611	$	369,645	$	254,966		69	%
Segment operating income		121,180		113,713		7,467		7	%		205,897		100,400		105,497		105	%

The increase in orphan ~~and rheumatology~~segment net sales during the six months ended June 30, ~~2019~~2020 is described in the Consolidated Results section above.

Segment operating income. Orphan ~~and rheumatology~~ segment operating income increased ~~$7.5~~$105.5 million to ~~$121.2~~$205.9 million during the six months ended June 30, ~~2019,~~2020, from ~~$113.7~~$100.4 million during the six months ended June 30, ~~2018.~~2019. The increase was primarily attributable to an increase in net sales of ~~$35.4~~$255.0 million primarily due to post-launch sales of TEPEZZA as described above, partially offset by an increase in selling, general and administrative expenses of ~~$24.7~~$102.6 million primarily due to increased costs relating to the launch of TEPEZZA and an increase of $23.2 million in ~~sales and marketing costs~~royalty expense, primarily related to ~~KRYSTEXXA and costs to prepare for the potential U.S. launch~~royalties payable on net sales of ~~teprotumumab.~~TEPEZZA.

The following table reflects our inflammation segment net sales and segment operating income for the six months ended June 30, ~~2019~~2020 and ~~2018~~2019 (in thousands, except percentages).

	For the Six Months Ended June 30,									For the Six Months Ended June 30,
	2019		2018		Change		% Change			2020		2019		Change			% Change
Net sales	$	191,665	$	152,736	$	38,929		25	%	$	194,077	$	231,373	$	(37,296	)		(16	%)
Segment operating income		91,139		36,311		54,828		151	%		90,038		111,919		(21,881	)		(20	%)

The decrease in inflammation segment net sales during the six months ended June 30, ~~2019~~2020 is described in the Consolidated Results section above.

Segment operating income. Inflammation segment operating income ~~increased $54.8~~decreased $21.9 million to ~~$91.1~~$90.0 million during the six months ended June 30, ~~2019,~~2020, from ~~$36.3~~$111.9 million during the six months ended June 30, ~~2018.~~2019. The ~~increase~~decrease was primarily attributable to ~~an increase~~a decrease in net sales of ~~$38.9~~$37.3 million as described above, ~~and~~partially offset by a decrease in ~~sales~~selling, general and ~~marketing costs~~administrative expenses of ~~$12.2 million mainly related to lower sample and patient assistant program administration expenses.~~$10.2 million.

EBITDA, or earnings before interest, taxes, depreciation and amortization, adjusted EBITDA, non-GAAP net income and non-GAAP earnings per share are used and provided by us as non-GAAP financial measures. These non-GAAP financial measures are intended to provide additional information on our performance, operations and profitability. Adjustments to our GAAP figures as well as EBITDA exclude acquisition/divestiture-related costs, upfront, progress and milestone payments related to license and collaboration agreements, drug substance harmonization costs, fees related to refinancing activities, restructuring and realignment costs, litigation settlements and charges related to discontinuation of the Friedreich’s ataxia program, as well as non-cash items such as share-based compensation, inventory step-up expense, depreciation and amortization, non-cash interest expense, long-lived assets impairment charges, loss on debt extinguishments, (gain) loss on sale of assets and other non-cash adjustments. Certain other special items or substantive events may also be included in the non-GAAP adjustments periodically when their magnitude is significant within the periods incurred. We maintain an established non-GAAP cost policy that guides the determination of what costs will be excluded in non-GAAP measures. We believe that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of our financial and operating performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of our historical financial results and trends and to facilitate comparisons between periods. In addition, these non-GAAP financial measures are among the indicators our management uses for planning and forecasting purposes and measuring our performance. For example, adjusted EBITDA is used by us as one measure of management performance under certain incentive compensation arrangements. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by us may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies.

Reconciliations of reported GAAP net loss to EBITDA, adjusted EBITDA and non-GAAP net income, and the related per share amounts, were as follows (in thousands, except share and per share amounts):

	For the Three Months Ended June 30,						For the Six Months Ended June 30,						For the Three Months Ended June 30,						For the Six Months Ended June 30,
	2019			2018			2019			2018			2020			2019			2020			2019
GAAP net loss	$	(5,120	)	$	(24,751	)	$	(37,983	)	$	(173,407	)	$	(80,010	)	$	(5,120	)	$	(93,601	)	$	(37,983	)
Depreciation (1)		1,443			1,551			2,916			3,104			6,907			1,443			14,072			2,916
Amortization and step-up:
Intangible amortization expense (2)		57,683			60,480			115,100			121,364			66,749			57,683			125,324			115,100
Inventory step-up expense ~~(3)~~		(25	)		53			90			17,129			—			(25	)		—			90
Interest expense, net (including amortization of debt discount and deferred financing costs)		22,033			31,030			49,563			61,484			18,571			22,033			35,915			49,563
(Benefit) expense for income taxes		(4,875	)		4,621			(6,795	)		5,566
Expense (benefit) for income taxes														82,964			(4,875	)		63,938			(6,795	)
EBITDA		71,139			72,984			122,891			35,240			95,181			71,139			145,648			122,891
Other non-GAAP adjustments:
Acquisition/divestiture-related costs ~~(4)~~(3)		1,200			1,078			2,546			5,803			47,103			1,200			47,097			2,546
Restructuring and realignment costs (5)		13			7,039			33			10,307
Impairment of long-lived assets (6)		—			—			—			33,647
Share-based compensation (7)		21,367			30,721			48,915			58,554
Loss on debt extinguishment (8)		11,878			—			17,464			—
Loss on sale of assets (9)		10,963			—			10,963			—
Charges related to discontinuation of Friedreich’s ataxia program (10)		1,300			272			1,221			1,222
Drug substance harmonization costs (11)		234			475			314			1,279
Upfront, progress and milestones payments related to license and collaboration agreements (12)		4,000			—			6,000			90
Fees related to refinancing activities (13)		1,033			15			1,175			42
Litigation settlements (14)		1,000			4,250			1,000			4,250
Share-based compensation ⁽⁴⁾														27,057			21,367			83,478			48,915
Loss on debt extinguishment ⁽⁵⁾														17,254			11,878			17,254			17,464
Upfront, progress and milestones payments related to license and collaboration agreements ⁽⁶⁾														3,000			4,000			3,000			6,000
Impairment of long-lived assets ⁽⁷⁾														1,072			—			1,072			—
Drug substance harmonization costs ⁽⁸⁾														—			234			290			314
Fees related to refinancing activities ⁽⁹⁾														—			1,033			54			1,175
Loss on sale of assets ⁽¹⁰⁾														—			10,963			—			10,963
Charges related to discontinuation of Friedreich’s ataxia program ⁽¹¹⁾														—			1,300			—			1,221
Litigation settlements ⁽¹²⁾														—			1,000			—			1,000
Restructuring and realignment costs ⁽¹³⁾														—			13			—			33
Total of other non-GAAP adjustments		52,988			43,850			89,631			115,194			95,486			52,988			152,245			89,631
Adjusted EBITDA	$	124,127		$	116,834		$	212,522		$	150,434		$	190,667		$	124,127		$	297,893		$	212,522

	For the Three Months Ended June 30,						For the Six Months Ended June 30,						For the Three Months Ended June 30,						For the Six Months Ended June 30,
	2019			2018			2019			2018			2020			2019			2020			2019
GAAP net loss	$	(5,120	)	$	(24,751	)	$	(37,983	)	$	(173,407	)	$	(80,010	)	$	(5,120	)	$	(93,601	)	$	(37,983	)
Non-GAAP adjustments:
Depreciation ⁽¹⁾														6,907			1,443			14,072			2,916
Amortization and step-up:
Intangible amortization expense (2)		57,683			60,480			115,100			121,364			66,749			57,683			125,324			115,100
Inventory step-up expense (3)		(25	)		53			90			17,129
Amortization of debt discount and deferred financing costs (15)		5,710			5,691			11,622			11,187
Share-based compensation (7)		21,367			30,721			48,915			58,554
Loss on debt extinguishment (8)		11,878			—			17,464			—
Loss on sale of assets (9)		10,963			—			10,963			—
Upfront, progress and milestone payments related to license and collaboration agreements (12)		4,000			—			6,000			90
Depreciation (1)		1,443			1,551			2,916			3,104
Charges relating to discontinuation of Friedreich's ataxia program (10)		1,300			272			1,221			1,222
Acquisition/divestiture-related costs (4)		1,200			1,078			2,546			5,803
Fees related to refinancing activities (13)		1,033			15			1,175			42
Litigation settlements (14)		1,000			4,250			1,000			4,250
Drug substance harmonization costs (11)		234			475			314			1,279
Restructuring and realignment costs (5)		13			7,039			33			10,307
Impairment of long-lived assets (6)		—			—			—			33,647
Amortization of debt discount and deferred financing costs ⁽¹⁴⁾														5,248			5,710			10,817			11,622
Inventory step-up expense														—			(25	)		—			90
Acquisition/divestiture-related costs ⁽³⁾														47,103			1,200			47,097			2,546
Share-based compensation ⁽⁴⁾														27,057			21,367			83,478			48,915
Loss on debt extinguishment ⁽⁵⁾														17,254			11,878			17,254			17,464
Upfront, progress and milestones payments related to license and collaboration agreements ⁽⁶⁾														3,000			4,000			3,000			6,000
Impairment of long-lived assets ⁽⁷⁾														1,072			—			1,072			—
Drug substance harmonization costs ⁽⁸⁾														—			234			290			314
Fees related to refinancing activities ⁽⁹⁾														—			1,033			54			1,175
Loss on sale of assets ⁽¹⁰⁾														—			10,963			—			10,963
Charges related to discontinuation of Friedreich’s ataxia program ⁽¹¹⁾														—			1,300			—			1,221
Litigation settlements ⁽¹²⁾														—			1,000			—			1,000
Restructuring and realignment costs ⁽¹³⁾														—			13			—			33
Total of pre-tax non-GAAP adjustments		117,799			111,625			219,359			267,978			174,390			117,799			302,458			219,359
Income tax effect of pre-tax non-GAAP adjustments (16)		(15,621	)		(6,356	)		(30,372	)		26,638
Other non-GAAP income tax adjustments (17)		(1,452	)		—			(1,452	)		(35,893	)
Income tax effect of pre-tax non-GAAP adjustments⁽¹⁵⁾														(25,797	)		(15,621	)		(57,059	)		(30,372	)
Other non-GAAP income tax adjustments ⁽¹⁶⁾														15,210			(1,452	)		15,210			(1,452	)
Total non-GAAP adjustments		100,726			105,269			187,535			258,723			163,803			100,726			260,609			187,535
Non-GAAP Net Income	$	95,606		$	80,518		$	149,552		$	85,316		$	83,793		$	95,606		$	167,008		$	149,552

Non-GAAP Earnings Per Share:
Weighted average ordinary shares – Basic		185,327,383			165,536,826			178,866,391			164,921,722			192,705,535			185,327,383			191,426,864			178,866,391

Non-GAAP Earnings Per Share – Basic
GAAP loss per share – Basic	$	(0.03	)	$	(0.15	)	$	(0.21	)	$	(1.05	)	$	(0.42	)	$	(0.03	)	$	(0.49	)	$	(0.21	)
Non-GAAP adjustments		0.55			0.64			1.05			1.57			0.85			0.55			1.36			1.05
Non-GAAP earnings per share – Basic	$	0.52		$	0.49		$	0.84		$	0.52		$	0.43		$	0.52		$	0.87		$	0.84

Non-GAAP Net Income													$	83,793		$	95,606		$	167,008		$	149,552
Effect of assumed exchange of Exchangeable Senior Notes, net of tax														1,692			—			3,567			—
Numerator - non-GAAP Net Income													$	85,485		$	95,606		$	170,575		$	149,552

Weighted average ordinary shares – Diluted
Weighted average ordinary shares – Basic		185,327,383			165,536,826			178,866,391			164,921,722			192,705,535			185,327,383			191,426,864			178,866,391
Ordinary share equivalents		7,897,507			3,820,913			7,658,133			3,678,249			21,838,670			7,897,507			22,084,476			7,658,133
Weighted average ordinary shares – Diluted		193,224,890			169,357,739			186,524,524			168,599,971
Denominator - weighted average ordinary shares – Diluted														214,544,205			193,224,890			213,511,340			186,524,524

Non-GAAP Earnings Per Share – Diluted
GAAP loss per share – Diluted	$	(0.03	)	$	(0.15	)	$	(0.21	)	$	(1.05	)	$	(0.42	)	$	(0.03	)	$	(0.49	)	$	(0.21	)
Non-GAAP adjustments		0.55			0.64			1.05			1.57			0.85			0.55			1.36			1.05
Diluted earnings per share effect of ordinary share equivalents		(0.03	)		(0.01	)		(0.04	)		(0.01	)		(0.03	)		(0.03	)		(0.07	)		(0.04	)
Non-GAAP earnings per share – Diluted	$	0.49		$	0.48		$	0.80		$	0.51		$	0.40		$	0.49		$	0.80		$	0.80

During the six months ended June 30, 2019, we recorded a loss on debt extinguishment of $17.5 million in the condensed consolidated statements of comprehensive loss, which reflected the write-off of the deferred financing fees and debt discount fees related to the prepayment of $250.0 million of 2023 Senior Notes and term loan repayment of $300.0 million.

During the three months ended June 30, 2019, we released a reserve related to an uncertain tax position in connection with an acquisition resulting in a non-GAAP tax adjustment of $1.5 million.

We have incurred losses on a GAAP basis in most fiscal years since our inception in June 2005 and, as of June 30, ~~2019,~~2020, we had an accumulated deficit of ~~$1,216.7~~$699.3 million. We expect that our sales and marketing expenses will continue to increase as a result of the commercialization of our medicines, including as a result of the commercial launch of TEPEZZA, but we believe these cost increases will be more than offset by higher net sales and gross ~~profits.~~profits in future periods. Additionally, we expect that our research and development costs will increase as we acquire or ~~license~~develop more development-stage medicine candidates and advance our candidates through the clinical development and regulatory approval processes.

46Following the highly successful launch of TEPEZZA, which has significantly exceeded expectations, we are in the process of expanding our production capacity to meet anticipated future demand for TEPEZZA. As of June 30, 2020, we had total purchase commitments, including the minimum annual order quantities and binding firm orders, with AGC Biologics A/S (formerly known as CMC Biologics A/S) for TEPEZZA drug substance of €100.9 million ($113.4 million converted at an exchange rate as of June 30, 2020 of 1.1236), to be delivered through June 2022. In addition, we had binding purchase commitments with Catalent Indiana, LLC for TEPEZZA drug product of $17.7 million, to be delivered through June 2021. We expect to enter into additional purchase commitments in connection with our efforts to expand production capacity in order to meet this anticipated increase in demand.

During the second quarter of 2020, our accounts receivables increased significantly from $425.4 million as of March 31, 2020, to $543.8 million as of June 30, 2020. This increase was primarily due to the timing of receipts for TEPEZZA sales. During the initial launch period, the payment terms for TEPEZZA have been extended and will then begin to decline following the implementation of the permanent J code for TEPEZZA on October, 1, 2020. As a result, we expect that cash inflows from TEPEZZA sales will increase significantly beginning in the second half of 2020, and in particular, the fourth quarter of 2020.

As a result of the COVID-19 pandemic and actions taken to slow its spread, the global credit and financial markets have experienced extreme volatility and disruptions, including diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. If the equity and credit markets deteriorate, it may make any additional debt or equity financing more difficult, more costly or more dilutive.

On June 3, 2020, we issued a notice of redemption, or the Redemption Notice, for all our outstanding Exchangeable Senior Notes. Pursuant to the Redemption Notice, on August 3, 2020, we were obligated to redeem any Exchangeable Senior Notes that had not been exchanged prior to such date at a redemption price in cash equal to 100% of the principal amount of such Exchangeable Senior Notes to be redeemed, plus accrued and unpaid interest, if any. During the three months ended June 30, 2020, we issued an aggregate of 7,225,368 of our ordinary shares to noteholders as a result of exchanges of $207.0 million in aggregate principal amount of Exchangeable Senior Notes. As of June 30, 2020, an aggregate principal amount of $193.0 million of Exchangeable Senior Notes were outstanding.

From July 1, 2020 through July 30, 2020, a total of $191.2 million in aggregate principal amount of Exchangeable Senior Notes were exchanged for an aggregate of 6,673,046 of our ordinary shares. On August 3, 2020, we redeemed the remaining $1.7 million in aggregate principal amount of Exchangeable Senior Notes and made aggregate cash payments to the holders of such Exchangeable Senior Notes of $1.8 million. As of the date of this Quarterly Report on Form 10-Q, there are no Exchangeable Senior Notes outstanding. We expect to record a loss on debt extinguishment of approximately $15.0 million in the third quarter of 2020 relating to the Exchangeable Senior Notes outstanding as of June 30, 2020.

In February 2020, we purchased a three-building campus in Deerfield, Illinois, for total consideration and directly attributable transaction costs of $118.5 million. The Deerfield campus totals 70 acres and consists of approximately 650,000 square feet of office space. We expect to move to the Deerfield campus in the fourth quarter of 2020 and market our Lake Forest office for sub-lease. We expect to make significant capital expenditures during 2020 in order to prepare the Deerfield campus for occupancy. In addition, if we are unable to sub-lease our existing Lake Forest office at rental rates similar to the rates under our existing lease or at all, we would be obligated to continue paying substantial rental payments through the end of the lease term in 2031.

On April 1, 2020, we acquired Curzion, a privately held development-stage biopharma company, for a $45.0 million upfront cash payment and are obligated to make additional payments contingent on the achievement of development and regulatory milestones. The $45.0 million was recorded as a research and development expense in the second quarter of 2020.

In April 2020, we entered into an agreement with S.R. One, Limited, or S.R. One, and an agreement with Lundbeckfond Invest A/S, or Lundbeckfond pursuant to which we acquired all of S.R. One’s and Lundbeckfond’s beneficial rights to proceeds from certain contingent future TEPEZZA milestone and royalty payments in exchange for a one-time payment of $55.0 million to each of the respective parties. The total payments of $110.0 million were recorded as TEPEZZA developed technology intangible assets in the second quarter of 2020.

In July 2020, we invested as a strategic limited partner in two venture capital funds: Forbion Growth Opportunities Fund I C.V., or the Forbion Fund, and Aisling Capital V, LP, or the Aisling Fund. We are committed to investing an aggregate $34.6 million in the two funds, comprising of a $20.0 million commitment to the Aisling Fund and a €13.0 million ($14.6 million when converted using a EUR-to-Dollar exchange rate at June 30, 2020 of 1.1236) commitment to the Forbion Fund, over each fund’s respective investment periods.

We have financed our operations to date through equity financings, debt financings and the issuance of convertible notes, along with cash flows from operations during the last several years. As of June 30,~~, 2019~~, 2020, we had ~~$866.0~~$718.1 million in cash and cash equivalents and total debt with a book value of ~~$1,366.8~~$1,176.8 million and ~~face~~principal value of ~~$1,443.0~~$1,211.0 million. We believe our existing cash and cash equivalents and our expected cash flows from our operations will be sufficient to fund our business needs for at least the next twelve months from the issuance of the financial statements in this Quarterly Report on Form 10-Q. ~~Part~~We do not have any financial covenants or non-financial covenants that we expect to be affected by the economic disruptions and negative effects of ~~our strategy is to expand and leverage our commercial capabilities and to develop~~the COVID-19 pandemic on the financial environment.

As of the date of this Quarterly Report on Form 10-Q, following the exchange or redemption of the remaining Exchangeable Senior Notes, we had total debt outstanding with a ~~pipeline~~principal value of rare disease medicine candidates by researching, developing and commercializing innovative medicines that address unmet treatment needs for rare and rheumatic diseases. To the extent we enter into transactions to acquire medicines or businesses in the future, we will most likely need to finance$1,018.0 million.

We have a significant ~~portion of those acquisitions through additional debt, equity or convertible debt financings, or through the use of cash on hand.~~

~~On March 11, 2019, we closed an underwritten public equity offering of 14.1 million ordinary shares at a price to the public of $24.50 per share,~~ ~~resulting in net proceeds of approximately $326.8 million~~ after deducting underwriting discounts and other estimated offering expenses payable by us. This included the exercise in full by the underwriters of their option to purchase up to 1.8 million additional ordinary shares.

~~On March 11, 2019, Horizon Pharma USA, Inc., our wholly owned subsidiary, or HPUSA, received $200.0 million aggregate principal~~ amount of revolving commitments, or the New Incremental Revolving Commitments, pursuant to an amendment to our Credit Agreement. The New Incremental Revolving Commitments were established pursuant to an incremental facility, or the Revolving Credit Facility, and will provide HPUSA with $200.0 million of additional borrowing capacity, which includesdebt outstanding on a $50.0 million letter of credit sub-facility. The New Incremental Revolving Commitments will terminate in March 2024. Borrowings under the Revolving Credit Facility are available for general corporate purposes. As of June 30, 2019, the Revolving Credit Facility was undrawn.

On March 18, 2019, HPUSA completed the repayment of $300.0 million of the outstanding principal amount of term loans under our Credit Agreement. Following this repayment, the outstanding principal balance of term loans under our Credit Agreement was $518.0 million and our total aggregate outstanding principal amount of indebtedness was $1,693.0 million.

On April 1, 2019, we delivered a notice of partial optional redemption of $250.0 million of the 6.625% Senior Notes due 2023, or the 2023 Senior Notes, to the trustee under the indenture governing the 2023 Senior Notes and the holders of the 2023 Senior Notes, which were redeemed on May 1, 2019. In connection with this early redemption, we paid a premium of $8.3 million on May 1, 2019. Following such redemption, our total aggregate outstanding principal amount of indebtedness was $1,443.0 million.

Onconsolidated basis. ~~May 22, 2019~~, HPUSA borrowed approximately $518.0 million aggregate principal amount of loans, or the May 2019 Refinancing Loans, pursuant to an amendment to our Credit Agreement. HPUSA used the proceeds of the May 2019 Refinancing Loans to repay the outstanding amounts under our prior term loans, which totaled approximately $518.0 million.

On July 16, 2019, HPUSA completed a private placement of $600.0 million aggregate principal amount of 5.5% Senior Notes due 2027, or the 2027 Senior Notes, to several investment banks acting as initial purchasers, in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act, who subsequently resold the 2027 Senior Notes to persons reasonably believed to be qualified institutional buyers in reliance on the exemption from registration provided by Rule 144A under the Securities Act and in offshore transactions to certain non-U.S. persons in reliance on Regulation S under the Securities Act.

We used the net proceeds from the offering of the 2027 Senior Notes, together with approximately $65.0 million in cash on hand, to redeem or prepay $625.0 million of our outstanding debt, consisting of (i) the outstanding $225.0 million principal amount of our 2023 Senior Notes, (ii) the outstanding $300.0 million principal amount of our ~~8.750% Senior Notes due 2024, or the 2024 Senior Notes,~~ and (iii) $100.0 million of the outstanding principal amount of senior secured term loans under the Credit Agreement, as well as to pay the related premiums and fees and expenses, excluding accrued interest, associated with such redemption and prepayment. On July 10, 2019, we delivered notice to redeem the 2023 Senior Notes and 2024 Senior Notes with a redemption date of August 9, 2019. On July 16, 2019, we irrevocably deposited sufficient funds with the trustee to redeem the 2023 Senior Notes and 2024 Senior Notes on August 9, 2019.

For a ~~more detailed~~ description of our debt agreements, see Note 13, Debt Agreements~~, and Note 20,~~ ~~Subsequent~~ ~~Events,~~ of the Notes to Condensed Consolidated Financial Statements, included in Item 1 of this Quarterly Report on Form 10-Q.

~~We have a significant amount of debt outstanding on a consolidated basis.~~ This substantial level of debt could have important consequences to our business, including, but not limited to: making it more difficult for us to satisfy our obligations; requiring a substantial portion of our cash flows from operations to be dedicated to the payment of principal and interest on our indebtedness, therefore reducing our ability to use our cash flows to fund acquisitions, capital expenditures, and future business opportunities; limiting our ability to obtain additional financing, including borrowing additional funds; increasing our vulnerability to, and reducing our flexibility to respond to, general adverse economic and industry conditions; limiting our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate; and placing us at a disadvantage as compared to our competitors, to the extent that they are not as highly leveraged. We may not be able to generate sufficient cash to service all of our indebtedness and may be forced to take other actions to satisfy our obligations under our indebtedness.

In addition, the indenture governing our 5.5% Senior Notes due 2027 and our Credit Agreement impose various covenants that limit our ability and/or our restricted subsidiaries’ ability to, among other things, pay dividends or distributions, repurchase equity, prepay junior debt and make certain investments, incur additional debt and issue certain preferred stock, incur liens on assets, engage in certain asset sales or merger transactions, enter into transactions with affiliates, designate subsidiaries as unrestricted subsidiaries; and allow to exist certain restrictions on the ability of restricted subsidiaries to pay dividends or make other payments to us.

During the six months ended June 30, ~~2019,~~2020, we issued an aggregate of ~~3.1~~4.0 million of our ordinary shares in connection with stock option exercises and the vesting of restricted stock units and ~~employee share purchase plan purchases.~~performance stock units. We received a total of ~~$17.5~~$25.9 million in proceeds in connection with such ~~issuances.~~stock option exercises.

The following table provides a summary of our cash position and cash flows for the six months ended June 30, ~~2019~~2020 and ~~2018~~2019 (in thousands):

During the six months ended June 30, 2020, net cash provided by operating activities of $37.0 million was primarily attributable to cash collections from gross sales, partially offset by payments made related to patient assistance costs for our inflammation segment medicines and government rebates for our orphan segment medicines, payments related to selling, general and administrative expenses and research and development expenses.

During the six months ended June 30, 2019, net cash provided by operating activities of $147.4 million was primarily attributable to cash collections from gross sales, partially offset by payments made during the six months ended June 30, 2019 related to patient assistance costs and commercial rebates for our inflammation segment medicines.

During the six months ended June 30, ~~2018,~~2020, net cash ~~provided by operating~~used in investing activities of $376.3 million was ~~$1.0 million. Cash provided by operating activities~~primarily attributable to payments for acquisitions of $262.3 million which consist of $215.2 million of milestone payments associated with the acquisition of River Vision Development Corp., or River Vision, and our agreements with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc, or together referred to as Roche, with S.R. One and with Lundbeckfond and $45.0 million due to the acquisition of Curzion in the second quarter of 2020. Additionally, $112.5 million was negatively impacted during the six months ended June 30, 2018 by cash payments of $55.5 million for interest on outstanding debt and cash payments of $27.3 million for income taxes. Our net cash inflow of $1.0 million for the six months ended June 30, 2018 reflects the high payments made related to patient assistance costs and commercial rebates for our inflammation segment medicines duringpaid in the first quarter of ~~2018.~~

~~Investing Cash Flows~~2020 in relation to the purchase of a three-building campus in Deerfield, Illinois.

During the six months ended June 30, 2019, net cash used in investing activities of $0.9 million was primarily attributable to the purchases of property and equipment of $6.9 million, partially offset by proceeds from the MIGERGOT transaction of $6.0 million.

During the six months ended June 30, ~~2018,~~2020, net cash used in ~~investing~~financing activities of ~~$12.8~~$19.1 million was primarily ~~associated~~attributable to payment of employee withholding taxes relating to share-based awards of $53.0 million, partially offset by the proceeds from the issuance of ordinary shares in connection with ~~the $12.0 million upfront amount paid to MedImmune LLC to license HZN-003 (formerly MEDI4945).~~

During the six months ended June 30, 2019, net cash used in financing activities of $239.0 million was primarily attributable to the repayment of $300.0 million of the outstanding principal amount of term loans under our ~~credit agreement, repayment~~Credit Agreement, redemption of $250.0 million of our 2023 Senior Notes ~~of $250.0 million~~ and an early redemption premium of $8.3 million, partially offset by net proceeds from the issuance of ordinary shares of $326.8 million.

~~During the six months ended June 30, 2018, net cash used in financing activities of $28.5 million was primarily attributable to the repayment of term loans of $27.7 million.~~

Financial Condition as of June 30, ~~2019~~2020 compared to December 31, ~~2018~~2019

Accounts receivable, net. Accounts receivable, net, ~~decreased $69.7~~increased $135.1 million, from ~~$464.7~~$408.7 million as of December 31, ~~2018~~2019 to ~~$395.0~~$543.8 million as of June 30, ~~2019.~~2020. The ~~decrease~~increase was primarily due to ~~lower gross sales~~the timing of ~~our medicines during~~receipts of accounts receivable for TEPEZZA sales. During the ~~second quarter~~initial launch period, the payment terms for TEPEZZA have been extended and will then begin to decline following the implementation of the permanent J code for TEPEZZA on October 1, 2020.

Inventories, net. Inventories, net, increased $12.3 million, from $53.8 million as of December 31, 2019 ~~when compared~~to $66.1 million as of June 30, 2020. The increase was primarily related to the ~~fourth quarter~~increases of ~~2018.~~KRYSTEXXA and TEPEZZA inventory held.

Prepaid expenses and other current assets.Prepaid expenses and other current assets increased ~~by $17.5~~$13.9 million, from ~~$68.2~~$143.6 million as of December 31, ~~2018~~2019 to ~~$85.7~~$157.5 million as of June 30, ~~2019.~~2020. The increase was primarily due to an increase in ~~prepaid income taxes of $9.8 million and an increase in~~ advance payments for TEPEZZA inventory of ~~$8.0~~$17.3 million.

~~Developed technology,~~Property and equipment, net. ~~Developed technology,~~Property and equipment, net, ~~decreased $131.6~~increased $108.7 million, from ~~$1,945.6~~$30.1 million as of December 31, ~~2018~~2019 to ~~$1,814.0~~$138.8 million as of June 30, ~~2019. The decrease~~2020. In February 2020, we purchased a three-building campus in Deerfield, Illinois, for total consideration and directly attributable transaction costs of $118.5 million.

Developed technology and other intangible assets, net. Developed technology and other intangible assets, net, increased $188.5 million, from $1,702.6 million as of December 31, 2019 to $1,891.1 million as of June 30, 2020. During the six months ended June 30, 2020, in connection with the acquisition of River Vision and our agreements with Roche, S.R. One and Lundbeckfond, we capitalized $313.9 million of developed technology related to TEPEZZA. This was ~~due to the~~partially offset by amortization of developed technology of ~~$115.1~~$125.3 million during the six months ended June 30, ~~2019 and~~2020.

Exchangeable Senior Notes. On June 3, 2020, we issued the ~~recording~~Redemption Notice for all of our outstanding Exchangeable Senior Notes with a ~~reduction~~redemption date of August 3, 2020. As of June 30, $207.0 million in aggregate principal amount of Exchangeable Senior Notes were exchanged. As of June 30, 2020, an aggregate principal amount of $193.0 million of Exchangeable Senior Notes were outstanding, which was partially offset by $18.5 million of unamortized debt discount on the ~~net book value~~consolidated balance sheet. The remaining carrying amount of ~~$17.0~~$174.5 million ~~related~~was reclassified to ~~the MIGERGOT transaction.~~

~~Other assets.~~ ~~Other assets increased $34.8 million, from $9.0 million as of December 31, 2018 to $43.8 million~~short-term debt as of June 30, 2019. Upon adoption of Accounting Standards Update No. 2016-02, Leases (Topic 842), or ASU No. 2016-02, on January 1, 2019, we established $37.1 million of liabilities and corresponding lease assets of $34.9 million on the condensed consolidated balance sheet for leases, primarily related to operating leases on rented office properties, that existed as of the January 1, 2019, adoption date. 2020.

~~Accrued expenses.~~ Accrued expenses decreased $27.5 million, from $215.7 million as of December 31, 2018 to $188.2 million as of June 30, 2019. This was primarily due to a decrease in payroll-related expenses of $22.1 million, a decrease in consulting and professional service fees of $3.5 million and a decrease in allowances for returns of $2.8 million.

~~Accrued trade discounts and rebates.~~ Accrued trade discounts and rebates decreased $59.1 million, from $457.8 million as of December 31, 2018 to $398.7 million as of June 30, 2019. This was primarily due to a $37.2 million decrease in accrued co-pay and other patient assistance costs and a $28.7 million decrease in accrued commercial rebates and wholesaler fees, partially offset by a $6.8 million increase in accrued government rebates and chargebacks.

~~Long-term debt, net of current.~~ Long-term debt, net of current, decreased $539.4 million, from $1,564.5 million as of December 31, 2018 to $1,025.1 million as of June 30, 2019. The decrease was primarily related to the repayment of $300.0 million of the outstanding principal amount of term loans under our Credit Agreement on March 18, 2019 and a $250.0 million redemption of the 2023 Senior Notes, on May 1, 2019. See Note 13, Debt Agreements, of the Notes to Condensed Consolidated Financial Statements, included in Item 1 of this Quarterly Report on Form 10-Q for further detail.

~~Other long-term liabilities.~~ Accounts payable.~~Other long-term liabilities~~Accounts payable increased ~~$35.4~~$84.5 million, from ~~$38.7~~$21.5 million as of December 31, ~~2018~~2019 to ~~$74.1~~$106.0 million as of June 30, ~~2019.~~2020. This increase was primarily due to ~~$37.6~~the timing of invoices received including an increase of $35.8 million in accounts payable related to ~~long-term lease liabilities~~co-pay and patient assistance costs, $17.6 million in accounts payable related to commercial rebates and wholesaler fees and $10.5 million in accounts payable related to government rebates.

Accrued expenses. Accrued expenses increased $180.3 million, from $235.2 million as of December 31, 2019 to $415.5 million as of June 30, ~~2019. Upon adoption~~2020. As of ~~ASU No. 2016-02~~June 30, 2020, we recorded a liability of $98.7 million in accrued expenses representing net sales milestones for TEPEZZA, composed of $67.0 million in relation to the expected future attainment of various net sales milestones payable under the acquisition agreement for River Vision and CHF30.0 million ($31.7 million when converted using a CHF-to-Dollar exchange rate as of June 30, 2020 of 1.0556) in relation to the expected future attainment of various net sales milestones payable to Roche. The timing of the payments is dependent on ~~January 1, 2019, we established $37.1~~when the applicable milestone thresholds are attained. We recorded a corresponding amount of $98.7 million ~~of liabilities and corresponding lease assets of $34.9 million~~as a finite lived intangible asset representing the developed technology for TEPEZZA on the condensed consolidated balance sheet ~~for leases, primarily related to operating leases on rented office properties, that existed~~ as of June 30, 2020. Additionally, income taxes payable increased by $63.9 million primarily due to the ~~January 1,~~mix of pre-tax income and losses incurred in various tax jurisdictions.

Accrued trade discounts and rebates. Accrued trade discounts and rebates decreased $177.8 million, from $466.4 million as of December 31, 2019 ~~adoption date.~~to $288.6 million as of June 30, 2020. This was primarily due to a decrease of $111.3 million in accrued co-pay and other patient assistance costs primarily due to lower utilization of our patient assistance programs, the impact of generic competition on VIMOVO sales and the timing of co-pay payments, a $61.5 million decrease in accrued commercial rebates and wholesaler fees primarily due to an increased proportion of orphan segment medicines sold and the impact of generic competition on VIMOVO sales and a $5.0 million decrease in accrued government rebates and chargebacks.

During the six months ended June 30, ~~2019,~~2020, there were no material changes outside of the ordinary course of business to our contractual obligations as previously disclosed in Part II, Item 7 of our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2018,~~2019, except for our entry into the following commitments described below.

On ~~March 18, 2019, HPUSA completed~~April 1, 2020, we acquired Curzion for a $45.0 million upfront cash payment and are obligated to make additional payments contingent on the ~~repayment~~achievement of ~~$300.0~~development and regulatory milestones. The $45.0 million was recorded as a research and development expense in the second quarter of 2020.

In April 2020, we entered into an agreement with S.R. One and an agreement with Lundbeckfond pursuant to which we acquired all of S.R. One’s and Lundbeckfond’s beneficial rights to proceeds from certain contingent future TEPEZZA milestone and royalty payments in exchange for a one-time payment of $55.0 million to each of the ~~outstanding principal amount~~respective parties. The total payments of ~~term loans under our Credit Agreement. Following this repayment,~~$110.0 million were recorded as TEPEZZA developed technology intangible assets in the ~~outstanding principal balance~~second quarter of ~~term loans under our Credit Agreement was $518.0 million.~~

On May 1, 2019, we redeemed $250.0 million of the 2023 Senior Notes under the indenture governing the 2023 Senior Notes. Following this repayment, our total aggregate outstanding principal amount of indebtedness was $1,443.0 million.

~~See Note 20,~~ ~~Subsequent Events,~~ ~~of the Notes to Condensed Consolidated Financial Statements, included in Item 1 of this Quarterly Report on Form 10-Q for details~~2020. As a result of our ~~2027 Senior Notes~~agreements with S.R. One and ~~related debt repayments.~~Lundbeckfond in April 2020, our remaining net obligations to make TEPEZZA payments to the former stockholders of River Vision was reduced by approximately 70.25%, after including payments to a third party.

49In July 2020, we invested as a strategic limited partner in two venture capital funds: Forbion Fund and the Aisling Fund. We are committed to investing an aggregate $34.6 million in the two funds, comprising of a $20.0 million commitment to the Aisling Fund and a €13.0 million ($14.6 million when converted using a EUR-to-Dollar exchange rate at June 30, 2020 of 1.1236) commitment to the Forbion Fund, over each fund’s respective investment periods.

The preparation of financial statements in accordance with U.S. GAAP principles requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenue and expenses. Certain of these policies are considered critical as these most significantly impact a company’s financial condition and results of operations and require the most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Actual results may vary from these estimates. A summary of our significant accounting policies is included in Note 2 to our Annual Report on Form 10-K for the year ended December 31, ~~2018.~~

~~Effective January 1, 2019 we adopted ASU No. 2016-02. See Note 2,~~ ~~Summary of Significant Accounting Policies~~, of the Notes to Condensed Consolidated Financial Statements, included in Item 1 of this Quarterly Report on Form 10-Q for details of the impact of this adoption. We modified our critical accounting policies related to leases following the adoption of ASU No. 2016-02, and our updated policies are described in Note 2, ~~Summary of Significant Accounting Policies, of the Notes to Condensed Consolidated Financial Statements, included in Item 1 of this Quarterly Report on Form 10-Q.~~

Effective January 1, 2019, we retrospectively changed our accounting for business combinations under ASC Topic 805, Business Combinations and now record acquired intangible assets and their related third-party contingent royalties on a net basis. Refer to Note 2, ~~Summary of Significant Accounting Policies, of the Notes to Condensed Consolidated Financial Statements, included in Item 1 of this Quarterly Report on Form 10-Q for our updated policy.~~2019.

During the six months ended June 30, 2019, other than the adoption of ASU No. 2016-02 and the resulting changes to our lease critical accounting policy and the changes to our accounting policy for contingent royalties and intangible assets as a result of our change in accounting for business combinations under ASC Topic 805, Business Combinations,2020, there have been no significant changes in our application of our critical accounting policies.

Since our inception, we have not engaged in any off-balance sheet arrangements, including the use of structured finance, special purpose entities or variable interest entities, other than the indemnification agreements discussed in Note 15, Commitments and Contingencies, of the Notes to Condensed Consolidated Financial Statements, included in Item 1 of this Quarterly Report on Form 10-Q.

We are exposed to various market risks, which include potential losses arising from adverse changes in market rates and prices, such as interest rates and foreign exchange fluctuations. We do not enter into derivatives or other financial instruments for trading or speculative purposes.

Interest Rate Risk. We are subject to interest rate fluctuation exposure through our borrowings under ~~the~~our Credit Agreement and our investment in money market accounts which bear a variable interest rate. ~~Loans~~Term loans under ~~the~~our Credit Agreement bear interest, at our option, at a rate equal to ~~either~~ the London Inter-Bank Offered Rate, or LIBOR, plus ~~an applicable margin of 2.50%~~2.25% per annum (subject to a ~~1.00%~~0.00% LIBOR floor), or the adjusted base rate plus 1.25% per annum with a step-down to LIBOR plus 2.00%. per annum or the adjusted base rate plus 1.00% per annum at the time our leverage ratio is less than or equal to 2.00 to 1.00. The adjusted base rate is defined as the greatest of (a) LIBOR (using a one-month interest period) plus 1.00%, (b) the prime rate, (c) the federal funds rate plus 0.50%, and (d) 1.00%. The loans under our incremental revolving credit facility (the “Revolving Credit Facility”) bear interest, at our option, at a rate equal to either LIBOR plus an applicable margin of 2.25% per annum (subject to a LIBOR floor of 0.00%), or the adjusted base rate plus 1.25% per annum with a step-down to LIBOR plus 2.00%. per annum or the adjusted base rate plus 1.00% per annum at the time our leverage ratio is less than or equal to 2.00 to 1.00. Our approximately $418.0 million of senior secured term loans under the Credit Agreement ~~are~~is based on LIBOR. As of June 30, ~~2019,~~2020, the Revolving Credit Facility was undrawn. The one-month LIBOR rate as of ~~August 1, 2019,~~July 31, 2020, which was the most recent date the interest rate on the term loan was fixed, was ~~2.44%~~0.19%, and as a result, the interest rate on our borrowings is currently ~~4.94%~~2.44% per annum. Because the United Kingdom Financial Conduct Authority, which regulates LIBOR, intends to phase out the use of LIBOR by the end of 2021, future borrowings under our Credit Agreement could be subject to reference rates other than LIBOR.

An increase in the LIBOR of 100 basis points ~~(1.00%) in~~above the ~~interest~~current LIBOR rate ~~on our outstanding loans at the date of filing of this Quarterly Report on Form 10-Q~~ would increase our interest expense related to the Credit Agreement by ~~$4.2~~$4.18 million per ~~year~~.year.

The goals of our investment policy are to preserve capital, fulfill liquidity needs and maintain fiduciary control of cash. To achieve our goal of maximizing income without assuming significant market risk, we maintain our excess cash and cash equivalents in money market funds. Because of the short-term maturities of our cash equivalents, we do not believe that a decrease in interest rates would have any material negative impact on the fair value of our cash equivalents.

Foreign Currency Risk. Our purchase costs of ~~teprotumumab~~TEPEZZA drug substance and ACTIMMUNE inventory isare principally denominated in Euros and isare subject to foreign currency risk. We have contracts relating to RAVICTI, QUINSAIR and PROCYSBI for sales in Canada which sales are subject to foreign currency risk. We also incur certain operating expenses in currencies other than the U.S. dollar in relation to our Irish operations and foreign subsidiaries. Therefore, we are subject to volatility in cash flows due to fluctuations in foreign currency exchange rates, particularly changes in the Euro and the Canadian dollar.

Inflation Risk.We do not believe that inflation has had a material impact on our business or results of operations during the periods for which the condensed consolidated financial statements are presented in this report.

Credit Risk.Historically, our accounts receivable balances have been highly concentrated with a select number of customers, consisting primarily of large wholesale pharmaceutical distributors who, in turn, sell the medicines to pharmacies, hospitals and other customers. As of June 30, ~~2019,~~2020 and December 31, ~~2018,~~2019, our top four customers accounted for approximately ~~83%~~92% and ~~85%~~84%, respectively, of our total outstanding accounts receivable balances.

Evaluation of Disclosure Controls and Procedures. As required by paragraph (b) of Rules 13a-15 and 15d-15 promulgated under the Exchange Act, our management, including our Chief Executive Officer and Chief Financial Officer, conducted an evaluation as of the end of the period covered by this report of the effectiveness of our disclosure controls and procedures as defined in Exchange Act Rules 13a-15(e) and 15d-15(e). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of June 30 ~~2019,~~, 2020, the end of the period covered by this report.

Changes in Internal Control Over Financial Reporting. During the quarter ended June 30, ~~2019,~~2020, there have been no material changes to our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f), that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

For a description of our legal proceedings, see Note 16, Legal Proceedings, of the Notes to Unaudited Condensed Consolidated Financial Statements, included in Item 1 of this Quarterly Report on Form 10-Q.

You should consider carefully the risks described below, together with all of the other information included in this report, and in our other filings with the Securities and Exchange Commission, or SEC, before deciding whether to invest in or continue to hold our ordinary shares. The risks described below are all material risks currently known, expected or reasonably foreseeable by us. If any of these risks actually occurs, our business, financial condition, results of operations or cash flow could be seriously harmed. This could cause the trading price of our ordinary shares to decline, resulting in a loss of all or part of your investment.

The risk factors set forth below with an asterisk (*) next to the title are new risk factors or risk factors containing changes, including any material changes, from the risk factors previously disclosed in Item 1A of our Annual Report on Form 10-K for the year ended December 31, ~~2018,~~2019, as filed with the SEC.

The COVID-19 global pandemic could adversely impact our business, including the commercialization of our medicines, our supply chain, our clinical trials, our liquidity and access to capital markets and our business development activities.*

On March 11, 2020, the World Health Organization made the assessment that a novel strain of coronavirus, which causes the COVID-19 disease, can be characterized as a pandemic. The President of the United States declared the COVID-19 pandemic a national emergency and many states and municipalities in the Unites States have announced aggressive actions to reduce the spread of the disease, including limiting non-essential gatherings of people, ceasing all non-essential travel, ordering certain businesses and government agencies to cease non-essential operations at physical locations and issuing “shelter-in-place” orders which direct individuals to shelter at their places of residence (subject to limited exceptions). Similarly, the Irish government has limited gatherings of people and encouraged employees to work from their homes, and may implement more aggressive policies in the future. In addition, in mid-March 2020 we implemented work-from-home policies for all employees and moved to a “virtual” model with respect to our physician, patient and partner support activities. As certain U.S. states have started to reduce restrictions, we are seeing physician offices beginning to reopen, which reopening varies on a state-by-state basis. As a result, our sales representatives in some areas have transitioned to being back out in the field and are working on ways to re-engage patients and physicians. However, as COVID-19 cases have increased in certain areas, certain U.S. states have started to reimplement restrictions and we have seen some physician offices re-establish limits on in-person visits. Restrictions in response to COVID-19 may continue to fluctuate in U.S. states and other geographies and we cannot guarantee that additional U.S. states that have previously reduced restrictions will not reimplement them or that other states will reduce restrictions in the near-term. The effects of government actions and our policies and those of third parties to reduce the spread of COVID-19 may negatively impact productivity and our ability to market and sell our medicines, cause disruptions to our supply chain and ongoing and future clinical trials and impair our ability to execute our business development strategy. These and other disruptions in our operations and the global economy could negatively impact our business, operating results and financial condition.

The commercialization of our medicines has been adversely impacted by COVID-19 and actions taken to slow its spread. For example, patients have postponed visits to healthcare provider facilities, certain healthcare providers have temporarily closed their offices or are restricting patient visits, healthcare provider employees may become generally unavailable and there could be disruptions in the operations of payors, distributors, logistics providers and other third parties that are necessary for our medicines to be prescribed, reimbursed and administered to patients. We also cannot predict how effective our virtual patient, physician and partner support initiatives will be with respect to marketing and supporting the administration and reimbursement of our medicines, or when we will be able to resume in-person sales and marketing activities.

Quarantines, shelter-in-place and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related to COVID-19 or other infectious diseases could impact personnel at third-party manufacturing facilities upon which we rely, or the availability or cost of materials, which could disrupt the supply chain for our medicines. In particular, some of our suppliers of certain materials used in the production of our drug products are located in regions that have been subject to COVID-19-related actions and policies that limit the conduct of normal business operations. To the extent our suppliers and service providers are unable to comply with their obligations under our agreements with them or they are otherwise unable to deliver or are delayed in delivering goods and services to us due to COVID-19, our ability to continue meeting commercial demand for our medicines in the United States or advancing development of our medicine candidates may become impaired. At this time, we consider our inventories on hand to be sufficient to meet our commercial requirements.

In addition, our clinical trials may be affected by COVID-19. Clinical site initiation and patient enrollment may be delayed due to prioritization of hospital resources toward COVID-19. Current or potential patients in our ongoing or planned clinical trials may also choose to not enroll, not participate in follow-up clinical visits or drop out of the trial as a precaution against contracting COVID-19. Further, some patients may not be able or willing to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Some clinical sites in the United States have started to slow or stop further enrollment of new patients in clinical trials, denied access to site monitors or otherwise curtailed certain operations. Similarly, our ability to recruit and retain principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, may be adversely impacted. These events could delay our clinical trials, increase the cost of completing our clinical trials and negatively impact the integrity, reliability or robustness of the data from our clinical trials.

The spread of COVID-19 and actions taken to reduce its spread may also materially affect us economically. As a result of the COVID-19 pandemic and actions taken to slow its spread, the global credit and financial markets have experienced extreme volatility and disruptions, including diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. If the equity and credit markets deteriorate, it may make any additional debt or equity financing more difficult, more costly or more dilutive. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, there could be a significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity and financial position or our business development activities.

COVID-19 continues to rapidly evolve. The extent to which COVID-19 may impact the commercialization of our medicines, our supply chain, our clinical trials, our access to capital and our business development activities, will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the pandemic, the duration of the pandemic and the efforts by governments and business to contain it, business closures or business disruptions and the impact on the economy and capital markets.

Our ability to generate revenues from our medicines is subject to attaining significant market acceptance among physicians, patients and healthcare payers.*

Our current medicines, and other medicines or medicine candidates that we may develop or acquire, may not attain market acceptance among physicians, patients, healthcare payers or the medical community. ~~We have a limited history of commercializing medicines and most~~Some of our medicines, in particular TEPEZZA, have not been on the market for an ~~extensive~~extended period of time, which subjects us to numerous risks as we attempt to increase our market share. We believe that the degree of market acceptance and our ability to generate revenues from our medicines will depend on a number of factors, including:

With respect to TEPEZZA, sales will depend on market acceptance and adoption by physicians and healthcare payers, as well as the ability and willingness of physicians who do not have in-house infusion capability to refer patients to infusion sites of care. With respect to KRYSTEXXA, our ability to grow sales will be affected by the success of our sales, marketing and clinical strategies, which are intended to expand the patient population and usage of KRYSTEXXA. This includes our marketing efforts in nephrology and our studies designed to improve the response rate to KRYSTEXXA and to evaluate the use of KRYSTEXXA in kidney transplant patients. With respect to RAVICTI, which is approved to treat a very limited patient population, our ability to grow sales will depend in large part on our ability to transition urea cycle disorder, or UCD, patients from BUPHENYL or generic equivalents, which are comparatively much less expensive, to RAVICTI and to encourage patients and physicians to continue RAVICTI therapy once initiated. With respect to PROCYSBI, which is also approved to treat a very limited patient population, our ability to grow sales will depend in large part on our ability to transition patients from the first-generation immediate-release cysteamine therapy to PROCYSBI, to identify additional patients with nephropathic cystinosis and to encourage patients and physicians to continue therapy once initiated. With respect to ACTIMMUNE, while it is the only FDA-approved treatment for chronic granulomatous disease, or CGD, and severe, malignant osteopetrosis, or SMO, they are very rare conditions and, as a result, our ability to grow ACTIMMUNE sales will depend on our ability to ~~access a wider patient population~~identify additional patients and encourage patients and physicians to continue treatment once initiated. Unless QUINSAIR is approved for marketing in additional countries, our ability to drive growth of this medicine will largely depend on expanding its use in Canada. With respect to KRYSTEXXA, our ability to grow sales will be affected by the success of our sales, marketing and clinical strategies, which could expand the patient population and usage of KRYSTEXXA. This includes our marketing efforts in nephrology and our studies designed to improve the response rate to KRYSTEXXA and to evaluate the use of KRYSTEXXA in kidney transplant patients. With respect to each of ~~BUPHENYL, RAYOS,~~ PENNSAID 2% w/w, or PENNSAID 2%, ~~DUEXIS~~RAYOS and ~~VIMOVO,~~DUEXIS, their higher cost compared to the generic or branded forms of their active ingredients alone may limit adoption by physicians, patients and healthcare payers. With respect to DUEXIS, ~~and VIMOVO,~~ studies indicate that physicians do not commonly co-prescribe gastrointestinal, or GI, protective agents to high-risk patients taking nonsteroidal anti-inflammatory drugs, or NSAIDs. We believe this is due in part to a lack of awareness among physicians prescribing NSAIDs regarding the risk of NSAID-induced upper GI ulcers, in addition to the inconvenience of prescribing two separate medications and patient compliance issues associated with multiple prescriptions. If physicians remain unaware of, or do not otherwise believe in, the benefits of combining GI protective agents with NSAIDs, our market opportunity for DUEXIS ~~and VIMOVO~~ will be limited. Some physicians may also be reluctant to prescribe DUEXIS ~~or VIMOVO~~ due to the inability to vary the dose of ibuprofen and naproxen, respectively, or if they believe treatment with NSAIDs or GI protective agents other than those contained in DUEXIS, ~~and VIMOVO,~~ including those of its competitors, would be more effective for their patients. If our current medicines or any other medicine that we may seek approval for, or acquire, fail to attain market acceptance, we may not be able to generate significant revenue to achieve or sustain profitability, which would have a material adverse effect on our business, results of operations, financial condition and prospects (including, possibly, the value of our ordinary shares).

The COVID-19 pandemic and actions taken to slow its spread has had and will continue to have a negative impact on sales of our medicines. For example, in March 2020 we transitioned our sales force to a virtual model such that they no longer had in-person interactions with healthcare professionals and while we have been working on ways to re-engage patients and physicians as certain U.S. states have started to reduce restrictions, the virtual model is still being used. While we have attempted to maintain the effectiveness of our sales and marketing efforts in the virtual model, it may not be as effective as in-person interactions in terms of conveying key information about our medicines or aiding physicians and their staff in prescribing and helping their patients obtain reimbursement for our medicines. Many physicians, in particular in primary care practices that prescribe our inflammation segment medicines, have reduced their operations in light of COVID-19, including delaying patient visits and writing new prescriptions, and we expect this to negatively impact sales in our inflammation segment. Similarly, many patients have deferred non-essential visits to healthcare providers, which has had a negative impact on prescriptions being written and filled. For example, due to reduced willingness of patients to visit physician offices and infusion centers, sales of KRYSTEXXA have been negatively impacted, and we expect this impact to continue in future quarters until healthcare activities and patient visits return to normal levels. It is also possible that a prolonged period of “shelter-in-place” orders and social distancing behaviors and the associated reduction of physician office visits could force various healthcare practices to permanently close or to consolidate with larger practices or healthcare groups, which could cause us to lose previously-established physician relationships. We cannot predict how long the COVID-19 pandemic will continue to negatively impact sales of our medicines and we expect that even after government-mandated restrictions are lifted, our sales force activities, healthcare provider operations and patients’ willingness to visit healthcare facilities will continue to be limited.

Our future prospects are highly dependent on our ability to successfully formulate and execute commercialization strategies for each of our medicines. Failure to do so would adversely impact our financial condition and prospects.*

A substantial majority of our resources are focused on the commercialization of our current medicines. Our ability to generate significant medicine revenues and to achieve commercial success in the near-term will initially depend almost entirely on our ability to successfully commercialize these medicines in the United States.

With respect to our rare disease medicines, TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI ~~ACTIMMUNE, BUPHENYL, QUINSAIR~~ and ~~KRYSTEXXA,~~ACTIMMUNE, our commercialization strategy includes efforts to increase awareness of the rare conditions that each medicine is designed to treat, enhancing efforts to identify target patients and in certain cases pursue opportunities for label expansion and more effective use through clinical trials. Our commercialization strategy for TEPEZZA has four components: (i) driving early uptake by continuing to define the role of TEPEZZA in the treatment of thyroid eye disease, or TED, and getting uptake from treating physicians; (ii) continuing to develop the TED market by driving awareness of the disease severity and benefits of treatment, educating the appropriate treating physicians on the urgency to diagnose and treat TED and continuing to drive patients’ awareness of TED; (iii) supporting TEPEZZA with our comprehensive approach that includes a high-touch, patient-centric model; and (iv) facilitating patient and physician access to TEPEZZA. Our strategy with respect to KRYSTEXXA includes existing rheumatology account growth, new rheumatology account growth and accelerating nephrology growth, as well as development efforts to enhance response rates through combination treatment with methotrexate and to shorten the infusion time. With respect to RAVICTI and PROCYSBI, our strategy includes accelerating the transition of patients from first-generation therapies, ~~and~~ increasing the diagnosis of the associated rare conditions through patient and physician ~~outreach. Our~~outreach; and increasing compliance rates.

We are focusing a significant portion of our commercial activities and resources on TEPEZZA, and we believe our ability to grow our long-term revenues, and a significant portion of the value of our company, relates to our ability to successfully commercialize TEPEZZA in the United States. As a newly-launched medicine for a disease that had no previously-approved treatments, successful commercialization of TEPEZZA is subject to many risks. There are numerous examples of unsuccessful product launches and failures to meet high expectations of market potential, including by pharmaceutical companies with more experience and resources than us. While we have established our commercial team and U.S. sales force, we will need to further train and develop the team in order to successfully commercialize TEPEZZA. There are many factors that could cause the launch and commercialization of TEPEZZA to be unsuccessful, including a number of factors that are outside our control. Because no medicine has previously been approved by the FDA for the treatment of TED, it is especially difficult to estimate TEPEZZA’s market potential or the time it will take to increase patient and physician awareness of TED and change current treatment paradigms. For example, shortly after the launch of TEPEZZA, we transitioned our sales force to a virtual model in light of the COVID-19 pandemic, which, combined with physicians generally reducing their own availability, has made it more challenging to execute on our strategy to educate physicians about TEPEZZA and the treatment of TED. In addition, some physicians that are potential prescribers of TEPEZZA do not have the necessary infusion capabilities to administer the medicine and may not otherwise be able or willing to refer their patients to third-party infusion centers, which may discourage them from treating their patients with ~~respect~~TEPEZZA. The commercial success of TEPEZZA depends on the extent to ~~KRYSTEXXA includes supporting three pillars~~which patients and physicians accept and adopt TEPEZZA as a treatment for TED. For example, if the patient population suffering from TED is smaller than we estimate, if it proves difficult to identify TED patients or educate physicians as to the availability and potential benefits of ~~growth: existing rheumatology account growth, new rheumatology account growth~~TEPEZZA, or if physicians are unwilling to prescribe or patients are unwilling to take TEPEZZA, the commercial potential of TEPEZZA will be limited. We also do not know how physicians, patients and ~~accelerating nephrology growth.~~payers will respond to the pricing of TEPEZZA. Physicians may not prescribe TEPEZZA and patients may be unwilling to use TEPEZZA if coverage is not provided or reimbursement is inadequate to cover a significant portion of the cost. Further, the status of reimbursement codes for TEPEZZA could also affect reimbursement. J codes, Q codes and C codes are reimbursement codes maintained by the Centers for Medicare & Medicaid Services, or CMS, that are typically used to report injectable drugs that ordinarily cannot be self-administered. While CMS assigned a permanent, product-specific J code for TEPEZZA on July 9, 2020, this J code does not become effective until October 1, 2020. Until the product-specific J code become effective, TEPEZZA will be reimbursed through a non-specific miscellaneous J code. The non-specific miscellaneous J code is used for a wide variety of products and health plans may have more difficulty determining the actual product used and billed for the patient. As a result, these claims must often be submitted with additional information and manually processed, which can create delays in claims processing times as well as increasing the likelihood for claim errors. These delays and claims errors may in turn slow adoption of TEPEZZA until a product-specific reimbursement code becomes effective. Thus, significant uncertainty remains regarding the commercial potential of TEPEZZA. If the launch or commercialization of TEPEZZA is unsuccessful or perceived as disappointing, the price of our ordinary shares could decline significantly and long-term success of the medicine and our company could be harmed.

With respect to our inflammation segment medicines, PENNSAID 2%, and DUEXIS, ~~and VIMOVO,~~ our strategy has included entering into rebate agreements with pharmacy benefit managers, or PBMs, for certain of our inflammation segment medicines where we believe the rebates and costs justify expanded formulary access for patients and ensuring patient ~~access~~assistance to these drugs when prescribed through our HorizonCares program. However, we cannot guarantee that we will be able to secure additional rebate agreements on commercially reasonable terms, that expected volume growth will sufficiently offset the rebates and fees paid to PBMs or that our existing agreements with PBMs will have the intended impact on formulary access. In addition, as the terms of our existing agreements with PBMs expire, we may not be able to renew the agreements on commercially favorable terms, or at all. For each of our inflammation segment medicines, we expect that our commercial success will depend on our sales and marketing efforts in the United States, reimbursement decisions by commercial payers, the expense we incur through our patient ~~access~~assistance program for fully bought down contracts and the rebates we pay to PBMs, as well as the impact of numerous efforts at federal, state and local levels to further reduce reimbursement and net pricing of inflammation segment medicines.

Our strategy for RAYOS in the United States is to focus on the rheumatology indications approved for RAYOS, including our collaboration with the Alliance for Lupus Research, to study the effect of RAYOS on the fatigue experienced by systemic lupus erythematosus, or SLE, ~~patients~~.patients.

If any of our commercial strategies are unsuccessful or we fail to successfully modify our strategies over time due to changing market conditions, our ability to increase market share for our medicines, grow revenues and to achieve and sustain profitability will be harmed.

53We are dependent on wholesale distributors for distribution of our products in the United States and, accordingly, our results of operations could be adversely affected if they encounter financial difficulties*

In 2019, four wholesale distributors accounted for substantially all of our sales in the United States. If one of our significant wholesale distributors encounters financial or other difficulties, such distributor may decrease the amount of business that it does with us, and we may be unable to collect all the amounts that the distributor owes on a timely basis or at all, which could negatively impact our business and results of operations.

In order to increase adoption and sales of our medicines, we will need to continue developing our commercial organization as well as recruit and retain qualified sales representatives.*

Part of our strategy is to continue to build a biopharma company to successfully execute the commercialization of our medicines in the U.S. market, and in selected markets outside the United States where we have commercial rights. We may not be able to successfully commercialize our medicines in the United States or in any other territories where we have commercial rights. In order to commercialize any approved medicines, we must continue to build our sales, marketing, distribution, managerial and other non-technical capabilities. As of June 30, ~~2019,~~2020, we had approximately ~~435~~450 sales representatives in the field, consisting of approximately 25200 orphan disease sales representatives ~~160 rheumatology~~(including approximately 50 TEPEZZA sales ~~specialists~~representatives) and 250 inflammation sales representatives. We currently have limited resources compared to some of our competitors, and the continued development of our own commercial organization to market our medicines and any additional medicines we may acquire will be expensive and time-consuming. We also cannot be certain that we will be able to continue to successfully develop this capability.

As a result of the evolving role of various constituents in the prescription decision making process, we focus on hiring sales representatives for our inflammation medicines and RAYOS with successful business to business experience. For example, we have faced challenges due to pharmacists increasingly switching a patient’s intended prescription from DUEXIS and VIMOVO to a generic or over-the-counter brand of their active ingredients, despite such substitution being off-label in the case of DUEXIS and VIMOVO. We have faced similar challenges for BUPHENYL, RAYOS and PENNSAID 2% with respect to generic brands. While we believe the profile of our representatives is better suited for this evolving environment, we cannot be certain that our representatives will be able to successfully protect our market for BUPHENYL, RAYOS, PENNSAID 2%, DUEXIS and VIMOVO or that we will be able to continue attracting and retaining sales representatives with our desired profile and skills. We will also have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain commercial personnel. To the extent we rely on additional third parties to commercialize any approved medicines, we may receive less revenue than if we commercialized these medicines ourselves. In addition, we may have little or no control over the sales efforts of any third parties involved in our commercialization efforts. In the event we are unable to successfully develop and maintain our own commercial organization or collaborate with a third-party sales and marketing organization, we may not be able to commercialize our medicines and medicine candidates and execute on our business plan.

~~If we are unable to effectively train and equip our sales force, our ability to successfully commercialize our medicines will be harmed.~~

As we continue to ~~acquire additional~~add medicines through development efforts and acquisition transactions, the members of our sales force may have limited experience promoting certain of our medicines. To the extent we employ an acquired entity’s ~~original~~ sales forces to promote acquired medicines, we may not be successful in continuing to retain these employees and we otherwise will have limited experience marketing these medicines under our commercial organization. ~~As a result, we~~In addition, none of the members of our sales force have promoted TEPEZZA or any other medicine for the treatment of TED prior to the launch of TEPEZZA. We are required to expend significant time and resources to train our sales force to be credible and persuasive in convincing physicians to prescribe and pharmacists to dispense our medicines. In addition, we must train our sales force to ensure that a consistent and appropriate message about our medicines is being delivered to our potential customers. Our sales representatives may also experience challenges promoting multiple medicines when we call on physicians and their office staff. We have experienced, and may continue to experience, turnover of the sales representatives that we hired or will hire, requiring us to train new sales representatives. If we are unable to effectively train our sales force and equip them with effective materials, including medical and sales literature to help them inform and educate physicians about the benefits of our medicines and their proper administration and label indication, as well as our patient ~~access~~assistance programs, our efforts to successfully commercialize our medicines could be put in jeopardy, which could have a material adverse effect on our financial condition, share price and operations.

For example, we have had to train our sales force to operate in a virtual environment due to the COVID-19 pandemic and are continuing to learn and implement new strategies and techniques to promote our medicines without the benefit of in-person interactions with healthcare providers and their staff. We may not be successful in finding effective ways to promote our medicines remotely or our competitors may be more successful than we are at adapting to virtual marketing.

IfAs a result of the evolving role of various constituents in the prescription decision making process, we ~~cannot successfully implement our patient access programs or increase formulary access and reimbursement~~focus on hiring sales representatives for our inflammation segment medicines ~~in the face of increasing pressure~~with successful business to reduce the price of medications, the adoption of our medicines by physicians, patients and payers may decline.*

~~There continues to be immense pressure from healthcare payers, PBMs and others to use less expensive or generic medicines or over-the-counter brands instead of certain branded medicines.~~business experience. For example, ~~some of the largest PBMs previously placed~~we have faced challenges due to pharmacists switching a patient’s intended prescription from DUEXIS ~~and VIMOVO on their formulary exclusion lists. Additional healthcare plans, including those that contract with these PBMs but use different formularies, may also choose~~ to ~~exclude our medicines from their formularies or restrict coverage to situations where~~ a generic or over-the-counter ~~medicine has been tried first. Many payers and PBMs also require patients to make co-payments for branded medicines, including many~~brand of our medicines, in order to incentivize the use of generic or other lower-priced alternatives instead. Legislation enacted in most states in the United States allows, or in some instances mandates, that a pharmacist dispenses an available generic equivalent when filling a prescription for a branded medicine, in the absence of specific instructions from the prescribing physician. Because our medicines (other than BUPHENYL) do not currently have FDA-approved generic equivalents in the United States, we do not believe our medicines should be subject to mandatory generic substitution laws. However, we understand that some pharmacies may attempt to obtain physician authorization to switch prescriptions for DUEXIS or VIMOVO to prescriptions for multiple generic medicines with similartheir active ~~pharmaceutical~~ ingredients, ~~or APIs, to ensure payment for the medicine if the physician’s prescription for the branded medicine is not immediately covered by the payer,~~ despite such substitution being off-label in the case of ~~DUEXIS~~DUEXIS. We have faced similar challenges for PENNSAID 2% and ~~VIMOVO. If these limitations in coverage and other incentives result in patients refusing~~RAYOS with respect to ~~fill prescriptions or being dissatisfied with~~generic brands. While we believe the out-of-pocket costs of their medications, or if pharmacies otherwise seek and receive physician authorization to switch prescriptions, not only would we lose sales on prescriptions that are ultimately not filled, but physicians may be dissuaded from writing prescriptions for our medicines in the first place in order to avoid potential patient non-compliance or dissatisfaction over medication costs, or to avoid spending the time and effort of responding to pharmacy requests to switch prescriptions.

~~Part~~profile of our ~~commercial strategy~~representatives is suited for this environment, we cannot be certain that our representatives will be able to ~~increase adoption and access to~~successfully protect our medicines in the face of these incentives to use generic alternatives is to offer physicians the opportunity to have patients fill prescriptions through independent pharmacies participating in our HorizonCares patient access program, including shipment of prescriptions to patients. We also have contracted with a third-party prescription clearinghouse that offers physicians a single point of contactmarket for processing prescriptions through these independent pharmacies, reducing physician administrative costs, increasing the fill rates for prescriptions and enabling physicians to monitor refill activity. Through HorizonCares, financial assistance may be available to reduce eligible patients’ out-of-pocket costs for prescriptions filled. Because of this assistance, eligible patients’ out-of-pocket cost for our medicines when dispensed through HorizonCares may be significantly lower than such costs when our medicines are dispensed outside of the HorizonCares program. However, to the extent physicians do not direct prescriptions currently filled through traditional pharmacies, including those associated with or controlled by PBMs, to pharmacies participating in our HorizonCares program, we may experience a significant decline in PENNSAID 2%, DUEXIS and VIMOVO prescriptions. Our ability to increase utilization of our patient access programs will depend on physician and patient awareness and comfort with the programs, and we have limited ability to influence whether physicians use our patient access programs to prescribe our medicinesRAYOS or whether patients will agree to receive our medicines through our HorizonCares program. In addition, the HorizonCares program is not available to federal health care program (such as Medicare and Medicaid) beneficiaries. We have also contracted with certain PBMs and other payers to secure formulary status and reimbursement for certain of our inflammation medicines, which generally require us to pay administrative fees and rebates to the PBMs and other payers for qualifying prescriptions. While we have business relationships with two of the largest PBMs, Express Scripts, Inc., or Express Scripts, and CVS Caremark, that have resulted in DUEXIS and VIMOVO being removed from the Express Scripts and CVS Caremark exclusion lists starting in 2017, as well as a rebate agreement with another PBM, Prime Therapeutics LLC, and we believe these agreements will secure formulary status for certain of our medicines, we cannot guarantee that we will be able to ~~agree~~continue attracting and retaining sales representatives with our desired profile and skills. We will also have to ~~terms~~compete with other ~~PBMs~~pharmaceutical and ~~other payers, or that such terms will be commercially reasonable~~biotechnology companies to ~~us. Despite our agreements with PBMs,~~recruit, hire, train and retain commercial personnel. To the extent ~~of formulary status and reimbursement will ultimately depend~~we rely on additional third parties to a large extent upon individual healthcare plan formulary decisions. If healthcare plans that contract with PBMs with which we have agreements do not adopt formulary changes recommended by the PBMs with respect to ourcommercialize any approved medicines, we may ~~not realize the expected access and reimbursement benefits from~~receive less revenue than if we commercialized these ~~agreements.~~medicines ourselves. In addition, we ~~generally pay higher rebates for prescriptions covered under plans that adopt a PBM-chosen formulary than for plans that adopt custom formularies. Consequently,~~may have little or no control over the ~~success~~sales efforts of our PBM contracting strategy will depend not only on our ability to expand formulary adoption among healthcare plans, but also upon the relative mix of healthcare plans that have PBM-chosen formularies versus custom formularies. If we are unable to realize the expected benefits of our contractual arrangements with the PBMs we may continue to experience reductions in net sales from our inflammation medicines and/or reductions in net pricing for our inflammation medicines due to increasing patient assistance costs. If we are unable to increase adoption of HorizonCares for filling prescriptions of our medicines and to secure formulary status and reimbursement through arrangements with PBMs and other payers, particularly with healthcare plans that use custom formularies, our ability to achieve net sales growth for our inflammation medicines would be impaired.

~~There has been negative publicity and inquiries from Congress and enforcement authorities regarding the use of specialty pharmacies and drug pricing. Our patient access programs are not~~any third parties involved in our commercialization efforts. In the prescribing of medicines and are solely to assist in ensuring that when a physician determines one of our medicines offers a potential clinical benefit to their patients and they prescribe one for an eligible patient, financial assistance may be available to reduce the patient’s out-of-pocket costs. In addition, all pharmacies that fill prescriptions for our medicines are fully independent, including those that participate in HorizonCares. We do not own or possess any option to purchase an ownership stake in any pharmacy that distributes our medicines, and our relationship with each pharmacy is non-exclusive and arm’s length. All of our sales are processed through pharmacies independent of us. Despite this, the negative publicity and interest from Congress and enforcement authorities regarding specialty pharmacies may result in physicians being less willing to participate in our patient access programs and thereby limit our ability to increase patient access and adoption of our medicines.

We may also encounter difficulty in forming and maintaining relationships with pharmacies that participate in our patient access programs. We currently depend on a limited number of pharmacies participating in HorizonCares to fulfill patient prescriptions under the HorizonCares program. If these HorizonCares participating pharmacies are unable to process and fulfill the volume of patient prescriptions directed to them under the HorizonCares program, our ability to maintain or increase prescriptions for our medicines will be impaired. The commercialization of our medicines and our operating results could be affected should any of the HorizonCares participating pharmacies choose not to continue participation in our HorizonCares program or by any adverse events at any of those HorizonCares participating pharmacies. For example, pharmacies that dispense our medicines could lose contracts that they currently maintain with managed care organizations, or MCOs, including PBMs. Pharmacies often enter into agreements with MCOs. They may be required to abide by certain terms and conditions to maintain access to MCO networks, including terms and conditions that could limit their ability to participate in patient access programs like ours. Failure to comply with the terms of their agreements with MCOs could result in a variety of penalties, including termination of their agreement, which could negatively impact the ability of those pharmacies to dispense our medicines and collect reimbursement from MCOs for such medicines.

The HorizonCares program may implicate certain federal and state laws related to, among other things, unlawful schemes to defraud, excessive fees for services, tortious interference with patient contracts and statutory or common law fraud. We have a comprehensive compliance program in place to address adherence with various laws and regulations relating to the selling, marketing and manufacturing of our medicines, as well as certain third-party relationships, including pharmacies. Specifically with respect to pharmacies, the compliance program utilizes a variety of methods and tools to monitor and audit pharmacies, including those that participate in the HorizonCares program, to confirm their activities, adjudication and practices are consistent with our compliance policies and guidance. Despite our compliance efforts, to the extent the HorizonCares program is found to be inconsistent with applicable laws or the pharmacies that participate in our patient access programs do not comply with applicable laws, we may be required to restructure or discontinue such programs, terminate our relationship with certain pharmacies, or be subject to other significant penalties. In November 2015, we received a subpoena from the U.S. Attorney’s Office for the Southern District of New York requesting documents and information related to our patient access programs and other aspects of our marketing and commercialization activities. We are unable to predict how long this investigation will continue or its outcome, but we have incurred and anticipate that we may continue to incur significant costs in connection with the investigation, regardless of the outcome. We may also become subject to similar investigations by other governmental agencies or Congress. The investigation by the U.S. Attorney’s Office and any additional investigations of our patient access programs and sales and marketing activities may result in damages, fines, penalties, exclusion, additional reporting requirements and/or oversight or other administrative sanctions against us.

If the cost of maintaining our patient access programs increases relative to our sales revenues, we could be forced to reduce the amount of patient financial assistance that we offer or otherwise scale back or eliminate such programs, which could in turn have a negative impact on physicians’ willingness to prescribe and patients’ willingness to fill prescriptions of our medicines. While we believe that our arrangements with PBMs will result in broader inclusion of certain of our inflammation medicines on healthcare plan formularies, and therefore increase payer reimbursement and lower our cost of providing patient access programs, these arrangements generally require us to pay administrative and rebate payments to the PBMs and/or other payers and their effectiveness will ultimately depend to a large extent upon individual healthcare plan formulary decisions that are beyond the control of the PBMs. If our arrangements with PBMs and other payers do not result in increased prescriptions and reductions in our costs to provide our patient access programs that are sufficient to offset the administrative fees and rebate payments to the PBMs and/or other payers, our financial results may continue to be harmed.

Ifevent we are unable to successfully ~~implement~~develop and maintain our own commercial ~~plans~~organization or collaborate with a third-party sales and ~~facilitate adoption by patients and physicians of any approved medicines through our sales,~~ marketing ~~and commercialization efforts, then~~organization, we ~~will~~may not be able to ~~generate sustainable revenues from~~commercialize our medicines and medicine ~~sales which will have a material adverse effect~~candidates and execute on our business ~~and prospects.~~plan.

Coverage and reimbursement may not be available, or reimbursement may be available at only limited levels, for our

medicines, which could make it difficult for us to sell our medicines profitably or to successfully execute planned medicine price increases.*

Market acceptance and sales of our medicines will depend in large part on global coverage and reimbursement policies and may be affected by future healthcare reform measures, both in the United States and other key international markets. Successful commercialization of our medicines will depend in part on the availability of governmental and third-party payer reimbursement for the cost of our medicines. Government health administration authorities, private health insurers and other organizations generally provide reimbursement for healthcare. In particular, in the United States, private health insurers and other third-party payers often provide reimbursement for medicines and services based on the level at which the government (through the Medicare or Medicaid programs) provides reimbursement for such treatments. In the United States, the European Union, or EU, and other significant or potentially significant markets for our medicines and medicine candidates, government authorities and third-party payers are increasingly attempting to limit or regulate the price of medicines and services, particularly for new and innovative medicines and therapies, which has resulted in lower average selling prices. Further, the increased scrutiny of prescription drug pricing practices and emphasis on managed healthcare in the United States and on country and regional pricing and reimbursement controls in the EU will put additional pressure on medicine pricing, reimbursement and usage, which may adversely affect our medicine sales and results of operations. These pressures can arise from rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and healthcare reform, pharmaceutical reimbursement policies and pricing in general. These pressures may create negative reactions to any medicine price increases, or limit the amount by which we may be able to increase our medicine prices, which may adversely affect our medicine sales and results of operations.

We expect to experience pricing pressures in connection with the sale of our medicines due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative proposals relating to outcomes and quality. For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, increased the mandated Medicaid rebate from 15.1% to 23.1%, expanded the rebate to Medicaid managed care utilization and increased the types of entities eligible for the federal 340B drug discount program. As concerns continue to grow over the need for tighter oversight, there remains the possibility that the Health Resources and Services Administration or another agency under the U.S. Department of Health and Human Services, or HHS, will propose a similar regulation or that Congress will explore changes to the 340B program through legislation. For example, a bill was introduced in 2018 that would require hospitals to report their low-income utilization of the program. Further, the CMS issued a final rule in 2018 that implemented civil monetary penalties for manufacturers who exceeded the ceiling price methodology for a covered outpatient drug when selling to a 340B covered entity. Pursuant to the final rule, after January 1, 2019, manufacturers must calculate 340B program ceiling prices on a quarterly basis. Moreover, manufacturers could be subject to a $5,000 penalty for each instance where they knowingly and intentionally overcharge a covered entity under the 340B program. With respect to KRYSTEXXA, the “additional rebate” scheme of the 340B pricing rules, as applied to the historical pricing of KRYSTEXXA both before and after we acquired the medicine, have resulted in a 340B ceiling price of one penny. A material portion of KRYSTEXXA prescriptions (normally in the range of 15 percent to 20 percent) are written by healthcare providers that are eligible for 340B drug pricing and therefore the reduction in 340B pricing to a penny has negatively impacted our net sales of KRYSTEXXA. The CMS had also finalized a proposal in calendar years 2018, 2019 and 2020 that would revise the Medicare hospital outpatient prospective payment system by creating a new, significantly reduced reimbursement methodology for drugs purchased under the 340B program for Medicare patients at hospital and other settings. That policy is currently undergoing litigation.

Patients are unlikely to use our medicines unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our medicines. Third-party payers may limit coverage to specific medicines on an approved list, also known as a formulary, which might not include all of the FDA-approved medicines for a particular indication. Moreover, a third-party payer’s decision to provide coverage for a medicine does not imply that an adequate reimbursement rate will be approved. Additionally, one third-party payer’s decision to cover a particular medicine does not ensure that other payers will also provide coverage for the medicine, or will provide coverage at an adequate reimbursement rate. Even though we have contracts with some PBMs in the United States, that does not guarantee that they will perform in accordance with the contracts, nor does that preclude them from taking adverse actions against us, which could materially adversely affect our operating results. In addition, the existence of such PBM contracts does not guarantee coverage by such PBM’s contracted health plans or adequate reimbursement to their respective providers for our medicines. For example, ~~two significant~~some PBMs have placed ~~DUEXIS and VIMOVO~~some of our medicines on their exclusion lists ~~beginning in 2015,~~from time to time, which has resulted in a loss of coverage for patients whose healthcare plans have adopted these PBM lists. While DUEXIS and VIMOVO were removed from the Express Scripts and CVS Caremark exclusion lists starting in 2017, we cannot guarantee that Express Scripts or CVS Caremark will not later add these medicines back to their exclusion lists or that we will be able to otherwise expand formulary access for DUEXIS and VIMOVO under health plans that contract with Express Scripts and/or CVS Caremark. Additional healthcare plan formularies may also exclude our medicines from coverage due to the actions of certain PBMs, future price increases we may implement, our use of the HorizonCares program or other free medicine programs whereby we assist qualified patients with certain out-of-pocket expenditures for our medicine, including donations to patient assistance programs offered by charitable foundations, or any other co-pay programs, or other reasons. If our strategies to mitigate formulary exclusions are not effective, these events may reduce the likelihood that physicians prescribe our medicines and increase the likelihood that prescriptions for our medicines are not filled.

Outside of the United States, the success of our medicines and medicine candidates will depend largely on obtaining and maintaining government coverage, because in many countries patients are unlikely to use prescription drugs that are not covered by their government healthcare programs. We market RAVICTI, PROCYSBI and QUINSAIR in Canada. Further, we cannot be certain that existing reimbursement in Canada will be maintained or that we will be able to secure reimbursement in additional countries. Negotiating coverage and reimbursement with governmental authorities can delay commercialization by twelve months or more. Coverage and reimbursement policies may adversely affect our ability to sell our medicines on a profitable basis. In many international markets, governments control the prices of prescription pharmaceuticals, including through the implementation of reference pricing, price cuts, rebates, revenue-related taxes and profit control, and we expect prices of prescription pharmaceuticals to decline over the life of the medicine or as volumes increase. As a result of these pricing practices, it may become difficult to achieve or sustain profitability or expected rates of growth in revenue or results of operations. Any shortfalls in revenue could adversely affect our business, financial condition and results of operations.

In light of such policies and the uncertainty surrounding proposed regulations and changes in the coverage and reimbursement policies of governments and third-party payers, we cannot be sure that coverage and reimbursement will be available for any of our medicines in any additional markets or for any other medicine candidates that we may develop. Also, we cannot be sure that reimbursement amounts will not reduce the demand for, or the price of, our medicines. If coverage and reimbursement are not available or are available only at limited levels, we may not be able to successfully commercialize our medicines.

We expect to experience pricing pressures in connection with the sale of our medicines due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative proposals relating to outcomes and quality. For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, increased the mandated Medicaid rebate from 15.1% to 23.1%, expanded the rebate to Medicaid managed care utilization and increased the types of entities eligible for the federal 340B drug discount program. As concerns continue to grow over the need for tighter oversight, there remains the possibility that the Health Resources and Services Administration or another agency under the U.S. Department of Health and Human Services, or HHS, will propose a similar regulation or that Congress will explore changes to the 340B program through legislation. For example, a bill was introduced in 2018 that would require hospitals to report their low-income utilization of the program. Further, the Centers for Medicare & Medicaid Services issued a final rule that would revise the Medicare hospital outpatient prospective payment system for calendar year 2019, including a new reimbursement methodology for drugs purchased under the 340B program for Medicare patients at the hospital setting and recently announced the same change for physician-based practices under 340B in 2019. Pursuant to the final rule, after January 1, 2019, manufacturers must calculate 340B program ceiling prices on a quarterly basis. Moreover, manufacturers could be subject to a $5,000 penalty for each instance where they knowingly and intentionally overcharge a covered entity under the 340B program. With respect to KRYSTEXXA, the “additional rebate” scheme of the 340B pricing rules, as applied to the historical pricing of KRYSTEXXA both before and after we acquired the medicine, have resulted in a 340B ceiling price of one penny. A material portion of KRYSTEXXA prescriptions (approximately twenty to twenty-five percent) are written by healthcare providers that are eligible for 340B drug pricing and therefore the reduction in 340B pricing to a penny has negatively impacted our net sales of KRYSTEXXA.

There may be additional pressure by payers, healthcare providers, state governments, federal regulators and Congress, to use generic drugs that contain the active ingredients found in our medicines or any other medicine candidates that we may develop or acquire. If we fail to successfully secure and maintain coverage and adequate reimbursement for our medicines or are significantly delayed in doing so, we will have difficulty achieving market acceptance of our medicines and expected revenue and profitability which would have a material adverse effect on our business, results of operations, financial condition and prospects.

We may also experience pressure from payers as well as state and federal government authorities concerning certain promotional approaches that we may implement such as our HorizonCares program or any other co-pay or free medicine programs whereby we assist qualified patients with certain out-of-pocket expenditures for our medicine, including donations to patient assistance programs offered by charitable foundations.programs. Certain state and federal enforcement authorities and members of Congress have initiated inquiries about co-pay assistance programs. Some state legislatures have been considering proposals that would restrict or ban co-pay ~~coupons.~~coupons for branded drugs. For example, legislation was ~~recently~~ signed into law in California that would limit the use of co-pay coupons in cases where a lower cost generic drug is available and if individual ingredients in combination therapies are available over the counter at a lower cost. It is possible that similar legislation could be proposed and enacted in additional states. Additionally, numerous organizations, including pharmaceutical manufacturers, have been subject to ongoing litigation, enforcement actions and settlements related to their patient assistance programs and support. If we are unsuccessful with our HorizonCares program or any other co-pay ~~initiatives or free medicine~~ programs, or we alternatively are unable to secure expanded formulary access through additional arrangements with PBMs or other payers, we would be at a competitive disadvantage in terms of pricing versus preferred branded and generic competitors. We may also experience financial pressure in the future which would make it difficult to support investment levels in areas such as managed care contract rebates, HorizonCares and other access tools.

We are solely dependent on third parties to commercialize certain of our medicines outside the United States. Failure of these third parties or any other third parties to successfully commercialize our medicines and medicine candidates in the applicable jurisdictions could have an adverse effect on our business.

Innomar Strategies Inc., or Innomar, is our exclusive distributor for RAVICTI, PROCYSBI and QUINSAIR in Canada. We rely on Orphan Pacific, Inc., or Orphan Pacific, for commercialization of BUPHENYL in Japan for which we currently have rights. We have limited contractual rights to force these third parties to invest significantly in commercialization of these medicines in our markets. In the event that Innomar, Orphan Pacific or any other third-party with any future commercialization rights to any of our medicines or medicine candidates fail to adequately commercialize those medicines or medicine candidates because they lack adequate financial or other resources, decide to focus on other initiatives or otherwise, our ability to successfully commercialize our medicines or medicine candidates in the applicable jurisdictions would be limited, which would adversely affect our business, financial condition, results of operations and prospects. In addition, our agreements with Innomar and Orphan Pacific, may be terminated by either party in the event of a bankruptcy of the other party or upon an uncured material breach by the other party. If these third parties terminated their agreements, we may not be able to secure an alternative distributor in the applicable territory on a timely basis or at all, in which case our ability to generate revenues from the sale of RAVICTI, PROCYSBI, BUPHENYL or QUINSAIR, outside the United States would be harmed.

Our medicines are subject to extensive regulation, and we may not obtain additional regulatory approvals for our medicines.*

The clinical development, manufacturing, labeling, packaging, storage, recordkeeping, advertising, promotion, export, marketing and distribution and other possible activities relating to our medicines and our medicine candidates are, and will be, subject to extensive regulation by the FDA and other regulatory agencies. Failure to comply with FDA and other applicable regulatory requirements may, either before or after medicine approval, subject us to administrative or judicially imposed sanctions.

To market any drugs or biologics outside of the United States, we and current or future collaborators must comply with numerous and varying regulatory and compliance related requirements of other countries. Approval procedures vary among countries and can involve additional medicine testing and additional administrative review periods, including obtaining reimbursement and pricing approval in select markets. The time required to obtain approval in other countries might differ from that required to obtain FDA approval. The regulatory approval process in other countries may include all of the risks associated with FDA approval as well as additional, presently unanticipated, risks. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may negatively impact the regulatory process in others.

Applications for regulatory approval, including a marketing authorization application, or MAA, for marketing new drugs in Europe, must be supported by extensive clinical and pre-clinical data, as well as extensive information regarding chemistry, manufacturing and controls, or CMC, to demonstrate the safety and effectiveness of the applicable medicine candidate. The number and types of pre-clinical studies and clinical trials that will be required for regulatory approval varies depending on the medicine candidate, the disease or the condition that the medicine candidate is designed to target and the regulations applicable to any particular medicine candidate. Despite the time and expense associated with pre-clinical and clinical studies, failure can occur at any stage, and we could encounter problems that cause us to repeat or perform additional pre-clinical studies, CMC studies or clinical trials. Regulatory authorities could delay, limit or deny approval of a medicine candidate for many reasons, including because they:

Even if we believe that data collected from our pre-clinical studies, CMC studies and clinical trials of our medicine candidates are promising and that our information and procedures regarding CMC are sufficient, our data may not be sufficient to support marketing approval by regulatory authorities, or regulatory interpretation of these data and procedures may be unfavorable. ~~For example, our biologics license application for teprotumumab for the treatment of active thyroid eye disease, or TED, may not be approved by FDA.~~ Even if approved, medicine candidates may not be approved for all indications requested and such approval may be subject to limitations on the indicated uses for which the medicine may be marketed, restricted distribution methods or other limitations. Our business and reputation may be harmed by any failure or significant delay in obtaining regulatory approval for the sale of any of our medicine candidates. We cannot predict when or whether regulatory approval will be obtained for any medicine candidate we develop.

We will evaluate all development opportunities, including all obligations to use commercial reasonable efforts to further develop QUINSAIR. However, we may determine not to pursue such further development.

The ultimate approval and commercial marketing of any of our medicines in additional indications or geographies is subject to substantial uncertainty. Failure to gain additional regulatory approvals would limit the potential revenues and value of our medicines and could cause our share price to decline.

We may be subject to penalties and litigation and large incremental expenses if we fail to comply with regulatory requirements or experience problems with our medicines.

Even after we achieve regulatory approvals, we are subject to ongoing obligations and continued regulatory review with respect to many operational aspects including our manufacturing processes, labeling, packaging, distribution, storage, adverse event monitoring and reporting, dispensation, advertising, promotion and recordkeeping. These requirements include submissions of safety and other post-marketing information and reports, ongoing maintenance of medicine registration and continued compliance with current good manufacturing practices, or cGMPs, good clinical practices, or GCPs, good pharmacovigilance practice, good distribution practices and good laboratory practices, or GLPs. If we, our medicines or medicine candidates, or the third-party manufacturing facilities for our medicines or medicine candidates fail to comply with applicable regulatory requirements, a regulatory agency may:

Moreover, existing regulatory approvals and any future regulatory approvals that we obtain will be subject to limitations on the approved indicated uses and patient populations for which our medicines may be marketed, the conditions of approval, requirements for potentially costly, post-market testing and requirements for surveillance to monitor the safety and efficacy of the medicines. In the European Economic Area, or EEA, the advertising and promotion of pharmaceuticals is strictly regulated. The direct-to-consumer promotion of prescription pharmaceuticals is not permitted, and some countries in the EEA require the notification and/or prior authorization of promotional or advertising materials directed at healthcare professionals. The FDA, European Medicines Agency, or EMA, and other authorities in the EEA countries strictly regulate the promotional claims that may be made about prescription ~~medicines, and our~~ ~~medicine~~ ~~labeling, advertising and promotion are subject to continuing regulatory review.~~ Physicians nevertheless may prescribe our medicines to their patients in a manner that is inconsistent with the approved label or that is off-label. Positive clinical trial results in any of our medicine development programs increase the risk that approved pharmaceutical forms of the same active pharmaceutical ingredients, or APIs, may be used off-label in those indications. If we are found to have improperly promoted off-label uses of approved medicines, we may be subject to significant sanctions, civil and criminal fines and injunctions prohibiting us from engaging in specified promotional conduct.

In addition, engaging in improper promotion of our medicines for off-label uses in the United States can subject us to false claims litigation under federal and state statutes. These false claims statutes in the United States include the federal False Claims Act, which allows any individual to bring a lawsuit against a pharmaceutical company on behalf of the federal government alleging submission of false or fraudulent claims or causing to present such false or fraudulent claims for payment by a federal program such as Medicare or Medicaid. Growth in false claims litigation has increased the risk that a pharmaceutical company will have to defend a false claim action, pay civil money penalties, settlement fines or restitution, agree to comply with burdensome reporting and compliance obligations and be excluded from Medicare, Medicaid and other federal and state healthcare programs.

The regulations, policies or guidance of regulatory agencies may change and new or additional statutes or government regulations may be enacted that could prevent or delay regulatory approval of our medicine candidates or further restrict or regulate post-approval activities. For example, in January 2014, the FDA released draft guidance on how drug companies can fulfill their regulatory requirements for post-marketing submission of interactive promotional media, and though the guidance provided insight into how the FDA views a company’s responsibility for certain types of social media promotion, there remains a substantial amount of uncertainty regarding internet and social media promotion of regulated medical products. We cannot predict the likelihood, nature or extent of adverse government regulation that may arise from pending or future legislation or administrative action, either in the United States or abroad. If we are unable to achieve and maintain regulatory compliance, we will not be permitted to market our drugs, which would materially adversely affect our business, results of operations and financial condition.

~~Our limited history of commercial operations makes evaluating our business and future prospects difficult and may increase the risk of any investment in our ordinary shares.~~

We face considerable risks and difficulties as a company with limited commercial operating history, particularly as a global consolidated entity with operating subsidiaries that also have limited operating histories. If we do not successfully address these risks, our business, prospects, operating results and financial condition will be materially and adversely harmed. Our limited commercial operating history, including our limited history commercializing our current medicines, makes it particularly difficult for us to predict our future operating results and appropriately budget for our expenses. In the event that actual results differ from our estimates or we adjust our estimates in future periods, our operating results and financial position could be materially affected. For example, we may underestimate the resources we will require to successfully integrate recent or future medicine or company acquisitions, or to commercialize our medicines, or not realize the benefits we expect to derive from our recent or future acquisitions. In addition, we have a limited history implementing our commercialization strategy focused on patient access, and we cannot guarantee that we will be able to successfully implement this strategy or that it will represent a viable strategy over the long term.

We have rights to medicines in certain jurisdictions but have no control over third parties that have rights to commercialize those medicines in other jurisdictions, which could adversely affect our commercialization of these medicines.*

Following our sale of the rights to RAVICTI ~~and AMMONAPS (known as BUPHENYL in the United States)~~ outside of North America and Japan to Medical Need Europe AB, part of the Immedica Group, or Immedica, in December 2018, Immedica has marketing and distribution rights to RAVICTI and AMMONAPS in those regions. Following our sale of the rights to interferon gamma 1b, known as IMUKIN, outside of the United States, Canada and Japan to Clinigen Group plc, or Clinigen, in July 2018, Clinigen has marketing and distribution rights to IMUKIN in those regions. Following our sale of the rights to PROCYSBI ~~and QUINSAIR~~ in the Europe, Middle East and Africa, or EMEA, regions to Chiesi Farmaceutici S.p.A., or Chiesi, in June 2017, or the Chiesi divestiture, Chiesi has marketing and distribution rights to PROCYSBI ~~and QUINSAIR~~ in the EMEA regions. Nuvo Pharmaceuticals Inc. (formerly known as Nuvo Research Inc.), or Nuvo, has retained its rights to PENNSAID 2% in territories outside of the United States. In March 2017, Nuvo announced that it had entered into an exclusive license agreement with Sayre Therapeutics PVT Ltd. to distribute, market and sell PENNSAID 2% in India, Sri Lanka, Bangladesh and Nepal, and in December 2017 Nuvo announced that it had entered into a license and distribution agreement with Gebro Pharma AG for the exclusive right to register, distribute, market and sell PENNSAID 2% in Switzerland and Liechtenstein. Grünenthal GmbH, or Grünenthal, acquired the rights to VIMOVO in territories outside of the United States, including the right to use the VIMOVO name and related trademark from AstraZeneca AB, or AstraZeneca, in October 2018. We have little or no control over Immedica’s activities with respect to RAVICTI ~~and AMMONAPS~~ outside of North America ~~and Japan, over Clinigen’s activities with respect to IMUKIN outside the United States, Canada~~ and Japan, over Chiesi’s activities with respect to PROCYSBI ~~and QUINSAIR~~ in the EMEA, or over Nuvo’s or its existing and future commercial partners’ activities with respect to PENNSAID 2% outside of ~~the United States, or over Grünenthal’s activities with respect to VIMOVO outside~~ the United States even though those activities could impact our ability to successfully commercialize these medicines. For example, Immedica or its assignees, ~~Clinigen or its assignees,~~ Chiesi or its assignees ~~Nuvo~~ or ~~its assignees or Grünenthal~~Nuvo or its assignees can make statements or use promotional materials with respect to RAVICTI, ~~and AMMONAPS, IMUKIN,~~ PROCYSBI ~~and QUINSAIR,~~or PENNSAID 2% ~~or VIMOVO,~~, respectively, outside of the United States that are inconsistent with our positioning of the medicines in the United States, and could sell RAVICTI, ~~and AMMONAPS, IMUKIN,~~ PROCYSBI ~~and QUINSAIR,~~or PENNSAID 2% ~~or VIMOVO,~~, respectively, in foreign countries at prices that are dramatically lower than the prices we charge in the United States. These activities and decisions, while occurring outside of the United States, could harm our commercialization strategy ~~in the United States, in particular because Grünenthal is continuing to market VIMOVO outside the United States under the same VIMOVO brand name that we are using~~ in the United States. In addition, medicine recalls or safety issues with these medicines outside the United States, even if not related to the commercial medicine we sell in the United States, could result in serious damage to the brand in the United States and impair our ability to successfully market them. We also rely on Immedica, ~~Clinigen,~~ Chiesi ~~Nuvo~~ and ~~Grünenthal~~Nuvo, or their assignees to provide us with timely and accurate safety information regarding the use of these medicines outside of the United States, as we have or will have limited access to this information ourselves.

We rely on third parties to manufacture commercial supplies of all of our medicines, and we currently intend to rely on third parties to manufacture commercial supplies of any other approved medicines. The commercialization of any of our medicines could be stopped, delayed or made less profitable if those third parties fail to provide us with sufficient quantities of medicine or fail to do so at acceptable quality levels or prices or fail to maintain or achieve satisfactory regulatory compliance.*

The facilities used by our third-party manufacturers to manufacture our medicines and medicine candidates must be approved by the applicable regulatory authorities. We do not control the manufacturing processes of third-party manufacturers and are currently completely dependent on our third-party manufacturing partners. ~~In addition,~~

We rely on AGC Biologics A/S (formerly known as CMC Biologics A/S), or AGC Biologics, as our exclusive manufacturer of the TEPEZZA drug substance and Catalent Indiana, LLC, or Catalent, for TEPEZZA drug product. Following the highly successful launch of TEPEZZA, which has significantly exceeded expectations, we are ~~required~~in the process of expanding our production capacity to ~~obtain Grünenthal’s (formerly AstraZeneca) consent prior~~meet anticipated future demand for TEPEZZA. If AGC Biologics failed to ~~engaging any third-party manufacturers~~supply TEPEZZA drug substance or Catalent failed to supply TEPEZZA drug product or either manufacturer was otherwise unable to meet our volume requirements due to unexpected market demand for ~~esomeprazole, one~~TEPEZZA, it may lead to TEPEZZA supply constraints. We rely on NOF Corporation, or NOF, as our exclusive supplier of the ~~APIs~~PEGylation agent that is a critical raw material in ~~VIMOVO, other than~~ the ~~third-party manufacturer(s)~~manufacture of KRYSTEXXA. If NOF failed to supply such PEGylation agent, it may lead to KRYSTEXXA supply constraints. A key excipient used ~~by Grünenthal~~in PENNSAID 2% as a penetration enhancer is dimethyl sulfoxide, or ~~its affiliates~~DMSO. We and Nuvo, our exclusive supplier of PENNSAID 2%, rely on a sole proprietary form of DMSO for which we maintain a substantial safety stock. However, should this supply become inadequate, damaged, destroyed or ~~licensees. To the extent such manufacturers are unwilling or unable~~unusable, we and Nuvo may not be able to ~~manufacture esomeprazole for us on commercially acceptable terms, we cannot guarantee that Grünenthal would consent to our use of alternate sources of supply.~~

qualify a second source. We rely on an exclusive supply agreement with Boehringer Ingelheim Biopharmaceuticals GmbH, or Boehringer Ingelheim Biopharmaceuticals, for manufacturing and supply of ACTIMMUNE. ACTIMMUNE is manufactured by starting with cells from working cell bank samples which are derived from a master cell bank. We and Boehringer Ingelheim Biopharmaceuticals separately store multiple vials of the master cell bank. In the event of catastrophic loss at our or Boehringer Ingelheim Biopharmaceuticals’ storage facility, it is possible that we could lose multiple cell banks and have the manufacturing capacity of ACTIMMUNE severely impacted by the need to substitute or replace the cell banks. We rely on NOF Corporation, or NOF, as our exclusive supplier of the PEGylation agent that is a critical raw material in the manufacture of KRYSTEXXA. If NOF failed to supply such PEGylation agent, it may lead to KRYSTEXXA supply constraints. In addition, a key excipient used in PENNSAID 2% as a penetration enhancer is dimethyl sulfoxide, or DMSO. We and Nuvo, our exclusive supplier of PENNSAID 2%, rely on a sole proprietary form of DMSO for which we maintain a substantial safety stock. However, should this supply become inadequate, damaged, destroyed or unusable, we and Nuvo may not be able to qualify a second source.

If any of our third-party manufacturers cannot successfully manufacture material that conforms to our specifications and the applicable regulatory authorities’ strict regulatory requirements, or pass regulatory inspection, they will not be able to secure or maintain regulatory approval for the manufacturing facilities. For example, BASF Corporation, or BASF, our manufacturer of one of the APIs in DUEXIS, ibuprofen in a direct compression blend called DC85, previously notified us that it was not able to supply DC85 due to a technical issue at its manufacturing facility in Bishop, ~~Texas.~~Texas during 2018. BASF have since resolved the technical issue and its manufacturing facility has ~~recently supplied us with a limited amount of DC85 and informed us of their intention to return~~returned to full ~~supply. While~~operation. BASF is continuing to supply DC85 to us and we consider our DUEXIS inventory on hand to be sufficient to meet current and future commercial ~~requirements,~~requirements; however, we currently do not have a supply agreement with BASF for DC85 and cannot guarantee ~~that BASF’s manufacturing facility will return to full operations or that~~ we will be able to enter into a new supply ~~agreement with BASF for DC85.~~agreement. In addition, we have no control over the ability of third-party manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or any other applicable regulatory authorities do not approve these facilities for the manufacture of our medicines or if they withdraw any such approval in the future, or if our suppliers or third-party manufacturers decide they no longer want to supply our primary active ingredients or manufacture our medicines, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our medicines. To the extent any third-party manufacturers that we engage with respect to our medicines are different from those currently being used for commercial supply in the United States, the FDA will need to approve the facilities of those third-party manufacturers used in the manufacture of our medicines prior to our sale of any medicine using these facilities.

Although we have entered into supply agreements for the manufacture and packaging of our medicines, our manufacturers may not perform as agreed or may terminate their agreements with us. We currently rely on single source suppliers for certain of our medicines. If our manufacturers terminate their agreements with us, we may have to qualify new back-up manufacturers. We rely on safety stock to mitigate the risk of our current suppliers electing to cease producing bulk drug ~~medicine~~product or ceasing to do so at acceptable prices and quality. However, we can provide no assurance that such safety stocks would be sufficient to avoid supply shortfalls in the event we have to identify and qualify new contract manufacturers.

The manufacture of medicines requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of medicines often encounter difficulties in production, particularly in scaling up and validating initial production. These problems include difficulties with production costs and yields, quality control, including stability of the medicine, quality assurance testing, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. Furthermore, if microbial, viral or other contaminations are discovered in the medicines or in the manufacturing facilities in which our medicines are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We cannot assure that issues relating to the manufacture of any of our medicines will not occur in the future. Additionally, our manufacturers may experience manufacturing difficulties due to resource constraints or as a result of labor disputes or unstable political environments. If our manufacturers were to encounter any of these difficulties, or otherwise fail to comply with their contractual obligations, our ability to commercialize our medicines or provide any medicine candidates to patients in clinical trials would be jeopardized.

Any delay or interruption in our ability to meet commercial demand for our medicines will result in the loss of potential revenues and could adversely affect our ability to gain market acceptance for these medicines. In addition, any delay or interruption in the supply of clinical trial supplies could delay the completion of clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to commence new clinical trials at additional expense or terminate clinical trials completely.

Failures or difficulties faced at any level of our supply chain, including any disruption caused by the COVID-19 pandemic, could materially adversely affect our business and delay or impede the development and commercialization of any of our medicines or medicine candidates and could have a material adverse effect on our business, results of operations, financial condition and prospects.

We face significant competition from other biotechnology and pharmaceutical companies, including those marketing generic medicines and our operating results will suffer if we fail to compete effectively.*

The biotechnology and pharmaceutical industries are intensely competitive. We have competitors both in the United States and international markets, including major multinational pharmaceutical companies, biotechnology companies and universities and other research institutions. Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff, experienced marketing and manufacturing organizations and well-established sales forces. Additional consolidations in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors and we will have to find new ways to compete and may have to potentially merge with or acquire other businesses to stay competitive. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors may succeed in developing, acquiring or in-licensing on an exclusive basis, medicines that are more effective and/or less costly than our medicines.

Although TEPEZZA does not face direct competition, other therapies, such as corticosteroids, have been used on an off-label basis to alleviate some of the symptoms of TED. While these therapies have not proved effective in treating the underlying disease, and carry with them significant side effects, their off-label use could reduce or delay treatment in the addressable patient population for TEPEZZA. Immunovant Inc. is also conducting Phase 2 clinical studies of a medicine candidate for the treatment of active TED, also referred to as Graves’ ophthalmopathy. While KRYSTEXXA faces limited direct competition, a number of competitors have medicines in Phase 1 or Phase 2 trials, including Selecta Biosciences Inc., or Selecta, which has presented Phase 2 clinical data and is conducting a six-month trial comparing their candidate that uses an immunomodulator to KRYSTEXXA alone. In July 2020, Selecta and Swedish Orphan Biovitrum AB, or Sobi, entered into a strategic licensing agreement under which Sobi will assume responsibility for certain development, regulatory, and commercial activities for this candidate. RAVICTI could face competition from a few medicine candidates that are in early-stage development, including a gene-therapy candidate by Ultragenyx Pharmaceutical Inc., a generic taste-masked formulation option of BUPHENYL by ACER Therapeutics Inc., and an enzyme replacement for a specific UCD subtype (ARG) by Aeglea Bio Therapeutics Inc. PROCYSBI faces competition from Cystagon (immediate-release cysteamine bitartrate capsules) for the treatment of cystinosis and Cystaran (cysteamine ophthalmic solution) for treatment of corneal crystal accumulation in patients with cystinosis. Additionally, we are also aware that AVROBIO, Inc. has an early-stage gene therapy candidate in development for the treatment of cystinosis. PENNSAID 2% faces competition from generic versions of diclofenac sodium topical solutions that are priced significantly less than the price we charge for PENNSAID 2%. The generic version of Voltaren Gel is the market leader in the topical NSAID category. Legislation enacted in most states in the United States allows, or in some instances mandates, that a pharmacist dispense an available generic equivalent when filling a prescription for a branded medicine, in the absence of specific instructions from the prescribing physician. DUEXIS faces competition from other NSAIDs, including Celebrex®, marketed by Pfizer Inc., and celecoxib, a generic form of the medicine marketed by other pharmaceutical companies. DUEXIS also faces significant competition from the separate use of NSAIDs for pain relief and GI protective medications to reduce the risk of NSAID-induced upper GI ulcers. Both NSAIDs and GI protective medications are available in generic form and may be less expensive to use separately than DUEXIS, despite such substitution being off-label in the case of DUEXIS. Because pharmacists often have economic and other incentives to prescribe lower-cost generics, if physicians prescribe PENNSAID 2% or DUEXIS, those prescriptions may not result in sales. If physicians do not complete prescriptions through our HorizonCares program or otherwise provide prescribing instructions prohibiting generic diclofenac sodium topical solutions as a substitute for PENNSAID 2%, the substitution of generic ibuprofen and famotidine separately as a substitution for DUEXIS, sales of PENNSAID 2% and DUEXIS may suffer despite any success we may have in promoting PENNSAID 2% or DUEXIS to physicians. In addition, other medicine candidates that contain ibuprofen and famotidine in combination or naproxen and esomeprazole in combination, while not currently known or FDA approved, may be developed and compete with DUEXIS in the future.

We have also entered into settlement and license agreements that may allow certain of our competitors to sell generic versions of certain of our medicines in the United States, subject to the terms of such agreements. We granted (i) a non-exclusive license (that is only royalty-bearing in some circumstances) to manufacture and commercialize a generic version of DUEXIS in the United States after January 1, 2023, (ii) non-exclusive licenses to manufacture and commercialize generic versions of PENNSAID 2% in the United States after October 17, 2027, (iii) a non-exclusive license to manufacture and commercialize a generic version of RAYOS tablets in the United States after December 23, 2022, and (iv) non-exclusive licenses to manufacture and commercialize generic versions of RAVICTI in the United States after July 1, 2025, or earlier under certain circumstances.

Patent litigation is currently pending in the United States District Court for the District of New Jersey against Actavis Laboratories UT, Inc., formerly known as Watson Laboratories, Inc., Actavis, Inc. and Actavis plc, or collectively Actavis, who intend to market a generic version of PENNSAID 2% prior to the expiration of certain of our patents listed in the FDA’s Orange Book, or the Orange Book. These cases arise from Paragraph IV Patent Certification notice letters from Actavis advising it had filed an Abbreviated New Drug Application, or ANDA, with the FDA seeking approval to market a generic version of PENNSAID 2% before the expiration of the patents-in-suit.

On February 27, 2020, following a judgment in federal court invalidating certain patents covering VIMOVO, Dr. Reddy’s launched a generic version of VIMOVO in the United States. While patent litigation against Dr. Reddy’s for infringement continues on additional patents in the New Jersey District Court, we now face generic competition for VIMOVO, which has negatively impacted net sales of VIMOVO in 2020. As a result, we have repositioned our promotional efforts previously directed to VIMOVO to the other inflammation segment medicines and expect that our VIMOVO net sales will continue to decrease in future periods.

Patent litigation is currently pending in the United States District Court for the District of Delaware and the United States District Court of New Jersey against Alkem Laboratories, Inc., or Alkem, and Teva Pharmaceuticals USA, Inc., or Teva USA, respectively, who each intend to market a generic version of DUEXIS prior to the expiration of certain of our patents listed in the Orange Book. These cases arise from Paragraph IV Patent Certification notice letters from Alkem and Teva USA advising they had filed an ANDA with the FDA seeking approval to market a generic version of DUEXIS before the expiration of the patents-in-suit.

If we are unsuccessful in any of the PENNSAID 2% cases or DUEXIS cases, we will likely face generic competition with respect to PENNSAID 2% and/or DUEXIS and sales of PENNSAID 2% and/or DUEXIS will be substantially harmed.

ACTIMMUNE is the only medicine currently approved by the FDA specifically for the treatment of CGD and SMO. While there are additional or alternative approaches used to treat patients with CGD and SMO, there are currently no medicines on the market that compete directly with ACTIMMUNE. A widely accepted protocol to treat CGD in the United States is the use of concomitant “triple prophylactic therapy” comprising ACTIMMUNE, an oral antibiotic agent and an oral antifungal agent. However, the FDA-approved labeling for ACTIMMUNE does not discuss this “triple prophylactic therapy,” and physicians may choose to prescribe one or both of the other modalities in the absence of ACTIMMUNE. Because of the immediate and life-threatening nature of SMO, the preferred treatment option for SMO is often to have the patient undergo a bone marrow transplant which, if successful, will likely obviate the need for further use of ACTIMMUNE in that patient. Likewise, the use of bone marrow transplants in the treatment of patients with CGD is becoming more prevalent, which could have a material adverse effect on sales of ACTIMMUNE and its profitability. We are aware of a number of research programs investigating the potential of gene therapy as a possible cure for CGD. Additionally, other companies may be pursuing the development of medicines and treatments that target the same diseases and conditions which ACTIMMUNE is currently approved to treat. As a result, it is possible that our competitors may develop new medicines that manage CGD or SMO more effectively, cost less or possibly even cure CGD or SMO. In addition, U.S. healthcare legislation passed in March 2010 authorized the FDA to approve biological products, known as biosimilars, that are similar to or interchangeable with previously approved biological products, like ACTIMMUNE, based upon potentially abbreviated data packages. Biosimilars are likely to be sold at substantially lower prices than branded medicines because the biosimilar manufacturer would not have to recoup the research and development and marketing costs associated with the branded medicine. Though we are not currently aware of any biosimilar under development, the development and commercialization of any competing medicines or the discovery of any new alternative treatment for CGD or SMO could have a material adverse effect on sales of ACTIMMUNE and its profitability.

BUPHENYL’s composition of matter patent protection and orphan drug exclusivity have expired. Because BUPHENYL has no regulatory exclusivity or listed patents, there is nothing to prevent a competitor from submitting an ANDA for a generic version of BUPHENYL and receiving FDA approval. Generic versions of BUPHENYL to date have been priced at a discount relative to RAVICTI, and physicians, patients, or payers may decide that this less expensive alternative is preferable to RAVICTI. If this occurs, sales of RAVICTI could be materially reduced, but we would nevertheless be required to make royalty payments to Bausch Health Companies Inc. (formerly Ucyclyd Pharma, Inc.), or Bausch, and another external party, at the same royalty rates. While Bausch and its affiliates are generally contractually prohibited from developing or commercializing new medicines, anywhere in the world, for the treatment of UCD or hepatic encephalopathy, or HE, which are chemically similar to RAVICTI, they may still develop and commercialize medicines that compete with RAVICTI. For example, medicines approved for indications other than UCD and HE may still compete with RAVICTI if physicians prescribe such medicines off-label for UCD or HE. We are also aware that Recordati S.p.A (formerly known as Orphan Europe SARL), or Recordati, is conducting clinical trials of carglumic acid to assess the efficacy for acute hyperammonemia in some of the UCD enzyme deficiencies for which RAVICTI is approved for chronic treatment. Carglumic acid is approved for maintenance therapy for chronic hyperammonemia and to treat hyperammonemic crises in N-acetylglutamate synthase deficiency, a rare UCD subtype, and is sold under the name Carbaglu. If the results of this trial are successful and Recordati is able to complete development and obtain approval of Carbaglu to treat additional UCD enzyme deficiencies, RAVICTI may face additional competition from this compound.

The availability and price of our competitors’ medicines could limit the demand, and the price we are able to charge, for our medicines. We will not successfully execute on our business objectives if the market acceptance of our medicines is inhibited by price competition, if physicians are reluctant to switch from existing medicines to our medicines, or if physicians switch to other new medicines or choose to reserve our medicines for use in limited patient populations.

In addition, established pharmaceutical companies may invest heavily to accelerate discovery and development of novel compounds or to acquire novel compounds that could make our medicines obsolete. Our ability to compete successfully with these companies and other potential competitors will depend largely on our ability to leverage our experience in clinical, regulatory and commercial development to:

If we are unable to maintain or realize the benefits of orphan drug exclusivity, we may face increased competition with respect to certain of our medicines.

Under the Orphan Drug Act of 1983, the FDA may designate a medicine as an orphan drug if it is a drug intended to treat a rare disease or condition affecting fewer than 200,000 people in the United States. A company that first obtains FDA approval for a designated orphan drug for the specified rare disease or condition receives orphan drug marketing exclusivity for that drug for a period of seven years from the date of its approval. PROCYSBI has been granted orphan drug exclusivity by the FDA, which we expect will provide orphan drug marketing exclusivity in the United States until December 2020, with exclusivity for PROCYSBI extending to 2022 for patients ages one to six years. In addition, TEPEZZA has been granted orphan drug exclusivity for treatment of active (dynamic) phase Graves’ ophthalmopathy, which we expect will provide orphan drug marketing exclusivity in the United States until January 2027. However, despite orphan drug exclusivity, the FDA can still approve another drug containing the same active ingredient and used for the same orphan indication if it determines that a subsequent drug is safer, more effective or makes a major contribution to patient care, and orphan exclusivity can be lost if the orphan drug manufacturer is unable to ensure that a sufficient quantity of the orphan drug is available to meet the needs of patients with the rare disease or condition. Orphan drug exclusivity may also be lost if the FDA later determines that the initial request for designation was materially defective. In addition, orphan drug exclusivity does not prevent the FDA from approving competing drugs for the same or similar indication containing a different active ingredient. If orphan drug exclusivity is lost and we were unable to successfully enforce any remaining patents covering the applicable medicine, we could be subject to generic competition and revenues from the medicine could decrease materially. In addition, if a subsequent drug is approved for marketing for the same or a similar indication as our medicines despite orphan drug exclusivity, we may face increased competition and lose market share with respect to these medicines.

If we cannot successfully implement our patient assistance programs or increase formulary access and reimbursement for our medicines in the face of increasing pressure to reduce the price of medications, the adoption of our medicines by physicians, patients and payers may decline.*

There continues to be immense pressure from healthcare payers, PBMs and others to use less expensive or generic medicines or over-the-counter brands instead of certain branded medicines. For example, some PBMs have placed certain of our medicines on their exclusion lists from time to time, which has resulted in a loss of coverage for patients whose healthcare plans have adopted these PBM lists. Additional healthcare plans, including those that contract with these PBMs but use different formularies, may also choose to exclude our medicines from their formularies or restrict coverage to situations where a generic or over-the-counter medicine has been tried first. Many payers and PBMs also require patients to make co-payments for branded medicines, including many of our medicines, in order to incentivize the use of generic or other lower-priced alternatives instead. Legislation enacted in most states in the United States allows, or in some instances mandates, that a pharmacist dispenses an available generic equivalent when filling a prescription for a branded medicine, in the absence of specific instructions from the prescribing physician. Because our medicines (other than BUPHENYL and VIMOVO) do not currently have FDA-approved generic equivalents in the United States, we do not believe our medicines should be subject to mandatory generic substitution laws. We understand that some pharmacies may attempt to obtain physician authorization to switch prescriptions for DUEXIS to prescriptions for multiple generic medicines with similar APIs to ensure payment for the medicine if the physician’s prescription for the branded medicine is not immediately covered by the payer, despite such substitution being off-label in the case of DUEXIS. If these limitations in coverage and other incentives result in patients refusing to fill prescriptions or being dissatisfied with the out-of-pocket costs of their medications, or if pharmacies otherwise seek and receive physician authorization to switch prescriptions, not only would we lose sales on prescriptions that are ultimately not filled, but physicians may be dissuaded from writing prescriptions for our medicines in the first place in order to avoid potential patient non-compliance or dissatisfaction over medication costs, or to avoid spending the time and effort of responding to pharmacy requests to switch prescriptions.

Part of our commercial strategy to increase adoption and access to our medicines in the face of these incentives to use generic alternatives is to offer physicians the opportunity to have eligible patients fill prescriptions through independent pharmacies participating in our HorizonCares patient assistance program, including shipment of prescriptions to patients. We also have contracted with a third-party prescription clearinghouse that offers physicians a single point of contact for processing prescriptions through these independent pharmacies, reducing physician administrative costs, increasing the fill rates for prescriptions and enabling physicians to monitor refill activity. Through HorizonCares, financial assistance may be available to reduce eligible patients’ out-of-pocket costs for prescriptions filled. Because of this assistance, eligible patients’ out-of-pocket cost for our medicines when dispensed through HorizonCares may be significantly lower than such costs when our medicines are dispensed outside of the HorizonCares program. However, to the extent physicians do not direct prescriptions currently filled through traditional pharmacies, including those associated with or controlled by PBMs, to pharmacies participating in our HorizonCares program, we may experience a significant decline in PENNSAID 2% and DUEXIS prescriptions. Our ability to increase utilization of our patient assistance programs will depend on physician and patient awareness and comfort with the programs, and we do not control whether physicians will ultimately use our patient assistance programs to prescribe our medicines or whether patients will agree to receive our medicines through our HorizonCares program. In addition, the HorizonCares program is not available to federal health care program (such as Medicare and Medicaid) beneficiaries. We have also contracted with certain PBMs and other payers to secure formulary status and reimbursement for certain of our inflammation segment medicines, which generally require us to pay administrative fees and rebates to the PBMs and other payers for qualifying prescriptions. While we have business relationships with two of the largest PBMs, Express Scripts, Inc., or Express Scripts, and CVS Caremark, as well as rebate agreements with other PBMs, and we believe these agreements will secure formulary status for certain of our medicines, we cannot guarantee that we will be able to agree to terms with other PBMs and other payers, or that such terms will be commercially reasonable to us. Despite our agreements with PBMs, the extent of formulary status and reimbursement will ultimately depend to a large extent upon individual healthcare plan formulary decisions. If healthcare plans that contract with PBMs with which we have agreements do not adopt formulary changes recommended by the PBMs with respect to our medicines, we may not realize the expected access and reimbursement benefits from these agreements. In addition, we generally pay higher rebates for prescriptions covered under plans that adopt a PBM-chosen formulary than for plans that adopt custom formularies. Consequently, the success of our PBM contracting strategy will depend not only on our ability to expand formulary adoption among healthcare plans, but also upon the relative mix of healthcare plans that have PBM-chosen formularies versus custom formularies. If we are unable to realize the expected benefits of our contractual arrangements with the PBMs we may continue to experience reductions in net sales from our inflammation segment medicines and/or reductions in net pricing for our inflammation segment medicines due to increasing patient assistance costs. If we are unable to increase adoption of HorizonCares for filling prescriptions of our medicines and to secure formulary status and reimbursement through arrangements with PBMs and other payers, particularly with healthcare plans that use custom formularies, our ability to achieve net sales growth for our inflammation segment medicines would be impaired.

There has been negative publicity and inquiries from Congress and enforcement authorities regarding the use of specialty pharmacies and drug pricing. Our patient assistance programs are not involved in the prescribing of medicines and are solely to assist in ensuring that when a physician determines one of our medicines offers a potential clinical benefit to their patients and they prescribe one for an eligible patient, financial assistance may be available to reduce the patient’s out-of-pocket costs. In addition, all pharmacies that fill prescriptions for our medicines are fully independent, including those that participate in HorizonCares. We do not own or possess any option to purchase an ownership stake in any pharmacy that distributes our medicines, and our relationship with each pharmacy is non-exclusive and arm’s length. All of our sales are processed through pharmacies independent of us. Despite this, the negative publicity and interest from Congress and enforcement authorities regarding specialty pharmacies may result in physicians being less willing to participate in our patient assistance programs and thereby limit our ability to increase patient assistance and adoption of our medicines.

We may also encounter difficulty in forming and maintaining relationships with pharmacies that participate in our patient assistance programs. We currently depend on a limited number of pharmacies participating in HorizonCares to fulfill patient prescriptions under the HorizonCares program. If these HorizonCares participating pharmacies are unable to process and fulfill the volume of patient prescriptions directed to them under the HorizonCares program, our ability to maintain or increase prescriptions for our medicines will be impaired. The commercialization of our medicines and our operating results could be affected should any of the HorizonCares participating pharmacies choose not to continue participation in our HorizonCares program or by any adverse events at any of those HorizonCares participating pharmacies. For example, pharmacies that dispense our medicines could lose contracts that they currently maintain with managed care organizations, or MCOs, including PBMs. Pharmacies often enter into agreements with MCOs. They may be required to abide by certain terms and conditions to maintain access to MCO networks, including terms and conditions that could limit their ability to participate in patient assistance programs like ours. Failure to comply with the terms of their agreements with MCOs could result in a variety of penalties, including termination of their agreement, which could negatively impact the ability of those pharmacies to dispense our medicines and collect reimbursement from MCOs for such medicines.

The HorizonCares program may implicate certain federal and state laws related to, among other things, unlawful schemes to defraud, excessive fees for services, healthcare kickbacks, tortious interference with patient contracts and statutory or common law fraud. We have a comprehensive compliance program in place to address adherence with various laws and regulations relating to the selling, marketing and manufacturing of our medicines, as well as certain third-party relationships, including pharmacies. Specifically, with respect to pharmacies, the compliance program utilizes a variety of methods and tools to monitor and audit pharmacies, including those that participate in the HorizonCares program, to confirm their activities, adjudication and practices are consistent with our compliance policies and guidance. Despite our compliance efforts, to the extent the HorizonCares program is found to be inconsistent with applicable laws or the pharmacies that participate in our patient assistance programs do not comply with applicable laws, we may be required to restructure or discontinue such programs, terminate our relationship with certain pharmacies, or be subject to other significant penalties. In November 2015, we received a subpoena from the U.S. Attorney’s Office for the Southern District of New York requesting documents and information related to our patient assistance programs and other aspects of our marketing and commercialization activities. We are unable to predict how long this investigation will continue or its outcome, but we have incurred and anticipate that we may continue to incur significant costs in connection with the investigation, regardless of the outcome. We may also become subject to similar investigations by other governmental agencies or Congress. The investigation by the U.S. Attorney’s Office and any additional investigations of our patient assistance programs and sales and marketing activities may result in significant damages, fines, penalties, exclusion, additional reporting requirements and/or oversight or other administrative sanctions against us.

If the cost of maintaining our patient assistance programs increases relative to our sales revenues, we could be forced to reduce the amount of patient financial assistance that we offer or otherwise scale back or eliminate such programs, which could in turn have a negative impact on physicians’ willingness to prescribe and patients’ willingness to fill prescriptions of our medicines. While we believe that our arrangements with PBMs will result in broader inclusion of certain of our inflammation segment medicines on healthcare plan formularies, and therefore increase payer reimbursement and lower our cost of providing patient assistance programs, these arrangements generally require us to pay administrative and rebate payments to the PBMs and/or other payers and their effectiveness will ultimately depend to a large extent upon individual healthcare plan formulary decisions that are beyond the control of the PBMs. If our arrangements with PBMs and other payers do not result in increased prescriptions and reductions in our costs to provide our patient assistance programs that are sufficient to offset the administrative fees and rebate payments to the PBMs and/or other payers, our financial results may continue to be harmed.

If we are unable to successfully implement our commercial plans and facilitate adoption by patients and physicians of any approved medicines through our sales, marketing and commercialization efforts, then we will not be able to generate sustainable revenues from medicine sales which will have a material adverse effect on our business and prospects.

Our business operations may subject us to numerous commercial disputes, claims and/or lawsuits and such litigation may be costly and time-consuming and could materially and adversely impact our financial position and results of operations.

Operating in the pharmaceutical industry, particularly the commercialization of medicines, involves numerous commercial relationships, complex contractual arrangements, uncertain intellectual property rights, potential product liability and other aspects that create heightened risks of disputes, claims and lawsuits. In particular, we may face claims related to the safety of our medicines, intellectual property matters, employment matters, tax matters, commercial disputes, competition, sales and marketing practices, environmental matters, personal injury, insurance coverage and acquisition or divestiture-related matters. Any commercial dispute, claim or lawsuit may divert management’s attention away from our business, we may incur significant expenses in addressing or defending any commercial dispute, claim or lawsuit, and we may be required to pay damage awards or settlements or become subject to equitable remedies that could adversely affect our operations and financial results.

We are currently in litigation with multiple generic drug manufacturers regarding intellectual property infringement. For example, we are currently involved in Hatch Waxman litigation with generic drug manufacturers related to DUEXIS, PENNSAID 2% and VIMOVO.

Similarly, from time to time we are involved in disputes with distributors, PBMs and licensing partners regarding our rights and performance of obligations under contractual arrangements. For example, we were previously in litigation with Express Scripts related to alleged breach of contract claims.

Litigation related to these disputes may be costly and time-consuming and could materially and adversely impact our financial position and results of operations if resolved against us.

A variety of risks associated with operating our business internationally could adversely affect our business.

In addition to our U.S. operations, we have operations in Ireland, Bermuda, the Grand Duchy of Luxembourg, or Luxembourg, Switzerland, Germany and in Canada. We face risks associated with our international operations, including possible unfavorable political, tax and labor conditions, which could harm our business. We are subject to numerous risks associated with international business activities, including:

Our business activities outside of the United States are subject to the FCPA and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate. The FCPA and similar anti-corruption laws generally prohibit offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to non-U.S. government officials in order to improperly influence any act or decision, secure any other improper advantage, or obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the company and to devise and maintain an adequate system of internal accounting controls. As described above, our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, the health care providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, any dealings with these prescribers and purchasers may be subject to regulation under the FCPA. Recently the SEC and the U.S. Department of Justice, or DOJ, have increased their FCPA enforcement activities with respect to pharmaceutical companies. In addition, under the Dodd–Frank Wall Street Reform and Consumer Protection Act, private individuals who report to the SEC original information that leads to successful enforcement actions may be eligible for a monetary award. We are engaged in ongoing efforts that are designed to ensure our compliance with these laws, including due diligence, training, policies, procedures and internal controls. However, there is no certainty that all employees and third-party business partners (including our distributors, wholesalers, agents, contractors, and other partners) will comply with anti-bribery laws. In particular, we do not control the actions of manufacturers and other third-party agents, although we may be liable for their actions. Violation of these laws may result in civil or criminal sanctions, which could include monetary fines, criminal penalties, and disgorgement of past profits, which could have a material adverse impact on our business and financial condition.

We are subject to tax audits around the world, and such jurisdictions may assess additional income tax against us. Although we believe our tax positions are reasonable, the final determination of tax audits could be materially different from our recorded income tax provisions and accruals. The ultimate results of an audit could have a material adverse effect on our operating results or cash flows in the period or periods for which that determination is made and could result in increases to our overall tax expense in subsequent periods.

These and other risks associated with our international operations may materially adversely affect our business, financial condition and results of operations.

If we fail to develop or acquire other medicine candidates or medicines, our business and prospects would be limited.

A key element of our strategy is to develop or acquire and commercialize a portfolio of other medicines or medicine candidates in addition to our current medicines, through business or medicine acquisitions. Because we do not engage in proprietary drug discovery, the success of this strategy depends in large part upon the combination of our regulatory, development and commercial capabilities and expertise and our ability to identify, select and acquire approved or clinically enabled medicine candidates for therapeutic indications that complement or augment our current medicines, or that otherwise fit into our development or strategic plans on terms that are acceptable to us. Identifying, selecting and acquiring promising medicines or medicine candidates requires substantial technical, financial and human resources expertise. Efforts to do so may not result in the actual acquisition or license of a particular medicine or medicine candidate, potentially resulting in a diversion of our management’s time and the expenditure of our resources with no resulting benefit. If we are unable to identify, select and acquire suitable medicines or medicine candidates from third parties or acquire businesses at valuations and on other terms acceptable to us, or if we are unable to raise capital required to acquire businesses or new medicines, our business and prospects will be limited.

Moreover, any medicine candidate we acquire may require additional, time-consuming development or regulatory efforts prior to commercial sale or prior to expansion into other indications, including pre-clinical studies if applicable, and extensive clinical testing and approval by the FDA and applicable foreign regulatory authorities. All medicine candidates are prone to the risk of failure that is inherent in pharmaceutical medicine development, including the possibility that the medicine candidate will not be shown to be sufficiently safe and/or effective for approval by regulatory authorities. In addition, we cannot assure that any such medicines that are approved will be manufactured or produced economically, successfully commercialized or widely accepted in the marketplace or be more effective or desired than other commercially available alternatives.

In addition, if we fail to successfully commercialize and further develop our medicines, there is a greater likelihood that we will fail to successfully develop a pipeline of other medicine candidates to follow our existing medicines or be able to acquire other medicines to expand our existing portfolio, and our business and prospects would be harmed.

We have experienced growth and expanded the size of our organization substantially in connection with our acquisition transactions, and we may experience difficulties in managing this growth as well as potential additional growth in connection with future medicine, development program or company acquisitions.*

As of December 31, 2013, we employed approximately 300 full-time employees as a consolidated entity. As of June 30, ~~2019,~~2020, we employed approximately ~~1,080~~1,225 full-time employees, including approximately ~~435~~450 sales representatives, representing a substantial change to the size of our organization. We have also experienced, and may continue to experience, turnover of the sales representatives that we hired or will hire in connection with the commercialization of our medicines, requiring us to hire and train new sales representatives. Our management, personnel, systems and facilities currently in place may not be adequate to support anticipated growth, and we may not be able to retain or recruit qualified personnel in the future due to competition for personnel among pharmaceutical businesses.

As our commercialization plans and strategies continue to develop, we will need to continue to recruit and train sales and marketing personnel. Our ability to manage any future growth effectively may require us to, among other things:

Our acquisitions have resulted in many changes, including significant changes in the corporate business and legal entity structure, the integration of other companies and their personnel with us, and changes in systems. We may encounter unexpected difficulties or incur unexpected costs, including:

If any of these factors impair our ability to continue to integrate our operations with those of any companies or businesses we acquire, we may not be able to realize the business opportunities, growth prospects and anticipated tax synergies from combining the businesses. In addition, we may be required to spend additional time or money on integration that otherwise would be spent on the development and expansion of our business.

We may not be successful in growing our commercial operations outside the United States, and could encounter other challenges in growing our commercial presence, including due to risks associated with political and economic instability, operating under different legal requirements and tax complexities. If we are unable to manage our commercial growth outside of the United States, our opportunities to expand sales in other countries will be limited or we may experience greater costs with respect to our ex-U.S. commercial operations.

We ~~are~~have also ~~broadening~~broadened our acquisition strategy to include development-stage assets or programs, which entails additional risk to us. For example, if we are unable to identify programs that ultimately result in approved medicines, we may spend material amounts of our capital and other resources evaluating, acquiring and developing medicines that ultimately do not provide a return on our investment. We have less experience evaluating development-stage assets and may be at a disadvantage compared to other entities pursuing similar opportunities. Regardless, development-stage programs generally have a high rate of failure and we cannot guarantee that any such programs will ultimately be successful. ~~We will also~~While we have significantly enhanced our research and development function over the last two years, we may need to enhance our clinical development and regulatory functions to properly evaluate and develop earlier-stage opportunities, which may include recruiting personnel that are knowledgeable in therapeutic areas we have not yet pursued. If we are unable to acquire promising development-stage assets or eventually obtain marketing approval for them, we may not be able to create a meaningful pipeline of new medicines and eventually realize a return on our investments.

Our management may also have to divert a disproportionate amount of its attention away from day-to-day activities and toward managing these growth and integration activities. Our future financial performance and our ability to execute on our business plan will depend, in part, on our ability to effectively manage any future growth and our failure to effectively manage growth could have a material adverse effect on our business, results of operations, financial condition and prospects.

RAVICTI and BUPHENYL face competition from generic NaPBA tablets and powder in treating UCD. Lucane Pharma, or Lucane, is seeking approval via an Abbreviated New Drug Application, or ANDA, in the United States for taste-masked NaPBA. If this ANDA is approved, this formulation may also compete with RAVICTI and BUPHENYL in treating UCD in the United States. PROCYSBI faces competition from Cystagon (immediate-release cysteamine bitartrate capsules) for the treatment of cystinosis and Cystaran (cysteamine ophthalmic solution) for treatment of corneal crystal accumulation in patients with cystinosis. While KRYSTEXXA faces limited direct competition, a number of competitors have drugs in Phase 1 or Phase 2 trials, including Selecta Biosciences Inc. which has presented clinical data from its Phase 2 study and initiated a six-month head-to-head trial comparing their candidate to KRYSTEXXA in March 2019. PENNSAID 2% faces competition from generic versions of diclofenac sodium topical solutions that are priced significantly less than the price we charge for PENNSAID 2%. The generic version of Voltaren Gel is the market leader in the topical NSAID category. Legislation enacted in most states in the United States allows, or in some instances mandates, that a pharmacist dispense an available generic equivalent when filling a prescription for a branded medicine, in the absence of specific instructions from the prescribing physician. DUEXIS and VIMOVO face competition from other NSAIDs, including Celebrex^®, marketed by Pfizer Inc., and celecoxib, a generic form of the medicine marketed by other pharmaceutical companies. DUEXIS and VIMOVO also face significant competition from the separate use of NSAIDs for pain relief and GI protective medications to reduce the risk of NSAID-induced upper GI ulcers. Both NSAIDs and GI protective medications are available in generic form and may be less expensive to use separately than DUEXIS or VIMOVO, despite such substitution being off-label in the case of DUEXIS and VIMOVO. Because pharmacists often have economic and other incentives to prescribe lower-cost generics, if physicians prescribe PENNSAID 2%, DUEXIS, or VIMOVO, those prescriptions may not result in sales. If physicians do not complete prescriptions through our HorizonCares program or otherwise provide prescribing instructions prohibiting generic diclofenac sodium topical solutions as a substitute for PENNSAID 2%, the substitution of generic ibuprofen and famotidine separately as a substitution for DUEXIS or generic naproxen and branded Nexium^® (esomeprazole) as a substitute for VIMOVO, sales of PENNSAID 2%, DUEXIS and VIMOVO may suffer despite any success we may have in promoting PENNSAID 2%, DUEXIS or VIMOVO to physicians. In addition, other medicine candidates that contain ibuprofen and famotidine in combination or naproxen and esomeprazole in combination, while not currently known or FDA approved, may be developed and compete with DUEXIS or VIMOVO, respectively, in the future.

We have also entered into settlement and license agreements that may allow certain of our competitors to sell generic versions of certain of our medicines in the United States, subject to the terms of such agreements. We granted (i) a non-exclusive license (that is only royalty-bearing in some circumstances) to manufacture and commercialize a generic version of DUEXIS in the United States after January 1, 2023, (ii) non-exclusive licenses to manufacture and commercialize generic versions of PENNSAID 2% in the United States after October 17, 2027, (iii) a non-exclusive license to manufacture and commercialize a generic version of RAYOS tablets in the United States after December 23, 2022, (iv) a non-exclusive license to manufacture and commercialize a generic version of VIMOVO in the United States after August 1, 2024, and (v) ~~non-exclusive licenses to manufacture and commercialize generic versions of RAVICTI in the United States after July 1, 2025,~~ ~~or earlier under certain circumstances.~~

~~Patent litigation is currently pending in the United States District Court for the District of New Jersey against~~ ~~Actavis Laboratories UT, Inc., formerly known as Watson Laboratories, Inc., Actavis, Inc. and Actavis plc, or collectively Actavis, who intend to market~~ a generic version of PENNSAID 2% prior to the expiration of certain of our patents listed in the FDA’s Orange Book, or the Orange Book. These cases arise from Paragraph IV Patent Certification notice letters from Actavis advising it had filed an ANDA with the FDA seeking approval to market a generic version of PENNSAID 2% before the expiration of the patents-in-suit.

Patent litigation is currently pending in the United States District Court for the District of New Jersey and the Court of Appeals for the Federal Circuit against Dr. Reddy’s Laboratories Inc. and Dr. Reddy’s Laboratories Ltd., or collectively Dr. Reddy’s, who intends to market a generic version of VIMOVO before the expiration of certain of our patents listed in the Orange Book. The cases arise from Paragraph IV Patent Certification notice letters from Dr. Reddy’s advising that it had filed an ANDA with the FDA seeking approval to market generic versions of VIMOVO before the expiration of the patents-in-suit. On July 30, 2019, the Federal Circuit Court of Appeals denied our request for a rehearing of the Court’s invalidity ruling against the 6,926,907 and 8,557,285 patents for VIMOVO coordinated-release tablets. As a result, the District Court will enter judgment invalidating the ‘907 and ‘285 patents, which could subsequently result in Dr. Reddy’s initiating an at-risk launch of a generic version of VIMOVO.

Patent litigation is currently pending in the United States District Court for the District of Delaware against Alkem Laboratories, Inc., or Alkem, who intends to market a generic version of DUEXIS prior to the expiration of certain of our patents listed in the Orange Book. This case arises from Paragraph IV Patent Certification notice letters from Alkem advising it had filed an ANDA with the FDA seeking approval to market a generic version of DUEXIS before the expiration of the patents-in-suit.

If we are unsuccessful in any of the VIMOVO cases, PENNSAID 2% cases or DUEXIS case, we will likely face generic competition with respect to VIMOVO, PENNSAID 2% and/or DUEXIS and sales of VIMOVO, PENNSAID 2% and/or DUEXIS will be substantially harmed.

BUPHENYL’s composition of matter patent protection and orphan drug exclusivity have expired. Because BUPHENYL has no regulatory exclusivity or listed patents, there is nothing to prevent a competitor from submitting an ANDA for a generic version of BUPHENYL and receiving FDA approval. Generic versions of BUPHENYL to date have been priced at a discount relative to BUPHENYL or RAVICTI, and physicians, patients, or payers may decide that this less expensive alternative is preferable to BUPHENYL and RAVICTI. If this occurs, sales of BUPHENYL and/or RAVICTI could be materially reduced, but we would nevertheless be required to make royalty payments to Bausch Health Companies Inc. (formerly Ucyclyd Pharma, Inc.), or Bausch, and another external party, at the same royalty rates. While Bausch and its affiliates are generally contractually prohibited from developing or commercializing new medicines, anywhere in the world, for the treatment of UCD or hepatic encephalopathy, or HE, which are chemically similar to RAVICTI, they may still develop and commercialize medicines that compete with RAVICTI. For example, medicines approved for indications other than UCD and HE may still compete with RAVICTI if physicians prescribe such medicines off-label for UCD or HE. We are also aware that Recordati S.p.A (formerly known as Orphan Europe SARL), or Recordati, is conducting clinical trials of carglumic acid to assess the short-term efficacy for hyperammonemia in some of the UCD enzyme deficiencies for which RAVICTI is approved for chronic treatment. Carglumic acid is approved for maintenance therapy for chronic hyperammonemia and to treat hyperammonemic crises in Nacetylglutamate synthase deficiency, a rare UCD subtype, and is sold under the name Carbaglu. If the results of this trial are successful and Recordati is able to complete development and obtain approval of Carbaglu to treat additional UCD enzyme deficiencies, RAVICTI would face additional competition from this compound.

If we are unable to maintain or realize the benefits of orphan drug exclusivity, we may face increased competition with respect to certain of our medicines.*

Under the Orphan Drug Act of 1983, the FDA may designate a medicine as an orphan drug if it is a drug intended to treat a rare disease or condition affecting fewer than 200,000 people in the United States. A company that first obtains FDA approval for a designated orphan drug for the specified rare disease or condition receives orphan drug marketing exclusivity for that drug for a period of seven years from the date of its approval. RAVICTI and PROCYSBI have been granted orphan drug exclusivity by the FDA, which we expect will provide orphan drug marketing exclusivity in the United States until February 2020 and December 2020, respectively, with exclusivity for PROCYSBI extending to 2022 for patients ages one to six years. In addition, teprotumumab has been granted orphan drug designation for treatment of active (dynamic) phase Graves’ orbitopathy and, if approved by the FDA for that indication, would be eligible for seven years of marketing exclusivity in the United States following such approval. However, despite orphan drug exclusivity, the FDA can still approve another drug containing the same active ingredient and used for the same orphan indication if it determines that a subsequent drug is safer, more effective or makes a major contribution to patient care, and orphan exclusivity can be lost if the orphan drug manufacturer is unable to ensure that a sufficient quantity of the orphan drug is available to meet the needs of patients with the rare disease or condition. Orphan drug exclusivity may also be lost if the FDA later determines that the initial request for designation was materially defective. In addition, orphan drug exclusivity does not prevent the FDA from approving competing drugs for the same or similar indication containing a different active ingredient. If orphan drug exclusivity is lost and we were unable to successfully enforce any remaining patents covering the applicable medicine, we could be subject to generic competition and revenues from the medicine could decrease materially. In addition, if a subsequent drug is approved for marketing for the same or a similar indication as our medicines despite orphan drug exclusivity, we may face increased competition and lose market share with respect to these medicines.

~~Litigation related to these disputes may be costly and time-consuming and could materially and adversely impact our financial position and results of operations if resolved against us.~~

~~A variety of risks associated with operating our business and marketing our medicines internationally could adversely affect our business.~~

In addition to our U.S. operations, we have operations in Ireland, Bermuda, the Grand Duchy of Luxembourg, or Luxembourg, Switzerland, Germany, Canada and in Israel (through Andromeda Biotech Ltd). RAVICTI received marketing authorization from Health Canada, or HC, in March 2016 and we launched RAVICTI in Canada in November 2016. PROCYSBI received marketing authorization from HC in June 2017 and we launched PROCYSBI in Canada in October 2017. BUPHENYL is currently marketed in Japan by Orphan Pacific. QUINSAIR received marketing authorization from HC in June 2015 and we launched QUINSAIR in Canada in December 2016. We face risks associated with our international operations, including possible unfavorable regulatory, pricing and reimbursement, political, tax and labor conditions, which could harm our business. We are subject to numerous risks associated with international business activities, including:

Our business activities outside of the United States are subject to the FCPA and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate, including the United Kingdom’s Bribery Act 2010, or the U.K. Bribery Act. The FCPA and similar anti-corruption laws generally prohibit offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to non-U.S. government officials in order to improperly influence any act or decision, secure any other improper advantage, or obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the company and to devise and maintain an adequate system of internal accounting controls. The U.K. Bribery Act prohibits giving, offering, or promising bribes to any person, including non-United Kingdom, or U.K., government officials and private persons, as well as requesting, agreeing to receive, or accepting bribes from any person. In addition, under the U.K. Bribery Act, companies which carry on a business or part of a business in the U.K. may be held liable for bribes given, offered or promised to any person, including non-U.K. government officials and private persons, by employees and persons associated with the company in order to obtain or retain business or a business advantage for the company. Liability is strict, with no element of a corrupt state of mind, but a defense of having in place adequate procedures designed to prevent bribery is available. Furthermore, under the U.K. Bribery Act there is no exception for facilitation payments. As described above, our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, the health care providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, any dealings with these prescribers and purchasers may be subject to regulation under the FCPA. Recently the SEC and the U.S. Department of Justice, or DOJ, have increased their FCPA enforcement activities with respect to pharmaceutical companies. In addition, under the Dodd–Frank Wall Street Reform and Consumer Protection Act, private individuals who report to the SEC original information that leads to successful enforcement actions may be eligible for a monetary award. We are engaged in ongoing efforts that are designed to ensure our compliance with these laws, including due diligence, training, policies, procedures and internal controls. However, there is no certainty that all employees and third-party business partners (including our distributors, wholesalers, agents, contractors, and other partners) will comply with anti-bribery laws. In particular, we do not control the actions of manufacturers and other third-party agents, although we may be liable for their actions. Violation of these laws may result in civil or criminal sanctions, which could include monetary fines, criminal penalties, and disgorgement of past profits, which could have a material adverse impact on our business and financial condition.

~~These and other risks associated with our international operations may materially adversely affect our business, financial condition and results of operations.~~

~~If we fail to develop or acquire other medicine candidates or medicines, our business and prospects would be limited.~~

Our prior medicine and company acquisitions and any other strategic transactions that we may pursue in the future could have a variety of negative consequences, and we may not realize the benefits of such transactions or attempts to engage in such transactions.*

We have completed multiple medicine and company acquisitions and our strategy is to engage in additional strategic transactions with third parties, such as acquisitions of companies or divisions of companies and asset purchases of medicines, medicine candidates or technologies that we believe will complement or augment our existing business. We may also consider a variety of other business arrangements, including spin-offs, strategic partnerships, joint ventures, restructurings, divestitures, business combinations and other investments. Any such transaction may require us to incur non-recurring and other charges, increase our near and long-term expenditures, pose significant integration challenges, create additional tax, legal, accounting and operational complexities in our business, require additional expertise, result in dilution to our existing shareholders and disrupt our management and business, which could harm our operations and financial results. For example, we assumed responsibility for the patent infringement litigation with respect to RAVICTI upon the closing of our acquisition of Hyperion Therapeutics, Inc., or Hyperion, and we have assumed responsibility for completing post-marketing clinical trials of RAVICTI that are required by the FDA, one of which is ongoing.

In connection with our acquisition of Raptor Pharmaceutical Corp., or Raptor, we assumed contractual obligations under agreements with Tripex Pharmaceuticals, LLC, or Tripex, and PARI Pharma GmbH, or PARI, related to QUINSAIR. Under the agreement with Tripex, as amended, if we do not spend a specified amount on the development of QUINSAIR for non-cystic fibrosis indications between January 1, 2018 and December 31, 2021 and if regulatory approval by the FDA for QUINSAIR for the CF indication is obtained prior to December 31, 2021, we may be obligated to pre-pay a milestone payment related to commercial sales of QUINSAIR for non-CF indications. This obligation is subject to certain exceptions due to, for example, manufacturing delays not under our control, or clinical trial suspension or delay ordered by the FDA. In October 2017, we triggered a milestone payment under this agreement and we paid Tripex $20.0 million in November 2017. Under the license agreement with PARI, we are required to comply with diligence milestones related to development and commercialization of QUINSAIR in the United States and to spend a specified minimum amount per year on development and/or commercialization activities in the United States until submission of the new drug application, or NDA, for QUINSAIR in the United States. If we do not comply with these obligations, our licenses to certain intellectual property related to QUINSAIR may become non-exclusive in the United States. We are ~~also~~ subject to contractual obligations under an amended and restated license agreement with the Regents of the University of California, San Diego, or UCSD, as amended, with respect to PROCYSBI. To the extent that we fail to perform our obligations under the agreement, UCSD may, with respect to ~~such indication,~~applicable indications, terminate the license or otherwise cause the license to become non-exclusive. If ~~one or more of these licenses~~this license was terminated, we would have no further right to use or exploit the related intellectual property, which would limit our ability to develop PROCYSBI ~~or QUINSAIR~~ in other indications, and could impact our ability to continue commercializing PROCYSBI ~~or QUINSAIR~~ in ~~their~~its approved indications. In connection with our acquisition of the U.S. rights to VIMOVO, we assumed primary responsibility for the existing patent infringement litigation with respect to VIMOVO, and have also agreed to reimburse certain legal expenses of Nuvo (formerly Aralez Pharmaceuticals Inc.) with respect to its continued involvement in such litigation.

We face significant competition in seeking appropriate strategic transaction opportunities and the negotiation process for any strategic transaction can be time-consuming and complex. In addition, we may not be successful in our efforts to engage in certain strategic transactions because our financial resources may be insufficient and/or third parties may not view our commercial and development capabilities as being adequate. We may not be able to expand our business or realize our strategic goals if we do not have sufficient funding or cannot borrow or raise additional capital. There is no assurance that following any of our recent acquisition transactions or any other strategic transaction, we will achieve the anticipated revenues, net income or other benefits that we believe justify such transactions. In addition, any failures or delays in entering into strategic transactions anticipated by analysts or the investment community could seriously harm our consolidated business, financial condition, results of operations or cash flow.

We may not be able to successfully maintain our current advantageous tax status and resulting tax rates, which could adversely affect our business and financial condition, results of operations and growth prospects.*

Our parent company is incorporated in Ireland and has subsidiaries maintained in multiple jurisdictions, including Ireland, the United States, Switzerland, Luxembourg, Germany, Canada ~~Bermuda~~ and Israel (through Andromeda Biotech Ltd). Prior to our merger transaction in September 2014 with Vidara Therapeutics International Public Limited Company, or Vidara, and such transaction, the Vidara Merger, Vidara wasBermuda. We are able to achieve a favorable tax rate through the performance of certain functions and ownership of certain assets in tax-efficient jurisdictions, including Ireland and Bermuda, together with the use of intra-company service and transfer pricing agreements, each on an arm’s length basis. ~~We are continuing a substantially similar structure and arrangements. Nevertheless, our~~Our effective tax rate may be different than experienced in the past due to numerous factors including, changes to the tax laws of jurisdictions that we operate in, ~~(including for example,~~ the enactment of new tax treaties or changes to existing tax ~~treaties),~~treaties, changes in the mix of our profitability from jurisdiction to jurisdiction, the implementation of the EU Anti-Tax Avoidance Directive (see further discussion below), the implementation of the Bermuda Economic Substance Act 2018 (effective December 31, 2018) and our inability to secure or sustain acceptable agreements with tax authorities (if applicable). Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations. Taxing authorities, such as the U.S. Internal Revenue Service, or IRS, actively audit and otherwise challenge these types of arrangements, and have done so in the pharmaceutical industry. We expect that these challenges will continue as a result of the recent increase in scrutiny and political attention on corporate tax structures. The IRS and/or the Irish tax authorities may challenge our structure and transfer pricing arrangements through an audit or lawsuit. Responding to or defending such a challenge could be expensive and consume time and other resources, and divert management’s time and focus from operating our business. We cannot predict whether taxing authorities will conduct an audit or file a lawsuit challenging this structure, the cost involved in responding to any such audit or lawsuit, or the outcome. If we are unsuccessful in defending such a challenge, we may be required to pay taxes for prior periods, as well as interest, fines or penalties, and may be obligated to pay increased taxes in the future, any of which could require us to reduce our operating expenses, decrease efforts in support of our medicines or seek to raise additional funds, all of which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.

The IRS may not agree with our conclusion that our parent company should be treated as a foreign corporation for U.S. federal income tax purposes following the combination of the businesses of Horizon Pharma, Inc., or HPI, our predecessor, and Vidara Therapeutics International Public Limited Company, or Vidara.

Although our parent company is incorporated in Ireland, the IRS may assert that it should be treated as a U.S. corporation (and, therefore, a U.S. tax resident) for U.S. federal income tax purposes pursuant to Section 7874 of the Internal Revenue Code of 1986, as amended, or the Code. A corporation is generally considered a tax resident in the jurisdiction of its organization or incorporation for U.S. federal income tax purposes. Because our parent company is an Irish incorporated entity, it would generally be classified as a foreign corporation (and, therefore, a non-U.S. tax resident) under these general rules. Section 7874 of the Code provides an exception pursuant to which a foreign incorporated entity may, in certain circumstances, be treated as a U.S. corporation for U.S. federal income tax purposes.

In July 2018, the IRS issued regulations under Section ~~7874 that finalized, with few changes, guidance that the IRS had previously issued in temporary form in 2016.~~7874. We do not believe that our classification as a foreign corporation for U.S. federal income tax purposes is affected by Section 7874 or the regulations thereunder, though the IRS may disagree.

Recent and future changes to U.S. and non-U.S. tax laws could materially adversely affect our company.*

Under current law, we expect our parent company to be treated as a foreign corporation for U.S. federal income tax purposes. However, changes to the rules in Section 7874 of the Code or regulations promulgated thereunder or other guidance issued by the U.S. Department of the Treasury, or the U.S. Treasury, or the IRS could adversely affect our parent company’s status as a foreign corporation for U.S. federal income tax purposes or the taxation of transactions between members of our group, and any such changes could have prospective or retroactive application. If our parent company is treated as a domestic corporation, more of our income will be taxed by the United States which may substantially increase our effective tax rate.

In January 2017, the U.S. Treasury and the IRS issued final regulations that expand the scope of transactions subject to the rules designed to eliminate the U.S. tax benefits of so-called inversion transactions. Under the regulations, the former stockholders of U.S. corporations acquired by a foreign corporation within thirty-six months of the signing date of the last such acquisition are aggregated for the purpose of determining whether the foreign corporation will be treated as a domestic corporation for U.S. federal tax purposes because at least 80 percent of the stock of the foreign corporation is held by former stockholders of a U.S. corporation. The requirement to aggregate the stockholders in such acquisitions for the purpose of determining whether the 80 percent threshold is met may limit our ability to use our stock to acquire U.S. corporations or their assets in the future.

In addition, the Organization for Economic Co-operation and Development, or the OECD, released its Base Erosion and Profit Shifting project final report on October 5, 2015. This report provides the basis for international standards for corporate taxation that are designed to prevent, among other things, the artificial shifting of income to tax havens and low-tax jurisdictions, the erosion of the tax base through interest deductions on intra-company debt and the artificial avoidance of permanent establishments (i.e., tax nexus with a jurisdiction). Legislation to adopt these standards has been enacted or is currently under consideration in a number of jurisdictions. On June 7, 2017, several countries, including many countries that we operate and have subsidiaries in, participated in the signing ceremony adopting the OECD’s Multilateral Convention to Implement Tax Treaty Related Measures to Prevent Base Erosion and Profit Shifting, commonly referred to as the MLI. The MLI came into effect on July 1, 2018. In January 2019, Ireland deposited the instrument of ratification of Ireland’s MLI choices with the OECD. Ireland’s MLI came into force on May 1, 2019, however the provisions in respect of withholding taxes and other taxes levied by Ireland ~~will~~did not come into effect for us until January 1, 2020 (with application also depending on whether the MLI has been ratified in other jurisdictions whose tax treaties with Ireland are affected). The MLI may modify affected tax treaties making it more difficult for us to obtain advantageous tax-treaty benefits. The number of affected tax treaties could eventually be in the thousands. As a result, our income may be taxed in jurisdictions where it is not currently taxed and at higher rates of tax than it is currently taxed, which may increase our effective tax rate.

The Irish Finance Act 2019, or Finance Act 2019, which was signed into law on December 22, 2019, introduced changes to Ireland’s transfer pricing rules, which came into force with effect from January 1, 2020. The changes introduce the 2017 version of the OECD Transfer Pricing Guidelines, or 2017 OECD Guidelines, as the reference guidelines for Ireland’s domestic transfer pricing regime. The 2017 OECD Guidelines were already applicable under Ireland’s international tax treaties and therefore the introduction of these guidelines should only affect transactions with non-tax treaty countries. In addition to updating Irish tax law for the 2017 OECD Guidelines, these changes also extend the transfer pricing rules to certain non-trading transactions and to certain capital transactions. We have restructured certain intercompany arrangements, such that we do not expect there to be a material impact on our effective tax rate as a result of the introduction of these provisions.

On July 12, 2016, the Anti-Tax Avoidance Directive, or ATAD, was formally adopted by the Economic and Financial Affairs Council of the EU. The stated objective of the ATAD is to provide for the effective and swift coordinated implementation of anti-base erosion and profit shifting measures at EU level. Like all directives, the ATAD is binding as to the results it aims to achieve though EU Member States are free to choose the form and method of achieving those results. In addition, the ATAD contains a number of optional provisions that present an element of choice as to how it will be implemented into law. On December 25, 2018, the Finance Act 2018 was signed into Irish law, which introduced certain elements of the ATAD, such as the Controlled Foreign Company, or CFC, regime, into Irish law. The CFC regime became effective as of January 1, 2019. ~~These~~The ATAD also set out a high-level framework for the introduction of Anti-hybrid provisions. Finance Act 2019 introduced Anti-hybrid legislation in Ireland with effect from January 1, 2020. We do not expect these legislative changes ~~are not expected~~ to have a material impact on our effective tax rate. The ~~remaining provisions~~timing of the ~~ATAD are expected to be incorporated~~introduction into Irish tax law ~~from 2020 onwards and, although~~of further ATAD measures, such as the interest limitation rules, is unclear. Although it is difficult at this stage to determine with precision the impact that these remaining provisions will have, their implementation could materially increase our effective tax rate.

On December 22, 2017, U.S. federal income tax legislation was signed into law (H.R. 1, “An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018”, informally titled the Tax Cuts and Jobs Act, or the Tax Act) that significantly ~~revises~~revised the Code in the United States. The Tax Act, among other things, ~~contains~~contained significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, limitation of the tax deduction for interest expense to 30% of adjusted earnings (except for certain small businesses), implementation of a “base erosion anti-abuse tax” which requires U.S. corporations to make an alternative determination of taxable income without regard to tax deductions for certain payments to affiliates, taxation of certain non-U.S. corporations’ earnings considered to be “global intangible low taxed income”, or GILTI, repeal of the alternative minimum tax, or AMT, for corporations and changes to a taxpayer’s ability to either utilize or refund the AMT credits previously generated, changes to the limitation on deductions for certain executive compensation particularly with respect to the removal of the previously allowed performance based compensation exception, changes in the attribution rules relating to shareholders of certain “controlled foreign corporations”, limitation of the deduction for net operating losses to 80% of current year taxable income and elimination of net operating loss carrybacks, one-time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, elimination of U.S. tax on foreign earnings (subject to certain important exceptions), immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits. For example, U.S. federal income tax law resulting in additional taxes owed by U.S. shareholders under the GILTI rules, together with the Tax Act’s change to the attribution rules related to “controlled foreign corporations” may discourage U.S. investors from owning or acquiring 10% or greater of our outstanding ordinary shares, which other shareholders may have viewed as beneficial or may otherwise negatively impact the trading price of our ordinary shares.

On March 27, 2020, H.R.748, the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, was enacted in the United States, which provides temporary relief from certain aspects of the Tax Act that had imposed limitations on the utilization of certain losses, interest expense deductions, and the timing of refunds of alternative minimum tax credits.

On April 8, 2020, the U.S. Treasury published in the Federal Register additional Proposed Regulations relating to Section 267A of the Code, conduit financing rules and the treatment of certain payments under the GILTI provisions. On July 9, 2020, the U.S. Treasury issued Final Regulations on the deduction for GILTI and “foreign derived intangible income” or FDII. On July 28, 2020, the U.S. Treasury issued Final Regulations under Section 163(j) of the Code relating to tax deductions for business interest expense and additional Proposed Regulations that provide guidance on various business interest expense deduction limitation issues not addressed in the Final Regulations. We are currently in the process of assessing these Final and Proposed Regulations and the potential impact on us. We do not expect these Final and Proposed Regulations to have a material impact on our effective tax rate.

We are unable to predict what ~~federal~~ tax ~~law~~laws may be proposed or enacted in the future or what effect such changes would have on our ~~business, but such changes, to~~business. To the extent ~~they~~new tax laws are ~~brought into tax legislation, regulations, policies~~enacted, or ~~practices,~~new guidance released, this could ~~affect our effective tax rates in the future in countries where we have operations and~~ have an adverse effect on our ~~overall~~future effective tax ~~rate~~rate. It could also lead to an increase in the ~~future, along with increasing the~~ complexity ~~burden~~ and cost of tax compliance. We urge our shareholders to consult with their legal and tax advisors with respect to ~~this legislation and~~ the potential tax consequences of investing in or holding our ordinary shares.

On December 20, 2018, the U.S. Treasury issued Proposed Regulations under Section 267A of the Code, or Section 267A Proposed Regulations, to clarify certain aspects of Section 267A of the Code, or Section 267A (commonly referred to as the “Anti-Hybrid Rules”; rules enacted as part of the Tax Act). The Section 267A Proposed Regulations were the first administrative guidance on Section 267A and provided several rules which expanded the reach and scope of the Anti-Hybrid Rules particularly involving the payment of interest and royalties by certain branches, reverse hybrid entities, and other hybrid mismatch arrangements. While Section 267A, as enacted under the Tax Act, does not appear to apply to the Company, the guidance and scope of the Section 267A Proposed Regulations with respect to Anti-Hybrid Rules may apply to the Company. We are currently in the process of assessing the provisions set forth in the Section 267A Proposed Regulations and their potential impact on the Company. To the extent that the Anti-Hybrid Rules are applicable to the Company, absent certain actions taken by the Company to restructure its intercompany financing arrangements, such application would have a material impact on our effective tax rate if and when the Section 267A Proposed Regulations become final as currently drafted.

On March 4, 2019, the U.S. Treasury issued Proposed Regulations under Section 250 of the Code, which provide guidance on both the computation of the deductions for GILTI and “foreign-derived intangible income”, or FDII, and the determination of FDII. We do not expect the Company to be subject to the GILTI inclusion nor is it expected that the potential FDII deduction would have a material impact on our effective tax rate.

If a United States person is treated as owning at least 10% of our ordinary shares, such holder may be subject to adverse U.S. federal income tax consequences.*

If a United States person is treated as owning (directly, indirectly, or constructively) at least 10% of the value or voting power of our ordinary shares, such person may be treated as a “United States shareholder” with respect to each “controlled foreign corporation” in our group (if any). Because our group includes one or more U.S. subsidiaries, certain of our non-U.S. subsidiaries could be treated as controlled foreign corporations (regardless of whether or not we are treated as a controlled foreign corporation). A United States shareholder of a controlled foreign corporation may be required to report annually and include in its U.S. taxable income its pro rata share of “Subpart F income,” “global intangible low-taxed income,” and investments in U.S. property by controlled foreign corporations, regardless of whether we make any distributions. An individual that is a United States shareholder with respect to a controlled foreign corporation generally would not be allowed certain tax deductions or foreign tax credits that would be allowed to a U.S. corporation that is a United States shareholder ~~that is~~with respect to a ~~U.S.~~controlled foreign corporation. Failure to comply with these reporting and tax paying obligations may subject a United States shareholder to significant monetary penalties and may prevent the statute of limitations from starting with respect to such shareholder’s U.S. federal income tax return for the year for which reporting was due. We cannot provide any assurances that we will assist investors in determining whether any of our non-U.S. subsidiaries is treated as a controlled foreign corporation or whether any investor is treated as a United States shareholder with respect to any such controlled foreign corporation or furnish to any United States shareholders information that may be necessary to comply with the aforementioned reporting and tax paying obligations. A United States investor should consult its advisors regarding the potential application of these rules to an investment in our ordinary shares.

If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.

Our ability to compete in the highly competitive biotechnology and pharmaceuticals industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, sales and marketing and scientific and medical personnel, including our executive officers composed of our Chairman, President and Chief Executive Officer, Timothy Walbert; our Executive Vice President, Chief Business Officer, Robert F. Carey; our Executive Vice President, Chief Financial Officer, Paul W. Hoelscher; our Executive Vice President, Chief Administrative Officer, Barry J. Moze; our Executive Vice President, Head of Research and Development and Chief Scientific Officer, Shao-Lee Lin, M.D., Ph.D; our Executive Vice President, Chief Commercial Officer, Vikram Karnani; our Executive Vice President, Chief Human Resources Officer, Irina P. Konstantinovsky; our Executive Vice President, General Counsel, Brian K. Beeler; our Executive Vice President, Technical Operations, Michael A. DesJardin and our Executive Vice President, Corporate Affairs, Chief Communications Officer, Geoffrey M. Curtis and Senior Vice President, Head of Medical Affairs and Outcomes Research, Jeffrey Kent, M.D., FACP, FACG.officers. In order to retain valuable employees at our company, in addition to salary and annual cash incentives, we provide a mix of performance stock units, or PSUs, that vest subject to attainment of specified corporate performance goals and continued services, stock options and restricted stock units, or RSUs, that vest over time subject to continued services. The value to employees of PSUs, stock options and RSUs will be significantly affected by movements in our share price that are beyond our control, and may at any time be insufficient to counteract more lucrative offers from other companies.

Despite our efforts to retain valuable employees, members of our management, sales and marketing, regulatory affairs, clinical development, medical affairs and development teams may terminate their employment with us on short notice. Although we have written employment arrangements with all of our employees, these employment arrangements generally provide for at-will employment, which means that our employees can leave our employment at any time, with or without notice. The loss of the services of any of our executive officers or other key employees and our inability to find suitable replacements could potentially harm our business, financial condition and prospects. We do not maintain “key man” insurance policies on the lives of these individuals or the lives of any of our other employees. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level, and senior managers as well as junior, mid-level, and senior sales and marketing and scientific and medical personnel.

Many of the other biotechnology and pharmaceutical companies with whom we compete for qualified personnel have greater financial and other resources, different risk profiles and longer histories in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high quality candidates than that which we have to offer. If we are unable to continue to attract and retain high quality personnel, the rate and success at which we can develop and commercialize medicines and medicine candidates will be limited.

We are, with respect to our current medicines, and will be, with respect to any other medicine or medicine candidate for which we obtain FDA or EMA approval or which we acquire, subject to ongoing FDA or EMA obligations and continued regulatory review, which may result in significant additional expense. Additionally, any other medicine candidate, if approved by the FDA or ~~the~~ EMA, could be subject to labeling and other restrictions and market withdrawal, and we may be subject to significant penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our medicines.*

Any regulatory approvals that we obtain for our medicine candidates may also be subject to limitations on the approved indicated uses for which the medicine may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials and surveillance to monitor the safety and efficacy of the medicine candidate. In addition, with respect to our current FDA-approved medicines (and with respect to our medicine candidates, if approved), the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the medicine are subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs, GCPs, International Council for Harmonisation, or ICH, guidelines and GLPs, which are regulations and guidelines enforced by the FDA for all of our medicines in clinical development, for any clinical trials that we conduct post-approval. With respect to RAVICTI, the FDA imposed several post-marketing requirements and a post-marketing commitment, which included obligations to conduct studies in UCD patients during the first two months of life, including a study of the pharmacokinetics in that age group and a randomized study to determine the safety and efficacy in UCD patients who are treatment naïve to phenylbutyrate treatment. In May 2017, the FDA approved our supplemental new drug application, or sNDA, for RAVICTI to expand the age range for chronic management of UCDs from two years of age and older to two months of age and older. In December 2018, we received FDA approval to expand the age range for the use of RAVICTI in the chronic management of UCDs in patients from birth to two months and as a result, we now have approval for patients of all ages. As part of these approvals to expand the age range for use of RAVICTI in the chronic management of UCDs in patients from birth, we have fulfilled, and subsequently received FDA confirmation of release from the requirement to conduct studies in UCD patients during the first two months of life. We are currently conducting a study to determine the effects of RAVICTI in patients with UCDs that are treatment naïve to phenylbutyrate.

In addition, the FDA closely regulates the marketing and promotion of drugs and biologics. The FDA does not regulate the behaviour of physicians in their choice of treatments. The FDA does, however, restrict manufacturers’ promotional communications. A significant number of pharmaceutical companies have been the target of inquiries and investigations by various U.S. federal and state regulatory, investigative, prosecutorial and administrative entities in connection with the promotion of medicines for off-label uses and other sales practices. These investigations have alleged violations of various U.S. federal and state laws and regulations, including claims asserting antitrust violations, violations of the Food, Drug and Cosmetic Act, false claims laws, the Prescription Drug Marketing Act, anti-kickback laws, and other alleged violations in connection with the promotion of medicines for unapproved uses, pricing and Medicare and/or Medicaid reimbursement. While Congress has recently considered legislation that would modify or eliminate restrictions for off-label promotion, we do not have sufficient information to anticipate if the current regulatory environment will change.

Later discovery of previously unknown problems with a medicine, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:

If we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would have a material adverse effect on our business, results of operations, financial condition and prospects.

We are subject to federal, state and foreign healthcare laws and regulations and implementation or changes to such healthcare laws and regulations could adversely affect our business and results of operations.*

The United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to regulate and to change the healthcare system in ways that could affect our ability to sell our medicines profitably. In the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs (including a number of proposals pertaining to prescription drugs, specifically), improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.

The healthcare system is highly regulated in the United States and, as a biopharma company that participates in government-regulated healthcare programs, we are subject to complex laws and regulations. If we are found to be in violation of any of these laws or any other federal or state regulations, we may be subject to significant civil and/or criminal penalties, damages, fines, exclusion, additional reporting requirements and/or oversight from federal health care programs and the restructuring of our operations. Any of these could have a material adverse effect on our business and financial results. ~~Since many of these laws have not been fully interpreted by the courts, there is an increased risk that we may be found in violation of one or more of their provisions.~~ Any action against us for violation of these laws, even if we ultimately are successful in our defense, will cause us to incur significant legal expenses and divert our management’s attention away from the operation of our business.

~~Some of the provisions of the ACA have yet to be implemented, and there have been~~There remain judicial and Congressional challenges to certain aspects of the ACA, as well as ~~recent~~ efforts by the Trump administration to repeal or replace certain aspects of the ACA. Since January 2017, President Trump has signed ~~two~~several Executive Orders and other directives designed to delay the implementation of certain provisions of the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing penalties, starting January 1, 2019, for not complying with the ACA’s individual mandate to carry health insurance, and ~~delaying~~eliminating the implementation of certain ACA-mandated fees, and increasing the ~~point-of-sale~~manufacturer coverage gap discount that is owed by pharmaceutical manufacturers of branded drugs and biosimilars who participate in Medicare Part D. In particular, the Tax Act included a provision which repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the “individual mandate”. In addition, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated “Cadillac” tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminates the health insurer tax. On December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the “individual mandate” was repealed by Congress as part of the Tax ~~Cuts and Jobs Act~~Act. Additionally, on December 18, 2019, the U.S. Court of ~~2017. While~~Appeals for the ~~Texas U.S.~~5th Circuit upheld the District Court ~~Judge, as well as the Trump administration and CMS, have stated~~ruling that the ~~ruling will have no immediate effect pending appeal~~individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ~~decision, it~~ACA are invalid as well. On March 2, 2020, the United States Supreme Court granted the petitions for writs of certiorari to review this case, and has allotted one hour for oral arguments, which are expected to occur in the fall or early 2021 due to effects of COVID-19. It is unclear how ~~this decision, subsequent appeals,~~such litigation and other efforts to repeal and replace the ACA will impact the ACA and our business.

Likewise, in the countries in the EU, legislators, policymakers and healthcare insurance funds continue to propose and implement cost-containing measures to keep healthcare costs down, due in part to the attention being paid to healthcare cost containment in the EU. Certain of these changes could impose limitations on the prices we will be able to charge for our products and any approved product candidates or the amounts of reimbursement available for these products from governmental agencies or third-party payers, may increase the tax obligations on pharmaceutical companies such as ours, or may facilitate the introduction of generic competition with respect to our products.

In addition, drug pricing by pharmaceutical companies in the United States has come under increased scrutiny. Specifically, there have been several recent state and U.S. ~~Congressional~~congressional inquiries, proposed federal and state legislation and state laws enacted ~~designed~~ to, among other things, bring more transparency to drug pricing by requiring drug companies subject to these laws to notify insurers and government regulators of price increases and provide an explanation of the reasons for the ~~increase,~~increases, reduce the out-of-pocket cost of prescription drugs, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs under Medicare, and reform government program reimbursement methodologies. This scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. For example, legislation ~~was recently~~ signed into law in 2017 in California ~~that~~ requires drug manufactures to provide advance notice and explanation to state regulators, health plans and insurers and PBMs for price increases of more than 16% over two ~~years. Moreover, in May 2018,~~years, or 10% within one year. At the federal level, the President’s budget proposal for the fiscal year 2021 includes a $135 billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. On March 10, 2020, the Trump administration sent “principles” for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary out-of-pocket pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly out-of-pocket expenses, and place limits on pharmaceutical price increases. These principles build upon the Trump administration’s previously released ~~its~~ “Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs”, or Blueprint. The Blueprint ~~contains~~contained several potential regulatory actions and legislative recommendations aimed at lowering prescription drug prices including measures to promote innovation and competition for biologics, changes to Medicare Part D to give plan sponsors more leverage when negotiating prices with manufacturers and updating the Medicare drug-pricing dashboard to make price increases and generic competition more transparent. ~~The recommendations~~HHS has solicited feedback on some of these measures and has implemented others under its existing authority. For example, in June 2020, the U.S. House of Representatives passed a bill, H.R. 1425, “Patient Protection and Affordable Care Advancement Act”, which proposes to utilize international price referencing metrics for Medicare reimbursement. Additionally, on July 24, 2020, President Trump announced four executive orders related to prescription drug pricing that attempt to implement several of the Trump administration proposals, including a policy that would tie Medicare Part B drug prices to international drug prices; one that directs HHS to finalize the Canadian drug importation proposed rule previously issued by HHS and makes other changes allowing for personal importation of drugs from Canada; one that directs HHS to finalize the rulemaking process on modifying the anti-kickback law safe harbors for plans, pharmacies, and PBMs; and one that reduces costs of insulin and injectable epinephrine to patients of federally qualified health centers. Although some of these and other measures may require additional regulation or legislation to become effective, Congress and the Trump Administration have both stated that they will continue to seek new legislative and/or administrative measures to control drug costs. In addition, Presidential candidate Biden’s campaign has recently indicated that if candidate Biden is elected, he would direct Medicare to negotiate drug prices using international prices as a reference.

In May 2019, CMS continued to implement proposals from the administration’s Blueprint by issuing a final rule to allow Medicare Advantage plans the option to use step therapy for Part B drugs beginning January 1, 2020. This final rule codified CMS’s policy change that was effective January 1, 2019. In addition, certain governmental initiatives, if enacted by Congress and HHS, could lead to changes to Medicare Parts B and D. Further, the Bipartisan Budget Act of 2018, among other things, ~~amends~~amended the ACA, effective January 1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the “donut hole”. The majority of our medicines are purchased by private payers, and much of the focus of pending legislation is on government program reimbursement. ~~Most recently,~~The federal government has also advanced proposals to establish pathways for importation of certain drugs and several states have taken action to implement importation plans or introduce legislation to do so. In December 2019, the ~~Office~~Further Consolidated Appropriations Act was signed into law which included the Creating and Restoring Equal Access to Equivalent Samples Act, or CREATES Act. The CREATES Act allows generic drug manufacturers to bring suit against a brand name manufacturer to compel the provision of ~~Inspector General~~brand samples if the generic manufacturer has made a request for samples and the brand manufacturer fails to deliver sufficient quantities of ~~HHS published a Proposed Rule~~the sample on commercially reasonable, market-based terms within 31 days of receipt of the request. The United States Senate has also renewed interest in ~~January 2019~~drug pricing legislation that ~~would, among other items, eliminate the current safe harbor protection under the Anti-Kickback Statute for pharmaceutical manufacturer rebates~~redesigns Medicare Part D and makes changes to Medicare Part ~~D plans, Medicaid MCOs~~B and Medicaid. Congress and the ~~PBMs with which such entities contract. We cannot know what form any such~~Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. Additionally, it is possible that additional governmental action ~~may take,~~is taken to address the likelihood it would be executed, enacted, effectuated or implemented or the market’s perception of how such legislation or regulation would affect us. Any reduction in reimbursement from government programs may result in a similar reduction in payments from private payers. The Trump administration’s budget proposal for fiscal year 2020 contains further drug price control measures that could be enacted during the 2020 budget process, through regulation or other future legislation.COVID-19 pandemic. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our current medicines and/or those for which we may receive regulatory approval in the future.

We are subject, directly or indirectly, to federal and state healthcare fraud and abuse, transparency laws and false claims laws. Prosecutions under such laws have increased in recent years and we may become subject to such litigation. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.*

In the United States, we are subject directly, or indirectly or through our customers, to various state and federal fraud and abuse and transparency laws, including, without limitation, the federal Anti-Kickback Statute, the federal False Claims Act, civil monetary penalty statutes prohibiting beneficiary inducements, and similar state and local laws, federal and state privacy and security laws, sunshine laws, government price reporting laws, and other fraud laws. Some states, such as Massachusetts, make certain reported information public. In addition, there are state and local laws that require pharmaceutical representatives to be licensed and comply with codes of conduct, transparency reporting, and other obligations. Collectively, these laws may affect, among other things, our current and proposed sales, marketing and educational programs, as well as other possible relationships with customers, pharmacies, physicians, payers, and patients. We are subject to similar laws in the EU/~~EEA,~~European Economic Area, including the EU General Data Protection Regulation (2016/679), or GDPR, under which fines of up to €20.0 million or up to 4% of the annual global turnover of the infringer, whichever is greater, could be imposed for significant non-compliance.

Compliance with these laws, including the development of a comprehensive compliance program, is difficult, costly and time consuming. Because of the breadth of these laws and the narrowness of available statutory and regulatory exemptions, it is possible that some of our business activities could be subject to challenge under one or more of such laws. Moreover, state governmental agencies may propose or enact laws and regulations that extend or contradict federal requirements. These risks may be increased where there are evolving interpretations of applicable regulatory requirements, such as those applicable to manufacturer co-pay ~~initiatives.~~programs. Pharmaceutical manufacturer co-pay ~~initiatives and free medicine~~ programs, including pharmaceutical manufacturer donations to patient assistance programs offered by charitable foundations, are the subject of ongoing litigation, enforcement actions and settlements (involving other manufacturers and to which we are not a party) and evolving interpretations of applicable regulatory requirements and certain state laws, and any change in the regulatory or enforcement environment regarding such programs could impact our ability to offer such programs. Other recent legislation and regulatory policies contain provisions that disincentivizes the use of co-pay coupons by requiring their value to be included in average sales price or best price calculations, potentially lowering reimbursement for drugs with a high use of copay coupons in Medicare Part B and Medicaid. If we are unsuccessful with our ~~HorizonCares programs, any other~~ co-pay ~~initiatives or free medicine~~ programs, we would be at a competitive disadvantage in terms of pricing versus preferred branded and generic competitors, or be subject to significant penalties. We are engaged in various business arrangements with current and potential customers, and we can give no assurance that such arrangements would not be subject to scrutiny under such laws, despite our efforts to properly structure such arrangements. Even if we structure our programs with the intent of compliance with such laws, there can be no certainty that we would not need to defend our business activities against enforcement or litigation. Further, we cannot give any assurances that prior business activities or arrangements of other companies that we acquire will not be scrutinized or subject to enforcement or litigation. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have an impact on our business, including the imposition of civil, criminal and administrative sanctions, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, imprisonment, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.

There has also been a trend of increased federal and state regulation of payments made to physicians and other healthcare providers. The ACA, among other things, imposed reporting requirements on drug manufacturers for payments made by them to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. In November 2019, HHS published a final 2020 Physician Fee Schedule rule which for calendar year 2021, expands the definition of “covered recipients” for which reporting of payments and transfers made during the previous year is required to be submitted beginning in 2022, to include physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists and certified nurse midwives. Failure to submit required information may result in significant civil monetary penalties.

On March 5, 2019, we received a civil investigative demand, or CID, from the DOJ pursuant to the Federal False Claims Act regarding assertions that certain of our payments to PBMs were potentially in violation of the Anti-Kickback Statute. The CID requests certain documents and information related to our payments to PBMs, pricing and our patient assistance program regarding DUEXIS, VIMOVO and PENNSAID 2%. We are cooperating with the investigation. While we believe that our payments and programs are compliant with the Anti-Kickback Statute, no assurance can be given as to the timing or outcome of the DOJ’s investigation, or that it will not result in a material adverse effect on our business.

We are unable to predict whether we could be subject to other actions under any of these or other healthcare laws, or the impact of such actions. If we are found to be in violation of, or to encourage or assist the violation by third parties of any of the laws described above or other applicable state and federal fraud and abuse laws, we may be subject to penalties, including significant administrative, civil and criminal penalties, damages, fines, withdrawal of regulatory approval, imprisonment, exclusion from government healthcare reimbursement programs, contractual damages, reputational harm, diminished profits and future earnings, injunctions and other associated remedies, or private “qui tam” actions brought by individual whistleblowers in the name of the government, and the curtailment or restructuring of our operations, all of which could have a material adverse effect on our business and results of operations. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business.

Our medicines or any other medicine candidate that we develop may cause undesirable side effects or have other properties that could delay or prevent regulatory approval or commercialization, result in medicine re-labeling or withdrawal from the market or have a significant impact on customer demand.*

Undesirable side effects caused by any medicine candidate that we develop could result in the denial of regulatory approval by the FDA or other regulatory authorities for any or all targeted indications, or cause us to evaluate the future of our development programs. ~~With respect to RAVICTI,~~In our Phase 3 clinical trial evaluating TEPEZZA for the treatment of active TED, the most ~~common side effects are~~commonly reported treatment-emergent adverse events were muscle spasms, nausea, alopecia, diarrhea, ~~nausea, decreased appetite, gas, vomiting, high blood levels of ammonia,~~fatigue, hyperglycemia, hearing impairment, dysgeusia, headache ~~tiredness~~ and dizziness. With respect to PROCYSBI, the most common side effects include vomiting, nausea, abdominal pain, breath odor, diarrhea, skin odor, fatigue, rash and headache. The most common side effects observed in pivotal trials for ACTIMMUNE were “flu-like” or constitutional symptoms such as fever, headache, chills, myalgia and fatigue. With respect to BUPHENYL, the most common side effects are change in the frequency of breathing, lack of or irregular menstruation, lower back, side, or stomach pain, mood or mental changes, muscle pain or twitching, nausea or vomiting, nervousness or restlessness, swelling of the feet or lower legs, unpleasant taste and unusual tiredness or weakness. With respect to QUINSAIR, the most common side effects include itching, wheezing, hives, rash, swelling, pale skin color, fast heartbeat and faintness.dry skin. With respect to KRYSTEXXA, the most commonly reported serious adverse reactions in the pivotal trial were gout flares, infusion reactions, nausea, contusion or ecchymosis, nasopharyngitis, constipation, chest pain, anaphylaxis, exacerbation of pre-existing congestive heart failure and vomiting. With respect to RAVICTI, the most common side effects are diarrhea, nausea, decreased appetite, gas, vomiting, high blood levels of ammonia, headache, tiredness and dizziness. The most common adverse events reported in a Phase 2 clinical trial of PENNSAID 2% were application site reactions, such as dryness, exfoliation, erythema, pruritus, pain, induration, rash and scabbing. With respect to PROCYSBI, the most common side effects include vomiting, nausea, abdominal pain, breath odor, diarrhea, skin odor, fatigue, rash and headache. In our two Phase 3 clinical trials with DUEXIS, the most commonly reported treatment-emergent adverse events were nausea, dyspepsia, diarrhea, constipation and upper respiratory tract infection. The most common side effects observed in pivotal trials for ACTIMMUNE were “flu-like” or constitutional symptoms such as fever, headache, chills, myalgia and fatigue. The most commonly reported treatment-emergent adverse events in the Phase 3 clinical trials with RAYOS included flare in rheumatoid arthritis related symptoms, abdominal pain, nasopharyngitis, headache, flushing, upper respiratory tract infection, back pain and weight gain. The most common adverse events reported in a Phase 2 clinical trial of PENNSAID 2% were application site reactions, such as dryness, exfoliation, erythema, pruritus, pain, induration, rash and scabbing. In our two Phase 3 clinical trials with DUEXIS, the most commonly reported treatment-emergent adverse events were nausea, dyspepsia, diarrhea, constipation and upper respiratory tract infection. In Phase 3 endoscopic registration clinical trials with VIMOVO, the most commonly reported treatment-emergent adverse events were erosive gastritis, dyspepsia, gastritis, diarrhea, gastric ulcer, upper abdominal pain, nausea and upper respiratory tract infection. In our Phase 3 clinical trial evaluating teprotumumab for the treatment of active TED, the most commonly reported treatment-emergent adverse events were nausea, muscle spasms, diarrhea, alopecia, hyperglycemia, dry skin, dysgeusia, headache, paresthesia, hearing impairment and weight loss.

The FDA or other regulatory authorities may also require, or we may undertake, additional clinical trials to support the safety profile of our medicines or medicine candidates.

In addition, if we or others identify undesirable side effects caused by our medicines or any other medicine candidate that we may develop that receives marketing approval, or if there is a perception that the medicine is associated with undesirable side effects:

If any of these events occurred with respect to our medicines, our ability to generate significant revenues from the sale of these medicines would be significantly harmed.

We rely on third parties to conduct our pre-clinical and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines or if they experience regulatory compliance issues, we may not be able to obtain regulatory approval for or commercialize our medicine candidates and our business could be substantially harmed.*

We have agreements with third-party contract research organizations, or CROs, to conduct our clinical programs, including those required for post-marketing commitments, and we expect to continue to rely on CROs for the completion of on-going and planned clinical trials. We may also have the need to enter into other such agreements in the future if we were to develop other medicine candidates or conduct clinical trials in additional indications for our existing medicines. ~~We have an agreement in place with Syneos Health, Inc. in connection with our Phase 3 extension trial to evaluate teprotumumab for the treatment of TED.~~ We also rely heavily on these parties for the execution of our clinical studies and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol. We, our CROs and our academic research organizations are required to comply with current GCP or ICH regulations. The FDA enforces these GCP or ICH regulations through periodic inspections of trial sponsors, principal investigators and trial sites. If we or our CROs or collaborators fail to comply with applicable GCP or ICH regulations, the data generated in our clinical trials may be deemed unreliable and our submission of marketing applications may be delayed or the FDA may require us to perform additional clinical trials before approving our marketing applications. We cannot assure that, upon inspection, the FDA will determine that any of our clinical trials comply or complied with GCP or ICH regulations. In addition, our clinical trials must be conducted with medicine produced under cGMP regulations, and may require a large number of test subjects. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of our CROs or collaborators violates federal or state fraud and abuse or false claims laws and regulations or ~~healthcare~~ privacy and security laws. We must also obtain certain third-party institutional review board, or IRB, and ethics committee approvals in order to conduct our clinical trials. Delays by IRBs and ethics committees in providing such approvals may delay our clinical trials.

If any of our relationships with these third-party CROs or collaborators terminate, we may not be able to enter into similar arrangements on commercially reasonable terms, or at all. If CROs or collaborators do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our medicines and medicine candidates. As a result, our results of operations and the commercial prospects for our medicines and medicine candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed.

Switching or adding additional CROs or collaborators can involve substantial cost and require extensive management time and focus. In addition, there is a natural transition period when a new CRO or collaborator commences work. As a result, delays may occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our CROs and collaborators, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition or prospects. In particular, the ability of our CROs to conduct certain of their operations, including monitoring of clinical sites, has been limited by the COVID-19 pandemic, and to the extent that our CROs are unable to fulfil their contractual obligations as a result of the COVID-19 pandemic or government orders in response to the pandemic, we may have limited or no recourse under the terms of our contractual agreements with our CROs.

Clinical development of drugs and biologics involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.*

Clinical testing is expensive and can take many years to complete, and its outcome is uncertain. Failure can occur at any time during the clinical trial process. The results of pre-clinical studies and early clinical trials of potential medicine candidates may not be predictive of the results of later-stage clinical trials. Medicine candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through pre-clinical studies and initial clinical testing. For example, in December 2016, we announced that the Phase 3 trial, Safety, Tolerability and Efficacy of ACTIMMUNE Dose Escalation in Friedreich’s ataxia, evaluating ACTIMMUNE for the treatment of Friedreich’s ataxia did not meet its primary endpoint. Additionally, we ~~previously made a decision to discontinue~~discontinued our ACTIMMUNE investigator-initiated trials in oncology to focus on our strategic pipeline where we see more promise and long-term intellectual property.

We may experience delays in clinical trials or investigator-initiated studies. We do not know whether any additional clinical trials will be initiated in the future, begin on time, need to be redesigned, enroll patients on time or be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including delays related to:

Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical trials and clinicians’ and patients’ perceptions as to the potential advantages of the medicine candidate being studied in relation to other available therapies, including any new drugs or biologics that may be approved for the indications we are investigating. ~~Furthermore, we rely and expect to rely on CROs and clinical trial sites to ensure the proper and timely conduct~~In addition, if patients drop out of our ~~future clinical~~ trials, ~~and while we have and intend~~miss scheduled doses or follow-up visits or otherwise fail to ~~have agreements governing their committed activities, we will have limited influence over their actual performance.~~follow trial protocols, or if our trials are otherwise disputed due to COVID-19 or actions taken to slow its spread, the integrity of data from our trials may be compromised or not accepted by the FDA or other regulatory authorities, which would represent a significant setback for the applicable program.

We could encounter delays if prescribing physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our medicine candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by us, our collaborators, the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a medicine candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we experience delays in the completion of, or if we terminate, any clinical trial of our medicine candidates, the commercial prospects of our medicine candidates will be harmed, and our ability to generate medicine revenues from any of these medicine candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our medicine development and approval process and jeopardize our ability to commence medicine sales and generate revenues.

Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval of one or more of our medicine candidates.

Any of these occurrences may harm our business, financial condition, results of operations and prospects significantly. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our medicine candidates.

Business interruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.*

Our operations could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics or health pandemics, such as the current COVID-19 pandemic, and other natural or man-made disasters or business interruptions. While we carry insurance for certain of these events and have implemented disaster management plans and contingencies, the occurrence of any of these business interruptions could seriously harm our business and financial condition and increase our costs and expenses. We conduct significant management operations at both our global headquarters located in Dublin, Ireland and our U.S. office located in Lake Forest, Illinois. If our Dublin or Lake Forest offices were affected by a natural or man-made disaster or other business interruption, our ability to manage our domestic and foreign operations could be impaired, which could materially and adversely affect our results of operations and financial condition. We currently rely, and intend to rely in the future, on third-party manufacturers and suppliers to produce our medicines and third-party logistics partners to ship our medicines. Our ability to obtain commercial supplies of our medicines could be disrupted and our results of operations and financial condition could be materially and adversely affected if the operations of these third-party suppliers or logistics partners were affected by a man-made or natural disaster or other business interruption. The ultimate impact of such events on us, our significant suppliers and our general infrastructure is unknown.

We are dependent on information technology systems, infrastructure and data, which exposes us to data security risks.*

We are dependent upon our own or third-party information technology systems, infrastructure and data, including mobile technologies, to operate our business. The multitude and complexity of our computer systems may make them vulnerable to service interruption or destruction, disruption of data integrity, malicious intrusion, or random attacks. Likewise, data privacy or security incidents or breaches by employees or others may pose a risk that sensitive data, including our intellectual property, trade secrets or personal information of our employees, patients, customers or other business partners may be exposed to unauthorized persons or to the public. ~~Cyber-attacks~~Cyberattacks are increasing in their frequency, sophistication and intensity. ~~Cyber-attacks~~Cyberattacks could include the deployment of harmful malware, denial-of-service, social engineering and other means to affect service reliability and threaten data confidentiality, integrity and availability. Changes in how our employees work and access our systems during the current COVID-19 pandemic could lead to additional opportunities for bad actors to launch cyberattacks or for employees to cause inadvertent security risks or incidents. Our business partners face similar risks and any security breach of their systems could adversely affect our security posture. A security breach or privacy violation that leads to disclosure or modification of or prevents access to patient information, including personally identifiable information or protected health information, could harm our reputation, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, require us to verify the correctness of database contents and otherwise subject us to litigation or other liability under laws and regulations that protect personal data, any of which could disrupt our business and/or result in increased costs or loss of revenue. The effects of a security breach or privacy violation could be further amplified during the current COVID-19 pandemic. Moreover, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches, which could lead to the loss of confidential information, trade secrets or other intellectual property.

Despite significant efforts to create security barriers to the above described threats, it is impossible for us to entirely mitigate these risks. We may be unable to anticipate or prevent techniques used to obtain unauthorized access or to compromise our systems because they change frequently and are generally not detected until after an incident has occurred. In addition, an accidental or intentional cybersecurity event could result in significant increases in costs, including costs for remediating the effects of such an event, fines imposed by regulators, lost revenues due to decrease in customer trust and network downtime, increases in insurance premiums due to cybersecurity incidents and damages to our reputation because of any such incident. While we have invested, and continue to invest, in the protection of our data and information technology infrastructure, there can be no assurance that our efforts will prevent service interruptions, or identify vulnerabilities or breaches in our systems, that could adversely affect our business and operations and/or result in the loss of critical or sensitive information, which could result in financial, legal, business or reputational harm to us. In addition, our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, ~~cyber-attacks~~cyberattacks and other related breaches.

We are subject to extensive laws and regulations related to data privacy, and our failure to comply with these laws and regulations could harm our business.*

We are subject to laws and regulations governing data privacy and the protection of personal information. These laws and regulations govern our processing of personal data, including the collection, access, use, analysis, modification, storage, transfer, security breach notification, destruction and disposal of personal data. There are foreign and state law versions of these laws and regulations to which we are currently and/or may in the future, be subject. For example, the collection and use of personal health data in the EU is governed by the GDPR. The GDPR, which is wide-ranging in scope, imposes several requirements relating to the consent of the individuals to whom the personal data relates, the information ~~provided~~disclosed to the individuals about our privacy practices, the security and confidentiality of the personal data, data breach notification and the use of third-party processors in connection with the processing of personal data. The GDPR also imposes strict rules on the transfer of personal data out of the EU to the United States, provides an enforcement authority and imposes potentially large monetary penalties for noncompliance. The GDPR requirements apply not only to third-party transactions, but also to transfers of information within our company, including employee information. The GDPR and similar data privacy laws of other jurisdictions place significant responsibilities on us and create potential liability in relation to personal data that we or our third-party service providers process, including in clinical trials conducted in the United States and EU. In addition, we expect that there will continue to be new proposed laws, regulations and industry standards relating to privacy and data protection in the United States, the EU and other jurisdictions, and we cannot determine the impact such future laws, regulations and standards may have on our business.

Further, Brexit has created uncertainty with regard to data protection regulation in the United Kingdom. In particular, while the Data Protection Act of 2018, that “implements” and complements the GDPR achieved Royal Assent on May 23, 2018 and is now effective in the United Kingdom, it is still unclear whether transfer of data from the European Economic Area to the United Kingdom will remain lawful under GDPR. During the period of “transition” (i.e., until December 31, 2020), EU law will continue to apply in the United Kingdom, including the GDPR, after which the GDPR will be converted into United Kingdom law. Beginning in 2021, the United Kingdom will be a “third country” under the GDPR. We may, however, incur liabilities, expenses, costs, and other operational losses under GDPR and applicable EU Member States and the United Kingdom privacy laws in connection with any measures we take to comply with them.

79Recent legal developments in Europe have created further complexity and uncertainty regarding transfers of personal data from the EU and United Kingdom to the United States. On July 16, 2020, the Court of Justice of the European Union, or CJEU, invalidated the EU-US Privacy Shield Framework, or Privacy Shield, under which personal data could be transferred from the EU and United Kingdom to United States entities who had self-certified under the Privacy Shield scheme. Nine of our United States entities have self-certified under the scheme to facilitate the transfer of personal data from the EU and United Kingdom to the United States. The United Kingdom’s supervisory authority may similarly invalidate use of the Privacy Shield as a vehicle for lawful data transfers from the United Kingdom to the United States. As such, our transfers of personal data to the United States may not comply with European data protection law and may increase our exposure to the GDPR’s heightened sanctions for violations of its cross-border data transfer restrictions, including fines of up to 4% of annual global revenue and injunctions against transfers. While the CJEU upheld the adequacy of the standard contractual clauses (a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism, and potential alternative to the Privacy Shield), it made clear that reliance on them alone may not necessarily be sufficient in all circumstances. Use of the standard contractual clauses must now be assessed on a case-by-case basis taking into account the legal regime applicable in the destination country, in particular applicable surveillance laws and rights of individuals and additional measures and/or contractual provisions may need to be put in place, however, the nature of these additional measures is currently uncertain. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the standard contractual clauses cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results.

Additionally, the California ~~recently enacted legislation that~~Consumer Privacy Act, or CCPA, went into effect on January 1, 2020. The CCPA has been dubbed the first “GDPR-like” law in the United ~~States.~~ ~~Known as the California Consumer Privacy Act, or CCPA,~~States since it creates new individual privacy rights for consumers (as that word is broadly defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. ~~When it goes into effect on January 1, 2020, the~~The CCPA ~~will require~~requires covered companies to provide new disclosures to California consumers (as that word is broadly defined in the CCPA), provide such consumers new ways to opt-out of certain sales of personal information, and allow for a new ~~cause~~private right of action for data breaches. ~~Legislators~~Despite amendments and multiple revisions of draft regulations (which have ~~stated that amendments will be proposed to the CCPA before it goes into effect, but~~now been finalized), it remains unclear ~~what, if any, modifications~~how the CCPA will be ~~made to this legislation or how it will be interpreted.~~ Asinterpreted, but as currently written, ~~the CCPA~~it will likely impact our business activities and exemplifies the vulnerability of our business to not only cyber threats but also the evolving regulatory environment related to personal data and protected health information. As we expand our operations and trials (both preclinical or clinical), the CCPA may increase our compliance costs and potential liability. Some observers have noted that the CCPA could mark the beginning of a trend toward more stringent privacy legislation in the United States. Other states are beginning to pass similar laws.

Compliance with these and any other applicable privacy and data security laws and regulations is a rigorous and time-intensive process, and we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules. If we fail to comply with any such laws or regulations, we may face significant fines and penalties that could adversely affect our business, financial condition and results of operations. Furthermore, the laws are not consistent, and compliance in the event of a widespread data breach is costly.

If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our medicines.

We face an inherent risk of product liability claims as a result of the commercial sales of our medicines and the clinical testing of our medicine candidates. For example, we may be sued if any of our medicines or medicine candidates allegedly causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the medicine, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our medicines and medicine candidates. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:

Our inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of medicines we develop. We currently carry product liability insurance covering our clinical studies and commercial medicine sales in the amount of $125.0 million in the aggregate. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. If we determine that it is prudent to increase our product liability coverage due to the on-going commercialization of our current medicines in the United States, and/or the potential commercial launches of any of our medicines in additional markets or for additional indications, we may be unable to obtain such increased coverage on acceptable terms or at all. Our insurance policies also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.

Our business involves the use of hazardous materials, and we and our third-party manufacturers must comply with environmental laws and regulations, which can be expensive and restrict how we do business.

Our third-party manufacturers’ activities involve the controlled storage, use and disposal of hazardous materials owned by us, including the components of our medicine candidates and other hazardous compounds. We and our manufacturers are subject to federal, state and local as well as foreign laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. Although we believe that the safety procedures utilized by our third-party manufacturers for handling and disposing of these materials comply with the standards prescribed by these laws and regulations, we cannot eliminate the risk of accidental contamination or injury from these materials. In the event of an accident, state, federal or foreign authorities may curtail the use of these materials and interrupt our business operations. We ~~do not~~ currently only maintain hazardous materials insurance ~~coverage.~~coverage related to our South San Francisco facility. If we are subject to any liability as a result of our third-party manufacturers’ activities involving hazardous materials, our business and financial condition may be adversely affected. In the future we may seek to establish longer-term third-party manufacturing arrangements, pursuant to which we would seek to obtain contractual indemnification protection from such third-party manufacturers potentially limiting this liability exposure.

Our employees, independent contractors, principal investigators, consultants, vendors, distributors and CROs may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.

We are exposed to the risk that our employees, independent contractors, principal investigators, consultants, vendors, distributors and CROs may engage in fraudulent or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or unauthorized activities that violate FDA regulations, including those laws that require the reporting of true, complete and accurate information to the FDA, manufacturing standards, federal and state healthcare fraud and abuse laws and regulations, and laws that require the true, complete and accurate reporting of financial information or data. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by our employees and other third parties may also include the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a Code of Business Conduct and Ethics, but it is not always possible to identify and deter misconduct by our employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, the exclusion from participation in federal and state healthcare programs and imprisonment.

We have a limited operating history and even less history operating as a combined organization following the acquisitions of Vidara, Hyperion, Crealta Holdings LLC, Raptor and River Vision Development Corp., or River Vision. We have financed our operations primarily through equity and debt financings and have incurred significant operating losses. We recorded an operating income of ~~$23.3~~$21.4 million for the six months ended June 30, ~~2019,~~2020 and operating income of $126.6 million and $37.9 million for the years ended December 31, 2019 and 2018, respectively. We recorded a net loss of $93.6 million for the sixmonths ended June 30, 2020, net income of $573.0 million for the year ended December 31, ~~2018, an operating loss of $339.4 million for the~~ ~~year ended December 31, 2017~~2019, and an ~~operating loss of $119.0 million for~~ ~~the~~ ~~year ended December 31, 2016. We recorded a net loss of $38.0 million for the six months ended June 30, 2019,~~ a net loss of $38.4 million for the year ended December 31, ~~2018, a net loss of $350.1 million for the year ended December 31, 2017 and a net loss of $147.1 million for the~~ ~~year ended~~ ~~December 31, 2016.~~2018. As of June 30, ~~2019,~~2020, we had an accumulated deficit of ~~$1,216.7~~$699.3 million. Our prior losses have resulted principally from costs incurred in our development activities for our medicines and medicine candidates, commercialization activities related to our medicines, costs associated with our acquisition transactions and costs associated with derivative liability accounting. Our prior losses, combined with possible future losses, have had and will continue to have an adverse effect on our shareholders’ equity and working capital. While we anticipate that we will generate operating profits in the future, whether we can accomplish this will depend on the revenues we generate from the sale of our medicines being sufficient to cover our operating expenses.

We have limited sources of revenues and significant expenses. We cannot be certain that we will achieve or sustain profitability, which would depress the market price of our ordinary shares and could cause our investors to lose all or a part of their investment.

Our ability to achieve and sustain profitability depends upon our ability to generate sales of our medicines. ~~We have a limited history~~The commercialization of ~~commercializing~~ our medicines ~~as a company, and commercialization~~ has been primarily in the United States. We may never be able to successfully commercialize our medicines or develop or commercialize other medicines in the United States, which we believe represents our most significant commercial opportunity. Our ability to generate future revenues depends heavily on our success in:

Even if we do generate additional medicine sales, we may not be able to achieve or sustain profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the market price of our ordinary shares and could impair our ability to raise capital, expand our business, diversify our medicine offerings or continue our operations.

Our operations have consumed substantial amounts of cash since inception. We expect to continue to spend substantial amounts to:

While we believe that our existing cash and cash equivalents will be sufficient to fund our operations based on our current expectations of continued revenue growth, we may need to raise additional funds if we choose to expand our commercialization or development efforts more rapidly than presently anticipated, if we develop or acquire additional medicines or acquire companies, or if our revenue does not meet expectations.

We cannot be certain that additional funding will be available on acceptable terms, or at all. As a result of the COVID-19 pandemic and actions taken to slow its spread, the global credit and financial markets have experienced extreme volatility and disruptions, including diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. If the equity and credit markets deteriorate, it may make any additional debt or equity financing more difficult, more costly and more dilutive. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our medicines or medicine candidates or one or more of our other research and development initiatives, or delay, cut back or abandon our plans to grow the business through acquisitions. We also could be required to:

In addition, if we are unable to secure financing to support future acquisitions, our ability to execute on a key aspect of our overall growth strategy would be impaired.

Any of the above events could significantly harm our business, financial condition and prospects.

We have incurred a substantial amount of debt, which could adversely affect our business, including by restricting our ability to engage in additional transactions or incur additional indebtedness, and prevent us from meeting our debt obligations.*

As of June 30, ~~2019,~~2020, we had ~~$1,366.8~~$1,176.8 million book value, or ~~$1,443.0~~$1,211.0 million aggregate principal amount of indebtedness, including ~~$518.0~~$418.0 million in secured indebtedness. In March 2019, we received $200.0 million of commitments under a new revolving credit facility under our credit agreement. In May 2019, we borrowed approximately $518.0 million aggregate principal amount of loans pursuant to an amendment to our credit agreement to refinance the then outstanding senior secured term loans outstanding under our credit agreement. In connection with the acquisition of Hyperion, we issued $475.0 million aggregate principal amount of 6.625% Senior Notes due 2023, or the 2023 Senior Notes, in April 2015. We subsequently redeemed $250.0 million of the 2023 Senior Notes in May 2019. In connection with the acquisition of Raptor, we issued $300.0 million aggregate principal amount of 8.750% Senior Notes due 2024, or the 2024 Senior Notes, in October 2016. In July 2019, we issued $600.0 million aggregate principal amount of 5.500% Senior Notes due 2027, or the 2027 Senior Notes, and used the net proceeds from the offering of the 2027 Senior Notes, together with approximately $65.0 million in cash on hand, to redeem or prepay $625.0 million of our outstanding debt, consisting of (i) the outstanding $225.0 million principal amount of our 2023 Senior Notes, (ii) the outstanding $300.0 million principal amount of our ~~8.750% Senior Notes due 2024, or the 2024 Senior Notes,~~ and (iii) $100.0 million of the outstanding principal amount of senior secured term loans under our credit agreement, as well as to pay the related premiums and fees and expenses, excluding accrued interest, associated with such redemption and prepayment. In March 2015, we issued $400.0 million aggregate principal amount of 2.50% Exchangeable Senior Notes due 2022, or the Exchangeable Senior Notes. Accordingly, we have a significant amount of debt outstanding on a consolidated basis.

This substantial level of debt could have important consequences to our business, including, but not limited to:

The credit agreement and the indenture governing ~~the~~our 5.5% Senior Notes due 2027, or 2027 Senior Notes, impose, and the terms of any future indebtedness may impose, various covenants that limit our ability and/or the ability of our restricted subsidiaries’ (as designated under such agreements) to, among other things, pay dividends or distributions, repurchase equity, prepay junior debt and make certain investments, incur additional debt and issue certain preferred stock, incur liens on assets, engage in certain asset sales, consolidate with or merge or sell all or substantially all of our assets, enter into transactions with affiliates, designate subsidiaries as unrestricted subsidiaries, and allow to exist certain restrictions on the ability of restricted subsidiaries to pay dividends or make other payments to us.

Our ability to obtain future financing and engage in other transactions may be restricted by these covenants. In addition, any credit ratings will impact the cost and availability of future borrowings and our cost of capital. Our ratings at any time will reflect each rating organization’s then opinion of our financial strength, operating performance and ability to meet our debt obligations. There can be no assurance that we will achieve a particular rating or maintain a particular rating in the future. A reduction in our credit ratings may limit our ability to borrow at acceptable interest rates. If our credit ratings were downgraded or put on watch for a potential downgrade, we may not be able to sell additional debt securities or borrow money in the amounts, at the times or interest rates or upon the more favorable terms and conditions that might otherwise be available. Any impairment of our ability to obtain future financing on favorable terms could have an adverse effect on our ability to refinance any of our then-existing debt and may severely restrict our ability to execute on our business strategy, which includes the continued acquisition of additional medicines or businesses.

We may not be able to generate sufficient cash to service all of our indebtedness and may be forced to take other actions to satisfy our obligations under our indebtedness, which may not be successful.*

Our ability to make scheduled payments under or to refinance our debt obligations depends on our financial condition and operating performance, which is subject to prevailing economic, industry and competitive conditions and to certain financial, business and other factors beyond our control. For example, we expect that the COVID-19 pandemic and actions taken to slow its spread will continue to have a negative impact on net sales of our medicines, which will in turn negatively impact our cash flows. Our ability to generate cash flow to meet our payment obligations under our debt may also depend on the successful implementation of our operating and growth strategies. Any refinancing of our debt could be at higher interest rates and may require us to comply with more onerous covenants, which could further restrict our business operations. We cannot assure that we will maintain a level of cash flows from operating activities sufficient to pay the principal, premium, if any, and interest on our indebtedness.

If our cash flows and capital resources are insufficient to fund our debt service obligations, we may be forced to reduce or delay capital expenditures, sell assets or business operations, seek additional capital or restructure or refinance our indebtedness. We cannot ensure that we would be able to take any of these actions, that these actions would be successful and permit us to meet our scheduled debt service obligations or that these actions would be permitted under the terms of existing or future debt agreements, including the indenture that ~~govern~~governs the 2027 Senior Notes and the credit agreement. In addition, any failure to make payments of interest and principal on our outstanding indebtedness on a timely basis would likely result in a reduction of our credit rating, which could harm our ability to incur additional indebtedness.

If we cannot make scheduled payments on our debt, we will be in default and, as a result:

We generally have broad discretion in the use of our cash and may not use it effectively.

Our management has broad discretion in the application of our cash, and investors will be relying on the judgment of our management regarding the use of our cash. Our management may not apply our cash in ways that ultimately increase the value of any investment in our securities. We expect to use our existing cash to fund commercialization activities for our medicines, to potentially fund additional medicine, medicine candidate or business acquisitions, to potentially fund additional regulatory approvals of certain of our medicines, to potentially fund development, life cycle management or manufacturing activities of our medicines and medicine candidates, to potentially fund share repurchases, and for working capital, milestone payments, capital expenditures and general corporate purposes. We may also invest our cash in short-term, investment-grade, interest-bearing securities. These investments may not yield a favorable return to our shareholders. If we do not invest or apply our cash in ways that enhance shareholder value, we may fail to achieve expected financial results, which could cause the price of our ordinary shares to decline.

Our ability to use net operating loss carryforwards and certain other tax attributes to offset U.S. income taxes may be limited.*

Under Sections 382 and 383 of the Code, if a corporation undergoes an “ownership change” (generally defined as a greater than 50 percent change (by value) in its equity ownership over a three-year period), the corporation’s ability to use pre-change net operating loss carryforwards and other pre-change tax attributes to offset post-change income may be limited. WeFor example, we continue to carry forward our annual limitation resulting from an ownership change date of August 2, 2012. The limitation on pre-change net operating losses incurred prior to the August 2, 2012 change date is approximately $7.7 million for ~~2019~~2020 through 2028. We continue to carry forward the annual limitation related to Hyperion of $50.0 million resulting from the last ownership change date in 2014 and the annual limitation related to Raptor of $0.2 million resulting from the last ownership change date in 2009. In addition, we recognized $32.2 million of federal net operating losses, $2.2 million of state net operating losses and $9.5 million of federal tax credits following our acquisition of River ~~Vision.~~Vision Development Corp. These acquired federal net operating losses and tax credits are subject to an annual limitation of $2.6 million. The net operating loss carryforward and tax credit carryforwardlimitations are cumulative such that any use of the carryforwards below the limitations in one year will result in a corresponding increase in the limitations for the subsequent tax year. Under the Tax Act, as modified by the CARES Act, U.S. federal net operating losses incurred in taxable years ~~ending~~beginning after December 31, 2017 may be carried forward indefinitely, but the deductibility of federal net operating losses generated in taxable years beginning after December 31, 2017, to the extent such net operating losses are carried forward into taxable years beginning after December 31, 2020, is limited to 80 percent of the then current year’s taxable income. Under the CARES Act, U.S. federal net operating losses arising in a tax year beginning after December 31, 2017, and before January 1, 2021, can be carried back five years. It remains uncertain if and to what extent various U.S. states will conform to the Tax Act and the CARES Act.

Following certain acquisitions of a U.S. corporation by a foreign corporation, Section 7874 of the Code limits the ability of the acquired U.S. corporation and its U.S. affiliates to utilize U.S. tax attributes such as net operating losses to offset U.S. taxable income resulting from certain transactions. Based on the limited guidance available, we expect this limitation is applicable for approximately ten years following ~~the~~our merger transaction with Vidara ~~Merger~~ with respect to certain intra-company transactions. As a result, we or our other U.S. affiliates may not be able to utilize ~~their~~ U.S. tax attributes to offset ~~their~~ U.S. taxable income or U.S. tax liability respectively, if any, resulting from certain intra-company taxable transactions during such period. Notwithstanding this limitation, we expect that we will be able to fully use our U.S. net operating losses and tax credits prior to their expiration. As a result of this limitation, however, it may take Horizon Therapeutics USA, Inc. (formerly known as Horizon Pharma USA, Inc. ~~(as~~and as the successor to HPI) longer to use its net operating losses and tax credits. Moreover, contrary to these expectations, it is possible that the limitation under Section 7874 of the Code on the utilization of U.S. tax attributes could prevent us from fully utilizing our U.S. tax attributes prior to their expiration if we do not generate sufficient taxable income or tax obligations.

Any limitation on our ability to use our net operating loss and tax credit carryforwards, including the carryforwards of companies that we acquire, will likely increase the taxes we would otherwise pay in future years if we were not subject to such limitations.

Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and share price.*

From time to time, including recently as a result of the COVID-19 pandemic and actions taken to slow its spread, global credit and financial markets have experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, and uncertainty about economic stability. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment and continued unpredictable and unstable market conditions. If the equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult to complete, more costly, and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and share price and could require us to delay or abandon commercialization or development plans. There is a risk that one or more of our current service providers, manufacturers and other partners may not survive an economic down-turn, which could directly affect our ability to attain our operating goals on schedule and on budget.

The United Kingdom’s referendum to leave the EU and the United Kingdom’s exit from the EU on January 31, 2020, or “Brexit,” has caused and may continue to cause disruptions to capital and currency markets worldwide. The full impact of ~~the~~ Brexit, ~~decision,~~ however, remains uncertain. ~~A process of negotiation will determine~~Pursuant to the ~~future terms of the United Kingdom’s relationship with the EU and there is the potential that~~formal withdrawal arrangements agreed to between the United Kingdom and the EU, ~~may not agree to a withdrawal arrangement before the date~~ the United Kingdom ~~leaves~~will be subject to a transition period, or Transition Period, until December 31, 2020, during which EU rules will continue to apply. Negotiations between the ~~EU.~~United Kingdom and the EU are expected to continue in relation to the customs and trading relationship between the United Kingdom and the EU following the expiry of the Transition Period. During this period of negotiation and afterwards, our results of operations and access to capital may be negatively affected by interest rate, exchange rate and other market and economic volatility, as well as political uncertainty. In the short and medium term, there is a risk of disrupted import and export processes due to a lack of administrative processing capacity by the respective United Kingdom and EU customs agencies that may delay time-sensitive shipments and may negatively impact our product supply chain. Brexit may also have a detrimental effect on our customers, distributors and suppliers, which would, in turn, adversely affect our revenues and financial condition.

At June 30, ~~2019,~~2020, we had ~~$866.0~~$718.1 million of cash and cash equivalents consisting of cash and money market funds. While we are not aware of any downgrades, material losses, or other significant deterioration in the fair value of our cash equivalents since June 30, ~~2019,~~2020, no assurance can be given that deterioration in conditions of the global credit and financial markets would not negatively impact our current portfolio of cash equivalents or our ability to meet our financing objectives. Dislocations in the credit market may adversely impact the value and/or liquidity of marketable securities owned by us.

If the London Inter-Bank Offered Rate, or LIBOR, is discontinued, interest payments under our credit agreement may be calculated using another reference rate.

In July 2017, the Chief Executive of the United Kingdom Financial Conduct Authority, or FCA, which regulates LIBOR, announced that the FCA intends to phase out the use of LIBOR by the end of 2021. In addition, the U.S. Federal Reserve, in conjunction with the Alternative Reference Rates Committee, a steering committee comprised of large U.S. financial institutions, is considering replacing U.S. dollar LIBOR with the Secured Overnight Financing Rate, or SOFR, a new index calculated by short-term repurchase agreements, backed by Treasury securities. Although there have been certain issuances utilizing SOFR, it is unknown whether this or any other alternative reference rate will attain market acceptance as a replacement for LIBOR. LIBOR is used as a benchmark rate throughout our credit agreement, and our credit agreement does not ~~provide fallback language for~~address all circumstances in which LIBOR ceases to be published. There remains uncertainty regarding the future utilization of LIBOR and the nature of any replacement rate, and any potential effects of the transition away from LIBOR on us are not known. The transition process may involve, among other things, increased volatility and illiquidity in markets for instruments that currently rely on LIBOR and may result in increased borrowing costs, the effectiveness of related transactions such as hedges, uncertainty under applicable documentation, including the credit agreement, or difficult and costly processes to amend such documentation. As a result, our ability to refinance our credit agreement or other indebtedness or to hedge our exposure to floating rate instruments may be impaired, which would adversely affect the operations of our business.

Changes in accounting rules or policies may affect our financial position and results of operations.

Accounting principles generally accepted in the United States, or GAAP, and related implementation guidelines and interpretations can be highly complex and involve subjective judgments. Changes in these rules or their interpretation, the adoption of new guidance or the application of existing guidance to changes in our business could significantly affect our financial position and results of operations. In addition, our operation as an Irish company with multiple subsidiaries in different jurisdictions adds additional complexity to the application of GAAP and this complexity will be exacerbated further if we complete additional strategic transactions. Changes in the application of existing rules or guidance applicable to us or our wholly owned subsidiaries could significantly affect our consolidated financial position and results of operations.

Covenants under the indenture governing our 2027 Senior Notes and our credit agreement may restrict our business and operations in many ways, and if we do not effectively manage our covenants, our financial conditions and results of operations could be adversely affected.*

The indenture governing the 2027 Senior Notes and the credit agreement impose various covenants that limit our ability and/or our restricted subsidiaries’ ability to, among other things:

If we are unable to successfully manage the limitations and decreased flexibility on our business due to our significant debt obligations, we may not be able to capitalize on strategic opportunities or grow our business to the extent we would be able to without these limitations.

Our failure to comply with any of the covenants could result in a default under the credit agreement or the indenture governing the 2027 Senior Notes, which could permit the administrative agent or the trustee, as applicable, or permit the lenders or the holders of the 2027 Senior Notes to cause the administrative agent or the trustee, as applicable, to declare all or part of any outstanding senior secured term loans or revolving loans, ~~the revolving commitments,~~or the 2027 Senior Notes to be immediately due and payable or to exercise any remedies provided to the administrative agent or the trustee, including, in the case of the credit agreement proceeding against the collateral granted to secure our obligations under the credit agreement. An event of default under the credit agreement or the indenture governing the 2027 Senior Notes could also lead to an event of default under the terms of the other ~~agreements and the indenture governing our Exchangeable Senior Notes.~~agreement. Any such event of default or any exercise of rights and remedies by our creditors could seriously harm our business.

If intangible assets that we have recorded in connection with our acquisition transactions become impaired, we could have to take significant charges against earnings.*

In connection with the accounting for our various acquisition transactions, we have recorded significant amounts of intangible assets. Under GAAP, we must assess, at least annually and potentially more frequently, whether the value of goodwill ~~and other indefinite-lived intangible assets~~ has been impaired. Amortizing intangible assets will be assessed for impairment in the event of an impairment indicator. For example, during the year ended December 31, 2018, we recorded an impairment of $33.6 million to fully write off the book value of developed technology related to PROCYSBI in Canada and Latin America. Such impairment and any reduction or other impairment of the value of goodwill or other intangible assets will result in a charge against earnings, which could materially adversely affect our results of operations and shareholders’ equity in future periods.

If we are unable to obtain or protect intellectual property rights related to our medicines and medicine candidates, we may not be able to compete effectively in our markets.*

We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our medicines and medicine candidates. The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own may fail to result in issued patents with claims that cover our medicines in the United States or in other foreign countries. If this were to occur, early generic competition could be expected against our current medicines and other medicine candidates in development. There is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found, which prior art can invalidate a patent or prevent a patent from issuing based on a pending patent application. In particular, because the APIs in RAYOS, DUEXIS and PENNSAID 2% ~~and VIMOVO~~ have been on the market as separate medicines for many years, it is possible that these medicines have previously been used off-label in such a manner that such prior usage would affect the validity of our patents or our ability to obtain patents based on our patent applications. In addition, claims directed to dosing and dose adjustment may be substantially less likely to issue in light of the Supreme Court decision in Mayo Collaborative Services v. Prometheus Laboratories, ~~Inc.~~Inc., where the court held that claims directed to methods of determining whether to adjust drug dosing levels based on drug metabolite levels in the red blood cells were not patent eligible because they were directed to a law of nature. This decision may have wide-ranging implications on the validity and scope of pharmaceutical method claims.

Even if patents do successfully issue, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed or invalidated.

Patent litigation is currently pending in the United States District Court for the District of New Jersey against Actavis, who intend to market a generic version of PENNSAID 2% prior to the expiration of certain of our patents listed in the Orange Book. These cases arise from Paragraph IV Patent Certification notice letters from Actavis advising they had filed an ANDA with the FDA seeking approval to market a generic version of PENNSAID 2% before the expiration of the patents-in-suit. For a more detailed description of the PENNSAID 2% litigation, see Note 16, Legal Proceedings, of the Notes to Unaudited Condensed Consolidated Financial Statements, included in Item 1 of this Quarterly Report on Form 10-Q.

Patent litigation is currently pending in the United States District Court for the District of New Jersey and the Court of Appeals for the Federal Circuit against Dr. Reddy’s ~~intending to market~~for marketing a generic version of VIMOVO before the expiration of certain of our patents listed in the Orange Book. The cases arise from Paragraph IV Patent Certification notice letters from Dr. Reddy’s, advising that it had filed an ANDA with the FDA seeking approval to market generic versions of VIMOVO before the expiration of the patents-in-suit. On July 30, 2019, the Federal Circuit Court of Appeals denied our request for a rehearing of the Court’s invalidity ruling against the 6,926,907 and 8,557,285 patents for VIMOVO coordinated-release tablets. As a result, the District Court entered judgment in September 2019 invalidating the ‘907 and ‘285 patents, which ended any restriction against the FDA from granting final approval to Dr. Reddy’s generic version of VIMOVO. On February 18, 2020, the FDA granted final approval for Dr. Reddy’s generic version of VIMOVO. On February 27, 2020, Dr. Reddy’s launched its generic version of VIMOVO in the United States. Patent litigation against Dr. Reddy’s for infringement continues with respect to certain patents in the New Jersey District Court. We have repositioned our promotional efforts previously directed to VIMOVO to the other inflammation segment medicines and expect that our VIMOVO net sales will continue to decrease in future periods. For a more detailed description of the VIMOVO litigation, see Note 16, Legal Proceedings, of the Notes to Unaudited Condensed Consolidated Financial Statements, included in Item 1 of this Quarterly Report on Form 10-Q.

Patent litigation is currently pending in the United States District Court for the District of Delaware and the United States District Court of New Jersey against Alkem and Teva USA, respectively, who ~~intends~~each intend to market a generic version of DUEXIS prior to the expiration of certain of our patents listed in the Orange Book. ~~This case arises~~These cases arise from Paragraph IV Patent Certification notice letters from Alkem and Teva USA advising itthey had filed an ANDA with the FDA seeking approval to market a generic version of DUEXIS before the expiration of the patents-in-suit. For a more detailed description of the DUEXIS litigation, see Note 16, Legal Proceedings, of the Notes to Unaudited Condensed Consolidated Financial Statements, included in Item 1 of this Quarterly Report on Form 10-Q.

We intend to vigorously defend our intellectual property rights relating to our medicines, but we cannot predict the outcome of the DUEXIS ~~case,~~cases and the PENNSAID 2% ~~cases and the VIMOVO~~ cases. Any adverse outcome in these matters or any new generic challenges that may arise could result in one or more generic versions of our medicines being launched before the expiration of the listed patents, which could adversely affect our ability to successfully execute our business strategy to increase sales of our medicines, and would negatively impact our financial condition and results of operations, including causing a significant decrease in our revenues and cash flows.

Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims. If the patent applications we hold with respect to our medicines fail to issue or if their breadth or strength of protection is threatened, it could dissuade companies from collaborating with us to develop them and threaten our ability to commercialize our medicines. We cannot offer any assurances about which, if any, patents will issue or whether any issued patents will be found not invalid and not unenforceable or will go unthreatened by third parties. Since patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we were the first to file any patent application related to our medicines or any other medicine candidates. Furthermore, if third parties have filed such patent applications, an interference proceeding in the United States can be provoked by a third-party or instituted by us to determine which party was the first to invent any of the subject matter covered by the patent claims of our applications.

In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our drug discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. Although we expect all of our employees to assign their inventions to us, and all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed or that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques.

Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. For example, if the issuance, in a given country, of a patent to us, covering an invention, is not followed by the issuance, in other countries, of patents covering the same invention, or if any judicial interpretation of the validity, enforceability, or scope of the claims in, or the written description or enablement in, a patent issued in one country is not similar to the interpretation given to the corresponding patent issued in another country, our ability to protect our intellectual property in those countries may be limited. Changes in either patent laws or in interpretations of patent laws in the United States and other countries may materially diminish the value of our intellectual property or narrow the scope of our patent protection. If we are unable to prevent material disclosure of the non-patented intellectual property related to our technologies to third parties, and there is no guarantee that we will have any such enforceable trade secret protection, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition.

Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.

Our commercial success depends in part on us avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions and inter party reexamination proceedings before the United States Patent and Trademark Office, or the U.S. PTO. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which our collaborators are developing medicine candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our medicine candidates may be subject to claims of infringement of the patent rights of third parties.

Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our medicines and/or any other medicine candidates. Because patent applications can take many years to issue, there may be currently pending patent applications, which may later result in issued patents that our medicine candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our medicine candidates, any molecules formed during the manufacturing process or any final medicine itself, the holders of any such patents may be able to block our ability to commercialize such medicine candidate unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patent may be able to block our ability to develop and commercialize the applicable medicine candidate unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all.

Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our medicine candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing medicines, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our medicine candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our medicine candidates, which could harm our business significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our medicines, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties.

If we fail to comply with our obligations in the agreements under which we license rights to technology from third parties, we could lose license rights that are important to our business.*

We are party to a number of technology licenses that are important to our business and expect to enter into additional licenses in the future. For example, we rely on a license from Bausch with respect to technology developed by Bausch in connection with the manufacturing of RAVICTI. The purchase agreement under which Hyperion purchased the rights to RAVICTI contains obligations to pay Bausch regulatory and sales milestone payments relating to RAVICTI, as well as royalties on the net sales of RAVICTI. On May 31, 2013, when Hyperion acquired BUPHENYL under a restated collaboration agreement with Bausch, Hyperion received a license to use some of the manufacturing technology developed by Bausch in connection with the manufacturing of BUPHENYL. The restated collaboration agreement also contains obligations to payBausch regulatory and sales milestone payments, as well as royalties on net sales of BUPHENYL. If we fail to make a required payment to Bausch and do not cure the failure within the required time period, Bausch may be able to terminate the license to use its manufacturing technology for RAVICTI and BUPHENYL. If we lose access to the Bausch manufacturing technology, we cannot guarantee that an acceptable alternative method of manufacture could be developed or acquired. Even if alternative technology could be developed or acquired, the loss of the Bausch technology could still result in substantial costs and potential periods where we would not be able to market and sell RAVICTI and/or BUPHENYL. We also license intellectual property necessary for commercialization of RAVICTI from an external party. This party may be entitled to terminate the license if we breach the agreement, including failure to pay required royalties on net sales of RAVICTI, or we do not meet specified diligence obligations in our development and commercialization of RAVICTI, and we do not cure the failure within the required time period. If the license is terminated, it may be difficult or impossible for us to continue to commercialize RAVICTI, which would have a material adverse effect on our business, financial condition and results of operations.

We also license rights to know-how and trademarks for ACTIMMUNE from Genentech Inc., or Genentech. Genentech may terminate the agreement upon our material default, if not cured within a specified period of time. Genentech may also terminate the agreement in the event of our bankruptcy or insolvency. Upon such a termination of the agreement, all intellectual property rights conveyed to us under the agreement, including the rights to the ACTIMMUNE trademark, revert to Genentech. If we fail to comply with our obligations under this agreement, we could lose the ability to market and distribute ACTIMMUNE, which would have a material adverse effect on our business, financial condition and results of operations.

In addition, we are subject to contractual obligations under our agreements with Tripex and PARI related to QUINSAIR. Under the agreement with Tripex, as amended, if we do not spend a specified amount on the development of QUINSAIR for non-CF indications between January 1, 2018 and December 31, 2021 and regulatory approval by the FDA for QUINSAIR for the CF indication is obtained prior to December 31, 2021, we may be obligated to pre-pay a milestone payment related to commercial sales of QUINSAIR for non-CF indications. This obligation is subject to certain exceptions due to, for example, manufacturing delays not under our control, or clinical trial suspension or delay ordered by the FDA. In October 2017, we triggered a milestone payment under this agreement and we paid Tripex $20.0 million in November 2017. Under the license agreement with PARI, we are required to comply with diligence milestones related to development and commercialization of QUINSAIR in the United States and to spend a specified minimum amount per year on development and/or commercialization activities in the United States until submission of the NDA for QUINSAIR in the United States. If we do not comply with these obligations, our licenses to certain intellectual property related to QUINSAIR may become non-exclusive in the United States. We are ~~also~~ subject to contractual obligations under our amended and restated license agreement with UCSD, as amended, with respect to PROCYSBI. If one or more of these licenses was terminated, we would have no further right to use or exploit the related intellectual property, which would limit our ability to develop PROCYSBI ~~or QUINSAIR~~ in other indications, and could impact our ability to continue commercializing PROCYSBI ~~or QUINSAIR~~ in ~~their~~its approved indications.

We also hold an exclusive license to patents and technology from Duke University, or Duke, and Mountain View Pharmaceuticals, Inc., or MVP, covering KRYSTEXXA. Duke and MVP may terminate the license if we commit fraud or for our willful misconduct or illegal conduct. Duke and MVP may also terminate the license upon our material breach of the agreement, if not cured within a specified period of time, or upon written notice if we have committed two or more material breaches under the agreement. Duke and MVP may also terminate the license in the event of our bankruptcy or insolvency. If the license is terminated, it may be impossible for us to continue to commercialize KRYSTEXXA, which would have a material adverse effect on our business, financial condition and results of operations.

We hold an exclusive license to Vectura Group plc’s, or Vectura, proprietary technology and know-how covering the delayed-release of corticosteroids relating to RAYOS. If we fail to comply with our obligations under our agreement with Vectura or our other license agreements, or if we are subject to a bankruptcy, the licensor may have the right to terminate the license, in which event we would not be able to market medicines covered by the license, including RAYOS.

We hold an exclusive, worldwide license from F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., or Roche, to patents and know-howfor ~~teprotumumab.~~TEPEZZA. We also have exclusive sub-licenses for rights licensed to Roche for ~~teprotumumab~~TEPEZZA by certain third-party licensors. Roche may have the right to terminate the license upon our breach, if not cured within a specified period of time. Roche may also terminate the license in the event of our bankruptcy or insolvency, or if we challenge the validity of Roche’s patents. If the license is terminated for our breach or based on our challenging the validity of Roche’s patents, then all rights and licenses granted to us by Roche would also terminate, and we may be required to assign and transfer to Roche certain filings and approvals, trademarks, and data in our possession necessary for the development and commercialization of ~~teprotumumab,~~TEPEZZA, and assign clinical trial agreements to the extent permitted. We may also be required to grant Roche an exclusive license under our patents and know-how for ~~teprotumumab,~~TEPEZZA, and to manufacture and supply ~~teprotumumab~~TEPEZZA to Roche for a transitional period. We also have a license ~~patents for teprotumumab from~~of patent rights to TEPEZZA under a license agreement with Lundquist Institute (formerly known as Los Angeles Biomedical Research Institute at Harbor-UCLA Medical ~~Center,~~Center), or ~~LA BioMed~~Lundquist. ~~LA BioMed may have~~Lundquist has the right to terminate the license agreement upon our material breach, if not cured within a specified period of time, or in the event of our bankruptcy or insolvency. If one or more of these licenses is terminated, it may be impossible for us to continue to commercialize ~~teprotumumab,~~TEPEZZA, which would have a material adverse effect on our business, financial condition and results of operations.

We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming and unsuccessful.

Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one of our patents, or a patent of one of our licensors, is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing.

There are numerous post grant review proceedings available at the U.S. PTO (including inter partes review, post-grant review and ex-parte reexamination) and similar proceedings in other countries of the world that could be initiated by a third-party that could potentially negatively impact our issued patents.

Interference proceedings provoked by third parties or brought by us may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our collaborators or licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States.

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our ordinary shares.

Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.

Periodic maintenance fees on any issued patent are due to be paid to the U.S. PTO and foreign patent agencies in several stages over the lifetime of the patent. The U.S. PTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or licensors that control the prosecution and maintenance of our licensed patents fail to maintain the patents and patent applications covering our medicine candidates, our competitors might be able to enter the market, which would have a material adverse effect on our business.

We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.

We employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees’ former employers or other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees.

The market price of our ordinary shares historically has been volatile and is likely to continue to be volatile, and you could lose all or part of any investment in our ordinary shares.*

The trading price of our ordinary shares has been volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. In addition to the factors discussed in this “Risk Factors” section and elsewhere in this report, these factors include:

In addition, the stock market in general, and The Nasdaq Global Select Market and the stock of biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may adversely affect the market price of our ordinary shares, regardless of our actual operating performance.

We have never declared or paid dividends on our share capital and we do not anticipate paying dividends in the foreseeable future.

We have never declared or paid any cash dividends on our ordinary shares. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future, including due to limitations that are currently imposed by our credit agreement and the ~~indentures~~indenture governing the ~~2024 Senior Notes and the 2023~~2027 Senior Notes. Any return to shareholders will therefore be limited to the increase, if any, of our ordinary share price.

We have incurred and will continue to incur significant increased costs as a result of operating as a public company and our management will be required to devote substantial time to compliance initiatives.

As a public company, we have incurred and will continue to incur significant legal, accounting and other expenses that we did not incur as a private company. In particular, the Sarbanes-Oxley Act of 2000, or the Sarbanes-Oxley Act, as well as rules subsequently implemented by the SEC and the Nasdaq Stock Market, Inc., or Nasdaq, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. These rules and regulations have substantially increased our legal and financial compliance costs and have made some activities more time-consuming and costly. These effects are exacerbated by our transition to an Irish company and the integration of numerous acquired businesses and operations into our historical business and operating structure. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. The increased costs will continue to decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our medicines or services. For example, these rules and regulations make it more difficult and more expensive for us to obtain and maintain director and officer liability insurance. We cannot predict or estimate the amount or timing of additional costs that we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. If we fail to comply with the continued listing requirements of Nasdaq, our ordinary shares could be delisted from The Nasdaq Global Select Market, which would adversely affect the liquidity of our ordinary shares and our ability to obtain future financing.

The Sarbanes-Oxley Act requires, among other things, that we maintain effective internal controls for financial reporting and disclosure controls and procedures. In particular, we are required to perform annual system and process evaluation and testing of our internal controls over financial reporting to allow management to report on the effectiveness of our internal controls over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act, or Section 404. Our independent registered public accounting firm is also required to deliver a report on the effectiveness of our internal control over financial reporting. Our testing, or the testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses. Our compliance with Section 404 requires that we incur substantial expense and expend significant management efforts, particularly because of our Irish parent company structure and international operations. If we are not able to comply with the requirements of Section 404 or if we or our independent registered public accounting firm identify deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses, the market price of our ordinary shares could decline and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities, which would require additional financial and management resources.

New laws and regulations as well as changes to existing laws and regulations affecting public companies, including the provisions of the Sarbanes-Oxley Act and rules adopted by the SEC and by Nasdaq, would likely result in increased costs as we respond to their requirements.

Sales of a substantial number of our ordinary shares in the public market could cause our share price to decline.*

If our existing shareholders sell, or indicate an intention to sell, substantial amounts of our ordinary shares in the public market, the trading price of such ordinary shares could decline. In addition, our ordinary shares that are either subject to outstanding options and restricted stock units or reserved for future issuance under our employee benefit plans are or may become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules and ~~Rule 144 under~~ the Securities Act of 1933, as amended, or the Securities Act. If these additional ordinary shares are sold, or if it is perceived that they will be sold, in the public market, the trading price of our ordinary shares could decline.

In addition, any conversion or exchange of our Exchangeable Senior Notes, whether pursuant to their terms or pursuant to privately negotiated transactions between the issuer and/or us and a holder of such securities, could depress the market price for our ordinary shares.

Future sales and issuances of our ordinary shares, securities convertible into our ordinary shares or rights to purchase ordinary shares or convertible securities could result in additional dilution of the percentage ownership of our shareholders and could cause our share price to decline.*

Additional capital may be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities or securities convertible into or exchangeable for ordinary shares, our shareholders may experience substantial dilution. We may sell ordinary shares, and we may sell convertible or exchangeable securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell such ordinary shares, convertible or exchangeable securities or other equity securities in subsequent transactions, existing shareholders may be materially diluted. New investors in such subsequent transactions could gain rights, preferences and privileges senior to those of holders of ordinary shares. We also maintain equity incentive plans, including our ~~Amended and Restated 2014~~2020 Equity Incentive Plan, 2014 Non-Employee Equity Plan, as amended, and ~~2014~~2020 Employee Share Purchase Plan, ~~as amended,~~ and intend to grant additional ordinary share awards under these and future plans, which will result in additional dilution to our existing shareholders.

Irish law differs from the laws in effect in the United States and may afford less protection to holders of our securities.

It may not be possible to enforce court judgments obtained in the United States against us in Ireland based on the civil liability provisions of the U.S. federal or state securities laws. In addition, there is some uncertainty as to whether the courts of Ireland would recognize or enforce judgments of U.S. courts obtained against us or our directors or officers based on the civil liabilities provisions of the U.S. federal or state securities laws or hear actions against us or those persons based on those laws. We have been advised that the United States currently does not have a treaty with Ireland providing for the reciprocal recognition and enforcement of judgments in civil and commercial matters. Therefore, a final judgment for the payment of money rendered by any U.S. federal or state court based on civil liability, whether or not based solely on U.S. federal or state securities laws, would not automatically or necessarily be enforceable in Ireland.

As an Irish company, we are governed by the Irish Companies Act 2014 (as amended), which differs in some material respects from laws generally applicable to U.S. corporations and shareholders, including, among others, differences relating to interested director and officer transactions and shareholder lawsuits. Likewise, the duties of directors and officers of an Irish company generally are owed to the company only. Shareholders of Irish companies generally do not have a personal right of action against directors or officers of the company and may exercise such rights of action on behalf of the company only in limited circumstances. Accordingly, holders of our securities may have more difficulty protecting their interests than would holders of securities of a corporation incorporated in a jurisdiction of the United States.

Provisions of our articles of association, ~~shareholder rights agreement~~ and Irish law could delay or prevent a takeover of us by a third party.*

Our articles of association could delay, defer or prevent a third-party from acquiring us, despite the possible benefit to our shareholders, or otherwise adversely affect the price of our ordinary shares. For example, our articles of association:

In February 2019, we adopted a shareholder rights agreement, or rights agreement, with a 12-month term under which shareholders have certain ordinary share purchase rights if a person or group acquires 10% (or 15% ~~in the case of an existing “13G Investor”~~ as defined in the rights agreement) or more of our outstanding ordinary shares without the prior approval of our board of directors. Until its expiration, the rights agreement could make it more difficult for a person or group to acquire a majority of our outstanding ordinary shares, and could otherwise prevent or delay an acquisition of us. The rights agreement could also reduce the price that investors might be willing to pay for our ordinary shares and result in the market price of our ordinary shares being lower than it would be without the rights agreement. In addition, the existence of the rights agreement itself may deter a potential acquiror from pursuing any acquisition of us at all. As a result, either by operation of the rights agreement or by its potential deterrent effect, acquisitions of us that our shareholders may consider in their best interests may not occur.

In addition, several mandatory provisions of Irish law could prevent or delay an acquisition of us. For example, Irish law does not permit shareholders of an Irish public limited company to take action by written consent with less than unanimous consent. We are also subject to various provisions of Irish law relating to mandatory bids, voluntary bids, requirements to make a cash offer and minimum price requirements, as well as substantial acquisition rules and rules requiring the disclosure of interests in our ordinary shares in certain circumstances.

These provisions may discourage potential takeover attempts, discourage bids for our ordinary shares at a premium over the market price or adversely affect the market price of, and the voting and other rights of the holders of, our ordinary shares. These provisions could also discourage proxy contests and make it more difficult for you and our other shareholders to elect directors other than the candidates nominated by our board of directors, and could depress the market price of our ordinary shares.

Any attempts to take us over will be subject to Irish Takeover Rules and subject to review by the Irish Takeover Panel.

We are subject to the Irish Takeover Rules, under which our board of directors will not be permitted to take any action which might frustrate an offer for our ordinary shares once it has received an approach which may lead to an offer or has reason to believe an offer is imminent.

In certain circumstances, the transfer of shares in an Irish incorporated company will be subject to Irish stamp duty, which is a legal obligation of the buyer. This duty is currently charged at the rate of 1.0 percent of the price paid or the market value of the shares acquired, if higher. Because our ordinary shares are traded on a recognized stock exchange in the United States, an exemption from this stamp duty is available to transfers by shareholders who hold ordinary shares beneficially through brokers, which in turn hold those shares through the Depositary Trust Company, or DTC, to holders who also hold through DTC. However, a transfer by or to a record holder who holds ordinary shares directly in his, her or its own name could be subject to this stamp duty. We, in our absolute discretion and insofar as the Irish Companies Act 2014 (as amended) or any other applicable law permit, may, or may provide that one of our subsidiaries will pay Irish stamp duty arising on a transfer of our ordinary shares on behalf of the transferee of such ordinary shares. If stamp duty resulting from the transfer of ordinary shares which would otherwise be payable by the transferee is paid by us or any of our subsidiaries on behalf of the transferee, then in those circumstances, we will, on our behalf or on behalf of such subsidiary (as the case may be), be entitled to (i) seek reimbursement of the stamp duty from the transferee, (ii) set-off the stamp duty against any dividends payable to the transferee of those ordinary shares and (iii) claim a first and permanent lien on the ordinary shares on which stamp duty has been paid by us or such subsidiary for the amount of stamp duty paid. Our lien shall extend to all dividends paid on those ordinary shares.

In certain circumstances, as an Irish tax resident company, we will be required to deduct Irish dividend withholding tax (currently at the rate of ~~20%~~25%) from dividends paid to our shareholders. Shareholders that are resident in the United States, EU countries (other than Ireland) or other countries with which Ireland has signed a tax treaty (whether the treaty has been ratified or not) generally should not be subject to Irish withholding tax so long as the shareholder has provided its broker, for onward transmission to our qualifying intermediary or other designated agent (in the case of shares held beneficially), or our or its transfer agent (in the case of shares held directly), with all the necessary documentation by the appropriate due date prior to payment of the dividend. However, some shareholders may be subject to withholding tax, which could adversely affect the price of our ordinary shares.

If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our share price and trading volume could decline.

The trading market for our ordinary shares will depend in part on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who cover us downgrade our rating or publish inaccurate or unfavorable research about our business, our share price could decline. If one or more of these analysts cease coverage of our company or fail to publish reports on our company regularly, demand for our ordinary shares could decrease, which might cause our share price and trading volume to decline.

Securities class action litigation could divert our management’s attention and harm our business and could subject us to significant liabilities.

The stock markets have from time to time experienced significant price and volume fluctuations that have affected the market prices for the equity securities of pharmaceutical companies. These broad market fluctuations may cause the market price of our ordinary shares to decline. In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biotechnology and biopharma companies have experienced significant stock price volatility in recent years. For example, following declines in our stock price, two federal securities class action lawsuits were filed in March 2016 against us and certain of our current and former officers alleging violations of the Securities Exchange Act of 1934, as amended, which lawsuits were dismissed by the plaintiffs in June 2018. Even if we are successful in defending any similar claims that may be brought in the future, such litigation could result in substantial costs and may be a distraction to our management, and may lead to an unfavorable outcome that could adversely impact our financial condition and prospects.

During the three months ended June 30, 2020, we issued an aggregate of 7,225,368 ordinary shares to certain holders of our 2.5% Exchangeable Senior Notes due 2022, or Exchangeable Senior Notes. The shares were issued as a result of such holders exercising their rights to exchange an aggregate principal amount of $207.0 million of the Exchangeable Senior Notes.

The offers, sales and issuances of the securities described above were deemed to be exempt from registration under the Securities Act in reliance on Section 4(a)(2) and 3(a)(9) of the Securities Act. No underwriters were involved in these transactions.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Ireland		Not Applicable
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

Connaught House, 1st Floor 1 Burlington Road, Dublin 4, D04 C5Y6, Ireland		Not Applicable
(Address of principal executive offices)		(Zip Code)


Title of each class	Trading Symbol	Name of each exchange on which registered
Ordinary shares, nominal value $0.0001 per share	HZNP	The Nasdaq Global Select Market

		Page
		No.
PART I. FINANCIAL INFORMATION
Item 1.	Financial Statements	1
	Condensed Consolidated Balance Sheets as of June 30, ~~2019~~2020 and as of December 31, ~~2018~~2019 (Unaudited)	1
	Condensed Consolidated Statements of Comprehensive Loss for the Three and Six Months Ended June 30, ~~2019~~2020 and ~~2018~~2019 (Unaudited)	2
	Condensed Consolidated Statements of Shareholders’ Equity for the Three and Six Months Ended June 30, ~~2019~~2020 and ~~2018~~2019 (Unaudited)	3
	Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, ~~2019~~2020 and ~~2018~~2019 (Unaudited)	4
	Notes to Unaudited Condensed Consolidated Financial Statements	5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	3330
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	5051
Item 4.	Controls and Procedures	51
PART II. OTHER INFORMATION
Item 1.	Legal Proceedings	52
Item 1A.	Risk Factors	52
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	97
Item 6.	Exhibits	9698
	Signatures	99100

	Consolidated Balance Sheet as of
	December 31, 2018
	As Previously Reported			Impact of Accounting Change (1)			As Adjusted
Prepaid expenses and other current assets	$	70,828		$	(2,610	)	$	68,218
Total current assets		1,548,426			(2,610	)		1,545,816
Developed technology, net		2,120,596			(174,957	)		1,945,639
Goodwill		426,441			(12,772	)		413,669
Other assets		23,029			(14,070	)		8,959
Total assets		4,146,371			(204,409	)		3,941,962
Accrued expenses		205,593			10,146			215,739
Accrued royalties - current portion		63,363			(63,363	)		—
Total current liabilities		761,904			(53,217	)		708,687
Accrued royalties - net of current		285,374			(285,374	)		—
Deferred tax liabilities, net		93,630			14,138			107,768
Other long-term liabilities		54,622			(15,905	)		38,717
Total long-term liabilities		2,330,310			(287,141	)		2,043,169
Accumulated deficit		(1,314,718	)		135,949			(1,178,769	)
Total shareholders' equity		1,054,157			135,949			1,190,106
Total liabilities and shareholders' equity		4,146,371			(204,409	)		3,941,962

	Consolidated Statement of Comprehensive Loss
	Three Months Ended June 30, 2018
	As Previously Reported			Revision (1)			As Revised			Impact of Accounting Change (2)			As Adjusted
Cost of goods sold	$	100,082		$	(795	)	$	99,287		$	(7,950	)	$	91,337
Gross profit		202,753			795			203,548			7,950			211,498
Total operating expenses		200,939			—			200,939			—			200,939
Operating income		1,814			795			2,609			7,950			10,559
Other income, net		347			—			347			(1	)		346
Total other expenses, net		(30,688	)		—			(30,688	)		(1	)		(30,689	)
Loss before expense for income taxes		(28,874	)		795			(28,079	)		7,949			(20,130	)
Expense for income taxes		3,962			—			3,962			659			4,621
Net loss		(32,836	)		795			(32,041	)		7,290			(24,751	)
Net loss per ordinary share - basic and diluted		(0.20	)		0.01			(0.19	)		0.04			(0.15	)
Comprehensive loss		(33,444	)		795			(32,649	)		7,290			(25,359	)

Large accelerated filer	☒	Accelerated filer	☐

Non-accelerated filer	☐	Smaller reporting company	☐

Emerging growth company	☐

Buildings		40 years
Land improvements		10 years
Machinery and equipment		5 to 7 years
Furniture and fixtures		3 to 5 years
Computer equipment		3 years
Software		3 years
Trade show equipment		3 years

Cash proceeds	$	6,000
Less net assets sold:
Developed technology		(16,999	)
Inventory		(236	)
Release of contingent consideration liability	272
Loss on sale of assets	$	(10,963	)

Cash proceeds	$	35,000
Less net assets sold:
Developed technology		(4,146	)
Transaction costs		(197	)
Gain on sale of assets	$	30,657

Cash proceeds including $715 for inventory	$	9,477
Contingent consideration receivable		3,502
Less net assets sold:
Inventory		(623	)
Transaction costs		(28	)
Gain on sale of assets	$	12,328

	Wholesaler Fees			Co-Pay and			Government
	and Commercial			Other Patient			Rebates and
	Rebates			Assistance			Chargebacks			Total
Balance at December 31, 2018	$	153,445		$	179,462		$	128,522		$	461,429
Current provisions relating to sales during the six months ended June 30, 2019		235,609			825,080			223,042			1,283,731
Adjustments relating to prior-year sales		(5,763	)		—			11,101			5,338
Payments relating to sales during the six months ended June 30, 2019		(111,153	)		(679,894	)		(80,068	)		(871,115	)
Payments relating to prior-year sales		(147,682	)		(179,462	)		(138,643	)		(465,787	)
Balance at June 30, 2019	$	124,456		$	145,186		$	143,954		$	413,596

	Six Months Ended June 30, 2020			Six Months Ended June 30, 2019
	Amount		% of Total Net Sales	Amount		% of Total Net Sales
United States	$	814,843	100%	$	598,612	100%
Rest of world		3,845	*		2,406	*
Net sales	$	818,688		$	601,018
*Less than 1%

	June 30, 2019			December 31, 2018
Term Loan Facility	$	518,026		$	818,026
2023 Senior Notes		225,000			475,000
2024 Senior Notes		300,000			300,000
Exchangeable Senior Notes		400,000			400,000
Total face value		1,443,026			1,993,026
Debt discount		(70,754	)		(87,038	)
Deferred financing fees		(5,494	)		(9,304	)
Total long-term debt		1,366,778			1,896,684
Less: long-term debt—current portion		—			—
Long-term debt, net of current portion	$	1,366,778		$	1,896,684

	June 30, 2020			December 31, 2019
Term Loan Facility due 2026	$	418,026		$	418,026
Senior Notes due 2027		600,000			600,000
Exchangeable Senior Notes due 2022		192,956			400,000
Total face value		1,210,982			1,418,026
Debt discount		(29,226	)		(59,922	)
Deferred financing fees		(4,934	)		(5,263	)
Total debt and Exchangeable Senior Notes		1,176,822			1,352,841
Less: Exchangeable Senior Notes—current		174,504			—
Long-term debt and Exchangeable Senior Notes, net	$	1,002,318		$	1,352,841

Location	Approximate Square Feet		Lease Expiry Date
Dublin, Ireland		18,900	November 4, 2029
Lake Forest, Illinois		160,000	March 31, 2031
Novato, California		61,000	August 31, 2021
~~Brisbane, California (1)~~		~~20,100~~	~~November 19, 2019~~
South San Francisco, California ~~(2)~~		20,000	January 31, 2030
Chicago, Illinois		9,200	December 31, 2028
Mannheim, Germany		4,800	December 31, ~~2020~~2022
Other		~~12,400~~8,800	~~May~~March 31, ~~2020~~2021 to September 15, 2022

2019	$	6,228
2020		6,680
2021		5,788
2022		4,565
2023		4,442
Thereafter		36,696
Total	$	64,399


TEPEZZA Worldwide Net Sales Threshold	Milestone Payment
>$250 million	$50 million
>$375 million	$75 million
>$500 million	$100 million

Exhibit Number		Description of Document

3.1		Memorandum and Articles of Association of Horizon Therapeutics Public Limited Company, as amended (incorporated by reference to Exhibit 3.1 to Horizon Therapeutics Public Limited Company’s Quarterly Report on Form 10-Q, filed on May 8, 2019).

4.1		Indenture dated March 13, 2015, by and among Horizon Therapeutics Public Limited Company, Horizon Pharma Investment Limited and U.S. Bank National Association (incorporated by reference to Exhibit 4.1 to Horizon Therapeutics Public Limited Company’s Current Report on Form 8-K, filed on March 13, 2015).

~~4.2~~		~~Form of 2.50% Exchangeable Senior Note due 2022 (incorporated by reference to Exhibit 4.1 to Horizon Therapeutics Public Limited Company’s Current Report on Form 8-K, filed on March 13, 2015).~~

~~4.3~~		Indenture, dated April 29, 2015, by and between Horizon Pharma Financing Inc. and U.S. Bank National Association (incorporated by reference to Exhibit 4.1 to Horizon Therapeutics Public Limited Company’s Current Report on Form 8-K, filed on April 29, 2015).

~~4.4~~		~~Form of 6.625% Senior Note due 2023 (incorporated by reference to Exhibit 4.1 to Horizon Therapeutics Public Limited Company’s Current Report on Form 8-K, filed on April 29, 2015).~~

~~4.5~~		First Supplemental Indenture, dated May 7, 2015, by and among Horizon Therapeutics Public Limited Company, certain subsidiaries of Horizon Therapeutics Public Limited Company and U.S. Bank National Association (incorporated by reference to Exhibit 10.2 to Horizon Therapeutics Public Limited Company’s Current Report on Form 8-K, filed on May 11, 2015).

~~4.6~~		Indenture, dated October 25, 2016, by and among Horizon Pharma, Inc., Horizon Pharma USA, Inc. and U.S. Bank National Association, as trustee (incorporated by reference to Exhibit 4.1 to Horizon Therapeutics Public Limited Company’s Current Report on Form 8-K, filed on October 25, 2016).

~~4.7~~		~~Form of 8.750% Senior Note due 2024 (incorporated by reference to Exhibit 4.1 to Horizon Therapeutics Public Limited Company’s Current Report on Form 8-K, filed on October 25, 2016).~~

~~4.8~~		First Supplemental Indenture, dated October 23, 2017, by and between Horizon Pharma Tepro, Inc. and U.S. Bank National Association (incorporated by reference to Exhibit 4.8 to Horizon Therapeutics Public Limited Company’s Quarterly Report on Form 10-Q, filed on November 7, 2018).

~~4.9~~		Second Supplemental Indenture, dated October 19, 2018, by and between Horizon Pharma Services LLC and U.S. Bank National Association (incorporated by reference to Exhibit 4.9 to Horizon Therapeutics Public Limited Company’s Quarterly Report on Form 10-Q, filed on November 7, 2018).

~~4.10~~		Second Supplemental Indenture, dated May 10, 2016, by and between Horizon Pharma Rheumatology LLC and U.S. Bank National Association (incorporated by reference to Exhibit 4.10 to Horizon Therapeutics Public Limited Company’s Quarterly Report on Form 10-Q, filed on November 7, 2018).

~~4.11~~		Third Supplemental Indenture, dated October 25, 2016, by and among Horizon Pharmaceutical LLC, Horizon Orphan LLC and U.S. Bank National Association (incorporated by reference to Exhibit 4.11 to Horizon Therapeutics Public Limited Company’s Quarterly Report on Form 10-Q, filed on November 7, 2018).

~~4.12~~		Fourth Supplemental Indenture, dated October 23, 2017, by and between Horizon Pharma Tepro, Inc. and U.S. Bank National Association (incorporated by reference to Exhibit 4.12 to Horizon Therapeutics Public Limited Company’s Quarterly Report on Form 10-Q, filed on November 7, 2018).

~~4.13~~		Fifth Supplemental Indenture, dated October 19, 2018, by and between Horizon Pharma Services LLC and U.S. Bank National Association (incorporated by reference to Exhibit 4.13 to Horizon Therapeutics Public Limited Company’s Quarterly Report on Form 10-Q, filed on November 7, 2018).

~~4.14~~		Sixth Supplemental Indenture, dated October 31, 2018, by and between Horizon Pharma USA, Inc. and U.S. Bank National Association (incorporated by reference to Exhibit 4.14 to Horizon Therapeutics Public Limited Company’s Quarterly Report on Form 10-Q, filed on November 7, 2018).

~~4.15~~		Third Supplemental Indenture, dated November 15, 2018, by and between Horizon Medicines LLC and U.S. Bank National Association (incorporated by reference to Exhibit 4.15 to Horizon Therapeutics Public Limited Company’s Annual Report on Form 10-K, filed on February 27, 2019).

~~Exhibit~~ ~~Number~~		~~Description of Document~~
~~4.16~~		Seventh Supplemental Indenture, dated November 15, 2018, by and between Horizon Medicines LLC and U.S. Bank National Association (incorporated by reference to Exhibit 4.16 to Horizon Therapeutics Public Limited Company’s Annual Report on Form 10-K, filed on February 27, 2019).

~~4.17~~		Rights Agreement, dated as of February 28, 2019, by and between Horizon Therapeutics Public Limited Company and Computershare Trust Company, N.A. (incorporated by reference to Exhibit 4.1 to Horizon Therapeutics Public Limited Company’s Current Report on Form 8-K, filed on February 28, 2019).

~~4.18~~		~~Indenture dated~~ as of July 16, 2019 by and between Horizon ~~Pharma~~Therapeutics USA, Inc., the guarantors party thereto and U.S. Bank National Association, as trustee (incorporated by reference to Exhibit 4.1 to Horizon Therapeutics Public Limited Company’s Current Report on Form 8-K, filed on July 16, 2019).

~~4.19~~4.2		Form of ~~5.500%~~5.5% Senior Note due 2027 (incorporated by reference to Exhibit 4.1 to Horizon Therapeutics Public Limited Company’s Current Report on Form 8-K, filed on July 16, 2019).

~~10.1~~4.3		~~Amendment No. 6,~~First Supplemental Indenture, dated ~~May 22,~~November 19, 2019, to Credit Agreement, dated May 7, 2015 (as amended by Amendment No. 1, dated October 25, 2016, Amendment No. 2, dated March 29, 2017, Amendment No. 3, dated October 23, 2017, Amendment No. 4, dated October 19, 2018 and Amendment No. 5, dated March 11, 2019), by and ~~among Horizon Pharma USA, Inc., as Borrower, Horizon Therapeutics Public~~between HZNP Finance Limited ~~Company, as Irish Holdco~~ and ~~a guarantor, the subsidiary guarantors party thereto, as subsidiary guarantors, the lenders party thereto and Citibank, N.A., as administrative agent and collateral agent~~U.S. Bank National Association (incorporated by reference to Exhibit ~~99.1 to Horizon Therapeutics Public Limited Company’s Current Report on Form 8-K, filed on May 22, 2019).~~

~~10.2+~~		~~Executive Employment Agreement, effective as of May 1, 2019, by and between Horizon Pharma USA, Inc. and Jeffery Kent, M.D., FACP, FACG (incorporated by reference to Exhibit 10.2~~4.5 to Horizon Therapeutics Public Limited Company’s Quarterly Report on Form 10-Q, filed on May ~~8, 2019)~~6, 2020).

~~10.3+~~4.4		Second Supplemental Indenture, dated April 23, 2020, by and among Horizon Properties Holding LLC, Curzion Pharmaceuticals, Inc. and U.S. Bank National Association (incorporated by reference to Exhibit 4.6 to Horizon Therapeutics Public Limited Company’s Quarterly Report on Form 10-Q, filed on May 6, 2020).

10.1+		Horizon Therapeutics Public Limited Company ~~Amended and Restated 2014~~2020 Equity Incentive Plan and Form of Option Agreement, Form of Stock Option Grant Notice, Forms of Restricted Stock Unit Agreement and Forms of Restricted Stock Unit Grant Notice ~~thereunder (incorporated by reference to Exhibit 10.7 to Horizon Therapeutics Public Limited Company’s Quarterly Report on Form 10-Q, filed on May 8, 2019).~~thereunder.

~~10.4+~~10.2+		Horizon Therapeutics Public Limited Company ~~2014 Non-Employee Equity~~2020 Employee Share Purchase Plan ~~as amended, and Form of Option Agreement, Form of Stock Option Grant Notice, Forms of Restricted Stock Unit Agreement and Forms of Restricted Stock Unit Grant Notice thereunder~~ (incorporated by reference to Exhibit ~~10.8~~99.2 to Horizon Therapeutics Public Limited Company’s ~~Quarterly~~Current Report on Form ~~10-Q,~~8-K, filed on May ~~8, 2019).~~

~~10.5+~~		~~Horizon Pharma Public Limited Company Non-Employee Director Compensation Policy, as amended.~~

10.6*		~~Amendment No.~~ 1, ~~to Commercial Supply Agreement, dated May 15, 2019, by and between AGC Biologics A/S (formerly known as CMC Biologics A/S) and Horizon Pharma Ireland Limited.~~2020).

31.1		Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act.

31.2		Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act.

32.1		Certification of Principal Executive Officer pursuant to Rule 13a-14(b) or 15d-14(b) of the Exchange Act and 18 U.S.C. Section 1350.
32.2		Certification of Principal Financial Officer pursuant to Rule 13a-14(b) or 15d-14(b) of the Exchange Act and 18 U.S.C. Section 1350.

Exhibit Number		Description of Document

101. INS		Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

101.SCH		Inline XBRL Taxonomy Extension Schema Document

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document

104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

	HORIZON THERAPEUTICS PLC

Date: August ~~7, 2019~~5, 2020	By:	/s/ Timothy Walbert
		Timothy Walbert
		Chairman, President and Chief Executive Officer (Principal Executive Officer)

Date: August ~~7, 2019~~5, 2020	By:	/s/ Paul W. Hoelscher
		Paul W. Hoelscher
		Executive Vice President, Chief Financial Officer (Principal Financial Officer)